<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE us-patent-application SYSTEM "us-patent-application-v46-2022-02-17.dtd" [ ]><us-patent-application lang="EN" dtd-version="v4.6 2022-02-17" file="US20230002334A1-20230105.XML" status="PRODUCTION" id="us-patent-application" country="US" date-produced="20221221" date-publ="20230105"><us-bibliographic-data-application lang="EN" country="US"><publication-reference><document-id><country>US</country><doc-number>20230002334</doc-number><kind>A1</kind><date>20230105</date></document-id></publication-reference><application-reference appl-type="utility"><document-id><country>US</country><doc-number>17777910</doc-number><date>20201126</date></document-id></application-reference><us-application-series-code>17</us-application-series-code><priority-claims><priority-claim sequence="01" kind="national"><country>CN</country><doc-number>PCT/CN2019/121927</doc-number><date>20191129</date></priority-claim></priority-claims><classifications-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>C</section><class>07</class><subclass>D</subclass><main-group>265</main-group><subgroup>16</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>C</section><class>07</class><subclass>D</subclass><main-group>498</main-group><subgroup>04</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>A</section><class>61</class><subclass>Q</subclass><main-group>19</main-group><subgroup>00</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>A</section><class>61</class><subclass>Q</subclass><main-group>11</main-group><subgroup>02</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr></classifications-ipcr><classifications-cpc><main-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>07</class><subclass>D</subclass><main-group>265</main-group><subgroup>16</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc></main-cpc><further-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>07</class><subclass>D</subclass><main-group>498</main-group><subgroup>04</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>Q</subclass><main-group>19</main-group><subgroup>00</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>Q</subclass><main-group>11</main-group><subgroup>02</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc></further-cpc></classifications-cpc><invention-title id="d2e61">TRPM8 MODULATORS</invention-title><us-parties><us-applicants><us-applicant sequence="00" app-type="applicant" designation="us-only" applicant-authority-category="assignee"><addressbook><orgname>Givaudan SA</orgname><address><city>VERNIER</city><country>CH</country></address></addressbook><residence><country>CH</country></residence></us-applicant></us-applicants><inventors><inventor sequence="00" designation="us-only"><addressbook><last-name>WANG</last-name><first-name>Chao</first-name><address><city>Shanghai</city><country>CN</country></address></addressbook></inventor><inventor sequence="01" designation="us-only"><addressbook><last-name>COCITO ARMANINO</last-name><first-name>Nicolas</first-name><address><city>Baden</city><country>CH</country></address></addressbook></inventor><inventor sequence="02" designation="us-only"><addressbook><last-name>CHARPENTIER</last-name><first-name>Julie</first-name><address><city>Basel</city><country>CH</country></address></addressbook></inventor><inventor sequence="03" designation="us-only"><addressbook><last-name>CHEN</last-name><first-name>Chun</first-name><address><city>Shanghai</city><country>CN</country></address></addressbook></inventor><inventor sequence="04" designation="us-only"><addressbook><last-name>EMTER</last-name><first-name>Roger</first-name><address><city>Zurich</city><country>CH</country></address></addressbook></inventor><inventor sequence="05" designation="us-only"><addressbook><last-name>GOEKE</last-name><first-name>Andreas</first-name><address><city>Duebendorf</city><country>CH</country></address></addressbook></inventor><inventor sequence="06" designation="us-only"><addressbook><last-name>HUANG</last-name><first-name>Feng</first-name><address><city>Shanghai</city><country>CN</country></address></addressbook></inventor><inventor sequence="07" designation="us-only"><addressbook><last-name>NATSCH</last-name><first-name>Andreas</first-name><address><city>Uetikon</city><country>CH</country></address></addressbook></inventor><inventor sequence="08" designation="us-only"><addressbook><last-name>ZHOU</last-name><first-name>Lijun</first-name><address><city>Shanghai</city><country>CN</country></address></addressbook></inventor><inventor sequence="09" designation="us-only"><addressbook><last-name>ZOU</last-name><first-name>Yue</first-name><address><city>Shanghai</city><country>CN</country></address></addressbook></inventor></inventors></us-parties><pct-or-regional-filing-data><document-id><country>WO</country><doc-number>PCT/EP2020/083453</doc-number><date>20201126</date></document-id><us-371c12-date><date>20220518</date></us-371c12-date></pct-or-regional-filing-data></us-bibliographic-data-application><abstract id="abstract"><p id="p-0001" num="0000">Disclosed are TRPM8 modulators as defined by formula (I) for achieving a cooling effect on skin and mucousa.</p></abstract><description id="description"><?summary-of-invention description="Summary of Invention" end="lead"?><heading id="h-0001" level="1">TECHNICAL FIELD</heading><p id="p-0002" num="0001">The present invention relates to a particular class of compounds capable to activate TRPM8 ion channels. It further relates to the use of said compounds for inducing a sensation of coldness, and to consumer products comprising these compounds.</p><heading id="h-0002" level="1">BACKGROUND</heading><p id="p-0003" num="0002">TRPM8 (transient receptor potential melastatin member 8, also known as Trp-p8 or MCR1) is activated by innocuous cool and thus plays an important role as sensor for temperature. The channels are widely distributed in different tissues (such as human skin and mucosa (such as oral mucosa, throat mucosa, nasal mucosa), male urogenital tract, lung epithelium cells and artery myoctes). They are Ca<sup>2+</sup>-permeable, nonselective cation channels that exhibit polymodal gating mechanisms, being activated by innocuous cool to cold temperature, membrane depolarization, and molecules which are known as cooling agents including natural and synthetic compounds. The receptor was described for the first time in 2002 as cold receptor in a number of publications.</p><p id="p-0004" num="0003">The present invention is based on the finding that a particular class of compounds can be used to drive a cooling response when brought into contact with TRPM8 receptor in-vitro and in-vivo.</p><p id="p-0005" num="0004">Compounds providing a cooling sensation have for a long time played an important role in the flavor and fragrance industry in order to produce an association with freshness and cleanliness. Cooling compounds are widely used in a variety of products such as foodstuffs, tobacco products, beverages, dentifrices, mouthwashes, toothpastes, and toiletries. The cooling sensation provided contributed to the appeal and acceptability of consumer products. In particular, oral care products, such as dentifrices and mouthwashes are formulated with coolants because they provide breath freshening effects and a clean, cool, fresh feeling in the mouth.</p><p id="p-0006" num="0005">A large number of compounds providing cooling sensations have been described. The most well-known natural occurring compound is menthol, in particular L-menthol. Among the synthetic compounds providing cooling sensations, many are derivatives of or are structurally related to menthol, i. e. containing the cyclohexane moiety, and derivatized with functional groups including carboxamide, ketal, ester, ether and alcohols.</p><p id="p-0007" num="0006">Applicant surprisingly found a new class of chemical compounds which differ significantly in structural terms from the TRPM8 modulators known hitherto. It was surprisingly found that this class of chemical compounds as herein further described can provide long lasting cooling on the human skin and/or mucosa at very low concentrations.</p><heading id="h-0003" level="1">SUMMARY</heading><p id="p-0008" num="0007">There is provided in a first aspect a compound of formula (I), a salt or solvate thereof (in particular for use in providing cooling sensation)</p><p id="p-0009" num="0000"><chemistry id="CHEM-US-00001" num="00001"><img id="EMI-C00001" he="27.77mm" wi="55.46mm" file="US20230002334A1-20230105-C00001.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0010" num="0008">wherein</p><p id="p-0011" num="0009">X is O and the dotted line represents a single bond;</p><p id="p-0012" num="0010">or</p><p id="p-0013" num="0011">X is selected from CR<sup>3 </sup>and NR<sup>3</sup>,<ul id="ul0001" list-style="none">    <li id="ul0001-0001" num="0000">    <ul id="ul0002" list-style="none">        <li id="ul0002-0001" num="0012">wherein R<sup>3 </sup>is selected from hydrogen, C<sub>1</sub>-C<sub>6 </sub>alkyl, C<sub>1</sub>-C<sub>7 </sub>alkyl substituted with one or two OH groups, C<sub>3</sub>-C<sub>7 </sub>cycloalkyl, C<sub>3</sub>-C<sub>7 </sub>cycloalkyl substituted with one or two OH groups, C<sub>5</sub>-C<sub>7 </sub>cycloalkenyl, C<sub>5</sub>-C<sub>7 </sub>cycloalkenyl substituted with one, two or three C<sub>1</sub>-C<sub>3 </sub>alkyl groups, and phenyl,</li>    </ul>    </li></ul></p><p id="p-0014" num="0013">and the dotted line represents a single bond or a double bond;</p><p id="p-0015" num="0014">R<sup>1 </sup>is selected from hydrogen,</p><p id="p-0016" num="0015">C<sub>1</sub>-C<sub>6 </sub>alkyl,</p><p id="p-0017" num="0016">C<sub>1</sub>-C<sub>7 </sub>alkyl substituted with one or two OH groups,</p><p id="p-0018" num="0017">C<sub>3</sub>-C<sub>7 </sub>alkenyl,</p><p id="p-0019" num="0018">phenyl optionally substituted with up to five (e.g. one, two or three) substituents selected from the group consisting of halogen (including Br, Cl, and F), C&#x2261;N, NO<sub>2</sub>, C<sub>1</sub>-C<sub>6 </sub>alkly, C<sub>1</sub>-C<sub>6 </sub>alkyl comprising up to 5 halogen atoms (including Br, Cl, and F), C<sub>1</sub>-C<sub>6 </sub>alkyloxy, C<sub>1</sub>-C<sub>6 </sub>alkyloxy comprising up to 5 halogen atoms (including Br, Cl, and F), C<sub>3</sub>-C<sub>7 </sub>cycloalkyl, &#x2014;C(O)O&#x2014;R<sup>10 </sup>wherein R<sup>10 </sup>is selected from hydrogen and C<sub>1</sub>-C<sub>3 </sub>alkyl, and &#x2014;SR<sup>11 </sup>wherein R<sup>11 </sup>is selected from hydrogen and C<sub>1</sub>-C<sub>3 </sub>alkyl (including ethyl and isopropyl),</p><p id="p-0020" num="0019">naphtyl optionally substituted with up to five (e.g. one, two or three) substituents selected from the group consisting of halogen (including Br, Cl, and F), C&#x2261;N, NO<sub>2</sub>, C<sub>1</sub>-C<sub>6 </sub>alkly, C<sub>1</sub>-C<sub>6 </sub>alkyl comprising up to 5 halogen atoms (including Br, Cl, and F), C<sub>1</sub>-C<sub>6 </sub>alkyloxy, C<sub>1</sub>-C<sub>6 </sub>alkyloxy comprising up to 5 halogen atoms (including Br, Cl, and F), C<sub>3</sub>-C<sub>7 </sub>cycloalkyl, &#x2014;C(O)O&#x2014;R<sup>10 </sup>wherein R<sup>10 </sup>is selected from hydrogen and C<sub>1</sub>-C<sub>3 </sub>alkyl, and &#x2014;SR<sup>11 </sup>wherein R<sup>11 </sup>is selected from hydrogen and C<sub>1</sub>-C<sub>3 </sub>alkyl (including ethyl and isopropyl), and</p><p id="p-0021" num="0020">C<sub>5</sub>-C<sub>10 </sub>mono- or bicyclic aryl wherein 1 or 2 C-atoms are replaced by a hetero atom independently selected from sulfur, nitrogen, and oxygen, optionally substituted with up to three (e.g. 1 or 2) substituents selected from the group consisting of halogen (including Br, Cl, and F), CEN, NO<sub>2</sub>, C<sub>1</sub>-C<sub>6 </sub>alkly, C<sub>1</sub>-C<sub>6 </sub>alkyl comprising up to 5 halogen atoms (including Br, Cl, and F), C<sub>1</sub>-C<sub>6 </sub>alkyloxy, C<sub>1</sub>-C<sub>6 </sub>alkyloxy comprising up to 5 halogen atoms (including Br, Cl, and F), C<sub>3</sub>-C<sub>7 </sub>cycloalkyl, &#x2014;C(O)O&#x2014;R<sup>10 </sup>wherein R<sup>10 </sup>is selected from hydrogen and C<sub>1</sub>-C<sub>3 </sub>alkyl, and &#x2014;SR<sup>11 </sup>wherein R<sup>11 </sup>is selected from hydrogen and C<sub>1</sub>-C<sub>3 </sub>alkyl (including ethyl and isopropyl);</p><p id="p-0022" num="0021">R<sup>2</sup>, R<sup>4</sup>, R<sup>5</sup>, and R<sup>7 </sup>are independently selected from hydrogen and C<sub>1</sub>-C<sub>6 </sub>alkyl;</p><p id="p-0023" num="0022">R<sup>6 </sup>is selected from hydrogen, C<sub>1</sub>-C<sub>6 </sub>alkyl (e.g. ethyl, isopropy), and C<sub>3</sub>-C<sub>7 </sub>cycloalkyl;</p><p id="p-0024" num="0023">R<sup>8 </sup>and R<sup>9 </sup>are independently selected from hydrogen, and C<sub>1</sub>-C<sub>6 </sub>alkly, or</p><p id="p-0025" num="0024">R<sup>8 </sup>and R<sup>9 </sup>form together with the C-atom to which they are attached a 3, 4, 5, 6, or 7-membered cycloalkyl ring;</p><p id="p-0026" num="0025">and</p><p id="p-0027" num="0026">n is 0, or n is 1 and R&#x2032; is selected from hydrogen, C<sub>1</sub>-C<sub>6 </sub>alkyl, C<sub>2</sub>-C<sub>6 </sub>alkyl substituted with one or two OH groups, C<sub>2</sub>-C<sub>6 </sub>alkenyl, or R&#x2032; forms together with the C-atom to which it is attached a carbonyl group (C&#x2550;O).</p><p id="p-0028" num="0027">In accordance with a second aspect there is provided a method of modulating (in-vitro and in-vivo modulation) of transient receptor potential melastatin member 8 (TRPM8) comprising bringing the receptor into contact with a compound of formula (I), or a salt or solvate thereof.</p><p id="p-0029" num="0028">There is provided in a third aspect a method of inducing a cooling sensation in a human or animal comprising contacting the human or animal with a compound of formula (I), or a salt or solvate thereof.</p><p id="p-0030" num="0029">There is provided in a fourth aspect consumer products, in particular consumer products which get into contact with the human skin and/or mucosa comprising a compound as defined by formula (I), or a salt or solvate thereof.</p><p id="p-0031" num="0030">There is provided in a fifth aspect a composition comprising a cool sensation wherein the composition comprises at least one compound of formula (I), a salt or solvate thereof, and a further cooling compound.</p><p id="p-0032" num="0031">There is provided in a sixth aspect pharmaceutical composition comprising one or more compounds as defined by formula (I), or a salt or solvate thereof.</p><p id="p-0033" num="0032">The details, examples and preferences provided in relation to any particular one or more of the stated aspects of the present invention will be further described herein and apply equally to all aspects of the present invention. Any combination of the embodiments, examples and preferences described herein in all possible variations thereof is encompassed by the present invention unless otherwise indicated herein, or otherwise clearly contradicted by context.</p><?summary-of-invention description="Summary of Invention" end="tail"?><?detailed-description description="Detailed Description" end="lead"?><heading id="h-0004" level="1">DETAILED DESCRIPTION</heading><p id="p-0034" num="0033">The present invention is based, at least in part, on the surprising finding of a new class of chemical compounds which differ significantly in structural terms from the TRPM8 modulators known hitherto, that are capable to activate the TRPM8 ion channel, which brings about a Ca<sup>2+</sup> influx into the cold-sensitive neurons. The electrical signal produced as a result is ultimately perceived as sensation of coldness. Applicant surprising fount that this class of chemical compounds as herein further described can provide long lasting cooling on the human skin and/or mucosa at very low concentrations.</p><p id="p-0035" num="0034">Thus, there is provided in a first aspect a compound of formula (I), a salt or solvate thereof (in particular for use in providing cooling sensations)</p><p id="p-0036" num="0000"><chemistry id="CHEM-US-00002" num="00002"><img id="EMI-C00002" he="27.77mm" wi="55.46mm" file="US20230002334A1-20230105-C00002.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0037" num="0035">wherein</p><p id="p-0038" num="0036">X is O and the dotted line represents a single bond;</p><p id="p-0039" num="0037">or</p><p id="p-0040" num="0038">X is selected from CR<sup>3 </sup>and NR<sup>3</sup>,<ul id="ul0003" list-style="none">    <li id="ul0003-0001" num="0000">    <ul id="ul0004" list-style="none">        <li id="ul0004-0001" num="0039">wherein R<sup>3 </sup>is selected from hydrogen, C<sub>1</sub>-C<sub>6 </sub>alkyl, C<sub>1</sub>-C<sub>7 </sub>alkyl substituted with one or two OH groups, C<sub>3</sub>-C<sub>7 </sub>cycloalkyl, C<sub>3</sub>-C<sub>7 </sub>cycloalkyl substituted with one or two OH groups, C<sub>5</sub>-C<sub>7 </sub>cycloalkenyl, C<sub>5</sub>-C<sub>7 </sub>cycloalkenyl substituted with one, two or three C<sub>1</sub>-C<sub>3 </sub>alkyl groups, and phenyl,</li>    </ul>    </li></ul></p><p id="p-0041" num="0040">and the dotted line represents a single bond or a double bond;</p><p id="p-0042" num="0041">R<sup>1 </sup>is selected from hydrogen,</p><p id="p-0043" num="0042">C<sub>1</sub>-C<sub>6 </sub>alkyl,</p><p id="p-0044" num="0043">C<sub>1</sub>-C<sub>7 </sub>alkyl substituted with one or two OH groups,</p><p id="p-0045" num="0044">C<sub>3</sub>-C<sub>7 </sub>alkenyl,</p><p id="p-0046" num="0045">phenyl optionally substituted with up to five (e.g. one, two or three) substituents selected from the group consisting of halogen (including Br, Cl, and F), C&#x2261;N, NO<sub>2</sub>, C<sub>1</sub>-C<sub>6 </sub>alkly, C<sub>1</sub>-C<sub>6 </sub>alkyl comprising up to 5 halogen atoms (including Br, Cl, and F), C<sub>1</sub>-C<sub>6 </sub>alkyloxy, C<sub>1</sub>-C<sub>6 </sub>alkyloxy comprising up to 5 halogen atoms (including Br, Cl, and F), C<sub>3</sub>-C<sub>7 </sub>cycloalkyl, &#x2014;C(O)O&#x2014;R<sup>10 </sup>wherein R<sup>10 </sup>is selected from hydrogen and C<sub>1</sub>-C<sub>3 </sub>alkyl, and &#x2014;SR<sup>11 </sup>wherein R<sup>11 </sup>is selected from hydrogen and C<sub>1</sub>-C<sub>3 </sub>alkyl (including ethyl and isopropyl),</p><p id="p-0047" num="0046">naphtyl optionally substituted with up to five (e.g. one, two or three) substituents selected from the group consisting of halogen (including Br, Cl, and F), C&#x2261;N, NO<sub>2</sub>, C<sub>1</sub>-C<sub>6 </sub>alkly, C<sub>1</sub>-C<sub>6 </sub>alkyl comprising up to 5 halogen atoms (including Br, Cl, and F), C<sub>1</sub>-C<sub>6 </sub>alkyloxy, C<sub>1</sub>-C<sub>6 </sub>alkyloxy comprising up to 5 halogen atoms (including Br, Cl, and F), C<sub>3</sub>-C<sub>7 </sub>cycloalkyl, &#x2014;C(O)O&#x2014;R<sup>10 </sup>wherein R<sup>10 </sup>is selected from hydrogen and C<sub>1</sub>-C<sub>3 </sub>alkyl, and &#x2014;SR<sup>11 </sup>wherein R<sup>11 </sup>is selected from hydrogen and C<sub>1</sub>-C<sub>3 </sub>alkyl (including ethyl and isopropyl), and</p><p id="p-0048" num="0047">C<sub>5</sub>-C<sub>10 </sub>mono- or bicyclic aryl wherein 1 or 2 C-atoms are replaced by a hetero atom independently selected from sulfur, nitrogen, and oxygen, optionally substituted with up to three (e.g. 1 or 2) substituents selected from the group consisting of halogen (including Br, Cl, and F), C&#x2261;N, NO<sub>2</sub>, C<sub>1</sub>-C<sub>6 </sub>alkly, C<sub>1</sub>-C<sub>6 </sub>alkyl comprising up to 5 halogen atoms (including Br, Cl, and F), C<sub>1</sub>-C<sub>6 </sub>alkyloxy, C<sub>1</sub>-C<sub>6 </sub>alkyloxy comprising up to 5 halogen atoms (including Br, Cl, and F), C<sub>3</sub>-C<sub>7 </sub>cycloalkyl, &#x2014;C(O)O&#x2014;R<sup>10 </sup>wherein R<sup>10 </sup>is selected from hydrogen and C<sub>1</sub>-C<sub>3 </sub>alkyl, and &#x2014;SR<sup>11 </sup>wherein R<sup>11 </sup>is selected from hydrogen and C<sub>1</sub>-C<sub>3 </sub>alkyl (including ethyl and isopropyl);</p><p id="p-0049" num="0048">R<sup>2</sup>, R<sup>4</sup>, R<sup>5</sup>, and R<sup>7 </sup>are independently selected from hydrogen and C<sub>1</sub>-C<sub>6 </sub>alkyl;</p><p id="p-0050" num="0049">R<sup>6 </sup>is selected from hydrogen, C<sub>1</sub>-C<sub>6 </sub>alkyl (e.g. ethyl, isopropy), and C<sub>3</sub>-C<sub>7 </sub>cycloalkyl;</p><p id="p-0051" num="0050">R<sup>8 </sup>and R<sup>9 </sup>are independently selected from hydrogen, and C<sub>1</sub>-C<sub>6 </sub>alkly, or</p><p id="p-0052" num="0051">R<sup>8 </sup>and R<sup>9 </sup>form together with the C-atom to which they are attached a 3, 4, 5, 6, or 7-membered cycloalkyl ring;</p><p id="p-0053" num="0052">and</p><p id="p-0054" num="0053">n is 0, or n is 1 and R&#x2032; is selected from hydrogen, C<sub>1</sub>-C<sub>6 </sub>alkyl, C<sub>2</sub>-C<sub>6 </sub>alkyl substituted with one or two OH groups, C<sub>2</sub>-C<sub>6 </sub>alkenyl, or R&#x2032; forms together with the C-atom to which it is attached a carbonyl group (C&#x2550;O).</p><p id="p-0055" num="0054">Non-limiting examples are compounds of formula (I), a salt or solvate thereof, wherein X is CR<sup>3 </sup>wherein R<sup>3 </sup>is selected from hydrogen, C<sub>1</sub>-C<sub>6 </sub>alkyl, C<sub>1</sub>-C<sub>7 </sub>alkyl substituted with one or two OH groups, C<sub>3</sub>-C<sub>7 </sub>cycloalkyl, C<sub>3</sub>-C<sub>7 </sub>cycloalkyl substituted with one or two OH groups, C<sub>5</sub>-C<sub>7 </sub>cycloalkenyl, C<sub>5</sub>-C<sub>7 </sub>cycloalkenyl substituted with one, two or three C<sub>1</sub>-C<sub>3 </sub>alkyl groups, and phenyl;</p><p id="p-0056" num="0055">and the dotted line represents a single bond or a double bond;</p><p id="p-0057" num="0056">Further non-limiting examples are compound of formula (I), a salt or solvate thereof, wherein X is CR<sup>3 </sup>wherein R<sup>3 </sup>is selected from hydrogen, C<sub>1</sub>-C<sub>6 </sub>alkyl, C<sub>1</sub>-C<sub>7 </sub>alkyl substituted with one or two OH groups, C<sub>3</sub>-C<sub>7 </sub>cycloalkyl, C<sub>3</sub>-C<sub>7 </sub>cycloalkyl substituted with one or two OH groups, C<sub>5</sub>-C<sub>7 </sub>cycloalkenyl, C<sub>5</sub>-C<sub>7 </sub>cycloalkenyl substituted with one, two or three C<sub>1</sub>-C<sub>3 </sub>alkyl groups, and phenyl;</p><p id="p-0058" num="0057">the dotted line represents a single bond; and n is 0.</p><p id="p-0059" num="0058">Further non-limiting examples are compound of formula (I), a salt or solvate thereof, wherein X is NR<sup>3</sup>, wherein R<sup>3 </sup>is selected from hydrogen, C<sub>1</sub>-C<sub>6 </sub>alkyl, C<sub>1</sub>-C<sub>7 </sub>alkyl substituted with one or two OH groups, C<sub>3</sub>-C<sub>7 </sub>cycloalkyl, C<sub>3</sub>-C<sub>7 </sub>cycloalkyl substituted with one or two OH groups, C<sub>5</sub>-C<sub>7 </sub>cycloalkenyl, C<sub>5</sub>-C<sub>7 </sub>cycloalkenyl substituted with one, two or three C<sub>1</sub>-C<sub>3 </sub>alkyl groups, and phenyl;</p><p id="p-0060" num="0059">and the dotted line represents a single bond or a double bond;</p><p id="p-0061" num="0060">Further non-limiting examples are compound of formula (I), a salt or solvate thereof, wherein X is NR<sup>3</sup>, wherein R<sup>3 </sup>is selected from hydrogen, C<sub>1</sub>-C<sub>6 </sub>alkyl, C<sub>1</sub>-C<sub>7 </sub>alkyl substituted with one or two OH groups, C<sub>3</sub>-C<sub>7 </sub>cycloalkyl, C<sub>3</sub>-C<sub>7 </sub>cycloalkyl substituted with one or two OH groups, C<sub>5</sub>-C<sub>7 </sub>cycloalkenyl, C<sub>5</sub>-C<sub>7 </sub>cycloalkenyl substituted with one, two or three C<sub>1</sub>-C<sub>3 </sub>alkyl groups, and phenyl; the dotted line represents a single bond; and n is 0.</p><p id="p-0062" num="0061">Further non-limiting examples are compound of formula (I), a salt or solvate thereof, wherein X is CR<sup>3</sup>, wherein R<sup>3 </sup>is selected from hydrogen, C<sub>1</sub>-C<sub>6 </sub>alkyl, C<sub>1</sub>-C<sub>7 </sub>alkyl substituted with one or two OH groups, C<sub>3</sub>-C<sub>7 </sub>cycloalkyl, C<sub>3</sub>-C<sub>7 </sub>cycloalkyl substituted with one or two OH groups, C<sub>5</sub>-C<sub>7 </sub>cycloalkenyl, C<sub>5</sub>-C<sub>7 </sub>cycloalkenyl substituted with one, two or three C<sub>1</sub>-C<sub>3 </sub>alkyl groups, and phenyl; and the dotted line represents a single bond; n is 0; and R<sup>1 </sup>is phenyl optionally substituted with up to five (e.g. one, two or three) substituents selected from the group consisting of halogen (including Br, Cl, and F), C&#x2261;N, NO<sub>2</sub>, C<sub>1</sub>-C<sub>6 </sub>alkly, C<sub>1</sub>-C<sub>6 </sub>alkyl comprising up to 5 halogen atoms (including Br, Cl, and F), C<sub>1</sub>-C<sub>6 </sub>alkyloxy, C<sub>1</sub>-C<sub>5 </sub>alkyloxy comprising up to 5 halogen atoms (including Br, Cl, and F), C<sub>3</sub>-C<sub>7 </sub>cycloalkyl, &#x2014;C(O)O&#x2014;R<sup>10 </sup>wherein R<sup>10 </sup>is selected from hydrogen and C<sub>1</sub>-C<sub>3 </sub>alkyl, and &#x2014;SR<sup>11 </sup>wherein R<sup>11 </sup>is selected from hydrogen and C<sub>1</sub>-C<sub>3 </sub>alkyl (including ethyl and isopropyl).</p><p id="p-0063" num="0062">Further, non-limiting examples are compounds of formula (Ia), a salt or solvate thereof,</p><p id="p-0064" num="0000"><chemistry id="CHEM-US-00003" num="00003"><img id="EMI-C00003" he="27.01mm" wi="53.85mm" file="US20230002334A1-20230105-C00003.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0065" num="0063">wherein</p><p id="p-0066" num="0064">X is selected C and N;</p><p id="p-0067" num="0065">R<sup>3 </sup>is selected from hydrogen, C<sub>1</sub>-C<sub>6 </sub>alkyl, C<sub>1</sub>-C<sub>7 </sub>alkyl substituted with one or two OH groups, C<sub>3</sub>-C<sub>7 </sub>cycloalkyl, C<sub>3</sub>-C<sub>7 </sub>cycloalkyl substituted with one or two OH groups, C<sub>5</sub>-C<sub>7 </sub>cycloalkenyl, C<sub>5</sub>-C<sub>7 </sub>cycloalkenyl substituted with one, two or three C<sub>1</sub>-C<sub>3 </sub>alkyl groups, and phenyl;</p><p id="p-0068" num="0066">R<sup>1 </sup>is selected from hydrogen,</p><p id="p-0069" num="0067">C<sub>1</sub>-C<sub>6 </sub>alkyl,</p><p id="p-0070" num="0068">C<sub>1</sub>-C<sub>7 </sub>alkyl substituted with one or two OH groups,</p><p id="p-0071" num="0069">C<sub>3</sub>-C<sub>7 </sub>alkenyl,</p><p id="p-0072" num="0070">phenyl optionally substituted with up to five (e.g. one, two or three) substituents selected from the group consisting of halogen (including Br, Cl, and F), C&#x2261;N, NO<sub>2</sub>, C<sub>1</sub>-C<sub>6 </sub>alkly, C<sub>1</sub>-C<sub>6 </sub>alkyl comprising up to 5 halogen atoms (including Br, Cl, and F), C<sub>1</sub>-C<sub>6 </sub>alkyloxy, C<sub>1</sub>-C<sub>6 </sub>alkyloxy comprising up to 5 halogen atoms (including Br, Cl, and F), C<sub>3</sub>-C<sub>7</sub>cycloalkyl, &#x2014;C(O)O&#x2014;R<sup>10 </sup>wherein R<sup>10 </sup>is selected from hydrogen and C<sub>1</sub>-C<sub>3 </sub>alkyl, and &#x2014;SR<sup>11 </sup>wherein R<sup>11 </sup>is selected from hydrogen and C<sub>1</sub>-C<sub>3 </sub>alkyl (including ethyl and isopropyl),</p><p id="p-0073" num="0071">naphtyl optionally substituted with up to five (e.g. one, two or three) substituents selected from the group consisting of halogen (including Br, Cl, and F), C&#x2261;N, NO<sub>2</sub>, C<sub>1</sub>-C<sub>6 </sub>alkly, C<sub>1</sub>-C<sub>6 </sub>alkyl comprising up to 5 halogen atoms (including Br, Cl, and F), C<sub>1</sub>-C<sub>6 </sub>alkyloxy, C<sub>1</sub>-C<sub>6 </sub>alkyloxy comprising up to 5 halogen atoms (including Br, Cl, and F), C<sub>3</sub>-C<sub>7 </sub>cycloalkyl, &#x2014;C(O)O&#x2014;R<sup>10 </sup>wherein R<sup>10 </sup>is selected from hydrogen and C<sub>1</sub>-C<sub>3 </sub>alkyl, and &#x2014;SR<sup>11 </sup>wherein R<sup>11 </sup>is selected from hydrogen and C<sub>1</sub>-C<sub>3 </sub>alkyl (including ethyl and isopropyl), and</p><p id="p-0074" num="0072">C<sub>5</sub>-C<sub>10 </sub>mono- or bicyclic aryl wherein 1 or 2 C-atoms are replaced by a hetero atom independently selected from sulfur, nitrogen, and oxygen, optionally substituted with up to three (e.g. 1 or 2) substituents selected from the group consisting of halogen (including Br, Cl, and F), C&#x2261;N, NO<sub>2</sub>, C<sub>1</sub>-C<sub>6 </sub>alkly, C<sub>1</sub>-C<sub>6 </sub>alkyl comprising up to 5 halogen atoms (including Br, Cl, and F), C<sub>1</sub>-C<sub>6 </sub>alkyloxy, C<sub>1</sub>-C<sub>6 </sub>alkyloxy comprising up to 5 halogen atoms (including Br, Cl, and F), C<sub>3</sub>-C<sub>7 </sub>cycloalkyl, &#x2014;C(O)O&#x2014;R<sup>10 </sup>wherein R<sup>10 </sup>is selected from hydrogen and C<sub>1</sub>-C<sub>3 </sub>alkyl, and &#x2014;SR<sup>11 </sup>wherein R<sup>11 </sup>is selected from hydrogen and C<sub>1</sub>-C<sub>3 </sub>alkyl (including ethyl and isopropyl);</p><p id="p-0075" num="0073">R<sup>2</sup>, R<sup>4</sup>, R<sup>5</sup>, and R<sup>7 </sup>are independently selected from hydrogen and C<sub>1</sub>-C<sub>6 </sub>alkyl;</p><p id="p-0076" num="0074">R<sup>6 </sup>is selected from hydrogen, C<sub>1</sub>-C<sub>6 </sub>alkyl (e.g. ethyl, isopropy), and C<sub>3</sub>-C<sub>7 </sub>cycloalkyl;</p><p id="p-0077" num="0075">R<sup>8 </sup>and R<sup>9 </sup>are independently selected from hydrogen, and C<sub>1</sub>-C<sub>6 </sub>alkly, or</p><p id="p-0078" num="0076">R<sup>8 </sup>and R<sup>9 </sup>form together with the C-atom to which they are attached a 3, 4, 5, 6, or 7-membered cycloalkyl ring.</p><p id="p-0079" num="0077">Further non-limiting examples are compounds of formula (Ia), a salt or solvate thereof, wherein X is C; and R<sup>3 </sup>is selected from hydrogen, C<sub>1</sub>-C<sub>6 </sub>alkyl, C<sub>1</sub>-C<sub>7 </sub>alkyl substituted with one or two OH groups, C<sub>3</sub>-C<sub>7 </sub>cycloalkyl, C<sub>3</sub>-C<sub>7 </sub>cycloalkyl substituted with one or two OH groups, C<sub>5</sub>-C<sub>7 </sub>cycloalkenyl, C<sub>5</sub>-C<sub>7 </sub>cycloalkenyl substituted with one, two or three C<sub>1</sub>-C<sub>3 </sub>alkyl groups, and phenyl.</p><p id="p-0080" num="0078">Further non-limiting examples are compound of formula (Ia), a salt or solvate thereof, wherein X is C;</p><p id="p-0081" num="0079">R<sup>1 </sup>is selected from hydrogen,</p><p id="p-0082" num="0080">C<sub>1</sub>-C<sub>6 </sub>alkyl,</p><p id="p-0083" num="0081">C<sub>1</sub>-C<sub>7 </sub>alkyl substituted with one or two OH groups,</p><p id="p-0084" num="0082">C<sub>3</sub>-C<sub>7 </sub>alkenyl,</p><p id="p-0085" num="0083">phenyl optionally substituted with up to five (e.g. one, two or three) substituents selected from the group consisting of halogen (including Br, Cl, and F), C&#x2261;N, NO<sub>2</sub>, C<sub>1</sub>-C<sub>6 </sub>alkly, C<sub>1</sub>-C<sub>6 </sub>alkyl comprising up to 5 halogen atoms (including Br, Cl, and F), C<sub>1</sub>-C<sub>6 </sub>alkyloxy, C<sub>1</sub>-C<sub>6 </sub>alkyloxy comprising up to 5 halogen atoms (including Br, Cl, and F), C<sub>3</sub>-C<sub>7 </sub>cycloalkyl, &#x2014;C(O)O&#x2014;R<sup>10 </sup>wherein R<sup>10 </sup>is selected from hydrogen and C<sub>1</sub>-C<sub>3 </sub>alkyl, and &#x2014;SR<sup>11 </sup>wherein R<sup>11 </sup>is selected from hydrogen and C<sub>1</sub>-C<sub>3 </sub>alkyl (including ethyl and isopropyl),</p><p id="p-0086" num="0084">naphtyl optionally substituted with up to five (e.g. one, two or three) substituents selected from the group consisting of halogen (including Br, Cl, and F), C&#x2261;N, NO<sub>2</sub>, C<sub>1</sub>-C<sub>6 </sub>alkly, C<sub>1</sub>-C<sub>6 </sub>alkyl comprising up to 5 halogen atoms (including Br, Cl, and F), C<sub>1</sub>-C<sub>6 </sub>alkyloxy, C<sub>1</sub>-C<sub>6 </sub>alkyloxy comprising up to 5 halogen atoms (including Br, Cl, and F), C<sub>3</sub>-C<sub>7 </sub>cycloalkyl, &#x2014;C(O)O&#x2014;R<sup>10 </sup>wherein R<sup>10 </sup>is selected from hydrogen and C<sub>1</sub>-C<sub>3 </sub>alkyl, and &#x2014;SR<sup>11 </sup>wherein R<sup>11 </sup>is selected from hydrogen and C<sub>1</sub>-C<sub>3 </sub>alkyl (including ethyl and isopropyl), and</p><p id="p-0087" num="0085">C<sub>5</sub>-C<sub>10 </sub>mono- or bicyclic aryl wherein 1 or 2 C-atoms are replaced by a hetero atom independently selected from sulfur, nitrogen, and oxygen, optionally substituted with up to three (e.g. 1 or 2) substituents selected from the group consisting of halogen (including Br, Cl, and F), C&#x2261;N, NO<sub>2</sub>, C<sub>1</sub>-C<sub>6 </sub>alkly, C<sub>1</sub>-C<sub>6 </sub>alkyl comprising up to 5 halogen atoms (including Br, Cl, and F), C<sub>1</sub>-C<sub>6 </sub>alkyloxy, C<sub>1</sub>-C<sub>6 </sub>alkyloxy comprising up to 5 halogen atoms (including Br, Cl, and F), C<sub>3</sub>-C<sub>7 </sub>cycloalkyl, &#x2014;C(O)O&#x2014;R<sup>10 </sup>wherein R<sup>10 </sup>is selected from hydrogen and C<sub>1</sub>-C<sub>3 </sub>alkyl, and &#x2014;SR<sup>11 </sup>wherein R<sup>11 </sup>is selected from hydrogen and C<sub>1</sub>-C<sub>3 </sub>alkyl (including ethyl and isopropyl);</p><p id="p-0088" num="0086">R<sup>2</sup>, R<sup>4</sup>, and R<sup>5 </sup>are independently selected from hydrogen and C<sub>1</sub>-C<sub>6 </sub>alkyl;</p><p id="p-0089" num="0087">R<sup>3 </sup>is hydrogen;</p><p id="p-0090" num="0088">R<sup>6 </sup>is selected from hydrogen, C<sub>1</sub>-C<sub>6 </sub>alkyl (e.g. ethyl, isopropy), and C<sub>3</sub>-C<sub>7 </sub>cycloalkyl;</p><p id="p-0091" num="0089">R<sup>7 </sup>is hydrogen;</p><p id="p-0092" num="0090">R<sup>8 </sup>and R<sup>9 </sup>are independently selected from hydrogen, and C<sub>1</sub>-C<sub>6 </sub>alkly, or</p><p id="p-0093" num="0091">R<sup>8 </sup>and R<sup>9 </sup>form together with the C-atom to which they are attached a 3, 4, 5, 6, or 7-membered cycloalkyl ring.</p><p id="p-0094" num="0092">Further non-limiting examples are compound of formula (Ia), a salt or solvate thereof, wherein X is C, and R<sup>3 </sup>is hydrogen; and R<sup>1 </sup>is selected from phenyl optionally substituted with up to five (e.g. one, two or three) substituents selected from the group consisting of halogen (including Br, Cl, and F), C&#x2261;N, NO<sub>z </sub>C<sub>1</sub>-C<sub>6 </sub>alkly, C<sub>1</sub>-C<sub>6 </sub>alkyl comprising up to 5 halogen atoms (including Br, Cl, and F), C<sub>1</sub>-C<sub>6 </sub>alkyloxy, C<sub>1</sub>-C<sub>6 </sub>alkyloxy comprising up to 5 halogen atoms (including Br, Cl, and F), C<sub>3</sub>-C<sub>7 </sub>cycloalkyl, &#x2014;C(O)O&#x2014;R<sup>10 </sup>wherein R<sup>10 </sup>is selected from hydrogen and C<sub>1</sub>-C<sub>3 </sub>alkyl, and &#x2014;SR<sup>11 </sup>wherein R<sup>11 </sup>is selected from hydrogen and C<sub>1</sub>-C<sub>3 </sub>alkyl (including ethyl and isopropyl).</p><p id="p-0095" num="0093">Further non-limiting examples are compound of formula (Ia), a salt or solvate thereof, wherein X is C; R<sup>1 </sup>is selected from phenyl optionally substituted with up to five (e.g. one, two or three) substituents selected from the group consisting of halogen (including Br, Cl, and F), CEN, NO<sub>2</sub>, C<sub>1</sub>-C<sub>5 </sub>alkly, C<sub>1</sub>-C<sub>6 </sub>alkyl comprising up to 5 halogen atoms (including Br, Cl, and F), C<sub>1</sub>-C<sub>6 </sub>alkyloxy, C<sub>1</sub>-C<sub>6 </sub>alkyloxy comprising up to 5 halogen atoms (including Br, Cl, and F), C<sub>3</sub>-C<sub>7 </sub>cycloalkyl, &#x2014;C(O)O&#x2014;R<sup>10 </sup>wherein R<sup>10 </sup>is selected from hydrogen and C<sub>1</sub>-C<sub>3 </sub>alkyl, and &#x2014;SR<sup>11 </sup>wherein R<sup>11 </sup>is selected from hydrogen and C<sub>1</sub>-C<sub>3 </sub>alkyl (including ethyl and isopropyl); R<sup>3 </sup>is hydrogen; and R<sup>7 </sup>is hydrogen.</p><p id="p-0096" num="0094">Further non-limiting examples are compound of formula (Ia), a salt or solvate thereof, wherein X is C; R<sup>1 </sup>is selected from phenyl optionally substituted with up to five (e.g. one, two or three) substituents selected from the group consisting of halogen (including Br, Cl, and F), C&#x2261;N, NO<sub>2</sub>, C<sub>1</sub>-C<sub>6 </sub>alkly, C<sub>1</sub>-C<sub>6 </sub>alkyl comprising up to 5 halogen atoms (including Br, Cl, and F), C<sub>1</sub>-C<sub>6 </sub>alkyloxy, C<sub>1</sub>-C<sub>6 </sub>alkyloxy comprising up to 5 halogen atoms (including Br, Cl, and F), C<sub>3</sub>-C<sub>7 </sub>cycloalkyl, &#x2014;C(O)O&#x2014;R<sup>10 </sup>wherein R<sup>10 </sup>is selected from hydrogen and C<sub>1</sub>-C<sub>3 </sub>alkyl, and &#x2014;SR<sup>11 </sup>wherein R<sup>11 </sup>is selected from hydrogen and C<sub>1</sub>-C<sub>3 </sub>alkyl (including ethyl and isopropyl); R<sup>3 </sup>is hydrogen; R<sup>4 </sup>is hydrogen, R<sup>5 </sup>is C<sub>1</sub>-C<sub>3 </sub>alkyl; and R<sup>7 </sup>is hydrogen.</p><p id="p-0097" num="0095">In one particular embodiment the compounds of formula (Ia) wherein X is C, are compound of formula (Ib) have the relative stereochemistry as depicted</p><p id="p-0098" num="0000"><chemistry id="CHEM-US-00004" num="00004"><img id="EMI-C00004" he="27.01mm" wi="53.93mm" file="US20230002334A1-20230105-C00004.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0099" num="0096">wherein</p><p id="p-0100" num="0097">R<sup>1 </sup>is selected from hydrogen,</p><p id="p-0101" num="0098">C<sub>1</sub>-C<sub>6 </sub>alkyl,</p><p id="p-0102" num="0099">C<sub>1</sub>-C<sub>7 </sub>alkyl substituted with one or two OH groups,</p><p id="p-0103" num="0100">C<sub>3</sub>-C<sub>7 </sub>alkenyl,</p><p id="p-0104" num="0101">phenyl optionally substituted with up to five (e.g. one, two or three) substituents selected from the group consisting of halogen (including Br, Cl, and F), C&#x2261;N, NO<sub>2</sub>, C<sub>1</sub>-C<sub>6 </sub>alkly, C<sub>1</sub>-C<sub>6 </sub>alkyl comprising up to 5 halogen atoms (including Br, Cl, and F), C<sub>1</sub>-C<sub>6 </sub>alkyloxy, C<sub>1</sub>-C<sub>6 </sub>alkyloxy comprising up to 5 halogen atoms (including Br, Cl, and F), C<sub>3</sub>-C<sub>7 </sub>cycloalkyl, &#x2014;C(O)O&#x2014;R<sup>10 </sup>wherein R<sup>10 </sup>is selected from hydrogen and C<sub>1</sub>-C<sub>3 </sub>alkyl, and &#x2014;SR<sup>11 </sup>wherein R<sup>11 </sup>is selected from hydrogen and C<sub>1</sub>-C<sub>3 </sub>alkyl (including ethyl and isopropyl),</p><p id="p-0105" num="0102">naphtyl optionally substituted with up to five (e.g. one, two or three) substituents selected from the group consisting of halogen (including Br, Cl, and F), C&#x2261;N, NO<sub>2</sub>, C<sub>1</sub>-C<sub>6 </sub>alkly, C<sub>1</sub>-C<sub>6 </sub>alkyl comprising up to 5 halogen atoms (including Br, Cl, and F), C<sub>1</sub>-C<sub>6 </sub>alkyloxy, C<sub>1</sub>-C<sub>6 </sub>alkyloxy comprising up to 5 halogen atoms (including Br, Cl, and F), C<sub>3</sub>-C<sub>7 </sub>cycloalkyl, &#x2014;C(O)O&#x2014;R<sup>10 </sup>wherein R<sup>10 </sup>is selected from hydrogen and C<sub>1</sub>-C<sub>3 </sub>alkyl, and &#x2014;SR<sup>11 </sup>wherein R<sup>11 </sup>is selected from hydrogen and C<sub>1</sub>-C<sub>3 </sub>alkyl (including ethyl and isopropyl), and</p><p id="p-0106" num="0103">C<sub>5</sub>-C<sub>10 </sub>mono- or bicyclic aryl wherein 1 or 2 C-atoms are replaced by a hetero atom independently selected from sulfur, nitrogen, and oxygen, optionally substituted with up to three (e.g. 1 or 2) substituents selected from the group consisting of halogen (including Br, Cl, and F), C&#x2261;N, NO<sub>2</sub>, C<sub>1</sub>-C<sub>6 </sub>alkly, C<sub>1</sub>-C<sub>6 </sub>alkyl comprising up to 5 halogen atoms (including Br, Cl, and F), C<sub>1</sub>-C<sub>6 </sub>alkyloxy, C<sub>1</sub>-C<sub>6 </sub>alkyloxy comprising up to 5 halogen atoms (including Br, Cl, and F), C<sub>3</sub>-C<sub>7 </sub>cycloalkyl, &#x2014;C(O)O&#x2014;R<sup>10 </sup>wherein R<sup>10 </sup>is selected from hydrogen and C<sub>1</sub>-C<sub>3 </sub>alkyl, and &#x2014;SR<sup>11 </sup>wherein R<sup>11 </sup>is selected from hydrogen and C<sub>1</sub>-C<sub>3 </sub>alkyl (including ethyl and isopropyl);</p><p id="p-0107" num="0104">R<sup>3 </sup>is selected from hydrogen, C<sub>1</sub>-C<sub>6 </sub>alkyl, C<sub>1</sub>-C<sub>7 </sub>alkyl substituted with one or two OH groups, C<sub>3</sub>-C<sub>7 </sub>cycloalkyl, C<sub>3</sub>-C<sub>7 </sub>cycloalkyl substituted with one or two OH groups, C<sub>5</sub>-C<sub>7 </sub>cycloalkenyl, C<sub>5</sub>-C<sub>7 </sub>cycloalkenyl substituted with one, two or three C<sub>1</sub>-C<sub>3 </sub>alkyl groups, and phenyl;</p><p id="p-0108" num="0105">R<sup>2</sup>, R<sup>4</sup>, R<sup>5</sup>, and R<sup>7 </sup>are independently selected from hydrogen and C<sub>1</sub>-C<sub>6 </sub>alkyl;</p><p id="p-0109" num="0106">R<sup>6 </sup>is selected from hydrogen, C<sub>1</sub>-C<sub>6 </sub>alkyl (e.g. ethyl, isopropy), and C<sub>3</sub>-C<sub>7 </sub>cycloalkyl;</p><p id="p-0110" num="0107">R<sup>8 </sup>and R<sup>9 </sup>are independently selected from hydrogen, and C<sub>1</sub>-C<sub>6 </sub>alkly, or</p><p id="p-0111" num="0108">R<sup>8 </sup>and R<sup>9 </sup>form together with the C-atom to which they are attached a 3, 4, 5, 6, or 7-membered cycloalkyl ring.</p><p id="p-0112" num="0109">Further non-limiting examples are compound of formula (Ib), a salt or solvate thereof, wherein X is C; R<sup>1 </sup>is selected from phenyl and phenyl substituted with up to five (e.g. one, two or three) substituents selected from the group consisting of halogen (including Br, Cl, and F), C&#x2261;N, NO<sub>2</sub>, C<sub>1</sub>-C<sub>6 </sub>alkly, C<sub>1</sub>-C<sub>6 </sub>alkyl comprising up to 5 halogen atoms (including Br, Cl, and F), C<sub>1</sub>-C<sub>6 </sub>alkyloxy, C<sub>1</sub>-C<sub>6 </sub>alkyloxy comprising up to 5 halogen atoms (including Br, Cl, and F), C<sub>3</sub>-C<sub>7 </sub>cycloalkyl, &#x2014;C(O)O&#x2014;R<sup>10 </sup>wherein R<sup>10 </sup>is selected from hydrogen and C<sub>1</sub>-C<sub>3 </sub>alkyl, and &#x2014;SR<sup>11 </sup>wherein R<sup>11 </sup>is selected from hydrogen and C<sub>1</sub>-C<sub>3 </sub>alkyl (including ethyl and isopropyl); and R<sup>3 </sup>is hydrogen.</p><p id="p-0113" num="0110">Further non-limiting examples are compound of formula (Ib), a salt or solvate thereof, wherein X is C; R<sup>1 </sup>is selected from phenyl optionally substituted with up to five (e.g. one, two or three) substituents selected from the group consisting of halogen (including Br, Cl, and F), CN, NO<sub>2</sub>, C<sub>1</sub>-C<sub>6 </sub>alkly, C<sub>1</sub>-C<sub>6 </sub>alkyl comprising up to 5 halogen atoms (including Br, Cl, and F), C<sub>1</sub>-C<sub>6 </sub>alkyloxy, C<sub>1</sub>-C<sub>6 </sub>alkyloxy comprising up to 5 halogen atoms (including Br, Cl, and F), C<sub>3</sub>-C<sub>7 </sub>cycloalkyl, &#x2014;C(O)O&#x2014;R<sup>10 </sup>wherein R<sup>10 </sup>is selected from hydrogen and C<sub>1</sub>-C<sub>3 </sub>alkyl, and &#x2014;SR<sup>11 </sup>wherein R<sup>11 </sup>is selected from hydrogen and C<sub>1</sub>-C<sub>3 </sub>alkyl (including ethyl and isopropyl); R<sup>3 </sup>is hydrogen; and R<sup>7 </sup>is hydrogen.</p><p id="p-0114" num="0111">Further non-limiting examples are compound of formula (Ib), a salt or solvate thereof, wherein X is C; R<sup>1 </sup>is selected from phenyl optionally substituted with up to five (e.g. one, two or three) substituents selected from the group consisting of halogen (including Br, Cl, and F), C&#x2261;N, NO<sub>2</sub>, C<sub>1</sub>-C<sub>6 </sub>alkly, C<sub>1</sub>-C<sub>6 </sub>alkyl comprising up to 5 halogen atoms (including Br, Cl, and F), C<sub>1</sub>-C<sub>6 </sub>alkyloxy, C<sub>1</sub>-C<sub>6 </sub>alkyloxy comprising up to 5 halogen atoms (including Br, Cl, and F), C<sub>3</sub>-C<sub>7 </sub>cycloalkyl, &#x2014;C(O)O&#x2014;R<sup>10 </sup>wherein R<sup>10 </sup>is selected from hydrogen and C<sub>1</sub>-C<sub>3 </sub>alkyl, and &#x2014;SR<sup>11 </sup>wherein R<sup>11 </sup>is selected from hydrogen and C<sub>1</sub>-C<sub>3 </sub>alkyl (including ethyl and isopropyl); R<sup>3 </sup>is hydrogen; R<sup>4 </sup>is hydrogen, R<sup>5 </sup>is C<sub>1</sub>-C<sub>3 </sub>alkyl; and R<sup>7 </sup>is hydrogen.</p><p id="p-0115" num="0112">Further non-limiting examples are compound of formula (Ib), a salt or solvate thereof, wherein R<sup>3 </sup>and R<sup>7 </sup>are both hydrogen, and R<sup>8 </sup>and R<sup>9 </sup>are both methyl.</p><p id="p-0116" num="0113">Further non-limiting examples are compound of formula (Ib), a salt or solvate thereof, wherein X is C, R<sup>1 </sup>is selected from phenyl and phenyl substituted with up to five (e.g. one, two or three) substituents selected from the group consisting of halogen (including Br, Cl, and F), C&#x2261;N, NO<sub>2</sub>, C<sub>1</sub>-C<sub>6 </sub>alkly, C<sub>1</sub>-C<sub>6 </sub>alkyl comprising up to 5 halogen atoms (including Br, Cl, and F), C<sub>1</sub>-C<sub>6 </sub>alkyloxy, C<sub>1</sub>-C<sub>6 </sub>alkyloxy comprising up to 5 halogen atoms (including Br, Cl, and F), C<sub>3</sub>-C<sub>7 </sub>cycloalkyl, &#x2014;C(O)O&#x2014;R<sup>10 </sup>wherein R<sup>10 </sup>is selected from hydrogen and C<sub>1</sub>-C<sub>3 </sub>alkyl, and &#x2014;SR<sup>11 </sup>wherein R<sup>11 </sup>is selected from hydrogen and C<sub>1</sub>-C<sub>3 </sub>alkyl (including ethyl and isopropyl); R<sup>3 </sup>and R<sup>7 </sup>are both hydrogen; and R<sup>8 </sup>and R<sup>9 </sup>are both methyl.</p><p id="p-0117" num="0114">Further non-limiting examples are compound of formula (Ib), a salt or solvate thereof, wherein X is C, R<sup>1 </sup>is selected from phenyl and phenyl substituted with up to five (e.g. one, two or three) substituents selected from the group consisting of halogen (including Br, Cl, and F), C&#x2261;N, NO<sub>2</sub>, C<sub>1</sub>-C<sub>6 </sub>alkly, C<sub>1</sub>-C<sub>6 </sub>alkyl comprising up to 5 halogen atoms (including Br, Cl, and F), C<sub>1</sub>-C<sub>6 </sub>alkyloxy, C<sub>1</sub>-C<sub>6 </sub>alkyloxy comprising up to 5 halogen atoms (including Br, Cl, and F), C<sub>3</sub>-C<sub>7 </sub>cycloalkyl, &#x2014;C(O)O&#x2014;R<sup>10 </sup>wherein R<sup>10 </sup>is selected from hydrogen and C<sub>1</sub>-C<sub>3 </sub>alkyl, and &#x2014;SR<sup>11 </sup>wherein R<sup>11 </sup>is selected from hydrogen and C<sub>1</sub>-C<sub>3 </sub>alkyl (including ethyl and isopropyl); R<sup>3 </sup>and R<sup>7 </sup>are both hydrogen; R<sup>e </sup>is methyl or isopropy; and R<sup>8 </sup>and R<sup>9 </sup>are both methyl.</p><p id="p-0118" num="0115">Further non-limiting examples are compound of formula (I), (Ia) and (Ib) wherein either R<sup>1 </sup>or R<sup>2 </sup>is not hydrogen.</p><p id="p-0119" num="0116">Further non-limiting examples are compound of formula (I), (Ia) and (Ib) wherein either R<sup>1 </sup>is not hydrogen.</p><p id="p-0120" num="0117">Further non-limiting examples are compound of formula (I), (Ia) and (Ib) wherein R<sup>1 </sup>is selected from C<sub>1</sub>-C<sub>6 </sub>alkyl, C<sub>1</sub>-C<sub>7 </sub>alkyl substituted with one or two OH groups, and C<sub>3</sub>-C<sub>7 </sub>alkenyl.</p><p id="p-0121" num="0118">Further non-limiting examples are compound of formula (I), (Ia) and (Ib) wherein R<sup>1 </sup>is selected from C<sub>1</sub>-C<sub>6 </sub>alkyl, C<sub>1</sub>-C<sub>7 </sub>alkyl substituted with one or two OH groups, and C<sub>3</sub>-C<sub>7 </sub>alkenyl; R<sup>2 </sup>is hydrogen or methyl; and R<sup>8 </sup>and R<sup>9 </sup>are methyl.</p><p id="p-0122" num="0119">Further non-limiting examples are compound of formula (I), (Ia) and (Ib) wherein R<sup>1 </sup>is selected from C<sub>1</sub>-C<sub>6 </sub>alkyl, C<sub>1</sub>-C<sub>7 </sub>alkyl substituted with one or two OH groups, and C<sub>3</sub>-C<sub>7 </sub>alkenyl; R<sup>2 </sup>is hydrogen or methyl; R<sup>4 </sup>is hydrogen, R<sup>5 </sup>is C<sub>1</sub>-C<sub>3 </sub>alkyl; and R<sup>8 </sup>and R<sup>9 </sup>are methyl.</p><p id="p-0123" num="0120">Further non-limiting examples are compound of formula (I), (Ia) and (Ib) wherein R<sup>1 </sup>is selected from C<sub>1</sub>-C<sub>6 </sub>alkyl, C<sub>1</sub>-C<sub>7 </sub>alkyl substituted with one or two OH groups, and C<sub>3</sub>-C<sub>7 </sub>alkenyl; R<sup>2 </sup>is hydrogen or methyl; R<sup>4 </sup>is hydrogen, R<sup>5 </sup>is C<sub>1</sub>-C<sub>3 </sub>alkyl; R<sup>6 </sup>is methyl or isopropyl; and R<sup>8 </sup>and R<sup>9 </sup>are methyl.</p><p id="p-0124" num="0121">Further non-limiting examples are compounds of formula (I), (Ia) or (Ib) selected from the group consisting of 1,3,3,5,7-pentamethyl-5-(3-methylbut-2-en-1-yl)octahydrobenzo[c]isoxazole; 1,3,3,5,7-pentamethyl-5-(4-methylpyridin-3-yl)octahydrobenzo[c]isoxazole; 1,3,3,5,7-pentamethyl-5-(pyridin-3-yl)octahydrobenzo[c]isoxazole; 1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole; 1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole hydrochloride; 1,3,3,6-tetramethyloctahydrobenzo[c]isoxazole; 1,3,3-trimethyl-6-((R)-4-methylcyclohex-3-en-1-yl)octahydrobenzo[c]isoxazole; 1,5,7-trimethylhexahydro-1H-spiro[benzo[c]isoxazole-3,1&#x2032;-cyclopentane]; 1-ethyl-3,3,5,7-tetramethyl-5-(3-methylbut-2-en-1-yl)octahydrobenzo[c]isoxazole; 1-isopropyl-3,3,5,7-tetramethyl-5-(3-methylbut-2-en-1-yl)octahydrobenzo[c]isoxazole; 1-isopropyl-3,3,5,7-tetramethyloctahydrobenzo[c]isoxazol-1-ium chloride; 1-isopropyl-3,3,5,7-tetramethyloctahydrobenzo[c]isoxazole; 1-isopropyl-5,7-dimethylhexahydro-1H-spiro[benzo[c]isoxazole-3,1&#x2032;-cyclopentane]; 2-(1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazol-5-yl)benzonitrile; 2-methyl-3-(1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazol-5-yl)benzonitrile; 5-(2,4-dimethoxyphenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole; 5-(2,5-dimethoxyphenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole; 5-(6-methoxypyridin-2-yl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole; 5,7-diethyl-1,3,3-trimethyloctahydrobenzo[c]isoxazole; 5-ethyl-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole; 6-isopentyl-1,4,4,8-tetramethyloctahydro-2H-benzo[d][1,3]oxazin-2-one; 6-isopentyl-1,4,4,8-tetramethyloctahydro-2H-benzo[d][1,3]oxazine; rac-(3aR,5R,7aR)-1,3,3-trimethyl-5-pentyloctahydrobenzo[c]isoxazole; rac-(3aR,5R,7aR)-1,3,3-trimethyl-5-propyloctahydrobenzo[c]isoxazole; rac-(3aR,5R,7aR)-1-ethyl-3,3-dimethyl-5-propyloctahydrobenzo[c]isoxazole; rac-(3aR,5R,7aR)-1-isopropyl-3,3-dimethyl-5-propyloctahydrobenzo[c]isoxazole; rac-(3aR,5R,7aR)-5-butyl-1,3,3-trimethyloctahydrobenzo[c]isoxazole; rac-(3aR,5R,7aR)-5-butyl-1-ethyl-3,3-dimethyloctahydrobenzo[c]isoxazole; rac-(3aR,5R,7aR)-5-butyl-1-isopropyl-3,3-dimethyloctahydrobenzo[c]isoxazole; rac-(3aR,5R,7aR)-5-ethyl-1-isopropyl-3,3-dimethyloctahydrobenzo[c]isoxazole; rac-(3aR,5R,7R,7aR)-1,3,3,5,7-pentamethyl-5-(2-(methylthio)phenyl)-octahydrobenzo[c]isoxazole; rac-(3aR,5R,7R,7aR)-1-ethyl-3,3,5,7-tetramethyl-5-(3-methylbut-2-en-1-yl)octahydrobenzo[c]isoxazole; rac-(3aR,5R,7R,7aR)-1-ethyl-3,3,5,7-tetramethyl-5-(o-tolyl)octahydrobenzo[c]isoxazole; rac-(3aR,5R,7R,7aR)-5-(3-chloro-2-methylphenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole; rac-(3aR,5R,7R,7aR)-5-(4-fluoro-2-methylphenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole; rac-(3aR,5R,7R,7aR)-5-(4-methoxyphenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole; rac-(3aR,5R,7S,7aR)-1,3,3,5,7-pentamethyl-5-(2-(methylthio)phenyl)octahydrobenzo[c]isoxazole; rac-(3aR,5R,7S,7aR)-1,3,3,5,7-pentamethyl-5-(2,4,5-trimethylphenyl)octahydrobenzo[c]isoxazole; rac-(3aR,5R,7S,7aR)-1,3,3,5,7-pentamethyl-5-(2-methyl-5-(tifluoromethyl)phenyl)octahydrobenzo[c]isoxazole; rac-(3aR,5R,7S,7aR)-1,3,3,5,7-pentamethyl-5-(4-(methylthio)phenyl)octahydrobenzo[c]isoxazole; rac-(3aR,5R,7S,7aR)-1,3,3,5,7-pentamethyl-5-(5-methylthiophen-2-yl)octahydrobenzo[c]isoxazole; rac-(3aR,5R,7S,7aR)-1,3,3,5,7-pentamethyl-5-(5-methylthiophen-3-yl)octahydrobenzo[c]isoxazole; rac-(3aR,5R,7S,7aR)-1,3,3,5,7-pentamethyl-5-(m-tolyl)octahydrobenzo[c]isoxazole; rac-(3aR,5R,7S,7aR)-1,3,3,5,7-pentamethyl-5-(naphthalen-1-yl)octahydrobenzo[c]isoxazole; rac-(3aR,5R,7S,7aR)-1,3,3,5,7-pentamethyl-5-(naphthalen-2-yl)octahydrobenzo[c]isoxazole; rac-(3aR,5R,7S,7aR)-1,3,3,5,7-pentamethyl-5-(o-tolyl)octahydrobenzo[c]isoxazole; rac-(3aR,5R,7S,7aR)-1,3,3,5,7-pentamethyl-5-(p-tolyl)octahydrobenzo[c]isoxazole; rac-(3aR,5R,7S,7aR)-1,3,3,5,7-pentamethyl-5-phenyloctahydrobenzo[c]isoxazole; rac-(3aR,5R,7S,7aR)-1,3,3,5,7-pentamethyl-5-propyloctahydrobenzo[c]isoxazole; rac-(3aR,5R,7S,7aR)-1,3,3,7-tetramethyl-5-(3-methylbut-2-en-1-yl)octahydrobenzo[c]isoxazole; rac-(3aR,5R,7S,7aR)-1,3,3,7-tetramethyl-5-(o-tolyl)octahydrobenzo[c]isoxazole; rac-(3aR,5R,7S,7aR)-1,3,3,7-tetramethyl-5-phenyloctahydrobenzo[c]isoxazole; rac-(3aR,5R,7S,7aR)-1-ethyl-3,3,5,7-tetramethyl-5-(3-methylbut-2-en-1-yl)octahydrobenzo[c]isoxazole; rac-(3aR,5R,7S,7aR)-1-ethyl-3,3,5,7-tetramethyl-5-(o-tolyl)octahydrobenzo[c]isoxazole; rac-(3aR,5R,7S,7aR)-1-ethyl-3,3,5,7-tetramethyl-5-phenyloctahydrobenzo[c]isoxazole; rac-(3aR,5R,7S,7aR)-1-ethyl-3,3,5,7-tetramethyloctahydrobenzo[c]isoxazole; rac-(3aR,5R,7S,7aR)-1-ethyl-5-(2-methoxyphenyl)-3,3,7-trimethyloctahydrobenzo[c]isoxazole; rac-(3aR,5R,7S,7aR)-1-isopropyl-3,3,5,7-tetramethyl-5-(3-methylbut-2-en-1-yl)octahydrobenzo[c]isoxazole; rac-(3aR,5R,7S,7aR)-1-isopropyl-3,3,5,7-tetramethyl-5-(o-tolyl)octahydrobenzo[c]isoxazole; rac-(3aR,5R,7S,7aR)-1-isopropyl-3,3,5,7-tetramethyl-5-phenyloctahydrobenzo[c]isoxazole; rac-(3aR,5R,7S,7aR)-1-isopropyl-3,3,5,7-tetramethyl-5-propyloctahydrobenzo[c]isoxazole; rac-(3aR,5R,7S,7aR)-1-isopropyl-3,3,7-trimethyl-5-(3-methylbut-2-en-1-yl)octahydrobenzo[c]isoxazole; rac-(3aR,5R,7S,7aR)-1-isopropyl-3,3,7-trimethyl-5-(o-tolyl)octahydrobenzo[c]isoxazole; rac-(3aR,5R,7S,7aR)-1-isopropyl-3,3,7-trimethyl-5-phenyloctahydrobenzo[c]isoxazole; rac-(3aR,5R,7S,7aR)-1-isopropyl-5-(2-methoxyphenyl)-3,3,5,7-tetramethyloctahydrobenzo[c]isoxazole; rac-(3aR,5R,7S,7aR)-1-isopropyl-5-(2-methoxyphenyl)-3,3,7-trimethyloctahydrobenzo[c]isoxazole; rac-(3aR,5R,7S,7aR)-1-isopropyl-5-(4-methoxyphenyl)-3,3,5,7-tetramethyloctahydrobenzo[c]isoxazole; rac-(3aR,5R,7S,7aR)-1-isopropyl-5-(6-methoxypyridin-2-yl)-3,3,5,7-tetramethyloctahydrobenzo[c]isoxazole; rac-(3aR,5R,7S,7aR)-5-(2,3-dimethylphenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole; rac-(3aR,5R,7S,7aR)-5-(2,4-difluorophenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole; rac-(3aR,5R,7S,7aR)-5-(2,4-dimethylphenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole; rac-(3aR,5R,7S,7aR)-5-(2,4-dimethylphenyl)-1,3,3,7-tetramethyloctahydrobenzo[c]isoxazole; rac-(3aR,5R,7S,7aR)-5-(2,5-difluorophenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole; rac-(3aR,5R,7S,7aR)-5-(2,5-dimethylphenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole; rac-(3aR,5R,7S,7aR)-5-(2,5-dimethylphenyl)-1,3,3,7-tetramethyloctahydrobenzo[c]isoxazole; rac-(3aR,5R,7S,7aR)-5-(2,6-dimethylphenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole; rac-(3aR,5R,7S,7aR)-5-(2-ethoxyphenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole; rac-(3aR,5R,7S,7aR)-5-(2-ethylphenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole; rac-(3aR,5R,7S,7aR)-5-(2-ethylphenyl)-1,3,3,7-tetramethyloctahydrobenzo[c]isoxazole; rac-(3aR,5R,7S,7aR)-5-(2-ethylphenyl)-1-isopropyl-3,3,7-trimethyloctahydrobenzo[c]isoxazole; rac-(3aR,5R,7S,7aR)-5-(2-fluorophenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole; rac-(3aR,5R,7S,7aR)-5-(2-methoxyphenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole; rac-(3aR,5R,7S,7aR)-5-(2-methoxyphenyl)-1,3,3,7-tetramethyloctahydrobenzo[c]isoxazole; rac-(3aR,5R,7S,7aR)-5-(3,4-difluorophenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole; rac-(3aR,5R,7S,7aR)-5-(3,5-difluorophenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole; rac-(3aR,5R,7S,7aR)-5-(3,5-dimethoxyphenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole; rac-(3aR,5R,7S,7aR)-5-(3,5-dimethylphenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole; rac-(3aR,5R,7S,7aR)-5-(3,5-dimethylphenyl)-1-isopropyl-3,3,5,7-tetramethyloctahydrobenzo[c]isoxazole; rac-(3aR,5R,7S,7aR)-5-(3-chloro-2-methylphenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole; rac-(3aR,5R,7S,7aR)-5-(3-chloro-2-methylphenyl)-1-isopropyl-3,3,7-trimethyloctahydrobenzo[c]isoxazole; rac-(3aR,5R,7S,7aR)-5-(3-fluoro-5-(trifluoromethyl)phenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole; rac-(3aR,5R,7S,7aR)-5-(3-fluorophenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole; rac-(3aR,5R,7S,7aR)-5-(3-isopropylphenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole; rac-(3aR,5R,7S,7aR)-5-(3-methoxyphenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole; rac-(3aR,5R,7S,7aR)-5-(4-(tert-butyl)phenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole; rac-(3aR,5R,7S,7aR)-5-(4-(tert-butyl)phenyl)-1,3,3,7-tetramethyloctahydrobenzo[c]isoxazole; rac-(3aR,5R,7S,7aR)-5-(4-(tert-butyl)phenyl)-1-isopropyl-3,3,7-trimethyloctahydrobenzo[c]isoxazole; rac-(3aR,5R,7S,7aR)-5-(4-chloro-2-methylphenyl)-1-isopropyl-3,3,7-trimethyloctahydrobenzo[c]isoxazole; rac-(3aR,5R,7S,7aR)-5-(4-fluoro-2-methoxyphenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole; rac-(3aR,5R,7S,7aR)-5-(4-fluoro-2-methylphenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole; rac-(3aR,5R,7S,7aR)-5-(4-fluoro-2-methylphenyl)-1,3,3,7-tetramethyloctahydrobenzo[c]isoxazole; rac-(3aR,5R,7S,7aR)-5-(4-fluorophenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole; rac-(3aR,5R,7S,7aR)-5-(4-fluorophenyl)-1-isopropyl-3,3,5,7-tetramethyloctahydrobenzo[c]isoxazole; rac-(3aR,5R,7S,7aR)-5-(4-methoxyphenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole; rac-(3aR,5R,7S,7aR)-5-(5-chloro-2-methylphenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole; rac-(3aR,5R,7S,7aR)-5-(5-chloro-2-methylphenyl)-1-isopropyl-3,3,7-trimethyloctahydrobenzo[c]isoxazole; rac-(3aR,5R,7S,7aR)-5-(5-fluoro-2-methylphenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole; rac-(3aR,5R,7S,7aR)-5-(5-fluoro-2-methylphenyl)-1,3,3,7-tetramethyloctahydrobenzo[c]isoxazole; rac-(3aR,5R,7S,7aR)-5-(benzo[d][1,3]dioxol-5-yl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole; rac-(3aR,5R,7S,7aR)-5-(furan-3-yl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole; rac-(3aR,5R,7S,7aR)-5,7-diethyl-1-isopropyl-3,3-dimethyloctahydrobenzo[c]isoxazole; rac-(3aR,5R,7S,7aR)-5-isopentyl-1-isopropyl-3,3,5,7-tetramethyloctahydrobenzo[c]isoxazole; rac-(3aR,5S,7aR)-1,3,3,5-tetramethyl-5-(3-methylbut-2-en-1-yl)octahydrobenzo[c]isoxazole; rac-(3aR,7aR)-1,3,3,4,5,7-hexamethyloctahydrobenzo[c]isoxazole; rac-(3aR,7aR)-1,3,3-trimethyl-6-phenyloctahydrobenzo[c]isoxazole; rac-(3aR,7aR)-1,5,7-triethyl-3,3-dimethyloctahydrobenzo[c]isoxazole; rac-(3aR,7aS)-1,3,3,4,5,7-hexamethyloctahydrobenzo[c]isoxazole; rac-(3aR,7S,7aR)-5,5-diethyl-1,3,3,7-tetramethyloctahydrobenzo[c]isoxazole; rac-(3aS,5R,7S,7aS)-5-(4-fluorophenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole; rac-(3aS,5S,7S,7aS)-1-ethyl-3,3,7-trimethyl-5-(3-methylbut-2-en-1-yl)octahydrobenzo[c]isoxazole; rac-2-chloro-5-((3aR,5R,7S,7aR)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazol-5-yl)benzonitrile; rac-2-chloro-5-((3aS,5R,7R,7aS)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazol-5-yl)benzonitrile; rac-2-methyl-5-((3aR,5R,7S,7aR)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazol-5-yl)benzonitrile; rac-3-((3aR,5R,7S,7aR)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazol-5-yl)benzonitrile; rac-3-((3aR,5R,7S,7aR)-1-ethyl-3,3,5,7-tetramethyloctahydrobenzo[c]isoxazol-5-yl)-4-methylbenzonitrile; rac-3-((3aR,5R,7S,7aR)-1-isopropyl-3,3,5,7-tetramethyloctahydrobenzo[c]isoxazol-5-yl)-4-methylbenzonitrile; rac-3-((3aR,5R,7S,7aR)-1-isopropyl-3,3,5,7-tetramethyloctahydrobenzo[c]isoxazol-5-yl)benzonitrile; rac-3-((3aR,5R,7S,7aR)-1-isopropyl-3,3,7-trimethyloctahydrobenzo[c]isoxazol-5-yl)-4-methoxybenzonitrile; rac-3-chloro-5-((3aR,5R,7S,7aR)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazol-5-yl)benzonitrile; rac-3-methyl-4-((3aR,5R,7S,7aR)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazol-5-yl)benzonitrile; rac-4-((3aR,5R,7S,7aR)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazol-5-yl)benzonitrile; rac-4-methoxy-3-((3aR,5R,7R,7aR)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazol-5-yl)benzonitrile; rac-4-methoxy-3-((3aR,5R,7S,7aR)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazol-5-yl)benzonitrile; rac-4-methyl-2-((3aR,5R,7S,7aR)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazol-5-yl)benzonitrile; rac-4-methyl-3-((3aR,5R,7S,7aR)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazol-5-yl)benzonitrile; rac-4-methyl-3-((3aR,5R,7S,7aR)-1,3,3,7-tetramethyloctahydrobenzo[c]isoxazol-5-yl)benzonitrile; rac-methyl 4-methyl-3-((3aR,5R,7S,7aR)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazol-5-yl)benzoate; rel-4-methyl-3-((3aR,5R,7S,7aR)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazol-5-yl)benzonitrile and rel-4-methyl-3-((3aS,5S,7R,7aS)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazol-5-yl)benzonitrile.</p><p id="p-0125" num="0122">As used hereinabove the prefix &#x201c;rac&#x201d; refers to the relative stereochemistry of the respective descriptors (R, S) disclosing the racemic mixture of both enantiomers; the prefix &#x201c;rel&#x201d; refers to the relative stereochemistry of the respective descriptors (R, S) referring to a single, unasigned enantiomer. Chemical names with no stereochemical descriptor (i.e. neither R nor S) refer to mixtures of diastereomers and enantiomers.</p><p id="p-0126" num="0123">As used in relation to compounds of formula (I) (which encompass the compounds of formula (Ia) and (Ib)) unless otherwise indicated &#x201c;alkyl&#x201d; refers to linear or branched alkyl, &#x201c;alkenyl&#x201d; refers to linear or branched alkyl comprising at least one carbon-to-carbon double bond, e.g. 2 or 3 double bonds; and &#x201c;cycloalkenyl&#x201d; refers to cycloalkyl comprising at least one carbon-to-carbon double bond with the proviso that the ring is not saturated.</p><p id="p-0127" num="0124">The compounds as defined by formula (I) (which encompass the compounds of formula (Ia) and (Ib)) comprise several chiral centers and as such may exist as a mixture of stereoisomers, or they may be resolved as isomerically pure forms. Resolving stereoisomers adds to the complexity of manufacture and purification of these compounds and so it is preferred to use the compounds as mixtures of their stereoisomers simply for economic reasons. However, if it is desired to prepare individual stereoisomers, this may be achieved according to methods known in the art, e.g. preparative HPLC and GC, crystallization or stereoselective synthesis. Accordingly, the chemical structures depicted herein encompass all possible stereoisomers forms of the illustrated compounds.</p><p id="p-0128" num="0125">It is also noted that the compounds as defined by formula (I) (which encompass the compounds of formula (Ia) and (Ib)) may exist in unsolvated forms as well as solvated forms, including hydrated forms and as N-oxides. In general, compounds may be hydrated, solvated or N-oxides. Certain compounds may exist in multiple crystalline or amorphous forms. In general, all physical forms are equivalent for the uses contemplated herein and are intended to be within the scope of the present invention.</p><p id="p-0129" num="0126">&#x201c;Solvate&#x201d; means a compound formed by solvation (the combination of solvent molecules with molecules or ions of the solute), or an aggregate that consists of a solute ion or molecule, i.e., a compound as defined by formula (I) (which encompass the compounds of formula (Ia) and (Ib)), with one or more solvent molecules. When water is the solvent, the corresponding solvate is &#x201c;hydrate&#x201d;. Further suitable solvents can be but are not limited to: acetone, acetonitrile, benzene, cyclohexane, dihydrolevoglucosenone, methyl-tetrahydrofuran, pentylene glycol, ethylene glycol, petroleum ether, ethyl lactate, methyl lactate, propyl lactate, diethylether, tert-butyl methyl ether, dimethylsulfoxide, N,N-dimethylformamide, N,N-dimethylacetamide, dioxane, ethanol, ethyl acetate, ethylene glycol, diethylene glycol, propylene glycol, heptane, hexane, methanol, toluene and xylene.</p><p id="p-0130" num="0127">&#x201c;Salt&#x201d; refers to a salt of a compound as defined by formula (I) (which encompass the compounds of formula (Ia) and (Ib)), which possesses the desired pharmacological activity of the parent compound. Such salts include: (1) acid addition salts, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or formed with organic acids such as amino acids, acetic acid, trifluoroacetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl) benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethane-disulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, 4-methylbicyclo[2.2.2]-oct-2-ene-1-carboxylic acid, glucoheptonic acid, 3-phenylpropionic acid, trimethylacetic acid, tertiary butylacetic acid, lauryl sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, muconic acid, and the like; or (2) salts formed when an acidic proton present in the parent compound is replaced by a metal ion, e.g., an alkali metal ion, an alkaline earth ion, or an aluminum ion; or coordinates with an organic base such as ethanolamine, diethanolamine, triethanolamine, N-methylglucamine and the like.</p><p id="p-0131" num="0128">The compounds as defined by formula (I) (which encompass the compounds of formula (Ia) and (Ib)) are &#x201c;TRPM8 agonist&#x201d;, which means that they have an agonistic effect on the cellular Ca<sup>2+</sup> ion permeability of the TRPM8 channels. Accordingly, by &#x201c;TRPM8 agonist&#x201d; is meant any compound, which when brought into contact with the TRPM8 receptor, produces an increase in fluorescence over background, using the FLIPR method as described, e.g., by Klein et al., (Chem. Senses 36: 649-658, 2011), which is also described in more details in the experimental part.</p><p id="p-0132" num="0129">Accordingly there is provided in a second aspect a method of modulating (in-vitro and in-vivo modulation) of transient receptor potential melastatin member 8 (TRPM8) comprising bringing the receptor into contact with a compound of formula (I), or a salt or solvate thereof.</p><p id="p-0133" num="0130">In certain embodiments of the second aspect of the invention the modulating method is an in-vitro method.</p><p id="p-0134" num="0131">There is provided in a third aspect a non-medical method of inducing a cooling sensation in a human or animal comprising contacting the human or animal with a compound of formula (I) (which encompass the compounds of formula (Ia) and (Ib)), or a salt or solvate thereof. In this context it should be noted with regard to compounds of formula (Ib) that one stereoisomer may be more potent than the other stereoisomer.</p><p id="p-0135" num="0132">In certain embodiments, the method is a method of achieving a cooling effect on the skin or mucosa comprising contacting the skin or mucosa with a product comprising one or more compounds of formula (I) (which encompass the compounds of formula (Ia) and (Ib)), or a salt or solvate thereof.</p><p id="p-0136" num="0133">The compounds of formula (I) (which encompass the compounds of formula (Ia) and (Ib)), may be applied directly or as a solution or suspension, comprising an effective amount of a compound of formula (I). An amount to be effective depends, inter alia, upon the target TRPM8 area of the body but also on the cooling potency of compound or mixture of compounds.</p><p id="p-0137" num="0134">There is provided in a fourth aspect consumer products, in particular consumer products which get into contact with the human skin and/or mucosa comprising a compound as defined by formula (I), which encompass the compounds of formula (Ia) and (Ib)).</p><p id="p-0138" num="0135">Consumer products which get in contact with the mucosa include, but are not limited to food products, beverages, chewing gum, tobacco and tobacco replacement products, dental care products, personal care products, including lip care products, sexual health and intimate care products.</p><p id="p-0139" num="0136">In certain embodiments dental care products are oral care products, tooth care products, cleaners for dental prostheses, adhesives for dental prostheses, and the like.</p><p id="p-0140" num="0137">In certain embodiments food products are iced consumable products such as ice cream, sorbet; confectioneries such as candies and chocolates; food products containing mint or mint flavour, sauces, dairy products such as milk-based drinks and yoghurts; and snacks.</p><p id="p-0141" num="0138">In certain embodiments tobacco replacement products are liquids or solids which are suitable to be consumed by electrical means, e.g., liquids to vape.</p><p id="p-0142" num="0139">In certain embodiments personal care products getting in contact with the mucosa are lip balms, nose sprays and eye drops.</p><p id="p-0143" num="0140">Consumer products which get in contact with the human skin include, but are not limited to cosmetic products. In certain embodiments cosmetic products are skincare products, especially bath products, skin washing and cleansing products, skincare products, eye makeup, nail care products, foot care products, and the like. In certain embodiments cosmetic products are products with specific effects, especially sunscreens, insect repellent products, tanning products, de-pigmenting products, deodorants, antiperspirants, hair removers, and shaving products. In a certain embodiments cosmetic products are hair care products, especially hair shampoos, hair care products, hair setting products, hair-shaping products, and hair coloring products as well as scalp-care products such as scalp-cooling shampoos and creams.</p><p id="p-0144" num="0141">In certain embodiments, the consumer product is selected from air care products, such as an air freshener or a &#x201c;ready to use&#x201d; powdered air freshener which can be used in the home space (rooms, refrigerators, cupboards, shoes or car) and/or in a public space (halls, hotels, malls, etc. . . . ).</p><p id="p-0145" num="0142">The consumer products can be in any physical form, such as a solid, semi-solid, plaster, solution, suspension, lotion, cream, foam, gel, paste, or a combination thereof. The physical form of the consumer product suitable manly depends on the specific actions, such as cleaning, softening, caring, cooling, and the like, such a consumer product should fulfill.</p><p id="p-0146" num="0143">In a certain embodiment consumer products getting in contact with the human skin are fabric care products (such as fabric detergents, fabric conditioner (including tumble dryer sheets), and scent boosters (liquid or solid)) which in a first step are applied to a fabric, e.g., when washing the fabric, said treaded fabrics then getting in contact with the human skin.</p><p id="p-0147" num="0144">The level of use for compounds of the present invention (compounds as defined by formula (I), which encompass compounds of formula (Ia) and (Ib)) depend, inter alia, upon the target TRPM8 area of the body but also on the cooling potency of compound or mixture of compounds. For examples in an oral application of a compound of the present invention, such as dentifrice, floss, chewing gum, or white strip, the levels of use may be from about 0.00001% (0.01 ppm) to about 0.1% (1000 ppm); from about 0.00005% (0.5 ppm) to about 0.1% (1000 ppm); from about 0.0001% (1 ppm) to about 0.05% (500 ppm); or from about 0.001% (10 ppm) to about 0.01% (100 ppm) by weight of the composition. When a compound of the present invention is used in a mouthwash, the level of use may be from about 0.000001% (10 ppb) to about 0.01% (100 ppm) or from about 0.0001% (1 ppm) to about 0.001% (10 ppm) by weight of the composition. When a compound of the present invention is delivered topically, for example in shampoos and lotions the levels may be from about 0.001% (10 ppm) to about 0.5% (5000 ppm) by weight of the composition or from about 0.01% (100 ppm) to about 0.4% (4000 ppm) by weight of the composition.</p><p id="p-0148" num="0145">The cooling potency (strength) of a compound is defined by its EC<sub>50 </sub>value. EC<sub>50 </sub>(half maximal effective concentration) refers to the concentration of a compound which induces a response halfway between the baseline and maximum after a specified exposure time. It is commonly used as a measure of potency. EC<sub>50 </sub>is a measure of concentration, expressed in &#x3bc;M (&#x3bc;molar) unites, where 1 &#x3bc;M is equivalent to 1 &#x3bc;mol/L.</p><p id="p-0149" num="0146">Compounds with an EC<sub>50 </sub>of 10 &#x3bc;M or less are perceived by the human as cooling. The lower the EC<sub>50 </sub>value the higher the cooling potency. For example, compounds having an EC<sub>50 </sub>value of about 0.1 &#x3bc;M are perceived as strong cooling compounds.</p><p id="p-0150" num="0147">Cooling properties of a compound however are not only defined by its strength (potency; EC50) but also its longevity, which refers to the period of time (in minutes) over which a cooling effect is perceived. The longevity can range from a few seconds after rinsing to several hours or even days. Another important property of cooling compounds is the onset speed, which refers to how fast the cooling effect is perceived after a compound gets in contact with with the mucosa or skin. Onset speeds can range from no perceivable delay, delivering the cooling sensation immediately upon contact, to a few seconds or even minutes after rinsing. The compounds of formula (I) (which encompass compounds of formula (Ia) and (Ib)) is a class of compounds which delivers the cooling sensation almost immediately upon contact.</p><p id="p-0151" num="0148">The above described &#x201c;onset speed&#x201d; is typically sought-after in particular for oral care products, since a cooling sensation is already noticed during the use of the respective product (e.g. during brushing with toothpaste or rinsing with mouthwash). This so called &#x201c;up-front&#x201d; coooling sensation enhances the consumer experience during the use of oral care products. It reinforces that the oral care product is actively delivering on its claimed benefits and is therefore associated with cleanliness and oral health. Moreover, compounds delivering this &#x201c;up-front&#x201d; cooling sensation combine well with compounds that deliver long-lasting cooling sensation, creating a sustained effect that starts during product use and lasts for several minutes or even hours after use. Depending on the desired effects to be achieved, a flavorist skilled in the art will know how to combine compounds with different cooling properties to create the desired temporal profile of the cooling effect.</p><p id="p-0152" num="0149">The compounds of formula (I) (which encompass the compounds of formula (Ia) and (Ib)) are very potent at relative low concentrations. Thus it is preferred to prepare a stock solution which is further diluted, before admixing it to a consumer product. Beside water, particular suitable solvents are triacetin and propylene glycol. One may also mention acetone, benzyl alcohol dihydrolevoglucosenone, methyl-tetrahydrofuran, pentylene glycol, ethylene glycol, ethyl lactate, methyl lactate, propyl lactate, dimethylsulfoxide, ethanol, ethyl acetate, ethylene glycol, diethylene glycol, propylene glycol, and triacetin which are suitable solvents for the compounds of formula (I) (which encompass the compounds of formula (Ia) and (Ib)). But other solvent systems comprising surfactants may also be used.</p><p id="p-0153" num="0150">To modify the cooling effect of a compound as defined herein by formula (I) (which encompass the compounds of formula (Ia) and (Ib)), the compound, a salt or solvate thereof may be combined with a compound selected from calcium ions and salts, magnesium ions and salts, arginine, or any chelating agent which is able to bind calcium or magnesium.</p><p id="p-0154" num="0151">These compounds are known to be able to modulate the concentration of such ions in the extracellular space and therefore influence the response of the TRPM8 ion-channel, leading to a change in the perceived cooling effect.</p><p id="p-0155" num="0152">According to Kizilbash et al. (WO2019/121193 A1) both, the cooling intensity and the flavour intensity may be enhanced when combined with agents which possess the property to potentiating said effects. Thus the compounds as defined herein by formula (I) may be combined in one particular embodiment with potentiating agents disclosed in WO2019/121193 which is incorporated by reference, in particular with regard to the potentiating agents. As a further enhancement agent one may cite N-lactoyl ethanolamine (2-hydroxy-N-(2-hydroxyethyl)propanamide; CAS 5422-34-4) which is known as an enhancer for cooling agents, for example, from PCT International publication WO 2008/107137 which is incorporated by reference, in particular with regard to the cooling enhancing substances as defined by formula (I).</p><p id="p-0156" num="0153">For the reasons given above a combination of cooling compounds possessing different cooling profiles might be desired, depending on the effects to be desired by the consumer.</p><p id="p-0157" num="0154">Thus there is provided in a fifth aspect a composition comprising a cool sensation wherein the composition comprises at least one compound of formula (I), a salt or solvate thereof, and a further cooling compound.</p><p id="p-0158" num="0155">In one particular embodiment the compounds of formula (I) (which encompass the compounds of formula (Ia) and (Ib)) may be combined with menthol (e.g., in form of peppermint oil, and/or spearmint oil), menthone, p-menthanecarboxamides, N-2,3-trimethyl-2-isopropyl-butanamide (WS-23), menthyl lactate (Frescolat&#xae; ML), menthone glycerol acetal (Frescolat&#xae; MGA), 3-(1-menthoxy)-propane-1,2-diol (TK-10), p-menthane-3,8-diol (known as Coolact 38D), isopulegol (known as Coolact P), monomenthyl succinate (Physcool&#xae;), monomenthyl glutarate, o-menthylglycerol, menthyl N,N-dimethylsuccinamate, 2-(sec-butyl)cyclohexan-1-one (Freskomenthe), N-(pyrazol-3-yl)-N-(thiophen-2-ylmethyl)-2-(p-tolyloxy)acetamide, 2-(4-ethylphenoxy)-N-(pyrazol-3-yl)-N-(thiophen-2-ylmethyl)acetamide, 3-(benzo[d][1,3]dioxol-5-yl)-N,N-diphenylacrylamide, 4-(2-(4-allyl-2,6-dimethoxyphenoxy)-1-ethoxypropyl)-2-methoxyphenol, 4-(2-(4-allyl-2,6-dimethoxyphenoxy)-1-((2-isopropyl-5-methylcyclohexyl)oxy)propyl)-2-methoxyphenol (including 4-(2-(4-allyl-2,6-dimethoxyphenoxy)-1-(((1S,2R,5S)-2-isopropyl-5-methylcyclohexyl)oxy)propyl)-2-methoxyphenol) and 4-(2-(4-allyl-2,6-dimethoxyphenoxy)-1-(((1R,2S,5R)-2-isopropyl-5-methylcyclohexyl)oxy)propyl)-2-methoxyphenol), N-(2-Hydroxy-2-phenylethyl)-2-isopropyl-5,5-dimethylcyclohexane-1-carboxamide, N-(4-(Cyanomethyl)phenyl)-2-isopropyl-5,5-dimethylcyclohexanecarboxamide and N-(3-Hydroxy-4-methoxyphenyl)-2-isopropyl-5,5-dimethylcyclohexanecarboxamide. Further cooling compounds with which the compounds of formula (I) may be combined are those descrbed in the international patent application PCT/EP2020/079009 of the applicant.</p><p id="p-0159" num="0156">Examples of p-methanecarboxamides include compounds such as N-ethyl-p-menthan-3-carboxamide (known commercially as WS-3), N-ethoxycarbonylmethyl-p-menthan-3-carboxamide (WS-5), N-(4-methoxyphenyl)-p-menthan-3-carboxamide (WS-12) and N-tert-butyl-p-menthan-3-carboxamide (WS-14), N-(4-(cyanomethyl)phenyl)-2-isopropyl-5-methylcyclohexane-1-carboxamide (known commercially as Evercool 180), 2-isopropyl-5-methyl-N-(2-(pyridin-2-yl)ethyl)cyclohexane-1-carboxamide (known commercially as Evercool 190), and (1R,2S,5R)&#x2014;N&#x2014;((S)-2-((R)-2-aminopropanamido)-2-phenylethyl)-2-isopropyl-5-methylcyclohexane-1-carboxamide.</p><p id="p-0160" num="0157">In order to achieve more than just a cooling effect, the compounds of formula (I) (which encompass the compounds of formula (Ia) and (Ib)), a salt or solvate thereof, may be combined with other actives, such as, flavours, fragrances, and sweetening agents.</p><p id="p-0161" num="0158">Examples of flavour ingredients include natural flavors, artificial flavors, spices, seasonings, and the like. Exemplary flavor ingredients include synthetic flavor oils and flavoring aromatics and/or oils, oleoresins, essences, and distillates, and a combination comprising at least one of the foregoing.</p><p id="p-0162" num="0159">Flavor oils include spearmint oil, cinnamon oil, oil of wintergreen (methyl salicylate), peppermint oil, Japanese mint oil, clove oil, bay oil, anise oil, eucalyptus oil, thyme oil, cedar leaf oil, oil of nutmeg, allspice, oil of sage, mace, oil of bitter almonds, and cassia oil; useful flavoring agents include artificial, natural and synthetic fruit flavors such as vanilla, and citrus oils including lemon, orange, lime, grapefruit, yuzu, sudachi, and fruit essences including apple, pear, peach, grape, raspberry, blackberry, gooseberry, blueberry, strawberry, cherry, plum, prune, raisin, cola, guarana, neroli, pineapple, apricot, banana, melon, apricot, cherry, tropical fruit, mango, mangosteen, pomegranate, papaya, and so forth.</p><p id="p-0163" num="0160">Additional exemplary flavors imparted by a flavoring composition include a milk flavor, a butter flavor, a cheese flavor, a cream flavor, and a yogurt flavor; a vanilla flavor; tea or coffee flavors, such as a green tea flavor, an oolong tea flavor, a tea flavor, a cocoa flavor, a chocolate flavor, and a coffee flavor; mint flavors, such as a peppermint flavor, a spearmint flavor, and a Japanese mint flavor; spicy flavors, such as an asafetida flavor, an ajowan flavor, an anise flavor, an angelica flavor, a fennel flavor, an allspice flavor, a cinnamon flavor, a chamomile flavor, a mustard flavor, a cardamom flavor, a caraway flavor, a cumin flavor, a clove flavor, a pepper flavor, a coriander flavor, a sassafras flavor, a savory flavor, a Zanthoxyli Fructus flavor, a perilla flavor, a juniper berry flavor, a ginger flavor, a star anise flavor, a horseradish flavor, a thyme flavor, a tarragon flavor, a dill flavor, a capsicum flavor, a nutmeg flavor, a basil flavor, a marjoram flavor, a rosemary flavor, a bayleaf flavor, and a wasabi (Japanese horseradish) flavor; a nut flavor such as an almond flavor, a hazelnut flavor, a macadamia nut flavor, a peanut flavor, a pecan flavor, a pistachio flavor, and a walnut flavor, alcoholic flavors, such as a wine flavor, a whisky flavor, a brandy flavor, a rum flavor, a gin flavor, and a liqueur flavor; floral flavors; and vegetable flavors, such as an onion flavor, a garlic flavor, a cabbage flavor, a carrot flavor, a celery flavor, mushroom flavor, and a tomato flavor.</p><p id="p-0164" num="0161">Generally any flavoring or food additive (including food colors) such as those described in &#x201c;Essential guide to food additives&#x201d;, Third edition 2008, page 101-321 (ISBN: 978-1-905224-50-0) by Leatherhead Food International Ltd., can be used. The publication is incorporated herein by reference.</p><p id="p-0165" num="0162">In one particular embodiment the compounds of formula (I) (which encompass the compounds of formula (Ia) and (Ib)) may be combined with anethole, menthol laevo, carvone laevo, ethyl maltol, vanillin, eucalyptol, eugenol, menthol racemic, cis-3-hexenol, linalol, mint oil (e.g. peppermint arvensis oil, peppermint piperita oil, spearmint native oil, spearmint scotch oil), corylone, ethyl butyrate, cis-3-hexenyl acetate, citral, eucalyptus oil, ethyl-vanillin, methyl salicylate, 2&#x2032;-hydroxypropiophenone, ethyl acetate, methyl dihydro jasmonate, geraniol, lemon oil, iso amyl acetate, thymol, ionone beta, linalyl acetate, decanal, cis jasmone, ethyl hexanoate, melonal (2,6-dimethylhept-5-enal), citronellol, ethyl aceto acetate, nutmeg oil and clove oil, or mixtures thereof.</p><p id="p-0166" num="0163">Examples of sweetening agents include, but are not limited to, sucrose, fructose, glucose, high fructose corn syrup, corn syrup, xylose, arabinose, rhamnose, erythritol, xylitol, mannitol, sorbitol, inositol, acesulfame potassium, aspartame, neotame, sucralose, and saccharine, and mixtures thereof; trilobatin, hesperetin dihydrochalcone glucoside, naringin dihydrochalcone, mogroside V, Luo Han Guo extract, rubusoside, rubus extract, glycyphyllin, isomogroside V, mogroside IV, siamenoside I, neomogroside, mukurozioside IIb, (+)-hernandulcin, 4&#x3b2;-hydroxyhernandulcin, baiyunoside, phlomisoside I, bryodulcoside, bryoside bryonoside, abrusosides A-E, cyclocarioside A, cyclocaryoside I, albiziasaponins A-E, glycyrrhizin, araboglycyrrhizin, periandrins I-V, pterocaryosides A and B, osladin, polypodosides A and B, telosmoside A8-18, phyllodulcin, huangqioside E neoastilbin, monatin, 3-acetoxy-5,7-dihydroxy-4&#x2032;-methoxyflavanone, 2R,3R-(+)-3-Acetoxy-5,7,4&#x2032;-trihydroxyflavanone, (2R,3R)-dihydroquercetin 3-O-acetate, dihydroquercetin 3-O-acetate 4&#x2032;-methyl ether, brazzein, curculin, mabinlin, monellin, neoculin, pentadin, thaumatin, and combinations thereof. Some of the compounds listed above are known sweetness enhancers as well as sweeteners. When used as sweetness enhancers they are normally used below their sweetness detection thresholds.</p><p id="p-0167" num="0164">In certain embodiments, the compounds of formula (I) (which encompass the compounds of formula (Ia) and (Ib)) may be combined with additional ingredients collectively refereed to orally acceptable carrier materials.</p><p id="p-0168" num="0165">In some aspects, the orally acceptable carrier may comprise one or more compatible solid or liquid excipients or diluents which are suitable for topical oral administration. By &#x201c;compatible,&#x201d; as used herein, is meant that the components of the composition are capable of being commingled without interaction in a manner which would substantially reduce stability and/or efficacy. The carriers can include the usual and conventional components of dentifrices, non-abrasive gels, subgingival gels, mouthwashes or rinses, mouth sprays, chewing gums, lozenges and breath mints. The choice of a carrier to be used is basically determined by the way the composition is to be introduced into the oral cavity. Carrier materials for toothpaste, tooth gel or the like include abrasive materials, sudsing agents, binders, humectants, flavoring and sweetening agents, etc. as disclosed in e.g., U.S. Pat. No. 3,988,433, to Benedict. Carrier materials for biphasic dentifrice formulations are disclosed in U.S. Pat. Nos. 5,213,790; 5,145,666 and 5,281,410 all to Lukacovic et al., and in U.S. Pat. Nos. 4,849,213 and 4,528,180 to Schaeffer. Mouthwash, rinse or mouth spray carrier materials typically include water, flavoring and sweetening agents, etc., as disclosed in, e.g., U.S. Pat. No. 3,988,433 to Benedict. Lozenge carrier materials typically include a candy base; chewing gum carrier materials include a gum base, flavoring and sweetening agents, as in, e.g., U.S. Pat. No. 4,083,955, to Grabenstetter et al., Sachet carrier materials typically include a sachet bag, flavoring and sweetening agents. For subgingival gels used for delivery of actives into the periodontal pockets or around the periodontal pockets, a &#x201c;subgingival gel carrier&#x201d; is chosen as disclosed in, e.g. U.S. Pat. Nos. 5,198,220 and 5,242,910 both to Damani. Carriers suitable for the preparation of compositions of the present disclosure are well known in the art. Their selection will depend on secondary considerations like taste, cost, and shelf stability, and the like.</p><p id="p-0169" num="0166">Further suitable types of orally acceptable carrier materials or excipients are listed in WO2010/059289, in particular on page 17-31, which is incorporated by reference.</p><p id="p-0170" num="0167">Scientific literature points out that the activation of TRPM8 channels may be useful for the treatment of most TRPM8-mediated pathologies (<i>J. Med. Chem. </i>2016, 59 (22), 10006-10029). Thus one may assume that the compounds of formula (I) might also be suitable for treating prostate carcinomas, bladder weakness, inflammation, or pain comprising contacting a patient with one or more compounds of formula (I) as defined herein. One may also assume that the compounds of formula (I) as defined herein are suitable for alleviating the symptoms of coughs and colds, irritations, sore throat or hoarseness, as well as the treatment of laryngopharyngeal dysphagia (<i>Int. J. Mol. Sci. </i>2018, 19, 4113).</p><p id="p-0171" num="0168">Thus there is provided in a sixth aspect pharmaceutical composition comprising one or more compounds as defined by formula (I) (which encompass compounds of formula (Ia) and (Ib)), or a salt or solvate thereof.</p><p id="p-0172" num="0169">Depending upon the particular treatment regimen contemplated, pharmaceutical compositions comprising one or more compounds of formula (I) may be administered parenterally, topically, orally, or locally. The pharmaceutical compositions may be a liquid, suspensions or a solid formulation.</p><p id="p-0173" num="0170">In certain embodiments, the pharmaceutical composition is nasal spray, topical cream, skin sprays, throat spray, or eye drops.</p><p id="p-0174" num="0171">The compounds of formula (I) are either compounds known per se or may be prepared by a person skilled in the art using known synthesis methods. For compounds of formula (I) wherin n is 0, may be prepared from aldehydes 2 by reacting them with a respective hydroxylamine R<sup>6</sup>NHOH or its salt form (e.g. hydrochloride), optionally in the presence of a base such as an inorganic base (e.g. potassium carbonate or sodium hydroxide) or an organic base. The reaction is usually performed under inert atmosphere such as argon or dinitrogen, in a suitable solvent such as toluene or xylene, typically at elevated temperatures such as 120&#xb0; C. or 140&#xb0; C. and often under removal of water by a Dean-Stark apparatus. The thus obtained compounds of formula (I) wherein n is 0, can be further converted into compounds of formula (I) wherein n is 1, e.g., by reducing the nitrogen-oxygen bond with typical reducing agents such as hydrogen under action of a palladium catalyst (e.g. palladium on charcoal) or zinc powder using an appropriate solvent such as ethyl acetate or tetrahydrofuran or toluene at suitable temperatures such as room temperature or elevated temperature (e.g. 50&#xb0; C.), and then condensing the resulting product with an appropriate reaction partner such as an aldehyde R&#x2032;CHO or carbonyl diimidazole to give the desired substitution in formula (I).</p><p id="p-0175" num="0000"><chemistry id="CHEM-US-00005" num="00005"><img id="EMI-C00005" he="72.47mm" wi="75.78mm" file="US20230002334A1-20230105-C00005.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0176" num="0172">X, R<sup>1</sup>, R<sup>2</sup>, R<sup>4</sup>-R<sup>9 </sup>and R&#x2032; having the same meaning as provided for formula (I).</p><p id="p-0177" num="0173">In general aldehydes 2 may be prepared by standard synthetic methods known to those skilled in the art. For example, aldehydes 2 wherein X is is CHR<sup>3 </sup>and the dotted line represents a single bond, may be prepared by controlled reduction of the &#x3b1;,&#x3b2;-unsaturated aldehydes 3 by reacting them with hydrogen gas in the presence of a catalyst such as Lindlar catalyst (palladium on calcium carbonate, poisoned by lead) in an appropriate solvent such as ethyl acetate at an appropriate temperature such as room temperature. Other methods for controlled reduction are known to those skilled in the art and conditions may vary depending on the substrate.</p><p id="p-0178" num="0174">In turn, aldehydes 3 may be prepared by condensation of aldehyde 4 and allylic alcohol by reacting them together (as depicted below), optionally in the presence of an acid catalyst such as a protic acid (e.g. triethylamine-hydrochloride or p-toluenesulfonic acid) or a Lewis acid. This is done in a suitable solvent such as xylenes or toluene or no solvent and at elevated temperatures (e.g. 80&#xb0; C., 120&#xb0; C. or 140&#xb0; C.), typically under removal of water by Dean-Stark apparatus.</p><p id="p-0179" num="0000"><chemistry id="CHEM-US-00006" num="00006"><img id="EMI-C00006" he="65.70mm" wi="75.78mm" file="US20230002334A1-20230105-C00006.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0180" num="0175">R<sup>1</sup>-R<sup>4</sup>, and R<sup>7</sup>-R<sup>9 </sup>having the same meaning as provided for formula (I).</p><p id="p-0181" num="0176">For compounds of formula (I) wherein R<sup>1 </sup>is selected from phenyl (optionally substituted as defined above), naphthyl (optionally substituted as defined above) and C<sub>5</sub>-C<sub>10 </sub>mono- or bicyclic aryl wherein 1 or 2 C-atoms are replaced by a hetero atom independently selected from sulfur, nitrogen, and oxygen, aldehyde 3 may be prepared from aldehyde 6 (which in turn can be prepared as described above). The conversion of aldehyde 6 to aldehyde 3 can be done by reacting aldehyde 6 with the respective aryl bromide R<sup>1</sup>Br (wherein R<sup>1 </sup>has the same meaning as provided for formula (I) above) in the presence of a palladium catalyst such as palladium acetate and a phosphine ligand such as tricyclohexylphosphine or tri-tert-butylphosphine. The reaction is typically carried out under inert atmosphere such as dinitrogen or argon, in the presence of a base such as an inorganic base (e.g. cesium carbonate or potassium carbonate or sodium phosphate), in a suitable solvent such as N,N-dimethylformamide, dimethylsulfoxide or N,N-dimethylacetamide and at elevated temperatures (e.g. 100&#xb0; C. or 120&#xb0; C.).</p><p id="p-0182" num="0000"><chemistry id="CHEM-US-00007" num="00007"><img id="EMI-C00007" he="28.96mm" wi="70.19mm" file="US20230002334A1-20230105-C00007.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0183" num="0177">R<sup>2</sup>-R<sup>4</sup>, and R<sup>7</sup>-R<sup>9 </sup>have the same meaning as provided for formula (I).</p><p id="p-0184" num="0178">The invention is now further described with reference to the following non-limiting examples. These examples are for the purpose of illustration only and it is understood that variations and modifications can be made by one skilled in the art.</p><heading id="h-0005" level="1">EXAMPLES</heading><heading id="h-0006" level="1">Example 1: (E)-2,4,7-trimethylocta-2,6-dienal (General Procedure)</heading><p id="p-0185" num="0179">A mixture of (E)-2-methylpent-2-enal (12.27 g, 125 mmol), 3-methylbut-2-en-1-ol (21.53 g, 250 mmol) and 1.5 g Et<sub>3</sub>N&#x2014;HCl in xylene was refluxed for 20 hours. During this period, water was collected and removed by using a Dean-Stark apparatus, and the reaction was monitored by GC. After cooling to room temperature, the reaction mixture was diluted with MTBE (methyl ether tert-butyl ether), and washed with water and brine, dried with MgSO<sub>4</sub>, filtered, then evaporated under reduced pressure to give crude product, which was purified by distillation to afford (E)-2,4,7-trimethylocta-2,6-dienal (14.20 g, yield: 68%).</p><heading id="h-0007" level="1">Example 2: (E)-4-methyl-3-(2,4,7-trimethyl-1-oxoocta-2,6-dien-4-yl)benzonitrile (General Procedure)</heading><p id="p-0186" num="0180">A mixture of 3-bromo-4-methylbenzonitrile (25.80 g, 132.00 mmol), (E)-2,4,7-trimethylocta-2,6-dienal (23.51 g, 132.00 mmol), diacetoxypalladium (1.48 g, 6.58 mmol), tri-tert-butylphosphane (2.66 g, 13.15 mmol), Cs<sub>2</sub>CO<sub>3 </sub>(42.80 g, 132.00 mmol) in DMF (N,N-dimethylformamide; 120 mL) was heated to 110-120&#xb0; C. under Ar atmosphere overnight, and the reaction was monitored by TLC, GC and GC-MS. After cooling to room temperature, the reaction mixture was diluted with MTBE, and filtered through a small pad of silica gel and the silica gel was washed with MTBE. The combined filtrates were concentrated in vacuo to give crude product, which was purified by distillation or flash chromatography (hexane/MTBE=50: 1-10:1) to afford aldehyde (E)-4-methyl-3-(2,4,7-trimethyl-1-oxoocta-2,6-dien-4-yl)benzonitrile (15.27 g, 52.60 mmol, 40% yield) as light yellow oil.</p><p id="p-0187" num="0181">GC/MS (EI): m/z (%): 281 (1) [M<sup>+</sup>], 213 (100), 198 (44), 184 (24), 170 (17), 154 (13), 140 (11), 127 (8), 115 (8), 69 (83). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 9.43 (s, 1H), 7.64 (s, 1H), 7.48-7.36 (m, 1H), 7.22 (d, J=7.9 Hz, 1H), 6.80 (s, 1H), 4.89 (t, J=7.4 Hz, 1H), 2.60 (d, J=10.8 Hz, 2H), 2.30 (s, 3H), 1.67 (s, 3H), 1.54 (d, J=7.2 Hz, 6H), 1.16 (s, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 195.6 (t), 160.8 (t), 145.5 (q), 142.0 (q), 138.5 (q), 136.1 (q), 132.9 (t), 130.4 (t), 130.2 (t), 119.4 (q), 118.5 (t), 110.0 (q), 44.8 (q), 39.8 (d), 26.1 (s), 24.8 (s), 23.3 (s), 18.1 (s), 9.8 (s).</p><heading id="h-0008" level="1">Example 3: (E)-2,4,7-trimethyl-4-(o-tolyl)octa-2,6-dienal</heading><p id="p-0188" num="0182">Following the general procedure described in Example 2: 1-bromo-2-methylbenzene (37.60 g, 220.00 mmol), (E)-2,4,7-trimethylocta-2,6-dienal (18.26 g, 110.00 mmol), diacetoxypalladium (1.23 g, 5.49 mmol), tricyclohexylphosphane (3.08 g, 10.98 mmol), Cs<sub>2</sub>CO<sub>3 </sub>(42.90 g, 132.00 mmol) in DMF (150 mL) were reacted to give the title product (22.56 g, 80% yield) as a light yellow oil.</p><p id="p-0189" num="0183">GC/MS (EI): m/z (%): 256 (1) [M<sup>+</sup>], 188 (93), 173 (100), 159(68), 128 (34), 115 (24), 105 (14), 91 (17), 77 (8), 69 (33). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 9.45 (s, 1H), 7.38 (d, J=9.6, 8.0 Hz, 1H), 7.26-7.05 (m, 3H), 6.88 (s, 1H), 5.01 (t, 1H), 2.67-2.50 (m, 2H), 2.23 (s, 3H), 1.83-1.71 (m, 1H), 1.70-1.51 (m, 9H), 1.20 (s, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 196.1 (t), 162.8 (t), 143.9 (q), 138.1 (q), 135.8 (q), 134.9 (q), 132.0 (t), 126.6 (t), 126.3 (t), 126.0 (t), 119.5 (t), 44.8 (q), 40.0 (d), 26.1 (s), 24.9 (s), 22.9 (s), 18.0 (s), 9.5 (s).</p><heading id="h-0009" level="1">Example 4: (E)-4-(4-fluoro-2-methylphenyl)-2,4,7-trimethylocta-2,6-dienal</heading><p id="p-0190" num="0184">Following the general procedure described in Example 2: 1-bromo-4-fluoro-2-methylbenzene (6.82 g, 36.10 mmol), (E)-2,4,7-trimethylocta-2,6-dienal (3.00 g, 18.04 mmol), diacetoxypalladium (0.20 g, 0.90 mmol), tricyclohexylphosphane (0.51 g, 1.80 mmol), Cs<sub>2</sub>CO<sub>3 </sub>(7.05 g, 21.65 mmol) in DMF (20 mL) were reacted to give the title product (0.90 g, 18% yield) as a yellow oil.</p><p id="p-0191" num="0185">GC/MS (EI): m/z (%): 274 (1) [M<sup>+</sup>], 206 (100), 191 (61), 177(72), 146 (31), 133 (19), 123 (20), 109 (14), 77 (4), 69 (53). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 9.41 (s, 1H), 7.34-7.27 (m, 1H), 6.86-6.80 (m, 2H), 4.95 (t, J=7.4 Hz, 1H), 2.64-2.48 (m, 2H), 2.20 (s, 3H), 1.96 (d, 1H), 1.67 (s, 3H), 1.57 (s, 3H), 1.50 (s, 3H), 1.20 (s, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 196.0 (t), 163.0 (q), 162.5 (t), 159.7 (q), 139.7 (q), 139.7 (q), 138.3 (q), 138.3 (q), 135.3 (q), 128.0 (t), 127.9 (t), 119.3 (t), 118.6 (t), 118.3 (t), 112.6 (t), 112.3 (t), 44.4 (q), 40.2 (d), 26.1 (s), 25.2 (s), 22.9 (s), 18.1 (s), 9.6 (s).</p><heading id="h-0010" level="1">Example 5: (E)-4-(5-chloro-2-methylphenyl)-2,4,7-trimethylocta-2,6-dienal</heading><p id="p-0192" num="0186">Following the general procedure described in Example 2: 2-bromo-4-chloro-1-methylbenzene (5.30 g, 25.80 mmol), (E)-2,4,7-trimethylocta-2,6-dienal (2.15 g, 12.90 mmol), diacetoxypalladium (0.15 g, 0.65 mmol), tri-tert-butylphosphane (0.26 g, 1.29 mmol), Cs<sub>2</sub>CO<sub>3 </sub>(5.04 g, 15.48 mmol) in DMF (20 mL) were reacted to give the title product (1.39 g, 37% yield) as a light yellow oil.</p><p id="p-0193" num="0187">GC/MS (EI): m/z (%): 290 (1) [M<sup>+</sup>], 222 (100), 207 (54), 193 (24), 186 (18), 172 (12), 157 (14), 128 (23), 115 (22), 69 (92). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 9.42-9.37 (m, 1H), 7.32 (d, J=2.0 Hz, 1H), 7.14-7.09 (m, 1H), 7.05-7.00 (m, 1H), 6.79 (s, 1H), 4.97 (t, J=7.4 Hz, 1H), 2.69-2.44 (m, 2H), 2.17 (s, 3H), 1.67 (s, 3H), 1.57 (s, 3H), 1.49 (s, 3H), 1.20 (s, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 195.8 (t), 161.5 (t), 145.9 (q), 138.3 (q), 134.3 (q), 133.2 (q), 131.7 (q), 131.4 (q), 126.6 (t), 126.5 (t), 121.5 (t), 119.0 (t), 44.8 (q), 39.8 (d), 26.1 (s), 24.8 (s), 22.3 (s), 18.1 (s), 9.7 (s).</p><heading id="h-0011" level="1">Example 6: (E)-3-(2,4,7-trimethyl-1-oxoocta-2,6-dien-4-yl)benzonitrile</heading><p id="p-0194" num="0188">Following the general procedure described in Example 2: 3-bromobenzonitrile (6.57 g, 36.10 mmol), (E)-2,4,7-trimethylocta-2,6-dienal (3.00 g, 18.04 mmol), diacetoxypalladium (0.20 g, 0.90 mmol), tri-tert-butylphosphane (0.37 g, 1.80 mmol), Cs<sub>2</sub>CO<sub>3 </sub>(5.88 g, 18.04 mmol) in DMF (20 mL) were reacted to give the title product (1.11 g, 23% yield) as a light yellow oil.</p><p id="p-0195" num="0189">GC/MS (EI): m/z (%): 267 (1) [M<sup>+</sup>], 199(87), 184 (39), 170 (13), 154 (14), 140 (9), 127 (11), 116 (10), 103 (4), 69 (100). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 9.42 (s, 1H), 7.56-7.36 (m, 4H), 6.75 (s, 1H), 5.04-4.82 (m, 1H), 2.49 (d, J=7.4 Hz, 2H), 1.65 (s, 3H), 1.53 (s, 3H), 1.46 (s, 3H), 1.25 (s, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 195.7 (t), 160.7 (t), 148.0 (q), 140.3 (q), 136.2 (q), 131.5 (t), 130.3 (t), 130.0 (t), 129.2 (t), 119.0 (q), 118.3 (t), 112.4 (q), 44.9 (q), 42.8 (d), 26.0 (s), 24.5 (s), 17.9 (s), 10.7 (s).</p><heading id="h-0012" level="1">Example 7: (E)-4-(2,5-dimethylphenyl)-2,4,7-trimethylocta-2,6-dienal</heading><p id="p-0196" num="0190">Following the general procedure described in Example 2: 2-bromo-1,4-dimethylbenzene (6.68 g, 36.10 mmol), (E)-2,4,7-trimethylocta-2,6-dienal (3.00 g, 18.04 mmol), diacetoxypalladium (0.20 g, 0.90 mmol), tri-tert-butylphosphane (0.37 g, 1.80 mmol), Cs<sub>2</sub>CO<sub>3 </sub>(7.05 g, 21.65 mmol) in DMF (20 mL) were reacted to give the title product (2.44 g, 50% yield) as a light yellow oil.</p><p id="p-0197" num="0191">GC/MS (EI): m/z (%): 270 (1) [M<sup>+</sup>], 202 (93), 187 (73), 173 (100), 159 (28), 143 (29), 128 (24), 115 (17), 91 (13), 69 (26). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 9.41 (s, 1H), 7.17 (s, 1H), 7.06-6.93 (m, 2H), 6.85 (s, 1H), 5.04 (t, J=7.4 Hz, 1H), 2.69-2.45 (m, 2H), 2.33 (s, 3H), 2.15 (s, 3H), 1.72 (s, 3H), 1.60 (s, 3H), 1.52 (s, 3H), 1.21 (s, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 196.2 (t), 163.0 (t), 143.9 (q), 138.1 (q), 135.2 (q), 134.9 (q), 132.6 (q), 132.0 (t), 127.3 (t), 127.0 (t), 119.7 (t), 44.7 (q), 40.1 (d), 26.1 (s), 25.0 (s), 22.5 (s), 21.4 (s), 18.1 (s), 9.6 (s).</p><heading id="h-0013" level="1">Example 8: (E)-4-(5-fluoro-2-methylphenyl)-2,4,7-trimethylocta-2,6-dienal</heading><p id="p-0198" num="0192">Following the general procedure described in Example 2: 2-bromo-4-fluoro-1-methylbenzene (6.34 g, 33.60 mmol), (E)-2,4,7-trimethylocta-2,6-dienal (3.00 g, 16.78 mmol), diacetoxypalladium (0.19 g, 0.84 mmol), tri-tert-butylphosphane (0.34 g, 1.68 mmol), Cs<sub>2</sub>CO<sub>3 </sub>(5.47 g, 16.78 mmol) in DMF (20 mL) were reacted to give the title product (1.00 g, 22% yield) as a light yellow oil.</p><p id="p-0199" num="0193">GC/MS (EI): m/z (%): 274 (1) [M<sup>+</sup>], 206 (100), 191 (69), 177(29), 159(12), 146 (25), 133 (15), 123 (12), 109 (10), 69 (69). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 9.43 (s, 1H), 7.16-6.98 (m, 2H), 6.92-6.74 (m, 2H), 5.13-4.86 (m, 1H), 2.70-2.48 (m, 2H), 2.18 (s, 3H), 1.67 (s, 3H), 1.58 (s, 3H), 1.50 (s, 3H), 1.21 (s, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 195.9 (t), 163.0 (t), 161.8 (t), 159.8 (t), 146.2 (q), 146.1 (q), 138.4 (q), 135.5 (q), 133.3 (t), 133.2 (t), 131.4 (q), 131.4 (q), 119.1 (t), 113.8 (t), 113.5 (t), 113.3 (t), 113.0 (t), 44.8 (q), 39.8 (d), 26.1 (s), 24.9 (s), 22.1 (s), 18.1 (s), 9.6 (s).</p><heading id="h-0014" level="1">Example 9: (E)-4-(2-methoxyphenyl)-2,4,7-trimethylocta-2,6-dienal</heading><p id="p-0200" num="0194">Following the general procedure described in Example 2: 1-bromo-2-methoxybenzene (6.75 g, 36.1 mmol), (E)-2,4,7-trimethylocta-2,6-dienal (3.00 g, 18.04 mmol), diacetoxypalladium (0.20 g, 0.90 mmol), tricyclohexylphosphane (0.51 g, 1.80 mmol), Cs<sub>2</sub>CO<sub>3 </sub>(7.05 g, 21.65 mmol) in DMF (20 mL) were reacted to give the title product (2.50 g, 51% yield) as a light yellow oil.</p><p id="p-0201" num="0195">GC/MS (EI): m/z (%): 272 (2) [M<sup>+</sup>], 203 (100), 188 (50), 175 (40), 161(17), 145 (12), 128 (14), 115 (15), 91 (16), 69 (9). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 9.27 (s, 1H), 7.20-7.15 (m, 1H), 7.13-7.05 (m, 1H), 6.83 (t, J=7.5 Hz, 1H), 6.76 (d, J=0.7 Hz, 1H), 6.70 (d, J=8.1 Hz, 1H), 4.89 (t, J=7.4 Hz, 1H), 3.55 (s, 3H), 2.55 (d, J=7.6 Hz, 2H), 1.55 (s, 3H), 1.46 (s, 3H), 1.38 (s, 3H), 1.13 (s, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 196.3 (t), 165.1 (t), 157.1 (q), 136.2 (q), 134.4 (q), 127.9 (t), 126.8 (t), 120.6 (t), 120.1 (t), 111.5 (t), 55.1 (s), 43.0 (q), 39.1 (d), 26.0 (s), 23.4 (s), 17.9 (s), 9.3 (s).</p><heading id="h-0015" level="1">Example 10: (E)-2,4,7-trimethyl-4-(p-tolyl)octa-2,6-dienal</heading><p id="p-0202" num="0196">Following the general procedure described in Example 2: 1-bromo-4-methylbenzene (6.09 g, 35.6 mmol), (E)-2,4,7-trimethylocta-2,6-dienal (2.96 g, 17.82 mmol), diacetoxypalladium (0.20 g, 0.89 mmol), triphenylphosphine (0.47 g, 1.78 mmol), Cs<sub>2</sub>CO<sub>3 </sub>(5.81 g, 17.82 mmol) in DMF (20 mL) were reacted to give the title product (1.75 g, 38% yield) as a colorless oil.</p><p id="p-0203" num="0197">GC/MS (EI): m/z (%): 256 (1) [M<sup>+</sup>], 188 (70), 187 (70), 172 (80), 159 (100), 128 (30), 115 (18), 105 (14), 91 (13), 69 (10). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 9.40 (s, 1H), 7.17-7.07 (m, 4H), 6.79 (d, J=5.7 Hz, 1H), 5.02 (t, J=7.3 Hz, 1H), 2.64-2.43 (m, 2H), 2.31 (s, 3H), 1.68 (s, 3H), 1.56 (s, 3H), 1.51 (s, 3H), 1.33 (s, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 196.4 (t), 163.3 (t), 143.6 (q), 139.9 (q), 135.7 (q), 135.0 (q), 129.1 (t), 126.5 (t), 119.6 (t), 44.6 (q), 42.7 (d), 26.1 (s), 25.0 (s), 21.0 (s), 18.1 (s), 10.5 (s).</p><heading id="h-0016" level="1">Example 11: (E)-4-(2,4-dimethylphenyl)-2,4,7-trimethylocta-2,6-dienal</heading><p id="p-0204" num="0198">Following the general procedure described in Example 2: 1-bromo-2,4-dimethylbenzene (4.78 g, 25.80 mmol), (E)-2,4,7-trimethylocta-2,6-dienal (2.15 g, 12.90 mmol), diacetoxypalladium (0.15 g, 0.65 mmol), tricyclohexylphosphane (0.36 g, 1.29 mmol), Cs<sub>2</sub>CO<sub>3 </sub>(4.20 g, 12.90 mmol) in DMF (35 mL) were reacted to give the title product (2.40 g, 69% yield) as a light yellow oil.</p><p id="p-0205" num="0199">GC/MS (EI): m/z (%): 270 (2) [M<sup>+</sup>], 202 (53), 186 (71), 173 (29), 159 (21), 143 (23), 128 (19), 115 (14), 91 (10), 69 (12). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 9.42 (s, 1H), 7.23 (d, J=8.0 Hz, 1H), 6.97 (d, J=8.0 Hz, 1H), 6.91 (s, 1H), 6.83 (s, 1H), 5.01 (t, J=7.4 Hz, 1H), 2.57 (qd, J=14.5, 7.7 Hz, 2H), 2.26 (s, 3H), 2.18 (s, 3H), 1.67 (s, 3H), 1.58 (s, 3H), 1.49 (s, 3H), 1.18 (s, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 195.9 (t), 162.9 (t), 140.9 (q), 138.1 (q), 135.9 (q), 135.5 (q), 134.7 (q), 132.8 (t), 126.6 (t), 126.2 (t), 119.7 (t), 44.4 (q), 40.2 (d), 26.0 (s), 25.0 (s), 22.7 (s), 20.7 (s), 18.0 (s), 9.5 (s).</p><heading id="h-0017" level="1">Example 12: (E)-4-(3-chloro-2-methylphenyl)-2,4,7-trimethylocta-2,6-dienal</heading><p id="p-0206" num="0200">Following the general procedure described in Example 2: 1-bromo-3-chloro-2-methylbenzene (5.30 g, 25.8 mmol), (E)-2,4,7-trimethylocta-2,6-dienal (2.15 g, 12.90 mmol), diacetoxypalladium (0.145 g, 0.645 mmol), tri-tert-butylphosphane (0.26 g, 1.29 mmol), Cs<sub>2</sub>CO<sub>3 </sub>(5.04 g, 15.48 mmol) in DMF (20 mL) were reacted to give the title product (1.51 g, 40% yield) as a light yellow oil.</p><p id="p-0207" num="0201">GC/MS (EI): m/z (%): 290 (1) [M<sup>+</sup>], 222 (100), 207 (61), 195 (34), 186 (36), 157 (14), 141 (27), 128 (27), 115 (24), 69 (94). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 9.42 (s, 1H), 7.29 (d, J=7.9 Hz, 2H), 7.18-7.10 (m, 1H), 6.86 (s, 1H), 4.97 (t, J=8.0, 6.8 Hz, 1H), 2.65-2.50 (m, 2H), 2.23 (s, 3H), 1.67 (s, 3H), 1.57 (s, 3H), 1.51 (s, 3H), 1.17 (s, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 195.8 (t), 162.1 (t), 146.3 (q), 137.8 (q), 136.4 (q), 135.3 (q), 133.9 (q), 127.8 (t), 126.6 (t), 124.9 (t), 119.0 (t), 45.2 (q), 40.2 (d), 26.0 (s), 25.2 (s), 20.3 (s), 18.0 (s), 9.5 (s).</p><heading id="h-0018" level="1">Example 13: (E)-4-(2-fluorophenyl)-2,4,7-trimethylocta-2,6-dienal</heading><p id="p-0208" num="0202">Following the general procedure described in Example 2: 1-bromo-2-fluorobenzene (6.32 g, 36.10 mmol), (E)-2,4,7-trimethylocta-2,6-dienal (3.00 g, 18.04 mmol), diacetoxypalladium (0.20 g, 0.90 mmol), tri-tert-butylphosphane (0.37 g, 1.80 mmol), Cs<sub>2</sub>CO<sub>3 </sub>(7.05 g, 21.65 mmol) in DMF (20 mL) were reacted to give the title product (1.4 g, 30% yield) as a light yellow oil.</p><p id="p-0209" num="0203">GC/MS (EI): m/z (%): 260 (1) [M<sup>+</sup>], 192 (100), 177 (99), 163 (31), 146 (21), 133 (14), 123 (14), 109 (30), 77(5), 69 (59). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 9.39 (s, 1H), 7.37-7.30 (m, 1H), 7.28-7.19 (m, 1H), 7.17-7.09 (m, 1H), 7.08-6.92 (m, 2H), 6.83 (s, 1H), 5.03-4.94 (m, 1H), 2.63 (d, J=7.4 Hz, 2H), 1.67 (s, 3H), 1.57 (s, 3H), 1.53 (s, 3H), 1.28 (s, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 196.2 (t), 162.2 (t), 138.1 (q), 138.1 (q), 135.3 (q), 133.2 (q), 133.1 (q), 128.5 (t), 128.4 (t), 127.6 (t), 127.6 (t), 123.9 (t), 123.9 (t), 119.0 (t), 116.1 (t), 115.8 (t), 42.5 (d), 39.8 (d), 39.8 (d), 26.0 (s), 23.4 (s), 17.9 (s), 9.5 (s).</p><heading id="h-0019" level="1">Example 14: (E)-4-(2,4,7-trimethyl-1-oxoocta-2,6-dien-4-yl)benzonitrile</heading><p id="p-0210" num="0204">Following the general procedure described in Example 2: 4-bromobenzonitrile (6.57 g, 36.10 mmol), (E)-2,4,7-trimethylocta-2,6-dienal (3.00 g, 18.04 mmol), diacetoxypalladium (0.20 g, 0.90 mmol), tri-tert-butylphosphane (0.37 g, 1.804 mmol), Cs<sub>2</sub>CO<sub>3 </sub>(5.88 g, 18.04 mmol) in DMF (20 mL) were reacted to give the title product (1.00 g, 21% yield) as a light yellow oil.</p><p id="p-0211" num="0205">GC/MS (EI): m/z (%): 267 (1) [M<sup>+</sup>], 199 (86), 184 (38), 170 (11), 154 (13), 140 (9), 127 (11), 116 (10), 103 (4), 69 (100). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 9.39 (s, 1H), 7.58 (d, J=12.8 Hz, 2H), 7.32 (d, J=8.2 Hz, 2H), 6.72 (s, 1H), 4.90 (t, J=7.2 Hz, 1H), 2.46 (d, J=7.4 Hz, 2H), 1.61 (s, 3H), 1.50 (s, 3H), 1.44 (s, 3H), 1.22 (s, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 195.6 (t), 160.7 (t), 152.0 (q), 140.3 (q), 136.1 (q), 132.1 (t), 127.5 (t), 118.7 (q), 118.3 (t), 110.1 (q), 45.2 (q), 42.7 (d), 25.9 (s), 24.4 (s), 17.9 (s), 10.7 (s).</p><heading id="h-0020" level="1">Example 15: (E)-4-(2,5-dimethoxyphenyl)-2,4,7-trimethylocta-2,6-dienal</heading><p id="p-0212" num="0206">Following the general procedure described in Example 2: 2-bromo-1,4-dimethoxybenzene (7.83 g, 36.10 mmol), (E)-2,4,7-trimethylocta-2,6-dienal (3.00 g, 18.04 mmol), diacetoxypalladium (0.20 g, 0.90 mmol), tricyclohexylphosphane (0.51 g, 1.80 mmol), Cs<sub>2</sub>CO<sub>3 </sub>(7.05 g, 21.65 mmol) in DMF (20 mL) were reacted to give the title product (3.25 g, 60% yield) as a yellow oil.</p><p id="p-0213" num="0207">GC/MS (EI): m/z (%): 274 (1) [M<sup>+</sup>], 206 (100), 191 (69), 177 (29), 159 (12), 146 (25), 133 (15), 123 (12), 109 (10), 69 (69). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 9.37 (s, 1H), 6.89 (s, 1H), 6.83 (s, 1H), 6.77-6.69 (m, 2H), 5.01 (t, J=15.8, 8.4 Hz, 1H), 3.77 (s, 3H), 3.63 (s, 3H), 2.62 (d, J=7.5 Hz, 2H), 1.68 (s, 3H), 1.58 (s, 3H), 1.45 (s, 3H), 1.26 (s, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 196.6 (t), 165.1 (t), 153.6 (q), 151.6 (q), 136.4 (q), 136.2 (q), 134.7 (q), 120.0 (t), 114.6 (t), 112.4 (t), 110.8 (t), 55.8 (s), 55.7 (s), 43.1 (q), 39.2 (d), 26.1 (s), 23.4 (s), 18.0 (s), 9.5 (s).</p><heading id="h-0021" level="1">Example 16: (E)-2-(2,4,7-trimethyl-1-oxoocta-2,6-dien-4-yl)benzonitrile</heading><p id="p-0214" num="0208">Following the general procedure described in Example 2: 2-bromobenzonitrile (4.70 g, 25.80 mmol), (E)-2,4,7-trimethylocta-2,6-dienal (2.15 g, 12.90 mmol), diacetoxypalladium (0.15 g, 0.65 mmol), tri-tert-butylphosphane (0.26 g, 1.29 mmol), Cs<sub>2</sub>CO<sub>3 </sub>(5.04 g, 15.48 mmol) in DMF (20 mL) were reacted to give the title product (1.26 g, 37% yield) as a light yellow oil.</p><p id="p-0215" num="0209">GC/MS (EI): m/z (%): 267 (1) [M<sup>+</sup>], 199 (43), 170 (100), 156 (23), 143 (7), 128 (14), 116 (9), 103 (4), 89 (3), 69 (58). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 9.48 (s, 1H), 7.67-7.48 (m, 3H), 7.38-7.29 (m, 1H), 6.95 (d, J=1.2 Hz, 1H), 4.94 (t, J=7.5 Hz, 1H), 2.73 (d, J=11.2 Hz, 2H), 1.66 (s, 3H), 1.58 (d, J=3.9 Hz, 6H), 1.17 (d, J=1.1 Hz, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 196.0 (t), 160.7 (t), 150.7 (q), 139.0 (q), 136.3 (q), 135.2 (t), 132.7 (t), 127.1 (t), 127.0 (t), 119.4 (q), 118.3 (t), 111.7 (q), 44.7 (q), 40.8 (d), 26.1 (s), 23.8 (s), 18.1 (s), 9.9 (s).</p><heading id="h-0022" level="1">Example 17: (E)-4-methyl-2-(2,4,7-trimethyl-1-oxoocta-2,6-dien-4-yl)benzonitrile</heading><p id="p-0216" num="0210">Following the general procedure described in Example 2: 2-bromo-4-methylbenzonitrile (3.28 g, 16.74 mmol), (E)-2,4,7-trimethylocta-2,6-dienal (1.56 g, 8.37 mmol), diacetoxypalladium (0.09 g, 0.42 mmol), tricyclohexylphosphane (0.24 g, 0.84 mmol), Cs<sub>2</sub>CO<sub>3 </sub>(3.27 g, 10.05 mmol) in DMF (20 mL) were reacted to give the title product (0.97 g, 41% yield) as a light yellow oil.</p><p id="p-0217" num="0211">GC/MS (EI): m/z (%): 281 (1) [M<sup>+</sup>], 253 (2), 213 (30), 184 (100), 170 (30), 153 (7), 142 (9), 128 (6), 115 (8), 69 (46). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 9.46 (s, 1H), 7.50 (d, J=7.8 Hz, 1H), 7.29 (s, 1H), 7.12 (d, J=7.8 Hz, 1H), 6.92 (d, J=1.1 Hz, 1H), 4.95 (t, J=7.5 Hz, 1H), 2.71 (d, J=7.5 Hz, 2H), 2.42 (s, 3H), 1.66 (s, 3H), 1.56 (d, J=5.9 Hz, 6H), 1.18 (d, J=1.0 Hz, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 196.0 (t), 160.8 (t), 150.6 (q), 143.5 (q), 138.8 (q), 136.1 (q), 135.0 (t), 127.8 (t), 127.7 (t), 119.7 (q), 118.4 (t), 108.6 (q), 44.5 (q), 40.8 (d), 26.1 (s), 23.8 (s), 22.1 (s), 18.1 (s), 9.9 (s).</p><heading id="h-0023" level="1">Example 18: (E)-4-(3-methoxyphenyl)-2,4,7-trimethylocta-2,6-dienal</heading><p id="p-0218" num="0212">Following the general procedure described in Example 2: 1-bromo-3-methoxybenzene (6.75 g, 36.10 mmol), (E)-2,4,7-trimethylocta-2,6-dienal (3.00 g, 18.04 mmol), diacetoxypalladium (0.20 g, 0.90 mmol), tricyclohexylphosphane (0.51 g, 1.80 mmol), Cs<sub>2</sub>CO<sub>3 </sub>(7.05 g, 21.65 mmol) in DMF (20 mL) were reacted to give the title product (1.20 g, 24% yield) as a light yellow oil.</p><p id="p-0219" num="0213">GC/MS (EI): m/z (%): 272 (2) [M<sup>+</sup>], 204 (82), 188 (100), 175 (72), 161 (18), 145 (21), 128 (20), 115 (21), 91 (20), 69 (22). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 9.42 (s, 1H), 7.25-7.18 (m, 1H), 6.87-6.79 (m, 2H), 6.78-6.71 (m, 2H), 5.00 (t, 1H), 3.79 (s, 3H), 2.61-2.44 (m, 2H), 1.66 (s, 3H), 1.55 (s, 3H), 1.50 (s, 3H), 1.32 (s, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 196.3 (t), 162.8 (t), 159.6 (q), 148.3 (q), 140.0 (q), 135.1 (q), 129.3 (t), 119.5 (t), 119.3 (t), 113.3 (t), 110.7 (t), 55.2 (s), 44.9 (q), 42.6 (d), 26.1 (s), 24.9 (s), 18.1 (s), 10.4 (s).</p><heading id="h-0024" level="1">Example 19: (E)-2,4,7-trimethyl-4-(naphthalen-2-yl)octa-2,6-dienal</heading><p id="p-0220" num="0214">Following the general procedure described in Example 2: 2-bromonaphthalene (6.23 g, 30.10 mmol), (E)-2,4,7-trimethylocta-2,6-dienal (2.50 g, 15.04 mmol), diacetoxypalladium (0.17 g, 0.752 mmol), tri-tert-butylphosphine (0.30 g, 1.50 mmol), Cs<sub>2</sub>CO<sub>3 </sub>(4.90 g, 15.04 mmol) in DMF (20 mL) were reacted to give the title product (1.00 g, 23% yield) as yellow oil.</p><p id="p-0221" num="0215">GC/MS (EI): m/z (%): 292 (1) [M<sup>+</sup>], 224 (100), 208 (69), 195 (29), 179 (12), 165 (25), 153 (15), 141 (12), 128 (10), 69 (69). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 9.38 (s, 1H), 7.76-7.69 (m, 3H), 7.63 (s, 1H), 7.41-7.35 (m, 2H), 7.31-7.24 (m, 1H), 6.77 (d, J=1.1 Hz, 1H), 4.94 (t, J=7.4 Hz, 1H), 2.63-2.45 (m, 2H), 1.56 (d, J=9.8 Hz, 6H), 1.47 (s, 3H), 1.20 (s, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 196.4 (t), 162.7 (t), 144.0 (q), 140.2 (q), 135.2 (q), 133.3 (q), 132.0 (q), 128.1 (t), 128.0 (t), 127.5 (t), 126.1 (t), 125.9 (t), 125.8 (t), 124.6 (t), 119.4 (t), 45.1 (q), 42.6 (d), 26.1 (s), 24.9 (s), 18.1 (s), 10.5 (s).</p><heading id="h-0025" level="1">Example 20: (E)-4-(2-ethylphenyl)-2,4,7-trimethylocta-2,6-dienal</heading><p id="p-0222" num="0216">Following the general procedure described in Example 2: 1-bromo-2-ethylbenzene (5.00 g, 27.00 mmol), (E)-2,4,7-trimethylocta-2,6-dienal (2.25 g, 13.51 mmol), diacetoxypalladium (0.15 g, 0.68 mmol), tri-tert-butylphosphane (0.27 g, 1.35 mmol), Cs<sub>2</sub>CO<sub>3 </sub>(5.28 g, 16.21 mmol) in DMF (20 mL) were reacted to give the title product (1.52 g, 42% yield) as a light yellow oil. GC/MS (EI): m/z (%): 270(1) [M<sup>+</sup>], 202 (66), 187 (16), 173 (100), 145 (27), 128 (30), 115 (19), 91 (14), 69 (29). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 9.41 (s, 1H), 7.36 (d, J=7.3 Hz, 1H), 7.24-7.14 (m, 3H), 6.95 (d, J=1.2 Hz, 1H), 5.02 (t, J=6.7, 1.3 Hz, 1H), 2.71-2.43 (m, 4H), 1.70 (s, 3H), 1.59 (s, 3H), 1.52 (s, 3H), 1.21 (s, 3H), 1.09 (t, J=7.6 Hz, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 196.1 (t), 163.4 (t), 143.8 (q), 142.0 (q), 137.8 (q), 135.0 (q), 130.1 (t), 126.8 (t), 126.0 (t), 125.8 (t), 119.6 (t), 44.5 (q), 41.1 (d), 27.6 (d), 26.1 (s), 25.1 (s), 18.1 (s), 15.5 (s), 9.7 (s).</p><heading id="h-0026" level="1">Example 21: (E)-2,4,7-trimethyl-4-(m-tolyl)octa-2,6-dienal</heading><p id="p-0223" num="0217">Following the general procedure described in Example 2: 1-bromo-3-methylbenzene (4.41 g, 25.80 mmol), (E)-2,4,7-trimethylocta-2,6-dienal (2.15 g, 12.90 mmol), diacetoxypalladium (0.15 g, 0.65 mmol), tricyclohexylphosphine (0.36 g, 1.29 mmol), Cs<sub>2</sub>CO<sub>3 </sub>(4.20 g, 12.90 mmol) in DMF (15 mL) were reacted to give the title product (2.04 g, 62% yield) as a light yellow oil.</p><p id="p-0224" num="0218">GC/MS (EI): m/z (%): 256(1) [M<sup>+</sup>], 188(100), 173 (84), 159 (89), 143 (20), 128 (34), 115 (21), 91 (17), 69 (22). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 9.43 (s, 1H), 7.23-7.13 (m, 1H), 7.10-6.98 (m, 3H), 6.79 (d, J=1.1 Hz, 1H), 5.05 (t, 1H), 2.61-2.46 (m, 2H), 2.34 (s, 3H), 1.69 (s, 3H), 1.54 (d, J=12.8 Hz, 6H), 1.34 (s, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 196.3 (t), 163.2 (t), 146.5 (q), 139.8 (q), 137.7 (q), 134.9 (q), 128.1 (t), 127.3 (t), 126.9 (t), 123.6 (t), 119.6 (t), 44.8 (q), 42.6 (d), 26.0 (s), 24.9 (s), 21.7 (s), 18.0 (s), 10.4 (s).</p><heading id="h-0027" level="1">Example 22: (E)-4-(benzo[d][1,3]dioxol-5-yl)-2,4,7-trimethylocta-2,6-dienal</heading><p id="p-0225" num="0219">Following the general procedure described in Example 2: 5-bromobenzo[d][1,3]dioxole (3.89 g, 19.35 mmol), (E)-2,4,7-trimethylocta-2,6-dienal (2.15 g, 12.90 mmol), diacetoxypalladium (0.15 g, 0.65 mmol), tricyclohexylphosphane (0.36 g, 1.29 mmol), Cs<sub>2</sub>CO<sub>3 </sub>(5.04 g, 15.48 mmol) in DMF (20 mL) were reacted to give the title product (1.26 g, 34% yield) as a light yellow oil.</p><p id="p-0226" num="0220">GC/MS (EI): m/z (%): 286 (3) [M<sup>+</sup>], 217 (29), 202 (33), 189 (100), 159 (45), 115 (29), 91 (19), 69 (11). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 9.41 (s, 1H), 6.78-6.70 (m, 4H), 5.94 (s, 2H), 5.00 (t, J=7.3 Hz, 1H), 2.55-2.41 (m, 2H), 1.68 (s, 3H), 1.56 (s, 3H), 1.47 (s, 3H), 1.36 (s, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 196.3 (t), 163.0 (t), 147.8 (q), 145.8 (q), 140.6 (q), 139.9 (q), 135.1 (q), 119.6 (t), 119.4 (t), 107.9 (t), 107.5 (t), 101.0 (d), 44.7 (q), 42.9 (d), 26.1 (s), 25.0 (s), 18.1 (s), 10.4 (s).</p><heading id="h-0028" level="1">Example 23: (E)-4-(6-methoxypyridin-2-yl)-2,4,7-trimethylocta-2,6-dienal</heading><p id="p-0227" num="0221">Following the general procedure described in Example 2: 2-bromo-6-methoxypyridine (5.11 g, 27.20 mmol), (E)-2,4,7-trimethylocta-2,6-dienal (2.26 g, 13.59 mmol), diacetoxypalladium (0.15 g, 0.68 mmol), tri-tert-butylphosphane (0.28 g, 1.36 mmol), Cs<sub>2</sub>CO<sub>3 </sub>(5.32 g, 16.31 mmol) in DMF (20 mL) were reacted to give the title product (2.12 g, 57% yield) as a light yellow oil.</p><p id="p-0228" num="0222">GC/MS (EI): m/z (%): 273 (2) [M<sup>+</sup>], 244 (16), 188 (100), 176 (49), 162 (53), 146 (27), 137 (28), 69 (39). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 9.39 (s, 1H), 7.45 (q, J=7.7 Hz, 1H), 6.83-6.67 (m, 2H), 6.53 (d, J=9.3 Hz, 1H), 5.01 (t, J=7.4 Hz, 1H), 3.88 (s, 3H), 2.67-2.54 (m, 2H), 1.65 (s, 3H), 1.53 (s, 6H), 1.34 (s, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 196.4 (t), 163.1 (q), 162.8 (q), 162.5 (t), 139.4 (q), 138.6 (t), 134.8 (q), 119.6 (t), 113.8 (t), 107.9 (t), 53.1 (s), 47.5 (q), 41.0 (d), 26.0 (s), 24.1 (s), 18.0 (s), 10.2 (s).</p><heading id="h-0029" level="1">Example 24: (E)-4-(2,4-dimethoxyphenyl)-2,4,7-trimethylocta-2,6-dienal</heading><p id="p-0229" num="0223">Following the general procedure described in Example 2: 1-bromo-2,4-dimethoxybenzene (7.83 g, 36.10 mmol), (E)-2,4,7-trimethylocta-2,6-dienal (3.00 g, 18.04 mmol), diacetoxypalladium (0.20 g, 0.90 mmol), tri-tert-butylphosphine (0.37 g, 1.80 mmol), Cs<sub>2</sub>CO<sub>3 </sub>(7.05 g, 21.65 mmol) in DMF (20 mL) were reacted to give the title product (3.40 g, 62% yield) as a light yellow oil.</p><p id="p-0230" num="0224">GC/MS (EI): m/z (%): 302 (1) [M<sup>+</sup>], 233 (100), 218 (34), 205 (97), 191 (26), 175 (18), 115 (9), 91 (8). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 9.43 (d, J=52.8 Hz, 1H), 7.15 (d, J=8.5 Hz, 1H), 6.81 (s, 1H), 6.45 (dd, J=8.5, 2.4 Hz, 1H), 6.41-6.37 (m, 1H), 4.97 (t, J=6.1 Hz, 1H), 3.75 (d, J=5.2 Hz, 3H), 3.65 (d, J=7.6 Hz, 3H), 2.65-2.55 (m, 2H), 1.64 (s, 3H), 1.54 (s, 3H), 1.43 (s, 3H), 1.24 (s, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 196.5 (t), 165.5 (t), 159.6 (q), 158.0 (q), 136.2 (q), 134.2 (q), 127.2 (t), 126.8 (q), 120.1 (t), 103.8 (t), 99.3 (t), 55.1 (s), 55.1 (s), 42.5 (q), 39.2 (d), 25.9 (s), 23.5 (s), 17.9 (s), 9.2 (s).</p><heading id="h-0030" level="1">Example 25: (E)-4-(3,5-dimethylphenyl)-2,4,7-trimethylocta-2,6-dienal</heading><p id="p-0231" num="0225">Following the general procedure described in Example 2: 1-bromo-3,5-dimethylbenzene (4.78 g, 25.8 mmol), (E)-2,4,7-trimethylocta-2,6-dienal (2.15 g, 12.90 mmol), diacetoxypalladium (0.15 g, 0.65 mmol), tricyclohexylphosphane (0.36 g, 1.29 mmol), Cs<sub>2</sub>CO<sub>3 </sub>(4.20 g, 12.90 mmol) in DMF (15 mL) were reacted to give the title product (2.15 g, 62% yield) as colorless oil.</p><p id="p-0232" num="0226">GC/MS (EI): m/z (%): 270 (1) [M<sup>+</sup>], 202 (57), 186 (100), 173 (89), 159 (22), 143 (27), 128 (17), 115 (12), 91 (9), 69 (10). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 9.45 (s, 1H), 6.88 (s, 3H), 6.78 (d, J=1.0 Hz, 1H), 5.06 (t, J=7.3 Hz, 1H), 2.63-2.45 (m, 2H), 2.32 (s, 6H), 1.71 (s, 3H), 1.60 (s, 3H), 1.51 (s, 3H), 1.38 (s, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 196.6 (t), 163.4 (t), 146.6 (q), 139.8 (q), 137.6 (q), 134.9 (q), 127.8 (t), 124.4 (t), 119.7 (t), 44.8 (q), 42.6 (d), 26.1 (s), 25.1 (s), 21.6 (s), 21.4 (s), 18.1 (s), 10.5 (s).</p><heading id="h-0031" level="1">Example 26: (E)-4-(4-methoxyphenyl)-2,4,7-trimethylocta-2,6-dienal</heading><p id="p-0233" num="0227">Following the general procedure described in Example 2: 1-bromo-4-methoxybenzene (4.50 g, 24.06 mmol), (E)-2,4,7-trimethylocta-2,6-dienal (2.00 g, 12.03 mmol), bis(tri-tert-butylphosphine)palladium(0) (0.31 g, 0.60 mmol), Cs<sub>2</sub>CO<sub>3 </sub>(4.70 g, 14.44 mmol) in DMF (20 mL) were reacted to give the title product (2.81 g, 86% yield) as a light yellow oil.</p><p id="p-0234" num="0228">GC/MS (EI): m/z (%): 272 (2) [M<sup>+</sup>], 203 (100), 188 (62), 175 (83), 160 (11), 145 (11), 115 (12), 91 (9). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 9.40 (s, 1H), 7.19-7.12 (m, 2H), 6.83 (d, 2H), 6.77 (s, 1H), 5.00 (t, 1H), 3.79 (s, 3H), 2.58-2.39 (m, 2H), 1.67 (s, 3H), 1.52 (d, J=14.9 Hz, 6H), 1.31 (s, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 196.4 (t), 163.5 (t), 157.8 (q), 139.8 (q), 138.6 (q), 135.0 (q), 127.8 (t), 127.7 (t), 119.6 (t), 114.2 (t), 113.6 (t), 55.4 (t), 55.2 (t), 44.3 (q), 42.8 (d), 26.1 (s), 25.0 (s), 18.1 (s), 10.4 (s).</p><heading id="h-0032" level="1">Example 27: (E)-2,4,7-trimethyl-4-(naphthalen-1-yl)octa-2,6-dienal</heading><p id="p-0235" num="0229">Following the general procedure described in Example 2: 1-bromonaphthalene (7.47 g, 36.10 mmol), (E)-2,4,7-trimethylocta-2,6-dienal (3.00 g, 18.04 mmol), diacetoxypalladium (0.20 g, 0.902 mmol), tricyclohexylphosphane (0.51 g, 1.80 mmol), Cs<sub>2</sub>CO<sub>3 </sub>(7.05 g, 21.65 mmol) in DMF (20 mL) were reacted to give the title product (2.1 g, 40% yield) as a light yellow oil.</p><p id="p-0236" num="0230">GC/MS (EI): m/z (%): 292 (4) [M<sup>+</sup>], 224 (59), 209 (27), 195 (100), 179 (46), 165 (58), 153 (24), 69 (13). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 9.44 (s, 1H), 7.96-7.71 (m, 3H), 7.57-7.35 (m, 4H), 7.14 (s, 1H), 4.97 (s, 1H), 2.79 (s, 2H), 1.64 (d, J=4.4 Hz, 3H), 1.50 (s, 3H), 1.19 (s, 3H), 1.00 (s, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 195.8 (t), 162.9 (t), 142.3 (q), 138.5 (q), 135.0 (q), 134.6 (q), 130.5 (q), 129.4 (t), 128.0 (t), 126.0 (t), 125.2 (t), 124.9 (t), 124.1 (t), 119.4 (t), 45.0 (q), 40.9 (d), 26.0 (s), 25.5 (s), 18.0 (s), 9.3 (s).</p><heading id="h-0033" level="1">Example 28: (E)-4-(3,5-dimethoxyphenyl)-2,4,7-trimethylocta-2,6-dienal</heading><p id="p-0237" num="0231">Following the general procedure described in Example 2: 1-bromo-3,5-dimethoxybenzene (7.83 g, 36.1 mmol), (E)-2,4,7-trimethylocta-2,6-dienal (3.00 g, 18.04 mmol), diacetoxypalladium (0.20 g, 0.90 mmol), tricyclohexylphosphane (0.51 g, 1.804 mmol), Cs<sub>2</sub>CO<sub>3 </sub>(7.05 g, 21.65 mmol) in DMF (20 mL) were reacted to give the title product (2.00 g, 29% yield) as a yellow oil.</p><p id="p-0238" num="0232">GC/MS (EI): m/z (%): 302 (6) [M<sup>+</sup>], 233 (100), 218 (86), 205 (49), 191 (34), 175 (27), 115 (12), 69 (19). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 9.41 (s, 1H), 6.47 (t, J=2.2 Hz, 1H), 6.42 (d, J=2.1 Hz, 2H), 6.33 (t, J=2.1 Hz, 1H), 5.03 (t, J=7.3 Hz, 1H), 3.77 (s, 6H), 2.50 (t, 2H), 1.69 (s, 3H), 1.57 (s, 3H), 1.49 (s, 3H), 1.39 (s, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 196.2 (t), 162.5 (t), 161.0 (q), 160.7 (q), 149.1 (q), 143.5 (q), 135.0 (q), 119.5 (t), 105.5 (t), 105.5 (t), 99.5 (t), 55.4 (s), 55.3 (q), 45.0 (d), 42.5 (s), 26.0 (s), 24.8 (s), 18.0 (s), 10.4 (s).</p><heading id="h-0034" level="1">Example 29: (E)-4-(3-isopropylphenyl)-2,4,7-trimethylocta-2,6-dienal</heading><p id="p-0239" num="0233">Following the general procedure described in Example 2: 1-bromo-3-isopropylbenzene (7.18 g, 36.1 mmol), (E)-2,4,7-trimethylocta-2,6-dienal (3.00 g, 18.04 mmol), diacetoxypalladium (0.20 g, 0.90 mmol), tri-tert-butylphosphine (0.37 g, 1.80 mmol), Cs<sub>2</sub>CO<sub>3 </sub>(7.05 g, 21.65 mmol) in DMF (20 mL) were reacted to give the title product (5.00 g, 97% yield) as a yellow oil.</p><p id="p-0240" num="0234">GC/MS (EI): m/z (%): 284(1) [M<sup>+</sup>], 216 (44), 187 (26), 173 (100), 158(21), 145 (46), 128 (20), 115 (12), 91 (11), 69 (14). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 9.41 (s, 1H), 7.26-7.18 (m, 1H), 7.08 (d, 3H), 6.79 (s, 1H), 5.04 (t, J=7.4 Hz, 1H), 2.97-2.79 (m, 1H), 2.52 (d, 2H), 1.68 (s, 3H), 1.53 (s, 6H), 1.31 (s, 3H), 1.22 (d, J=6.9 Hz, 6H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 196.4 (t), 163.3 (t), 148.8 (q), 146.3 (q), 139.8 (q), 135.0 (q), 128.2 (t), 125.2 (t), 124.1 (t), 124.0 (t), 119.6 (t), 45.1 (q), 42.7 (d), 34.3 (t), 26.1 (s), 25.1 (s), 24.2 (s), 24.1 (s), 18.0 (s), 10.5 (s).</p><heading id="h-0035" level="1">Example 30: (E)-2,4,7-trimethyl-4-(pyridin-3-yl)octa-2,6-dienal</heading><p id="p-0241" num="0235">Following the general procedure described in Example 2: 3-bromopyridine (5.70 g, 36.1 mmol), (E)-2,4,7-trimethylocta-2,6-dienal (3.00 g, 18.04 mmol), diacetoxypalladium (0.20 g, 0.90 mmol), tricyclohexylphosphane (0.51 g, 1.80 mmol), Cs<sub>2</sub>CO<sub>3 </sub>(7.05 g, 21.65 mmol) in DMF (20 mL) were reacted to give the title product (0.6 g, 14% yield) as a light yellow oil.</p><p id="p-0242" num="0236">GC/MS (EI): m/z (%): 243(2) [M<sup>+</sup>], 214 (10), 200 (11), 175 (55), 158 (39), 146 (100), 132 (61), 69 (47). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 9.42 (s, 1H), 8.52 (d, J=2.3 Hz, 1H), 8.46 (dd, J=4.7, 1.3 Hz, 1H), 7.58-7.49 (m, 1H), 7.25-7.20 (m, 1H), 6.77 (s, 1H), 4.99 (t, J=7.4 Hz, 1H), 2.52 (d, J=7.4 Hz, 2H), 1.66 (s, 3H), 1.56 (s, 3H), 1.47 (s, 3H), 1.30 (s, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 195.9 (t), 161.0 (t), 148.5 (t), 147.7 (t), 141.8 (q), 140.3 (q), 136.1 (q), 134.3 (t), 123.2 (t), 118.5 (t), 43.7 (q), 42.8 (d), 26.1 (s), 24.5 (s), 18.0 (s), 10.8 (s).</p><heading id="h-0036" level="1">Example 31: (E)-4-methoxy-3-(2,4,7-trimethyl-1-oxoocta-2,6-dien-4-yl)benzonitrile</heading><p id="p-0243" num="0237">Following the general procedure described in Example 2: 3-bromo-4-methoxybenzonitrile (5.04 g, 23.77 mmol), (E)-2,4,7-trimethylocta-2,6-dienal (2.16 g, 11.89 mmol), diacetoxypalladium (0.13 g, 0.594 mmol), tri-tert-butylphosphane (0.24 g, 1.19 mmol), Cs<sub>2</sub>CO<sub>3 </sub>(7.75 g, 23.77 mmol) in DMF (50 mL) were reacted to give the title product (1.91 g, 54% yield) as a light yellow oil.</p><p id="p-0244" num="0238">GC/MS (EI): m/z (%): 297 (1) [M<sup>+</sup>], 229 (100), 214 (15), 200 (33), 186 (28), 170 (11), 160 (9), 146 (10), 116 (11), 69 (48). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 9.33 (s, 1H), 7.64-7.45 (m, 2H), 6.87 (d, J=7.7 Hz, 1H), 6.75 (s, 1H), 4.86 (t, J=7.4 Hz, 1H), 3.74 (s, 3H), 2.78-2.46 (m, 2H), 1.61 (s, 3H), 1.48 (d, J=11.8 Hz, 6H), 1.17 (s, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 196.0 (t), 162.8 (t), 160.3 (q), 136.6 (q), 135.6 (q), 135.4 (q), 132.8 (t), 131.0 (t), 119.4 (q), 119.0 (t), 111.6 (t), 103.9 (q), 55.5 (s), 43.0 (q), 38.6 (d), 25.9 (s), 23.2 (s), 17.9 (s), 9.5 (s).</p><heading id="h-0037" level="1">Example 32: (E)-4-(2,5-difluorophenyl)-2,4,7-trimethylocta-2,6-dienal</heading><p id="p-0245" num="0239">Following the general procedure described in Example 2: 2-bromo-1,4-difluorobenzene (5.00 g, 25.90 mmol), (E)-2,4,7-trimethylocta-2,6-dienal (2.32 g, 12.95 mmol), diacetoxypalladium (0.09 g, 0.39 mmol), tri-tert-butylphosphane (0.16 g, 0.78 mmol), Cs<sub>2</sub>CO<sub>3 </sub>(8.44 g, 25.90 mmol) in DMF (30 mL) were reacted to give the title product (1.19 g, 33% yield) as a light yellow oil.</p><p id="p-0246" num="0240">GC/MS (EI): m/z (%): 278 (1) [M<sup>+</sup>], 210 (100), 195 (15), 181 (11), 164 (15), 147 (10), 127 (20), 119 (4), 101 (5), 69 (71). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 9.37 (s, 1H), 7.08-6.84 (m, 3H), 6.76 (d, J=1.9 Hz, 1H), 4.95 (t, J=7.3 Hz, 1H), 2.57 (d, J=11.2 Hz, 2H), 1.65 (s, 3H), 1.54 (s, 3H), 1.48 (s, 3H), 1.28 (s, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 195.9 (t), 161.0 (t), 138.3 (q), 138.3 (q), 135.8 (q), 118.6 (t), 117.2 (t), 117.0 (t), 116.8 (t), 116.7 (t), 114.8 (t), 114.8 (t), 114.6 (t), 114.5 (t), 114.4 (t), 114.3 (t), 42.6 (q), 39.7 (d), 39.7 (d), 26.0 (s), 23.4 (s), 17.9 (s), 9.6 (s).</p><heading id="h-0038" level="1">Example 33: (E)-4-(3,5-difluorophenyl)-2,4,7-trimethylocta-2,6-dienal</heading><p id="p-0247" num="0241">Following the general procedure described in Example 2: 1-bromo-3,5-difluorobenzene (5.00 g, 25.9 mmol), (E)-2,4,7-trimethylocta-2,6-dienal (2.32 g, 12.95 mmol), diacetoxypalladium (0.09 g, 0.39 mmol), tri-tert-butylphosphane (0.18 g, 0.78 mmol), Cs<sub>2</sub>CO<sub>3 </sub>(8.44 g, 25.90 mmol) in DMF (30 mL) were reacted to give the title product (1.48 g, 41% yield) as a light yellow oil.</p><p id="p-0248" num="0242">GC/MS (EI): m/z (%): 278 (1) [M<sup>+</sup>], 210 (80), 192 (46), 181 (13), 164 (19), 151 (13), 127 (13), 119 (4), 101 (4), 69 (100). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 9.42 (s, 1H), 6.92-6.54 (m, 4H), 4.96 (t, J=10.6, 4.3 Hz, 1H), 2.48 (d, J=7.5 Hz, 2H), 1.67 (s, 3H), 1.53 (s, 3H), 1.49 (s, 3H), 1.33 (d, J=1.1 Hz, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 195.8 (t), 164.8 (q), 164.6 (q), 161.5 (q), 161.3 (q), 160.8 (t), 150.9 (q), 140.5 (q), 136.0 (q), 118.5 (t), 110.0 (t), 109.9 (t), 109.8 (t), 109.7 (t), 102.2 (t), 101.8 (t), 101.5 (t), 45.0 (q), 42.7 (d), 26.1 (s), 24.6 (s), 18.0 (s), 10.6 (s).</p><heading id="h-0039" level="1">Example 34: (E)-2-chloro-5-(2,4,7-trimethyl-1-oxoocta-2,6-dien-4-yl)benzonitrile</heading><p id="p-0249" num="0243">Following the general procedure described in Example 2: 5-bromo-2-chlorobenzonitrile (5.00 g, 23.10 mmol), (E)-2,4,7-trimethylocta-2,6-dienal (3.00 g, 18.04 mmol), diacetoxypalladium (0.20 g, 0.90 mmol), tri-tert-butylphosphane (0.37 g, 1.80 mmol), Cs<sub>2</sub>CO<sub>3 </sub>(7.05 g, 21.65 mmol) in DMF (20 mL) were reacted to give the title product (1.00 g, 18% yield) as a yellow oil.</p><p id="p-0250" num="0244">GC/MS (EI): m/z (%): 301 (1) [M<sup>+</sup>], 233 (45), 218 (13), 198 (6), 190 (5), 166 (5), 153 (9), 140 (6), 127 (5), 69 (100). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 9.43 (s, 1H), 7.55 (d, J=1.7 Hz, 1H), 7.47-7.37 (m, 2H), 6.72 (d, J=1.0 Hz, 1H), 4.93 (t, J=7.4 Hz, 1H), 2.48 (d, J=7.4 Hz, 2H), 1.67 (s, 3H), 1.53 (s, 3H), 1.48 (s, 3H), 1.30 (s, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 195.5 (t), 160.0 (t), 146.4 (q), 140.5 (q), 136.7 (q), 134.7 (q), 132.7 (t), 132.1 (t), 129.9 (t), 118.0 (t), 116.2 (q), 113.3 (q), 44.7 (q), 42.8 (d), 26.1 (s), 24.6 (s), 18.1 (s), 10.9 (s).</p><heading id="h-0040" level="1">Example 35: (E)-3-chloro-5-(2,4,7-trimethyl-1-oxoocta-2,6-dien-4-yl)benzonitrile</heading><p id="p-0251" num="0245">Following the general procedure described in Example 2: 3-bromo-5-chlorobenzonitrile (5.00 g, 23.10 mmol), (E)-2,4,7-trimethylocta-2,6-dienal (3.00 g, 18.04 mmol), diacetoxypalladium (0.20 g, 0.90 mmol), tri-tert-butylphosphane (0.37 g, 1.80 mmol), Cs<sub>2</sub>CO<sub>3 </sub>(7.05 g, 21.65 mmol) in DMF (20 mL) were reacted to give the title product (0.23 g, 4% yield) as a yellow oil.</p><p id="p-0252" num="0246">GC/MS (EI): m/z (%): 301 (1) [M<sup>+</sup>], 233 (35), 215 (6), 204 (5), 190 (3), 166 (4), 153 (8), 140 (5), 127 (4), 69 (100). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 9.41 (s, 1H), 7.52-7.37 (m, 3H), 6.70 (s, 1H), 4.93 (t, J=7.4 Hz, 1H), 2.46 (d, J=7.4 Hz, 2H), 1.65 (s, 3H), 1.51 (s, 3H), 1.45 (s, 3H), 1.28 (s, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 195.4 (t), 159.4 (t), 150.2 (q), 140.5 (q), 136.7 (q), 135.2 (q), 131.7 (t), 129.6 (t), 128.6 (t), 117.9 (t), 117.5 (q), 113.7 (q), 44.9 (q), 42.6 (d), 26.0 (s), 24.4 (s), 17.9 (s), 10.8 (s).</p><heading id="h-0041" level="1">Example 36: (E)-4-(3,4-difluorophenyl)-2,4,7-trimethylocta-2,6-dienal</heading><p id="p-0253" num="0247">Following the general procedure described in Example 2: 4-bromo-1,2-difluorobenzene (5.00 g, 25.9 mmol), (E)-2,4,7-trimethylocta-2,6-dienal (2.32 g, 12.95 mmol), diacetoxypalladium (0.09 g, 0.39 mmol), tri-tert-butylphosphane (0.16 g, 0.78 mmol), Cs<sub>2</sub>CO<sub>3 </sub>(8.44 g, 25.90 mmol) in DMF (30 mL) were reacted to give the title product (1.27 g, 35% yield) as a light yellow oil.</p><p id="p-0254" num="0248">GC/MS (EI): m/z (%): 278 (1) [M<sup>+</sup>], 210 (88), 195 (36), 181 (28), 164 (21), 151 (14), 141 (11), 127 (24), 101 (5), 69 (100). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 9.41 (s, 1H), 7.15-6.89 (m, 3H), 6.72 (d, J=1.0 Hz, 1H), 4.96 (t, J=7.4 Hz, 1H), 2.47 (d, J=7.4 Hz, 2H), 1.67 (s, 3H), 1.50 (d, J=6.0 Hz, 6H), 1.31 (d, J=0.8 Hz, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 195.9 (t), 161.5 (t), 151.9 (q), 151.7 (q), 150.5 (q), 150.3 (q), 148.6 (q), 148.4 (q), 147.2 (q), 147.0 (q), 143.8 (q), 143.7 (q), 143.7 (q), 140.3 (q), 135.8 (q), 122.9 (t), 122.8 (t), 122.7 (t), 122.6 (t), 118.7 (t), 117.1 (t), 116.9 (t), 116.0 (t), 115.7 (t), 44.5 (q), 42.9 (d), 26.1 (s), 24.8 (s), 18.0 (s), 10.6 (s).</p><heading id="h-0042" level="1">Example 37: (E)-2-methyl-5-(2,4,7-trimethyl-1-oxoocta-2,6-dien-4-yl)benzonitrile</heading><p id="p-0255" num="0249">Following the general procedure described in Example 2: 5-bromo-2-methylbenzonitrile (5.00 g, 25.5 mmol), (E)-2,4,7-trimethylocta-2,6-dienal (3.00 g, 18.04 mmol), diacetoxypalladium (0.20 g, 0.90 mmol), tri-tert-butylphosphane (0.37 g, 1.804 mmol), Cs<sub>2</sub>CO<sub>3 </sub>(7.05 g, 21.65 mmol) in DMF (20 mL) were reacted to give the title product (2.10 g, 41% yield) as a yellow oil.</p><p id="p-0256" num="0250">GC/MS (EI): m/z (%): 281 (1) [M<sup>+</sup>], 213 (100), 198 (74), 184 (26), 170 (24), 154 (14), 140 (9), 130 (10), 115 (10), 69 (100). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 9.41 (s, 1H), 7.47 (d, J=1.6 Hz, 1H), 7.34 (dd, J=8.2, 1.8 Hz, 1H), 7.23 (d, J=8.2 Hz, 1H), 6.73 (s, 1H), 4.93 (t, J=7.3 Hz, 1H), 2.55-2.41 (m, 5H), 1.66 (s, 3H), 1.50 (d, J=5.4 Hz, 6H), 1.27 (s, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 195.8 (t), 161.1 (t), 145.0 (q), 140.2 (q), 139.9 (q), 136.0 (q), 131.4 (t), 130.5 (t), 130.3 (t), 118.5 (t), 118.3 (q), 112.7 (q), 44.5 (q), 42.7 (d), 26.0 (s), 24.6 (s), 20.0 (s), 18.0 (s), 10.7 (s).</p><heading id="h-0043" level="1">Example 38: (E)-2,4,7-trimethyl-4-(2-(methylthio)phenyl)octa-2,6-dienal</heading><p id="p-0257" num="0251">Following the general procedure described in Example 2: (2-bromophenyl)(methyl)-sulfane (5.71 g, 28.1 mmol), (E)-2,4,7-trimethylocta-2,6-dienal (2.51 g, 14.05 mmol), diacetoxypalladium (0.16 g, 0.70 mmol), tri-tert-butylphosphane (0.28 g, 1.41 mmol), Cs<sub>2</sub>CO<sub>3 </sub>(4.58 g, 14.05 mmol) in DMF (80 mL) were reacted to give the title product (2.31 g, 57% yield) as a light yellow oil.</p><p id="p-0258" num="0252">GC/MS (EI): m/z (%): 288 (1) [M<sup>+</sup>], 273 (29), 245 (28), 217 (80), 205 (35), 172 (89), 163 (80), 144 (100), 129 (73), 69 (61). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 9.46 (s, 1H), 7.42-7.34 (m, 2H), 7.26-7.20 (m, 2H), 6.99 (d, J=0.9 Hz, 1H), 5.02 (t, J=7.5 Hz, 1H), 2.87-2.68 (m, 2H), 2.33 (s, 3H), 1.69 (s, 3H), 1.60 (s, 3H), 1.55 (s, 3H), 1.20 (d, J=0.7 Hz, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 196.3 (t), 162.6 (t), 146.4 (q), 136.7 (q), 136.3 (q), 134.9 (q), 131.0 (t), 127.2 (t), 126.4 (t), 126.1 (t), 119.6 (t), 45.1 (q), 39.6 (d), 26.0 (s), 24.0 (s), 19.2 (s), 18.0 (s), 9.5 (s).</p><heading id="h-0044" level="1">Example 39: (E)-4-(3-fluoro-5-(trifluoromethyl)phenyl)-2,4,7-trimethylocta-2,6-dienal</heading><p id="p-0259" num="0253">Following the general procedure described in Example 2: 1-bromo-3-fluoro-5-(trifluoromethyl)benzene (8.77 g, 36.10 mmol), (E)-2,4,7-trimethylocta-2,6-dienal (3.00 g, 18.04 mmol), diacetoxypalladium (0.20 g, 0.90 mmol), tri-tert-butylphosphane (0.37 g, 1.81 mmol), Cs<sub>2</sub>CO<sub>3 </sub>(7.05 g, 21.65 mmol) in DMF (20 mL) were reacted to give the title product (1.75 g, 30% yield) as a light yellow oil.</p><p id="p-0260" num="0254">GC/MS (EI): m/z (%): 328 (1) [M<sup>+</sup>], 309 (3), 260 (100), 242 (15), 231 (9), 195 (6), 177 (6), 146 (6), 133 (3), 69 (41). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 9.44 (s, 1H), 7.28 (s, 1H), 7.17 (t, J=10.4 Hz, 2H), 6.74 (s, 1H), 4.98 (t, J=7.5 Hz, 1H), 2.50 (d, J=7.5 Hz, 2H), 1.67 (s, 3H), 1.54 (s, 3H), 1.47 (s, 3H), 1.31 (s, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 195.7 (t), 164.2 (q), 160.9 (q), 160.3 (t), 150.7 (q), 150.6 (q), 140.6 (q), 136.5 (q), 119.5 (t), 119.4 (t), 118.3 (t), 117.6 (t), 117.3 (t), 111.0 (t), 110.9 (t), 110.6 (t), 110.6 (t), 45.2 (q), 42.8 (d), 26.0 (s), 24.8 (s), 18.0 (s), 10.8 (s).</p><heading id="h-0045" level="1">Example 40: (E)-4-(2,3-dimethylphenyl)-2,4,7-trimethylocta-2,6-dienal</heading><p id="p-0261" num="0255">Following the general procedure described in Example 2: 1-bromo-2,3-dimethylbenzene (6.68 g, 36.10 mmol), (E)-2,4,7-trimethylocta-2,6-dienal (3.00 g, 18.04 mmol), diacetoxypalladium (0.20 g, 0.90 mmol), tricyclohexylphosphane (0.51 g, 1.80 mmol), Cs<sub>2</sub>CO<sub>3 </sub>(7.05 g, 21.65 mmol) in DMF (20 mL) were reacted to give the title product (1.65 g, 34% yield) as a light yellow oil.</p><p id="p-0262" num="0256">GC/MS (EI): m/z (%): 270 (1) [M<sup>+</sup>], 202 (88), 201 (26), 187 (100), 186 (82), 173 (89), 171 (21), 159 (31), 157 (28), 143 (35), 141 (26), 69 (29). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 9.55 (s, 1H), 7.37 (d, J=6.7 Hz, 1H), 7.25-7.17 (m, 2H), 7.04 (s, 1H), 5.16 (t, J=7.4 Hz, 1H), 2.86-2.60 (m, 2H), 2.35 (s, 3H), 2.21 (s, 3H), 1.83 (s, 3H), 1.70 (s, 3H), 1.64 (s, 3H), 1.28 (s, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 196.2 (t), 163.5 (t), 144.3 (q), 138.0 (q), 137.6 (q), 134.9 (q), 134.4 (q), 128.5 (t), 125.6 (t), 124.1 (t), 119.7 (t), 44.9 (q), 40.5 (d), 26.1 (s), 25.4 (s), 21.2 (s), 19.6 (s), 18.1 (s), 9.5 (s).</p><heading id="h-0046" level="1">Example 41: (E)-2,4,7-trimethyl-4-(2-methyl-5-(trifluoromethyl)phenyl)octa-2,6-dienal</heading><p id="p-0263" num="0257">Following the general procedure described in Example 2: 2-bromo-1-methyl-4-(trifluoromethyl)benzene (5.00 g, 20.92 mmol), (E)-2,4,7-trimethylocta-2,6-dienal (1.74 g, 10.46 mmol), diacetoxypalladium (0.12 g, 0.52 mmol), tri-tert-butylphosphane (0.21 g, 1.05 mmol), Cs<sub>2</sub>CO<sub>3 </sub>(4.09 g, 12.55 mmol) in DMF (20 mL) were reacted to give the title product (1.50 g, 44% yield) as a yellow oil.</p><p id="p-0264" num="0258">GC/MS (EI): m/z (%): 324 (1) [M<sup>+</sup>], 305 (88), 256 (100), 241 (55), 236 (6), 22 (19), 225 (21), 159 (31), 221 (28), 191 (3), 177 (4), 69 (57). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 9.44 (s, 1H), 7.59 (s, 1H), 7.41 (d, J=7.9 Hz, 1H), 7.22 (d, J=7.9 Hz, 1H), 6.83 (s, 1H), 4.96 (t, J=7.3 Hz, 1H), 2.70-2.49 (m, 2H), 2.29 (s, 3H), 1.67 (s, 3H), 1.56 (s, 6H), 1.18 (s, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 195.8 (t), 161.4 (t), 144.9 (q), 140.2 (q), 138.4 (q), 135.8 (q), 132.4 (t), 128.6 (q), 128.2 (q), 123.4 (t), 123.4 (t), 123.2 (t), 123.2 (t), 118.8 (t), 44.9 (q), 39.9 (d), 26.0 (s), 24.9 (s), 22.9 (s), 18.0 (s), 9.7 (s).</p><heading id="h-0047" level="1">Example 42: (E)-4-(2-ethoxyphenyl)-2,4,7-trimethylocta-2,6-dienal</heading><p id="p-0265" num="0259">Following the general procedure described in Example 2: 1-bromo-2-ethoxybenzene (7.26 g, 36.10 mmol), (E)-2,4,7-trimethylocta-2,6-dienal (3.00 g, 18.04 mmol), diacetoxypalladium (0.20 g, 0.90 mmol), tricyclohexylphosphane (0.51 g, 1.80 mmol), Cs<sub>2</sub>CO<sub>3 </sub>(7.05 g, 21.65 mmol) in DMA (20 mL) were reacted to give the title product (2.16 g, 42% yield) as a light yellow oil.</p><p id="p-0266" num="0260">GC/MS (EI): m/z (%): 286 (5) [M<sup>+</sup>], 218 (37), 217 (100), 189 (60), 188 (25), 161 (42), 147 (30), 133 (21), 91 (17), 69 (13). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 9.38 (s, 1H), 7.32-7.27 (m, 1H), 7.24-7.16 (m, 1H), 6.97-6.87 (m, 2H), 6.80 (d, J=8.1 Hz, 1H), 5.01 (t, J=7.5 Hz, 1H), 4.07-3.72 (m, 2H), 2.76-2.56 (m, 2H), 1.67 (s, 3H), 1.59 (s, 3H), 1.49 (s, 3H), 1.31 (t, J=7.0 Hz, 3H), 1.23 (s, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 196.7 (t), 165.8 (t), 156.4 (q), 136.1 (q), 134.6 (q), 134.4 (q), 127.8 (t), 126.9 (t), 120.4 (t), 120.2 (t), 111.8 (t), 63.4 (d), 43.1 (q), 39.2 (d), 26.1 (s), 23.4 (s), 18.0 (s), 15.0 (s), 9.5 (s).</p><heading id="h-0048" level="1">Example 43: (E)-2,4,7-trimethyl-4-(4-methylpyridin-3-yl)octa-2,6-dienal</heading><p id="p-0267" num="0261">Following the general procedure described in Example 2: 3-bromo-4-methylpyridine (5.00 g, 29.1 mmol), (E)-2,4,7-trimethylocta-2,6-dienal (2.42 g, 14.53 mmol), diacetoxypalladium (0.16 g, 0.73 mmol), tri-tert-butylphosphane (0.29 g, 1.45 mmol), Cs<sub>2</sub>CO<sub>3 </sub>(5.68 g, 17.44 mmol) in DMF (20 mL) were reacted to give the title product (1.18 g, 30% yield) as a light yellow oil.</p><p id="p-0268" num="0262">GC/MS (EI): m/z (%): 257 (5) [M<sup>+</sup>], 228 (5), 214 (8), 189 (65), 174 (28), 160 (100), 146 (71), 130 (14), 121 (10), 69 (45). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 9.36 (s, 1H), 8.51 (s, 1H), 8.30 (d, J=4.9 Hz, 1H), 6.96 (d, J=4.8 Hz, 1H), 6.74 (s, 1H), 4.88 (t, J=6.9 Hz, 1H), 2.54 (d, J=7.4 Hz, 2H), 2.17 (s, 3H), 1.59 (s, 3H), 1.50 (d, J=10.2 Hz, 6H), 1.14 (s, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 195.5 (t), 160.9 (t), 147.9 (t), 147.7 (q), 145.0 (q), 139.1 (q), 138.5 (q), 135.6 (q), 126.4 (t), 118.6 (t), 43.5 (q), 39.8 (d), 25.9 (s), 24.3 (s), 22.1 (s), 18.0 (s), 9.7 (s).</p><heading id="h-0049" level="1">Example 44: (E)-2,4,7-trimethyl-4-(5-methylthiophen-3-yl)octa-2,6-dienal</heading><p id="p-0269" num="0263">Following the general procedure described in Example 2: 4-bromo-2-methylthiophene (5.00 g, 28.20 mmol), (E)-2,4,7-trimethylocta-2,6-dienal (2.52 g, 14.12 mmol), diacetoxypalladium (0.10 g, 0.42 mmol), tri-tert-butylphosphane (0.17 g, 0.85 mmol), Cs<sub>2</sub>CO<sub>3 </sub>(9.20 g, 28.20 mmol) in DMF (30 mL) were reacted to give the title product (1.80 g, 49% yield) as a light yellow oil.</p><p id="p-0270" num="0264">GC/MS (EI): m/z (%): 262 (1) [M<sup>+</sup>], 193 (43), 178 (65), 165 (100), 149 (11), 135 (7), 111 (7), 69 (9). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 9.36 (s, 1H), 6.71 (d, J=1.4 Hz, 1H), 6.64 (d, J=1.2 Hz, 1H), 6.54 (s, 1H), 5.04 (t, J=7.3 Hz, 1H), 2.56-2.44 (m, 2H), 2.41 (d, J=0.7 Hz, 3H), 1.68 (s, 3H), 1.56 (s, 3H), 1.46 (s, 3H), 1.42 (d, J=1.1 Hz, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 196.2 (t), 161.9 (t), 147.4 (q), 139.8 (q), 139.7 (q), 134.8 (q), 125.3 (t), 119.5 (t), 117.3 (t), 42.9 (q), 41.7 (d), 26.0 (s), 25.3 (s), 18.0 (s), 15.4 (s), 9.7 (s).</p><heading id="h-0050" level="1">Example 45: (E)-4-(furan-3-yl)-2,4,7-trimethylocta-2,6-dienal</heading><p id="p-0271" num="0265">Following the general procedure described in Example 2: 3-bromofuran (3.31 g, 22.51 mmol), (E)-2,4,7-trimethylocta-2,6-dienal (2.01 g, 11.25 mmol), diacetoxypalladium (0.08 g, 0.34 mmol), tri-tert-butylphosphane (0.14 g, 0.68 mmol), Cs<sub>2</sub>CO<sub>3 </sub>(7.33 g, 22.51 mmol) in DMF (30 mL) were reacted to give the title product (1.12 g, 43% yield) as a light yellow oil.</p><p id="p-0272" num="0266">GC/MS (EI): m/z (%): 232 (2) [M<sup>+</sup>], 164 (46), 163 (30), 148 (7), 135 (100), 121 (7), 107 (12), 91 (40), 69 (24). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 9.36 (s, 1H), 7.35 (t, J=1.4 Hz, 1H), 7.20 (s, 1H), 6.58 (d, J=1.1 Hz, 1H), 6.21 (d, J=0.7 Hz, 1H), 5.06 (t, J=7.3 Hz, 1H), 2.55-2.33 (m, 2H), 1.68 (s, 3H), 1.61-1.49 (m, 6H), 1.44 (s, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 196.2 (t), 161.0 (t), 143.1 (t), 139.7 (q), 138.4 (t), 134.9 (q), 131.3 (q), 119.3 (t), 109.7 (t), 41.4 (d), 39.4 (q), 25.9 (s), 25.3 (s), 18.0 (s), 9.9 (s).</p><heading id="h-0051" level="1">Example 46: (E)-4-(2,4-difluorophenyl)-2,4,7-trimethylocta-2,6-dienal</heading><p id="p-0273" num="0267">Following the general procedure described in Example 2: 1-bromo-2,4-difluorobenzene (5.44 g, 28.20 mmol), (E)-2,4,7-trimethylocta-2,6-dienal (2.52 g, 14.10 mmol), diacetoxypalladium (0.10 g, 0.42 mmol), tri-tert-butylphosphane (0.17 g, 0.85 mmol), Cs<sub>2</sub>CO<sub>3 </sub>(9.19 g, 28.20 mmol) in DMF (30 mL) were reacted to give the title product (1.35 g, 35% yield) as a light yellow oil.</p><p id="p-0274" num="0268">GC/MS (EI): m/z (%): 278(1) [M<sup>+</sup>], 276 (3), 210 (98), 195 (41), 181 (27), 164 (22), 141 (21), 127 (45), 69 (100). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 9.41 (s, 1H), 7.36-7.24 (m, 1H), 6.92-6.83 (m, 1H), 6.82-6.78 (m, 1H), 6.77-6.69 (m, 1H), 4.97 (t, J=7.3 Hz, 1H), 2.61 (d, J=7.6 Hz, 2H), 1.67 (s, 3H), 1.56 (s, 3H), 1.53 (s, 3H), 1.31 (s, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 196.0 (t), 163.6 (q), 163.4 (q), 162.5 (q), 162.3 (q), 161.6 (t), 160.3 (q), 160.2 (q), 159.2 (q), 159.0 (q), 138.3 (q), 138.2 (q), 135.6 (q), 129.3 (q), 129.3 (q), 129.2 (q), 129.1 (q), 128.5 (t), 128.5 (t), 128.4 (t), 128.3 (t), 118.8 (t), 110.9 (t), 110.9 (t), 110.7 (t), 110.6 (t), 104.8 (t), 104.4 (t), 104.4 (t), 104.1 (t), 42.3 (q), 42.3 (q), 39.9 (d), 26.0 (s), 23.6 (s), 17.9 (s), 9.6 (s).</p><heading id="h-0052" level="1">Example 47: (E)-4-(4-chloro-2-methylphenyl)-2,4,7-trimethylocta-2,6-dienal</heading><p id="p-0275" num="0269">Following the general procedure described in Example 2: 1-bromo-4-chloro-2-methylbenzene (4.94 g, 24.06 mmol), (E)-2,4,7-trimethylocta-2,6-dienal (2.00 g, 12.03 mmol), diacetoxypalladium (0.14 g, 0.60 mmol), tricyclohexylphosphane (0.34 g, 1.20 mmol), Cs<sub>2</sub>CO<sub>3 </sub>(4.70 g, 14.43 mmol) in DMF (20 mL) were reacted to give the title product (0.86 g, 25% yield) as a yellow oil.</p><p id="p-0276" num="0270">GC/MS (EI): m/z (%): 290 (1) [M<sup>+</sup>], 222 (100), 207 (69), 193 (50), 186 (63), 158 (26), 141 (34), 128 (32), 115 (32), 69 (98). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 9.42 (s, 1H), 7.34-7.23 (m, 1H), 7.20-7.05 (m, 2H), 6.80 (s, 1H), 4.93 (s, 1H), 2.55 (s, 2H), 2.20 (s, 3H), 1.66 (s, 3H), 1.56 (s, 3H), 1.49 (s, 3H), 1.20 (s, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 196.0 (t), 162.2 (t), 142.6 (q), 138.4 (q), 138.0 (q), 135.5 (q), 132.3 (q), 131.8 (t), 128.0 (t), 126.1 (t), 119.2 (t), 44.6 (q), 40.1 (d), 26.2 (s), 25.1 (s), 22.8 (s), 18.2 (s), 9.8 (s).</p><heading id="h-0053" level="1">Example 48: (E)-4-(4-fluorophenyl)-2,4,7-trimethylocta-2,6-dienal</heading><p id="p-0277" num="0271">Following the general procedure described in Example 2: 1-bromo-4-fluorobenzene (2.93 g, 16.74 mmol), (E)-2,4,7-trimethylocta-2,6-dienal (1.56 g, 8.37 mmol), diacetoxypalladium (0.09 g, 0.42 mmol), tricyclohexylphosphane (0.24 g, 0.84 mmol), Cs<sub>2</sub>CO<sub>3 </sub>(3.27 g, 10.05 mmol) in DMF (20 mL) were reacted to give the title product (1.20 g, 55% yield) as a yellow oil.</p><p id="p-0278" num="0272">GC/MS (EI): m/z (%): 260 (1)[M<sup>+</sup>], 192 (100), 177 (57), 163 (25), 146 (22), 133 (14), 109 (16), 95 (2), 83 (2), 69 (65). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 9.40 (s, 1H), 7.23-7.14 (m, 2H), 6.95 (t, J=8.7 Hz, 2H), 6.75 (d, J=1.0 Hz, 1H), 4.97 (t, J=7.4 Hz, 1H), 2.48 (d, J=7.4 Hz, 2H), 1.64 (s, 3H), 1.49 (s, 6H), 1.28 (d, J=0.9 Hz, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 196.0 (t), 162.8 (q), 162.5 (t), 159.6 (q), 142.2 (q), 142.1 (q), 139.9 (q), 135.3 (q), 128.2 (t), 128.1 (t), 119.1 (t), 115.1 (t), 114.8 (t), 44.4 (q), 42.9 (d), 26.0 (s), 24.8 (s), 17.9 (s), 10.4 (s).</p><heading id="h-0054" level="1">Example 49: (E)-4-(3-fluorophenyl)-2,4,7-trimethylocta-2,6-dienal</heading><p id="p-0279" num="0273">Following the general procedure described in Example 2: 1-bromo-3-fluorobenzene (2.93 g, 16.74 mmol), (E)-2,4,7-trimethylocta-2,6-dienal (1.56 g, 8.37 mmol), diacetoxypalladium (0.094 g, 0.419 mmol), tricyclohexylphosphane (0.24 g, 0.84 mmol), Cs<sub>2</sub>CO<sub>3 </sub>(3.27 g, 10.05 mmol) in DMF (20 mL) were reacted to give the title product (1.18 g, 54% yield) as a yellow oil.</p><p id="p-0280" num="0274">GC/MS (EI): m/z (%): 260 (1) [M<sup>+</sup>], 192 (100), 177 (59), 163 (65), 146 (27), 133 (17), 109 (23), 96 (3), 83 (3), 69 (45). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 9.43 (s, 1H), 7.31-7.21 (m, 1H), 7.07-6.86 (m, 3H), 6.76 (d, J=1.1 Hz, 1H), 5.00 (t, J=7.4 Hz, 1H), 2.60-2.40 (m, 2H), 1.68 (s, 3H), 1.52 (d, J=5.0 Hz, 6H), 1.32 (d, J=1.0 Hz, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 196.0 (t), 164.5 (q), 161.9 (t), 161.3 (q), 149.3 (q), 149.3 (q), 140.1 (q), 135.5 (q), 129.8 (t), 129.7 (t), 122.5 (t), 122.4 (t), 119.0 (t), 113.9 (t), 113.6 (t), 113.2 (t), 112.9 (t), 44.9 (q), 44.8 (q), 42.7 (d), 26.0 (s), 24.7 (s), 18.0 (s), 10.5 (s).</p><heading id="h-0055" level="1">Example 50: (E)-2,4,7-trimethyl-4-phenylocta-2,6-dienal</heading><p id="p-0281" num="0275">To a three-necked round-bottomeed flask equipped with a magnetic stirrer, Dean-Stark and Water condensor, was added 3-methylbut-2-en-1-ol (9.69 g, 110.00 mmol), (E)-2-methyl-4-phenylpent-2-enal (11.71 g, 55.10 mmol), and triethylamine hydrochloride (0.38 g, 2.76 mmol) in xylene (30 ml) to give a light colorless solution. The reaction mixture was stirred and heated to a refluxing temperature at 150&#xb0; C. Water was collected from Dean-Stark. The reaction was heated at refluxing for 16 hours. Then cooled to room temperature and filtered through a short silica gel pad. Washed with MTBE (150 mL). The crude product was concentrated in rotary evaporator remove excessive xylene and alcohol. Then purified by distillation, kugelrohr (0.03 mbar/155&#xb0; C.) to obtain the title product (5.691 g, 22.07 mmol, 40.0% yield) as a light yellow oil.</p><p id="p-0282" num="0276">GC/MS (EI): m/z (%): 242 (1) [M<sup>+</sup>], 174 (100), 159 (57), 145(49), 128 (27), 115 (20), 105 (11), 91 (19), 77 (10), 69 (22). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 9.42 (s, 1H), 7.30-7.23 (m, 5H), 6.79 (d, J=1.1 Hz, 1H), 5.09-4.93 (m, 1H), 2.60-2.44 (m, 2H), 1.67 (s, 3H), 1.53 (d, J=3.5 Hz, 6H), 1.31 (d, J=1.1 Hz, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 196.3 (t), 163.0 (t), 146.5 (q), 139.9 (q), 135.1 (q), 128.3 (t), 126.6 (t), 126.2 (t), 119.4 (t), 44.9 (q), 42.7 (d), 26.0 (s), 24.8 (s), 18.0 (s), 10.4 (s).</p><heading id="h-0056" level="1">Example 51: (E)-2-methyl-3-(2,4,7-trimethyl-1-oxoocta-2,6-dien-4-yl)benzonitrile</heading><p id="p-0283" num="0277">Following the general procedure described in Example 2: 3-iodo-2-methylbenzonitrile (2.00 g, 8.23 mmol), (E)-2,4,7-trimethylocta-2,6-dienal (2.74 g, 16.46 mmol), diacetoxypalladium (0.09 g, 0.41 mmol), tri-tert-butylphosphane (0.17 g, 0.82 mmol), Cs<sub>2</sub>CO<sub>3 </sub>(3.22 g, 9.87 mmol) in DMF (60 mL) were reacted to give the title product (0.42 g, 18% yield) as a light yellow oil.</p><p id="p-0284" num="0278">GC/MS (EI): m/z (%): 281 (1) [M<sup>+</sup>], 213 (62), 198 (38), 184 (13), 170 (10), 154 (11), 140 (8), 69 (100)</p><heading id="h-0057" level="1">Example 52: (E)-2,4,7-trimethyl-4-(5-methylthiophen-2-yl)octa-2,6-dienal</heading><p id="p-0285" num="0279">Following the general procedure described in Example 2: 2-bromo-5-methylthiophene (1.75 g, 9.88 mmol), (E)-2,4,7-trimethylocta-2,6-dienal (4.93 g, 29.7 mmol), diacetoxypalladium (0.11 g, 0.49 mmol), tricyclohexylphosphane (0.28 g, 0.99 mmol), Cs<sub>2</sub>CO<sub>3 </sub>(6.44 g, 19.77 mmol) in DMF (35 mL) were reacted to give the title product (0.54 g, 21% yield) as a light yellow oil.</p><p id="p-0286" num="0280">GC/MS (EI): m/z (%): 262 (1) [M<sup>+</sup>], 193 (73), 178 (54), 165 (100), 149 (10), 135 (8), 125 (8), 111 (10), 91 (9), 59 (13).</p><heading id="h-0058" level="1">Example 53: (E)-2,4,7-trimethyl-4-(2,4,5-trimethylphenyl)octa-2,6-dienal</heading><p id="p-0287" num="0281">Following the general procedure described in Example 2: 1-bromo-2,4,5-trimethylbenzene (5.00 g, 25.10 mmol), (E)-2,4,7-trimethylocta-2,6-dienal (2.25 g, 12.56 mmol), diacetoxypalladium (0.09 g, 0.38 mmol), tri-tert-butylphosphane (0.15 g, 0.75 mmol), Cs<sub>2</sub>CO<sub>3 </sub>(8.18 g, 25.10 mmol) in DMF (30 mL) were reacted to give the title product (1.51 g, 42% yield) as a light yellow oil.</p><p id="p-0288" num="0282">GC/MS (EI): m/z (%): 284 (1) [M<sup>+</sup>], 215 (54), 200 (68), 187 (100), 173 (31), 157 (26), 141 (15), 128 (10), 115 (9), 69 (11).</p><heading id="h-0059" level="1">Example 54: (E)-4-(2,6-dimethylphenyl)-2,4,7-trimethylocta-2,6-dienal</heading><p id="p-0289" num="0283">Following the general procedure described in Example 2: 2-bromo-1,3-dimethylbenzene (6.68 g, 36.1 mmol), (E)-2,4,7-trimethylocta-2,6-dienal (3.00 g, 18.0 mmol), diacetoxypalladium (0.20 g, 0.90 mmol), tri-tert-butylphosphane (0.37 g, 1.80 mmol), Cs<sub>2</sub>CO<sub>3 </sub>(7.05 g, 21.7 mmol) in DMF (20 mL) were reacted to give the title product (1.02 g, 21% yield) as a yellow oil.</p><p id="p-0290" num="0284">GC/MS (EI): m/z (%): 270 (1) [M<sup>+</sup>], 202 (48), 186 (90), 173 (100), 159 (51), 143 (49), 129 (56), 109 (51).</p><heading id="h-0060" level="1">Example 55: (E)-2,4,7-trimethylocta-2,6-dienal</heading><p id="p-0291" num="0285">A mixture of (E)-2-methylbut-2-enal (100 g, 1161 mmol), 3-methylbut-2-en-1-ol (195 g, 2322 mmol) and 7.99 g Et<sub>3</sub>N&#x2014;HCl in xylene was refluxed for 36 hours. During this period, water was collected and removed from Dean-Stark apparatus, and the reaction was monitored by GC. After cooled to room temperature, the reaction mixture was diluted with MTBE, and washed with water and brine, dried with MgSO<sub>4</sub>, filtered, then evaporated under reduced pressure to give crude product, which was purified by distillation to afford (E)-2,7-dimethylocta-2,6-dienal (77.5 g, 44% yield) as a colorless oil.</p><heading id="h-0061" level="1">Example 56: (E)-4-methyl-3-(2,4,7-trimethyl-1-oxoocta-2,6-dien-4-yl)benzonitrile (General Procedure)</heading><p id="p-0292" num="0286">A mixture of 3-bromo-4-methylbenzonitrile (4.62 g, 23.55 mmol), (E)-2,7-dimethylocta-2,6-dienal (1.82 g, 11.77 mmol), diacetoxypalladium (0.13 g, 0.59 mmol), tri-tert-butylphosphane (0.24 g, 1.18 mmol), Cs<sub>2</sub>CO<sub>3 </sub>(3.84 g, 11.77 mmol) in DMF (20 mL) was heated to 110-120&#xb0; C. under Ar atmosphere overnight, and the reaction was monitored by TLC, GC and GC-MS. After cooling to room temperature, the reaction mixture was diluted with MTBE, and filtered through a small pad of silica gel and the silica gel was washed with MTBE. Then the combined filtrates were concentrated in vacuo to give crude product, which was purified by distillation or flash chromatography (hexane/MTBE=50: 1-10:1) to afford (E)-3-(2,7-dimethyl-1-oxoocta-2,6-dien-4-yl)-4-methylbenzonitrile (1.03 g yield: 31%) as light yellow oil.</p><p id="p-0293" num="0287">GC/MS (EI): m/z (%): 267 (1) [M<sup>+</sup>], 199 (100), 184 (21), 170 (11), 154 (11), 140 (13), 127 (9), 115 (8), 103 (5), 69 (83). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 9.44 (s, 1H), 7.55 (s, 1H), 7.47-7.40 (m, 1H), 7.27 (d, J=8.0 Hz, 1H), 6.50 (d, J=9.6 Hz, 1H), 5.02 (t, J=7.1 Hz, 1H), 4.04 (q, J=16.7, 7.4 Hz, 1H), 2.49 (t, J=7.2 Hz, 2H), 2.40 (s, 3H), 1.76 (s, 3H), 1.67 (s, 3H), 1.58 (s, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 194.9 (t), 154.8 (t), 142.5 (q), 141.7 (q), 139.5 (q), 134.9 (q), 131.4 (t), 130.3 (t), 130.1 (t), 120.0 (t), 119.0 (q), 110.4 (q), 40.8 (t), 33.9 (d), 25.7 (s), 20.1 (s), 17.9 (s), 9.8 (s).</p><heading id="h-0062" level="1">Example 57: (E)-2,7-dimethyl-4-phenylocta-2,6-dienal</heading><p id="p-0294" num="0288">Following the general procedure described in Example 56: bromobenzene (4.07 g, 25.90 mmol), (E)-2,7-dimethylocta-2,6-dienal (2.15 g, 12.96 mmol), diacetoxypalladium (0.15 g, 0.65 mmol), tricyclohexylphosphine (0.36 g, 1.30 mmol), Cs<sub>2</sub>CO<sub>3 </sub>(5.07 g, 15.56 mmol) in DMF (20 mL) were reacted to give the title product (2.04 g, 69% yield) as a light yellow oil.</p><p id="p-0295" num="0289">GC/MS (EI): m/z (%): 228 (1) [M<sup>+</sup>], 160 (100), 145 (41), 131(30), 115(28), 91 (40), 77 (12), 69 (71), 53 (12). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 9.42 (s, 1H), 7.36-7.28 (m, 2H), 7.26-7.21 (m, 3H), 6.59 (d, J=9.9 Hz, 1H), 5.03 (t, J=7.1 Hz, 1H), 3.82 (dd, J=16.9, 7.7 Hz, 1H), 2.59-2.42 (m, 2H), 1.78 (s, 3H), 1.65 (s, 3H), 1.58 (s, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 195.4 (t), 156.9 (t), 142.6 (q), 138.8 (q), 134.1 (q), 128.9 (t), 127.6 (t), 127.0 (t), 121.0 (t), 45.6 (t), 34.8 (d), 25.9 (s), 18.1 (s), 9.7 (s).</p><heading id="h-0063" level="1">Example 58: (E)-4-(2,4-dimethylphenyl)-2,7-dimethylocta-2,6-dienal</heading><p id="p-0296" num="0290">Following the general procedure described in Example 56: 1-bromo-2,4-dimethylbenzene (7.29 g, 39.4 mmol), (E)-2,7-dimethylocta-2,6-dienal (3.00 g, 19.71 mmol), diacetoxypalladium (0.22 g, 0.99 mmol), tricyclohexylphosphane (0.55 g, 1.971 mmol), Cs<sub>2</sub>CO<sub>3 </sub>(7.70 g, 23.65 mmol) in DMF (20 mL) were reacted to give the title product (1.60 g, 32% yield) as a yellow oil.</p><p id="p-0297" num="0291">GC/MS (EI): m/z (%): 256 (2) [M<sup>+</sup>], 188 (72), 173 (43), 172 (50), 159 (100), 144 (22), 129 (14), 69 (15). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 9.41 (s, 1H), 7.17 (d, J=7.8 Hz, 1H), 7.06-6.98 (m, 2H), 6.53 (d, J=13.2, 6.6 Hz, 1H), 5.07 (t, J=7.1 Hz, 1H), 4.00 (q, J=17.0, 7.5 Hz, 1H), 2.46 (t, J=18.9, 11.5 Hz, 2H), 2.30 (d, J=1.9 Hz, 6H), 1.78 (d, J=0.9 Hz, 3H), 1.67 (s, 3H), 1.61 (s, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 195.5 (t), 157.5 (t), 138.5 (q), 137.9 (q), 136.2 (q), 135.7 (q), 133.9 (q), 131.5 (t), 127.3 (t), 126.3 (t), 121.2 (t), 40.9 (t), 34.3 (d), 25.8 (s), 21.0 (s), 19.7 (s), 18.0 (s), 9.7 (s).</p><heading id="h-0064" level="1">Example 59: (E)-4-(4-chloro-2-methylphenyl)-2,7-dimethylocta-2,6-dienal</heading><p id="p-0298" num="0292">Following the general procedure described in Example 56: 1-bromo-4-chloro-2-methylbenzene (8.10 g, 39.40 mmol), (E)-2,7-dimethylocta-2,6-dienal (3.00 g, 19.71 mmol), diacetoxypalladium (0.22 g, 0.99 mmol), tricyclohexylphosphane (0.55 g, 1.97 mmol), Cs<sub>2</sub>CO<sub>3 </sub>(7.70 g, 23.65 mmol) in DMF (20 mL) were reacted to give the title product (1.00 g, 18% yield) as a yellow oil.</p><p id="p-0299" num="0293">GC/MS (EI): m/z (%): 276 (1)[M<sup>+</sup>], 208 (88), 193 (37), 179 (30), 172 (40), 144 (27), 129 (18), 69 (100). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 9.41 (s, 1H), 7.22-7.10 (m, 3H), 6.51 (d, J=9.5 Hz, 1H), 5.03 (t, J=7.1 Hz, 1H), 3.97 (q, J=16.7, 7.5 Hz, 1H), 2.45 (t, J=7.2 Hz, 2H), 2.30 (s, 3H), 1.75 (s, 3H), 1.66 (s, 3H), 1.58 (s, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 195.2 (t), 156.3 (t), 139.5 (q), 139.0 (q), 137.8 (q), 134.4 (q), 132.1 (q), 130.5 (t), 127.9 (t), 126.6 (t), 120.6 (t), 40.7 (t), 34.2 (d), 25.8 (s), 19.6 (s), 18.0 (s), 9.8 (s).</p><heading id="h-0065" level="1">Example 60: (E)-4-(2,5-dimethylphenyl)-2,7-dimethylocta-2,6-dienal</heading><p id="p-0300" num="0294">Following the general procedure described in Example 56: 2-bromo-1,4-dimethylbenzene (7.29 g, 39.4 mmol), (E)-2,7-dimethylocta-2,6-dienal (3.00 g, 19.71 mmol), diacetoxypalladium (0.22 g, 0.99 mmol), tricyclohexylphosphane (0.55 g, 1.97 mmol), Cs<sub>2</sub>CO<sub>3 </sub>(7.70 g, 23.65 mmol) in DMF (20 mL) were reacted to give the title product (1.44 g, 28% yield) as a yellow oil.</p><p id="p-0301" num="0295">GC/MS (EI): m/z (%): 256 (2) [M<sup>+</sup>], 188 (100), 173 (86), 172 (52), 159 (76), 144 (23), 115 (10), 69 (36). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 9.41 (s, 1H), 7.06 (d, J=8.5 Hz, 2H), 6.96 (d, J=7.5 Hz, 1H), 6.55 (d, J=11.8 Hz, 1H), 5.07 (t, J=7.1 Hz, 1H), 4.08-3.94 (m, 1H), 2.47 (t, J=17.3, 10.1 Hz, 2H), 2.34 (s, 3H), 2.29 (s, 3H), 1.78 (s, 3H), 1.67 (s, 3H), 1.61 (s, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 195.4 (t), 157.3 (t), 140.7 (q), 138.5 (q), 135.9 (q), 133.9 (q), 132.5 (q), 130.5 (t), 127.2 (t), 127.0 (t), 121.1 (t), 41.1 (t), 34.3 (d), 25.7 (s), 21.1 (s), 19.2 (s), 17.9 (s), 9.7 (s).</p><heading id="h-0066" level="1">Example 61: (E)-4-(5-chloro-2-methylphenyl)-2,7-dimethylocta-2,6-dienal</heading><p id="p-0302" num="0296">Following the general procedure described in Example 56: 2-bromo-4-chloro-1-methylbenzene (8.10 g, 39.4 mmol), (E)-2,7-dimethylocta-2,6-dienal (3.00 g, 19.71 mmol), diacetoxypalladium (0.22 g, 0.99 mmol), tricyclohexylphosphane (0.55 g, 1.97 mmol), Cs<sub>2</sub>CO<sub>3 </sub>(7.70 g, 23.65 mmol) in DMF (20 mL) were reacted to give the title product (0.62 g, 11% yield) as a yellow oil.</p><p id="p-0303" num="0297">GC/MS (EI): m/z (%): 276 (1) [M<sup>+</sup>], 210 (25), 208 (78), 173 (28), 141 (12), 128 (13), 115 (8), 69 (100). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 9.42 (s, 1H), 7.21 (s, 1H), 7.14-7.04 (m, 2H), 6.48 (d, J=11.3 Hz, 1H), 5.03 (t, J=7.2 Hz, 1H), 3.97 (q, J=16.9, 7.4 Hz, 1H), 2.46 (t, J=7.3 Hz, 2H), 2.28 (s, 3H), 1.76 (s, 3H), 1.66 (s, 3H), 1.59 (s, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 195.2 (t), 155.9 (t), 142.8 (q), 139.2 (q), 134.5 (q), 134.2 (q), 132.2 (q), 131.9 (t), 126.6 (t), 120.5 (t), 41.2 (t), 34.2 (d), 25.8 (s), 19.2 (s), 18.0 (s), 9.8 (s).</p><heading id="h-0067" level="1">Example 62: (E)-4-(4-fluoro-2-methyl phenyl)-2,7-dimethylocta-2,6-dienal</heading><p id="p-0304" num="0298">Following the general procedure described in Example 56: 1-bromo-4-fluoro-2-methylbenzene (7.45 g, 39.4 mmol), (E)-2,7-dimethylocta-2,6-dienal (3.00 g, 19.71 mmol), diacetoxypalladium (0.22 g, 0.99 mmol), tricyclohexylphosphane (0.553 g, 1.971 mmol), Cs<sub>2</sub>CO<sub>3 </sub>(7.70 g, 23.65 mmol) in DMF (20 mL) were reacted to give the title product (1.03 g, 20% yield) as a yellow oil.</p><p id="p-0305" num="0299">GC/MS (EI): m/z (%): 260 (1) [M<sup>+</sup>], 192 (100), 177 (46), 163 (59), 146 (26), 133 (19), 123 (26), 109 (10), 77 (5), 69 (50). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 9.41 (s, 1H), 7.24-7.16 (m, 1H), 6.94-6.82 (m, 2H), 6.51 (dd, J=9.6, 1.0 Hz, 1H), 5.03 (t, J=7.2 Hz, 1H), 3.97 (q, J=16.9, 7.4 Hz, 1H), 2.45 (t, J=7.2 Hz, 2H), 2.31 (s, 3H), 1.75 (s, 3H), 1.65 (s, 3H), 1.57 (s, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 195.3 (t), 162.8 (q), 159.6 (q), 156.7 (t), 138.8 (q), 138.2 (q), 138.1 (q), 136.6 (q), 134.3 (q), 128.0 (t), 127.9 (t), 120.7 (t), 117.3 (t), 117.1 (t), 113.4 (t), 113.1 (t), 40.6 (t), 34.3 (d), 25.8 (s), 19.8 (s), 17.9 (s), 9.7 (s).</p><heading id="h-0068" level="1">Example 63: (E)-4-(3-chloro-2-methylphenyl)-2,7-dimethylocta-2,6-dienal</heading><p id="p-0306" num="0300">Following the general procedure described in Example 56: 1-bromo-3-chloro-2-methylbenzene (5.00 g, 24.33 mmol), (E)-2,7-dimethylocta-2,6-dienal (1.85 g, 12.17 mmol), diacetoxypalladium (0.14 g, 0.61 mmol), tricyclohexylphosphane (0.34 g, 1.22 mmol), Cs<sub>2</sub>CO<sub>3 </sub>(4.76 g, 14.60 mmol) in DMF (20 mL) were reacted to give the title product (0.40 g, 12% yield) as a yellow oil.</p><p id="p-0307" num="0301">GC/MS (EI): m/z (%): 276 (1) [M<sup>+</sup>], 210 (22), 208 (66), 173 (55), 141 (12), 128 (13), 115 (9), 69 (100). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 9.43 (s, 1H), 7.31-7.26 (m, 1H), 7.21-7.11 (m, 2H), 6.54 (d, J=9.3 Hz, 1H), 5.05 (t, J=6.5 Hz, 1H), 4.22-3.96 (m, 1H), 2.48 (t, J=7.1 Hz, 2H), 2.39 (s, 3H), 1.76 (s, 3H), 1.68 (s, 3H), 1.60 (s, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 195.2 (t), 156.3 (t), 143.1 (q), 139.2 (q), 135.3 (q), 134.5 (q), 133.9 (q), 127.7 (t), 127.1 (t), 125.1 (t), 120.7 (t), 41.9 (t), 34.4 (d), 25.8 (s), 18.0 (s), 16.0 (s), 9.8 (s).</p><heading id="h-0069" level="1">Example 64: (E)-4-(2-methoxyphenyl)-2,7-dimethylocta-2,6-dienal</heading><p id="p-0308" num="0302">Following the general procedure described in Example 56: 1-bromo-2-methoxybenzene (7.37 g, 39.4 mmol), (E)-2,7-dimethylocta-2,6-dienal (3.00 g, 19.71 mmol), diacetoxypalladium (0.22 g, 0.99 mmol), tricyclohexylphosphane (0.55 g, 1.97 mmol), Cs<sub>2</sub>CO<sub>3 </sub>(7.70 g, 23.65 mmol) in DMF (20 mL) were reacted to give the title product (1.90 g, 37% yield) as a yellow oil.</p><p id="p-0309" num="0303">GC/MS (EI): m/z (%): 258 (3) [M<sup>+</sup>], 189 (100), 174 (64), 161 (51), 145 (13), 128 (19), 115 (25), 107 (8), 91 (40), 69 (19). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 9.41 (s, 1H), 7.26-7.16 (m, 2H), 6.99-6.83 (m, 2H), 6.61 (dd, J=9.8, 1.1 Hz, 1H), 5.06 (t, J=7.1 Hz, 1H), 4.30-4.13 (m, 1H), 3.83 (s, 3H), 2.60-2.41 (m, 2H), 1.77 (d, J=1.1 Hz, 3H), 1.66 (s, 3H), 1.60 (s, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 195.8 (t), 157.4 (t), 157.1 (q), 138.9 (q), 133.6 (q), 130.7 (q), 128.0 (t), 127.8 (t), 121.5 (t), 120.8 (t), 110.8 (t), 55.4 (s), 39.4 (t), 33.1 (d), 25.8 (s), 18.0 (s), 9.5 (s).</p><heading id="h-0070" level="1">Example 65: (E)-4-(5-fluoro-2-methylphenyl)-2,7-dimethylocta-2,6-dienal</heading><p id="p-0310" num="0304">Following the general procedure described in Example 56: 2-bromo-4-fluoro-1-methylbenzene (7.45 g, 39.40 mmol), (E)-2,7-dimethylocta-2,6-dienal (3.00 g, 19.71 mmol), diacetoxypalladium (0.22 g, 0.99 mmol), tricyclohexylphosphane (0.55 g, 1.97 mmol), Cs<sub>2</sub>CO<sub>3 </sub>(7.70 g, 23.65 mmol) in DMF (20 mL) were reacted to give the title product (1.45 g, 28% yield) as a yellow oil.</p><p id="p-0311" num="0305">GC/MS (EI): m/z (%): 260 (1) [M<sup>+</sup>], 192 (100), 177 (23), 163 (18), 146 (23), 133 (17), 123 (15), 109 (8), 69 (82). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 9.42 (s, 1H), 7.10 (dd, J=8.1, 6.2 Hz, 1H), 6.96 (dd, J=10.2, 2.6 Hz, 1H), 6.83 (td, J=8.3, 2.7 Hz, 1H), 6.49 (dd, J=9.6, 1.0 Hz, 1H), 5.04 (t, J=7.2 Hz, 1H), 3.99 (dd, J=15.9, 7.7 Hz, 1H), 2.46 (t, J=7.3 Hz, 2H), 2.28 (s, 3H), 1.76 (d, J=1.0 Hz, 3H), 1.66 (s, 3H), 1.59 (s, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 195.2 (t), 163.3 (q), 160.1 (q), 156.0 (t), 142.9 (q), 142.9 (q), 139.1 (q), 134.4 (q), 131.8 (t), 131.7 (t), 131.3 (q), 131.3 (q), 120.6 (t), 113.5 (t), 113.4 (t), 113.2 (t), 113.1 (t), 41.34 (t), 41.3 (t), 34.1 (d), 25.8 (s), 19.0 (s), 17.9 (s), 9.8 (s).</p><heading id="h-0071" level="1">Example 66: (E)-2,7-dimethyl-4-(o-tolyl)octa-2,6-dienal</heading><p id="p-0312" num="0306">Following the general procedure described in Example 56: 1-bromo-2-methylbenzene (4.43 g, 25.9 mmol), (E)-2,7-dimethylocta-2,6-dienal (2.15 g, 12.96 mmol), diacetoxypalladium (0.15 g, 0.65 mmol), tricyclohexylphosphine (0.36 g, 1.30 mmol), Cs<sub>2</sub>CO<sub>3 </sub>(5.07 g, 15.56 mmol) in DMF (20 mL) were reacted to give the title product (1.89 g, 60% yield) as a light yellow oil.</p><p id="p-0313" num="0307">GC/MS (EI): m/z (%): 242 (1) [M<sup>+</sup>], 174 (100), 159 (81), 145 (70), 128 (58), 115 (45), 105 (26), 91 (20), 69 (52). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 9.40 (s, 1H), 7.25-7.09 (m, 4H), 6.54 (d, J=9.7, 1.1 Hz, 1H), 5.04 (t, J=7.2 Hz, 1H), 4.01 (q, J=9.5, 7.4 Hz, 1H), 2.53-2.42 (m, 2H), 2.31 (s, 3H), 1.75 (d, J=1.1 Hz, 3H), 1.64 (s, 3H), 1.57 (s, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 195.4 (t), 157.2 (t), 140.9 (q), 138.6 (q), 135.7 (q), 134.0 (q), 130.6 (t), 126.6 (t), 126.4 (t), 121.0 (t), 41.1 (t), 34.2 (d), 25.8 (s), 19.7 (s), 17.9 (s), 9.7 (s).</p><heading id="h-0072" level="1">Example 67: (E)-4-(2-ethylphenyl)-2,7-dimethylocta-2,6-dienal</heading><p id="p-0314" num="0308">Following the general procedure described in Example 56: 1-bromo-2-ethylbenzene (5.00 g, 27.0 mmol), (E)-2,7-dimethylocta-2,6-dienal (2.36 g, 13.51 mmol), diacetoxypalladium (0.15 g, 0.68 mmol), tricyclohexylphosphane (0.38 g, 1.35 mmol), Cs<sub>2</sub>CO<sub>3 </sub>(5.28 g, 16.21 mmol) in DMF (20 mL) were reacted to give the title product (2.01 g, 58% yield) as a yellow oil. GC/MS (EI): m/z (%): 256 (1)[M<sup>+</sup>], 188 (73), 173 (10), 159 (100), 141 (17), 131 (30), 115 (25), 103 (4), 91 (20), 69 (24).</p><heading id="h-0073" level="1">Example 68: (E)-4-(4-fluoro-2-methoxyphenyl)-2,4,7-trimethylocta-2,6-dienal</heading><p id="p-0315" num="0309">Following the general procedure described in Example 56: 1-bromo-4-fluoro-2-methoxybenzene (3.43 g, 16.7 mmol), (E)-2,4,7-trimethylocta-2,6-dienal (1.56 g, 8.37 mmol), diacetoxypalladium (0.094 g, 0.42 mmol), tricyclohexylphosphane (0.235 g, 0.84 mmol), Cs<sub>2</sub>CO<sub>3 </sub>(3.27 g, 10.1 mmol) in DMF (20 mL) were reacted to give the title product (1.86 g, 73% yield) as a light yellow oil.</p><p id="p-0316" num="0310">GC/MS (EI): m/z (%): 290 (1) [M<sup>+</sup>], 221 (100), 206 (35), 193 (46), 179 (18), 139 (19), 109 (18), 69 (10).</p><heading id="h-0074" level="1">Example 69: (E)-2,4,7-trimethyl-4-(3-methylbut-2-en-1-yl)octa-2,6-dienal</heading><p id="p-0317" num="0311">Following the general procedure described in Example 1: 2,4,7-trimethylocta-2,6-dienal, 3-methylbut-2-en-1-ol and Et<sub>3</sub>N&#x2014;HCl were reacted in xylene to give the title product as a colorless oil.</p><p id="p-0318" num="0312">GC/MS (EI): m/z (%): 234 (1) [M<sup>+</sup>], 166 (82), 151 (9), 137 (22), 123 (56), 108 (61), 95 (58), 81 (21), 69 (100), 55 (17). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 9.31 (s, 1H), 6.33 (s, 1H), 5.07 (t, J=7.1 Hz, 2H), 2.33-2.06 (m, 4H), 1.84 (s, 3H), 1.69 (s, 6H), 1.59 (s, 6H), 1.18 (s, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 196.8 (t), 163.6 (t), 138.6 (q), 134.2 (q), 120.1 (t), 42.5 (q), 39.4 (d), 26.1 (s), 24.4 (s), 18.1 (s), 10.1 (s).</p><heading id="h-0075" level="1">Example 70: (E)-2,7-dimethyl-4-(3-methylbut-2-en-1-yl)octa-2,6-dienal</heading><p id="p-0319" num="0313">Following the general procedure described in Example 1: 2,7-dimethylocta-2,6-dienal, 3-methylbut-2-en-1-ol and Et<sub>3</sub>N&#x2014;HCl were reacted in xylene to give the title product as a colorless oil.</p><p id="p-0320" num="0314">GC/MS (EI): m/z (%): 220 (4) [M<sup>+</sup>], 205(3), 177 (3), 152 (55), 137 (7), 109 (38), 95 (20), 82 (44), 77 (10), 69 (100). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 9.39 (s, 1H), 6.26 (d, J=10.2 Hz, 1H), 5.04 (t, J=9.0, 4.3 Hz, 2H), 2.74-2.53 (m, 1H), 2.30-2.12 (m, 2H), 2.09-1.94 (m, 2H), 1.69 (d, J=14.5 Hz, 9H), 1.58 (s, 6H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 195.7 (t), 159.2 (t), 139.0 (q), 133.5 (q), 121.4 (t), 40.4 (t), 32.8 (d), 25.8 (s), 17.9 (s), 9.7 (s).</p><heading id="h-0076" level="1">Example 71: 4-ethyl-2-methylhex-2-enal</heading><p id="p-0321" num="0315">A solution of 2-ethylbutanal (50 g, 0.5 mol) in Methanol (100 mL) was treated at room temperature with a solution of sodium hydroxide (3.99 g, 100 mmol) in water (5 mL). The resulting solution was cooled to 0&#xb0; C. then treated dropwise over 3 h under vigorous stirring with propionaldehyde (72.5 g, 1.25 mol) and then allowed to warm to r.t. overnight. The resulting mixture was neutralized by addition of acetic acid and concentrated under reduced pressure. The residue was extracted with MTBE (3&#xd7;150 mL), the combined extracts washed with brine, dried over MgSO<sub>4 </sub>and concentrated under reduced pressure to give an oil which was subjected to Kugelrohr distillation (0.9 mbar, 80&#xb0; C.) to give 4-ethyl-2-methylhex-2-enal (25 g, 36% yield) as a colorless oil.</p><p id="p-0322" num="0316">GC/MS (EI): m/z (%): 140 (13) [M<sup>+</sup>], 125 (12), 111 (100), 97 (19), 83 (22), 69 (28), 55 (71).</p><heading id="h-0077" level="1">Example 72: (E)-4,4-diethyl-2,7-dimethylocta-2,6-dienal</heading><p id="p-0323" num="0317">Following the general procedure described in Example 1: 4-ethyl-2-methylhex-2-enal, 3-methylbut-2-en-1-ol and Et<sub>3</sub>N&#x2014;HCl were reacted in xylene to give the title product as a colorless oil.</p><p id="p-0324" num="0318">GC/MS (EI): m/z (%): 208 (1) [M<sup>+</sup>], 140 (100), 125 (20), 111 (79), 95 (22), 81 (19), 69 (66), 55 (31).</p><heading id="h-0078" level="1">Example 73: (E)-4-ethyl-2,4,7-trimethylocta-2,6-dienal</heading><p id="p-0325" num="0319">Following the general procedure described in Example 1: 2,4-dimethylhept-2-enal, 3-methylbut-2-en-1-ol and Et<sub>3</sub>N&#x2014;HCl were reacted in xylene to give the title product as a colorless oil.</p><p id="p-0326" num="0320">GC/MS (EI): m/z (%): 208 (1) [M<sup>+</sup>], 140 (100), 125 (9), 111 (40), 97 (42), 83 (10), 69 (66), 55 (17).</p><heading id="h-0079" level="1">Example 74: (E)-4-(3-methylbut-2-en-1-yl)non-2-enal</heading><p id="p-0327" num="0321">Following the general procedure described in Example 1: non-2-enal, 3-methylbut-2-en-1-ol and Et<sub>3</sub>N&#x2014;HCl were reacted in xylene to give the title product as a colorless oil.</p><p id="p-0328" num="0322">GC/MS (EI): m/z (%): 208 (1) [M<sup>+</sup>], 140 (48), 111 (2), 96 (25), 83 (26), 69 (100), 55 (10).</p><heading id="h-0080" level="1">Example 75: (E)-4-butyl-7-methylocta-2,6-dienal</heading><p id="p-0329" num="0323">Following the general procedure described in Example 1: oct-2-enal, 3-methylbut-2-en-1-ol and Et<sub>3</sub>N&#x2014;HCl were reacted in xylene to give the title product as a colorless oil.</p><p id="p-0330" num="0324">GC/MS (EI): m/z (%): 194 (2) [M<sup>+</sup>], 126 (67), 95 (6), 83 (34), 69 (17), 55 (10).</p><heading id="h-0081" level="1">Example 76: (E)-4-ethyl-2,4,7-trimethylocta-2,6-dienal</heading><p id="p-0331" num="0325">Following the general procedure described in Example 1: 2,4-dimethylhex-2-enal, 3-methylbut-2-en-1-ol and Et<sub>3</sub>N&#x2014;HCl were reacted in xylene to give the title product as a light yellow oil.</p><p id="p-0332" num="0326">GC/MS (EI): m/z (%): 194 (1) [M<sup>+</sup>], 165 (2), 126 (100), 111 (22), 109 (22), 97 (53), 69 (54), 55 (25).</p><heading id="h-0082" level="1">Example 77: (E)-4,7-dimethyl-4-(3-methylbut-2-en-1-yl)octa-2,6-dienal</heading><p id="p-0333" num="0327">Following the general procedure described in Example 1: 4,7-dimethylocta-2,6-dienal, 3-methylbut-2-en-1-ol and Et<sub>3</sub>N&#x2014;HCl were reacted in xylene to give the title product as a colorless oil.</p><p id="p-0334" num="0328">GC/MS (EI): m/z (%): 220 (1) [M<sup>+</sup>], 152 (67), 137 (14), 123 (25), 109 (54), 94 (47), 81 (42), 69 (100), 59 (18), 53 (16).</p><heading id="h-0083" level="1">Example 78: 7-methyl-3-phenyloct-6-enal</heading><p id="p-0335" num="0329">A mixture of phenylboronic acid (1.76 g, 14.47 mmol), (E)-7-methylocta-2,6-dienal (1.00 g), and diacetoxypalladium (0.041 g, 0.18 mmol) was stirred in 50 mL toluene to give a red solution. Then tri-phenylphosphane (0.19 g, 0.72 mmol), K<sub>2</sub>CO<sub>3 </sub>(2.00 g, 14.47 mmol) and Cs<sub>2</sub>CO<sub>3 </sub>(0.24 g, 0.72 mmol) were added and the mixture stirred at 80&#xb0; C. under Ar atmosphere overnight, while monitoring the reaction by GC and GC-MS. The reaction was then quenched with water, and extracted with MTBE. The combined organic layers were washed with brine, dried over MgSO4, filtered and concentrated to give the crude product as a brown oil, which was purified by distillation (180&#xb0; C., 0.12 mbar) to give 7-methyl-3-phenyloct-6-enal (1.20 g, 4.27 mmol, 59.0% yield) as a colorless oil.</p><p id="p-0336" num="0330">GC/MS (EI): m/z (%): 216 (18) [M<sup>+</sup>], 198 (29), 183 (24), 157 (38), 142 (34), 129 (78), 118 (74), 105 (100), 91 (71), 77 (44), 69 (51), 55 (52).</p><heading id="h-0084" level="1">Example 79: 7-methyl-3-((R)-4-methylcyclohex-3-en-1-yl)oct-6-enal</heading><p id="p-0337" num="0331">A mixture of [Carbonyl(hydrido)tris(triphenylphosphane)rhodium(I)] ([RhH(CO)(PPh<sub>3</sub>)<sub>3</sub>]) (1.40 g, 1.52 mmol), triphenylphosphane (1.28 g, 4.89 mmol) and (R)-1-methyl-4-(6-methylhepta-1,5-dien-2-yl)cyclohex-1-ene (50.00 g, 245.00 mmol) were stirred in a 100 mL autoclave and heated to 80&#xb0; C. under 4 Mpa pressure of syngas atmosphere for about 36 h until the inside pressure did not decrease any more. The mixture was purified by distillation (0.068 mbar, 175&#xb0; C.) to give (S)-7-methyl-3-((R)-4-methylcyclohex-3-en-1-yl)oct-6-enal (35.00 g, 149.33 mmol) as a colorless oil.</p><p id="p-0338" num="0332">GC/MS (EI): m/z (%): 216 (38) [M<sup>+</sup>], 201 (16), 159 (23), 137 (38), 121 (40), 105 (60), 95 (100), 79 (96), 67 (90), 55 (64).</p><heading id="h-0085" level="1">Example 80: 4-isopentyl-2,4,7-trimethyloct-6-enal</heading><p id="p-0339" num="0333">A mixture of Lindlar catalyst (Pd/CaCO3, lead poisoned, 5 wt %, 0.1 g), (E)-2,4,7-trimethyl-4-(3-methylbut-2-en-1-yl)octa-2,6-dienal (4.12 g, 17.01 mmol), and and Ethyl acetate (40 mL) was stirred under hydrogen atmosphere at r.t. overnight, and the reaction was monitored by GC and GC-MS. The mixture was filtered through a small pad of MgSO4 and the filtrate was washed with MTBE. The combined filtrates were concentrated in vacuo to give crude product 4-isopentyl-2,4,7-trimethyloct-6-enal as a colorless oil (3.08 g, 12.9 mmol, 76% yield), which was used for next step without further purification.</p><p id="p-0340" num="0334">GC/MS (EI): m/z (%): 238 (1) [M<sup>+</sup>], 220 (2), 169 (15), 151 (20), 109 (30), 95 (100), 81 (28), 69 (98), 55 (49).</p><heading id="h-0086" level="1">Example 81: 4-methyl-3-(1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazol-5-yl)benzonitrile (General Procedure)</heading><heading id="h-0087" level="1">Example 81a: 4-methyl-3-(2,4,7-trimethyl-1-oxooct-6-en-4-yl)benzonitrile</heading><p id="p-0341" num="0335">A mixture of lindlar catalyst (Pd/CaCO<sub>3</sub>, lead poisoned, 5 wt %, 0.2 g), (E)-4-methyl-3-(2,4,7-trimethyl-1-oxoocta-2,6-dien-4-yl)benzonitrile (10.3 g, 35.4 mmol), and and Ethyl acetate (40 mL) was stirred under hydrogen atmosphere at r.t. and the reaction was monitored by GC and GC-MS until a conversion &#x3e;85% was observed. The mixture was then filtered through a small pad of MgSO<sub>4 </sub>and the filtrate was washed with MTBE. The combined filtrates were concentrated in vacuo to give crude product 4-methyl-3-(2,4,7-trimethyl-1-oxooct-6-en-4-yl)benzonitrile (7.1 g, 24.9 mmol, 70% yield), which was used for next step without further purification.</p><heading id="h-0088" level="1">Example 81b: 4-methyl-3-(1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazol-5-yl)benzonitrile</heading><p id="p-0342" num="0336">A mixture of N-methylhydroxylamine hydrochloride (5.06 g, 60.60 mmol) and K<sub>2</sub>CO<sub>3 </sub>(4.46 g, 32.30 mmol) was stirred in Toluene (50 mL) under Ar atmosphere at r.t. for 15 minutes, then 4-methyl-3-(2,4,7-trimethyl-1-oxooct-6-en-4-yl)benzonitrile (13.95 g, 40.4 mmol) was added and stirred at r.t. for 5 minutes. The mixture was heated to reflux under Ar atmosphere overnight and the reaction was monitored by GC and GC-MS. During this period, water was collected and removed by using Dean-Stark apparatus. After cooling to room temperature, excess K<sub>2</sub>CO<sub>3 </sub>was added, and the reaction mixture was filtered and the filter was washed with MTBE. The combined filtrates were concentrated in vacuo to give crude product, which was purified by flash chromatography (Hexane/MTBE=4:1-1:3) to afford rac-4-methyl-3-((3aR,5R,7S,7aR)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazol-5-yl)benzonitrile (2.72 g, 8.52 mmol, 21% yield) as a yellow wax, rac-4-methyl-3-((3aS,5R,7S,7aS)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazol-5-yl)benzonitrile (0.41 g, 1.33 mmol, 21% yield) as a yellow oil and rac-4-methyl-3-((3aS,5R,7R,7aS)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazol-5-yl)benzonitrile (2.52 g, 8.08 mmol, 20% yield) as a yellow oil. The obtained rac-4-methyl-3-((3aR,5R,7S,7aR)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazol-5-yl)benzonitrile was further recrystalized from a mixture of ether and CH<sub>2</sub>Cl<sub>2 </sub>to give rac-4-methyl-3-((3aR,5R,7S,7aR)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazol-5-yl)benzonitrile as a white solid.</p><p id="p-0343" num="0337">rac-4-methyl-3-((3aR,5R,7S,7aR)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazol-5-yl)benzonitrile: GC/MS (EI): m/z (%): 312 (37) [M<sup>+</sup>], 297 (4), 266 (20), 196 (6), 182 (6), 144 (14), 126 (100), 100 (47), 87 (55), 70 (17). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 7.67 (s, 1H), 7.50-7.35 (m, 1H), 7.23 (s, 1H), 2.99-2.53 (m, 6H), 2.32 (t, J=10.7 Hz, 1H), 2.19-1.85 (m, 4H), 1.69-1.55 (m, 1H), 1.53-1.39 (m, 4H), 1.28 (s, 3H), 1.22-1.00 (m, 6H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 149.8 (q), 142.3 (q), 134.2 (t), 129.7 (t), 129.6 (t), 119.7 (q), 109.9 (q), 79.5 (q), 77.4 (t), 53.8 (t), 49.0 (s), 45.2 (d), 40.0 (q), 35.9 (d), 33.3 (t), 27.0 (s), 25.1 (s), 24.5 (s), 24.2 (s), 20.4 (s).</p><p id="p-0344" num="0338">rac-4-methyl-3-((3aS,5R,7S,7aS)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazol-5-yl)benzonitrile: GC/MS (EI): m/z (%): 312 (37) [M<sup>+</sup>], 297 (6), 266 (4), 196 (3), 182 (4), 144 (9), 126 (100), 113 (44), 98 (95), 87 (21).</p><p id="p-0345" num="0339">rac-4-methyl-3-((3aS,5R,7R,7aS)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazol-5-yl)benzonitrile: GC/MS (EI): m/z (%): 312 (58) [M<sup>+</sup>], 297 (6), 266 (22), 196 (7), 182 (7), 144 (17), 126 (89), 113 (25), 100 (38), 98 (45), 87 (100), 70 (20).</p><p id="p-0346" num="0340">A sample of rac-4-methyl-3-((3aR,5R,7S,7aR)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazol-5-yl)benzonitrile could be further separated by chiral HPLC (Phenomenex Lux Cellulose-1, 4.6&#xd7;150 mm, 3 um Hexane/Isopropanol, 96:4% v/v, isocratic for 20 min) to give the two enantiomerically pure fractions rel-4-methyl-3-((3aR,5R,7S,7aR)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazol-5-yl)benzonitrile (first peak to elute&#x2014;retention time ca. 9 min) and rel-4-methyl-3-((3aS,5S,7R,7aS)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazol-5-yl)benzonitrile (second peak to elute&#x2014;retention time ca. 12 min).</p><p id="p-0347" num="0341">In the preparation of similar examples, where N-methylhydroxylamine hydrochloride was replaced by N-ethylhydroxylamine or N-isopropylhydroxylamine, the same procedure was used, whereby the base (K<sub>2</sub>CO<sub>3</sub>) was omitted and toluene was occasionally substituted for xylenes as reaction solvent where indicated.</p><heading id="h-0089" level="1">Example 82: rac-(3aR,5R,7S,7aR)-1,3,3,5,7-pentamethyl-5-(o-tolyl)octahydrobenzo[c]isoxazole</heading><p id="p-0348" num="0342">Following the general procedure described in Example 81 b: 2,4,7-trimethyl-4-(o-tolyl)oct-6-enal (3.15 g, 10.59 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-methylhydroxylamine hydrochloride (1.33 g, 15.88 mmol), K<sub>2</sub>CO<sub>3 </sub>(1.17 g, 8.47 mmol) in toluene (50 mL) were reacted to give the title product (0.70 g, 23% yield) as a light yellow oil.</p><p id="p-0349" num="0343">GC/MS (EI): m/z (%): 287 (64) [M<sup>+</sup>], 272 (5), 171 (12), 157 (14), 126 (100), 119 (23), 100 (47), 87 (56), 70 (12). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 7.46-7.35 (m, 1H), 7.22-7.09 (m, 3H), 2.84 (s, 3H), 2.58 (s, 3H), 2.41-2.25 (m, 1H), 2.19-2.06 (m, 1H), 2.05-1.90 (m, 3H), 1.67 (t, J=12.9 Hz, 1H), 1.59-1.49 (m, 1H), 1.46 (s, 3H), 1.28 (s, 3H), 1.18-1.01 (m, 6H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 148.3 (q), 136.0 (q), 133.5 (t), 126.2 (t), 126.0 (t), 125.5 (t), 79.5 (q), 77.2 (t), 53.9 (t), 48.9 (s), 45.3 (d), 39.7 (q), 35.9 (d), 33.3 (t), 27.0 (s), 25.1 (s), 24.6 (s), 23.8 (s), 20.4 (s).</p><heading id="h-0090" level="1">Example 83: rac-(3aR,5R,7S7aR)-1-isopropyl-3,3,5,7-tetramethyl-5-(o-tolyl)octahydrobenzo[c]isoxazole</heading><p id="p-0350" num="0344">Following the general procedure described in Example 81b: 2,4,7-trimethyl-4-(o-tolyl)oct-6-enal (520 mg, 1.51 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-isopropylhydroxylamine hydrochloride, K<sub>2</sub>CO<sub>3 </sub>(170 mg, 1.21 mmol) in toluene (50 mL) were reacted to give the title product (320 mg, 67% yield) as a light yellow oil.</p><p id="p-0351" num="0345">GC/MS (EI): m/z (%): 315 (44) [M<sup>+</sup>], 300 (100), 241 (1), 185 (9), 171 (8), 154 (69), 128 (22), 126 (25), 115 (24), 98 (3). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 7.40 (d, J=7.7 Hz, 1H), 7.21-7.06 (m, 3H), 3.31-3.09 (m, 1H), 2.57 (s, 3H), 2.48-2.26 (m, 2H), 1.98 (dd, J=10.3, 3.2 Hz, 3H), 1.69-1.51 (m, 2H), 1.47 (s, 3H), 1.31 (s, 3H), 1.26 (d, J=6.7 Hz, 3H), 1.11-1.01 (m, 8H), 0.99-0.92 (m, 1H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 148.4 (q), 136.0 (q), 133.4 (t), 126.1 (t), 125.9 (t), 125.4 (t), 78.0 (q), 68.5 (t), 55.0 (t), 53.0 (t), 45.7 (d), 39.5 (t), 35.9 (d), 33.6 (t), 27.1 (s), 24.6 (s), 24.3 (s), 23.8 (s), 22.6 (s), 20.5 (s), 13.4 (s).</p><heading id="h-0091" level="1">Example 84: rac-(3aR,5R,7S,7aR)-1-ethyl-3,3,5,7-tetramethyl-5-(o-tolyl)octahydrobenzo[c]isoxazole</heading><p id="p-0352" num="0346">Following the general procedure described in Example 81b: 2,4,7-trimethyl-4-(0-tolyl)oct-6-enal (298 mg, 0.81 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-ethylhydroxylamine hydrochloride (118 mg, 1.21 mmol), K<sub>2</sub>CO<sub>3 </sub>(89 mg, 0.65 mmol) in toluene (50 mL) were reacted to give the title product (95 mg, 39% yield) as a light yellow oil.</p><p id="p-0353" num="0347">GC/MS (EI): m/z (%): 301 (2) [M<sup>+</sup>], 300 (8), 286 (77), 185 (10), 171 (12), 132 (100), 117 (20), 105 (20), 91 (15), 68 (9). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 7.40 (d, J=7.7 Hz, 1H), 7.21-7.06 (m, 3H), 3.09-2.92 (m, 1H), 2.88-2.73 (m, 1H), 2.57 (s, 3H), 2.36-2.22 (m, 2H), 2.07-1.90 (m, 3H), 1.73-1.51 (m, 2H), 1.46 (s, 3H), 1.31-1.21 (m, 6H), 1.11 (s, 3H), 1.02 (d, J=6.2 Hz, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 148.3 (q), 136.0 (q), 133.4 (t), 126.1 (t), 126.0 (t), 125.5 (t), 79.5 (q), 74.8 (t), 56.5 (d), 53.2 (t), 45.4 (d), 39.7 (q), 36.0 (d), 33.9 (t), 31.0 (s), 26.6 (s), 24.8 (s), 23.8 (s), 20.5 (s), 13.9 (s).</p><heading id="h-0092" level="1">Example 85: rac-(3aR,5R,7S7aR)-5-(4-fluoro-2-methylphenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole</heading><p id="p-0354" num="0348">Following the general procedure described in Example 81b: 4-(4-fluoro-2-methylphenyl)-2,4,7-trimethyloct-6-enal (400 mg, 1.45 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-methylhydroxylamine hydrochloride (181 mg, 2.17 mmol), K<sub>2</sub>CO<sub>3 </sub>(160 mg, 1.16 mmol) in toluene (50 mL) were reacted to give the title product (110 mg, 25% yield) as a yellow oil.</p><p id="p-0355" num="0349">GC/MS (EI): m/z (%): 305 (100) [M<sup>+</sup>], 150 (42), 137 (38), 126 (85), 123 (22), 100 (42), 98 (28), 87 (48). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 7.49-7.21 (m, 1H), 7.01-6.65 (m, 2H), 3.27-2.67 (m, 3H), 2.60-2.51 (m, 2H), 2.31 (s, 1H), 2.21-1.81 (m, 4H), 1.65-1.38 (m, 5H), 1.36-0.99 (m, 10H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 162.5 (q), 159.2 (q), 144.1 (q), 138.7 (q), 127.3 (t), 119.7 (t), 112.1 (t), 79.4 (q), 73.8 (t), 53.9 (t), 48.9 (s), 45.5 (d), 39.4 (q), 36.1 (d), 33.3 (t), 26.9 (s), 25.0 (s), 24.8 (s), 23.7 (s), 20.3 (s).</p><p id="p-0356" num="0350">From the same reaction, an additional diastereomer was isolated: rac-(3aR,5R,7R,7aR)-5-(4-fluoro-2-methylphenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole (138 mg, 31% yield) as a yellow oil. GC/MS (EI): m/z (%): 305 (71) [M<sup>+</sup>], 150 (30), 126 (100), 113 (29), 100 (52), 98 (49), 87 (96), 70 (25).</p><heading id="h-0093" level="1">Example 86: rac-(3aR,5R,7S7aR)-5-(5-chloro-2-methylphenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole</heading><p id="p-0357" num="0351">Following the general procedure described in Example 81b: 4-(5-chloro-2-methylphenyl)-2,4,7-trimethyloct-6-enal (412 mg, 1.15 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-methylhydroxylamine hydrochloride (145 mg, 1.73 mmol), K<sub>2</sub>CO<sub>3 </sub>(128 mg, 0.92 mmol) in toluene (50 mL) were reacted to give the title product (120 mg, 32% yield) as a light yellow oil.</p><p id="p-0358" num="0352">GC/MS (EI): m/z (%): 321 (46) [M<sup>+</sup>], 306 (3), 275 (2), 205 (4), 191 (5), 153 (26), 126 (100), 100 (44), 87 (56), 70 (12). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 7.33 (s, 1H), 7.15-7.00 (m, 2H), 2.83 (s, 3H), 2.52 (s, 3H), 2.38-2.21 (m, 1H), 2.14-2.05 (m, 1H), 1.95 (d, J=12.8 Hz, 3H), 1.60 (t, J=12.8 Hz, 1H), 1.48-1.39 (m, 4H), 1.29 (s, 3H), 1.17 (s, 3H), 1.09-1.01 (m, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 150.2 (q), 134.6 (t), 134.5 (t), 131.7 (q), 126.0 (t), 125.9 (t), 79.5 (q), 77.1 (t), 53.8 (t), 49.1 (s), 45.1 (d), 39.8 (q), 35.7 (d), 33.3 (t), 27.0 (s), 25.0 (s), 24.4 (s), 23.2 (s), 20.4 (s).</p><heading id="h-0094" level="1">Example 87: rac-3-((3aR,5R,7S,7aR)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazol-5-yl)benzonitrile</heading><p id="p-0359" num="0353">Following the general procedure described in Example 81b: 3-(2,4,7-trimethyl-1-oxooct-6-en-4-yl)benzonitrile (6.00 g, 13.48 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-methylhydroxylamine hydrochloride (1.69 g, 20.23 mmol), K<sub>2</sub>CO<sub>3 </sub>(1.49 g, 10.79 mmol) in toluene (50 mL) were reacted to give the title product (1.20 g, 30% yield) as a yellow oil.</p><p id="p-0360" num="0354">GC/MS (EI): m/z (%): 298 (36) [M<sup>+</sup>], 283 (6), 252 (11), 182 (10), 168 (9), 126 (100), 100 (41), 87 (50), 70 (16). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 7.72-7.57 (m, 2H), 7.53-7.35 (m, 2H), 2.90-2.59 (m, 3H), 2.43-2.21 (m, 1H), 2.14-1.90 (m, 2H), 1.89-1.71 (m, 2H), 1.58-1.45 (m, 1H), 1.40 (d, J=12.7 Hz, 1H), 1.34 (s, 3H), 1.25 (s, 3H), 1.19-0.96 (m, 6H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 152.5 (q), 129.9 (t), 129.7 (t), 129.2 (t), 129.1 (t), 119.2 (q), 112.4 (q), 79.3 (q), 77.4 (t), 53.7 (t), 48.9 (s), 45.8 (d), 38.8 (q), 36.8 (d), 33.1 (t), 26.9 (s), 26.4 (s), 24.9 (s), 20.1 (s).</p><heading id="h-0095" level="1">Example 88: rac-(3aR,5R,7S,7aR)-5-(2,5-dimethylphenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole</heading><p id="p-0361" num="0355">Following the general procedure described in Example 81b: 4-(2,5-dimethylphenyl)-2,4,7-trimethyloct-6-enal (500 mg, 1.84 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-methylhydroxylamine hydrochloride (230 mg, 2.75 mmol), K<sub>2</sub>CO<sub>3 </sub>(203 mg, 1.47 mmol) in toluene (50 mL) were reacted to give the title product (168 mg, 30% yield) as a yellow oil.</p><p id="p-0362" num="0356">GC/MS (EI): m/z (%): 301 (68) [M<sup>+</sup>], 286 (3), 255 (2), 171 (20), 126 (100), 119 (19), 100 (38), 87 (47), 70 (11). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 7.20 (s, 1H), 7.06 (d, J=7.6 Hz, 1H), 6.96 (d, J=7.6 Hz, 1H), 2.91-2.67 (m, 3H), 2.53 (s, 3H), 2.39-2.25 (m, 4H), 2.18-2.06 (m, 1H), 1.97 (d, J=12.8 Hz, 3H), 1.68 (d, J=12.8 Hz, 1H), 1.59-1.48 (m, 1H), 1.45 (s, 3H), 1.34-1.22 (m, 4H), 1.18-1.13 (m, 2H), 1.06 (d, J=6.0 Hz, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 148.0 (q), 135.2 (q), 133.4 (t), 132.7 (q), 126.7 (t), 126.3 (t), 79.5 (q), 77.2 (t), 53.9 (t), 48.9 (s), 45.3 (d), 39.5 (s), 35.8 (d), 33.3 (t), 27.1 (s), 27.0 (s), 25.0 (s), 24.6 (s), 23.4 (s), 21.4 (s), 20.4 (s).</p><heading id="h-0096" level="1">Example 89: rac-3-((3aR,5R,7S,7aR)-1-ethyl-3,3,5,7-tetramethyloctahydrobenzo[c]isoxazol-5-yl)-4-methylbenzonitrile</heading><p id="p-0363" num="0357">Following the general procedure described in Example 81 b: 4-methyl-3-(2,4,7-trimethyl-1-oxooct-6-en-4-yl)benzonitrile (300 mg, 0.79 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-ethylhydroxylamine (73 mg, 1.19 mmol) in toluene (50 mL) were reacted to give the title product (50 mg, 19% yield) as a yellow oil.</p><p id="p-0364" num="0358">GC/MS (EI): m/z (%): 326 (24) [M<sup>+</sup>], 311 (23), 266 (14), 196 (5), 182 (5), 140 (100), 114 (37), 101 (38). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 7.64 (s, 1H), 7.39 (d, J=7.9 Hz, 1H), 7.22 (d, J=7.9 Hz, 1H), 3.07-2.91 (m, 1H), 2.87-2.72 (m, 1H), 2.59 (s, 3H), 2.33-2.22 (m, 2H), 2.04-1.87 (m, 3H), 1.62-1.51 (m, 1H), 1.45-1.37 (m, 4H), 1.30-1.21 (m, 6H), 1.18-1.07 (m, 3H), 1.02 (d, J=6.1 Hz, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 149.5 (q), 142.1 (q), 133.9 (t), 129.5 (t), 129.4 (t), 119.5 (q), 109.7 (q), 79.3 (q), 74.5 (t), 56.4 (d), 52.8 (t), 45.0 (d), 39.8 (q), 35.8 (d), 33.6 (t), 26.5 (s), 24.6 (s), 24.3 (s), 24.0 (s), 20.3 (s), 13.7 (s).</p><heading id="h-0097" level="1">Example 90: rac-(3aR,5R,7S,7aR)-5-(5-fluoro-2-methylphenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole</heading><p id="p-0365" num="0359">Following the general procedure described in Example 81b: 4-(5-fluoro-2-methylphenyl)-2,4,7-trimethyloct-6-enal (400 mg, 1.45 mmol) (obtained from the corresponding &#x3b2;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-methylhydroxylamine hydrochloride (181 mg, 2.17 mmol), K<sub>2</sub>CO<sub>3 </sub>(160 mg, 1.16 mmol) in toluene (50 mL) were reacted to give the title product (60 mg, 14% yield) as a yellow oil.</p><p id="p-0366" num="0360">GC/MS (EI): m/z (%): 305 (71) [M<sup>+</sup>], 150 (11), 137 (30), 126 (100), 123 (23), 100 (45), 98 (34), 87 (57). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 7.16-6.96 (m, 2H), 6.79 (td, J=8.1, 2.6 Hz, 1H), 2.93-2.64 (m, 3H), 2.51 (s, 3H), 2.36-2.21 (m, 1H), 2.09 (t, J=10.3 Hz, 1H), 2.03-1.84 (m, 3H), 1.60 (t, J=12.9 Hz, 1H), 1.51-1.39 (m, 4H), 1.25 (s, 3H), 1.19-0.96 (m, 6H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 162.8 (q), 159.6 (q), 150.5 (q), 150.4 (q), 134.4 (t), 134.3 (t), 131.4 (q), 131.3 (q), 112.9 (t), 112.6 (t), 112.5 (t), 112.2 (t), 79.4 (q), 77.1 (t), 53.8 (t), 48.9 (s), 45.0 (d), 39.7 (q), 35.6 (d), 33.2 (t), 26.9 (s), 25.0 (s), 24.3 (s), 23.0 (s), 20.3 (s).</p><heading id="h-0098" level="1">Example 91: rac-3-((3aR,5R,7S,7aR)-1-isopropyl-3,3,5,7-tetramethyloctahydrobenzo[c]isoxazol-5-yl)benzonitrile</heading><p id="p-0367" num="0361">Following the general procedure described in Example 81b: 3-(2,4,7-trimethyl-1-oxooct-6-en-4-yl)benzonitrile (200 mg, 0.74 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-isopropylhydroxylamine (167 mg, 2.23 mmol) in xylene (70 mL) were reacted to give the title product (55 mg, 23% yield) as a yellow oil.</p><p id="p-0368" num="0362">GC/MS (EI): m/z (%): 326 (24) [M<sup>+</sup>], 311 (100), 252 (4), 196 (10), 182 (5), 154 (51), 126 (20), 115 (9). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 7.69-7.58 (m, 2H), 7.52-7.36 (m, 2H), 3.27-3.10 (m, 1H), 2.46-2.25 (m, 2H), 2.06-1.91 (m, 1H), 1.86-1.72 (m, 2H), 1.54-1.39 (m, 2H), 1.34 (s, 3H), 1.30 (s, 3H), 1.23 (s, 3H), 1.10-0.98 (m, 9H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 152.7 (q), 130.0 (t), 129.6 (t), 129.2 (t), 129.1 (t), 119.3 (q), 112.4 (q), 77.9 (q), 68.8 (t), 55.0 (t), 52.9 (t), 46.1 (d), 38.7 (q), 36.7 (d), 33.5 (t), 27.2 (s), 26.5 (s), 24.3 (s), 22.6 (s), 20.3 (s), 13.7 (s).</p><heading id="h-0099" level="1">Example 92: rac-3-((3aR,5R,7S,7aR)-1-isopropyl-3,3,5,7-tetramethyloctahydrobenzo[c]isoxazol-5-yl)-4-methylbenzonitrile</heading><p id="p-0369" num="0363">Following the general procedure described in Example 81b: 4-methyl-3-(2,4,7-trimethyl-1-oxooct-6-en-4-yl)benzonitrile (3.534 g, 12.38 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-isopropylhydroxylamine (2.79 g, 37.10 mmol) in xylene (70 mL) were reacted to give the title product rac-3-((3aR,5R,7S,7aR)-1-isopropyl-3,3,5,7-tetramethyloctahydrobenzo[c]isoxazol-5-yl)-4-methylbenzonitrile (589 mg, 14% yield) as a white solid.</p><p id="p-0370" num="0364">GC/MS (EI): m/z (%): 340 (23) [M<sup>+</sup>], 325 (89), 266 (7), 196 (5), 182 (5), 154 (100), 126 (37), 115 (30). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 7.65 (s, 1H), 7.40 (d, J=7.8 Hz, 1H), 7.23 (d, J=7.8 Hz, 1H), 3.35-3.05 (m, 1H), 2.62 (s, 3H), 2.48-2.22 (m, 2H), 2.05-1.85 (m, 3H), 1.61-1.37 (m, 5H), 1.31 (s, 3H), 1.25 (d, J=6.6 Hz, 3H), 1.14-0.94 (m, 9H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 149.8 (q), 142.2 (q), 134.0 (t), 129.5 (t), 129.4 (t), 119.5 (q), 109.7 (q), 77.9 (q), 68.3 (t), 55.0 (t), 52.8 (t), 45.4 (d), 39.7 (q), 35.7 (d), 33.5 (t), 27.1 (s), 24.2 (s), 24.1 (s), 22.6 (s), 20.4 (s), 13.4 (s).</p><p id="p-0371" num="0365">From the same reaction, two additional isomers were isolated: rac-3-((3aS,5R,7S,7aS)-1-isopropyl-3,3,5,7-tetramethyloctahydrobenzo[c]isoxazol-5-yl)-4-methylbenzonitrile (234 mg, 6% yield) and rac-3-((3aS,5R,7R,7aS)-1-isopropyl-3,3,5,7-tetramethyloctahydrobenzo[c]isoxazol-5-yl)-4-methylbenzonitrile (765 mg, 18% yield) as a light yellow oils.</p><p id="p-0372" num="0366">rac-3-((3aS,5R,7S,7aS)-1-isopropyl-3,3,5,7-tetramethyloctahydrobenzo[c]isoxazol-5-yl)-4-methylbenzonitrile: GC/MS (EI): m/z (%): 340 (11) [M<sup>+</sup>], 325 (24), 247 (27), 154 (63), 141 (43), 126 (100), 115 (24), 84(30).</p><p id="p-0373" num="0367">rac-3-((3aS,5R,7R,7aS)-1-isopropyl-3,3,5,7-tetramethyloctahydrobenzo[c]isoxazol-5-yl)-4-methylbenzonitrile: GC/MS (EI): m/z (%): 340 (20) [M<sup>+</sup>], 325 (100), 266 (6), 210(9), 154 (52), 141(23), 126 (45), 115 (43).</p><heading id="h-0100" level="1">Example 93: rac-(3aR,5R,7S,7aR)-5-(2-methoxyphenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole</heading><p id="p-0374" num="0368">Following the general procedure described in Example 81b: 4-(2-methoxyphenyl)-2,4,7-trimethyloct-6-enal (500 mg, 1.82 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-methylhydroxylamine hydrochloride (228 mg, 2.73 mmol), K<sub>2</sub>CO<sub>3 </sub>(201 mg, 1.46 mmol) in toluene (50 mL) were reacted to give the title product (123 mg, 22% yield) as a yellow oil.</p><p id="p-0375" num="0369">GC/MS (EI): m/z (%): 303 (92) [M<sup>+</sup>], 288 (5), 257 (9), 201 (15), 180 (17), 135 (31), 126 (100), 100 (37), 87 (44). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 7.31 (d, J=7.8 Hz, 1H), 7.25-7.16 (m, 1H), 6.99-6.83 (m, 2H), 3.84 (s, 3H), 2.93-2.61 (m, 3H), 2.40-2.26 (m, 1H), 2.17-1.84 (m, 4H), 1.73 (t, J=12.7 Hz, 1H), 1.57 (t, J=12.7 Hz, 1H), 1.43 (s, 3H), 1.30-1.25 (m, 3H), 1.19-1.11 (m, 3H), 1.07-0.98 (m, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 158.3 (q), 138.3 (q), 127.3 (t), 126.0 (t), 120.5 (t), 111.9 (t), 79.5 (q), 77.5 (t), 55.0 (s), 53.7 (t), 48.9 (s), 44.1 (d), 38.7 (q), 34.6 (d), 33.0 (t), 26.9 (s), 25.0 (s), 23.6 (s), 20.3 (s).</p><heading id="h-0101" level="1">Example 94: rac-(3aR,5R,7S,7aR)-1,3,3,5,7-pentamethyl-5-phenyloctahydrobenzo[c]isoxazole</heading><p id="p-0376" num="0370">Following the general procedure described in Example 81b: 2,4,7-trimethyl-4-phenyloct-6-enal (2.11 g, 8.04 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-methylhydroxylamine hydrochloride (1.01 g, 12.06 mmol), K<sub>2</sub>CO<sub>3 </sub>(0.89 mg, 6.43 mmol) in toluene (50 mL) were reacted to give the title product (0.78 g, 35% yield) as a light yellow oil.</p><p id="p-0377" num="0371">GC/MS (EI): m/z (%): 273 (52) [M<sup>+</sup>], 258 (5), 227 (3), 171 (11), 180 (9), 157 (15), 126 (100), 100 (40), 87 (44). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 7.45-7.38 (m, 2H), 7.37-7.29 (m, 2H), 7.24-7.16 (m, 1H), 2.90-2.66 (m, 3H), 2.43-2.25 (m, 1H), 2.13-2.02 (m, 1H), 2.01-1.90 (m, 1H), 1.87-1.75 (m, 2H), 1.65-1.52 (m, 1H), 1.50-1.42 (m, 1H), 1.36 (s, 3H), 1.27 (s, 3H), 1.19-0.99 (m, 6H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 151.2 (q), 128.3 (t), 125.9 (t), 125.1 (t), 79.4 (q), 77.7 (t), 53.9 (t), 48.9 (s), 46.1 (d), 38.6 (q), 37.0 (d), 33.2 (t), 27.0 (s), 26.6 (s), 25.0 (s), 20.2 (s).</p><heading id="h-0102" level="1">Example 95: rac-(3aR,5R,7S,7aR)-5-(2,4-dimethylphenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole</heading><p id="p-0378" num="0372">Following the general procedure described in Example 81b: 4-(2,4-dimethylphenyl)-2,4,7-trimethyloct-6-enal (1.02 g, 1.88 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-methylhydroxylamine hydrochloride (0.24 g, 2.82 mmol), K<sub>2</sub>CO<sub>3 </sub>(0.21 g, 1.50 mmol) in toluene (50 mL) were reacted to give the title product (0.15 g, 27% yield) as a light yellow oil.</p><p id="p-0379" num="0373">GC/MS (EI): m/z (%): 301 (54) [M<sup>+</sup>], 286 (6), 255 (3), 185 (12), 171 (14), 126 (100), 119 (23), 100 (42), 87 (58), 70 (12). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 7.34-7.22 (m, 1H), 7.04-6.92 (m, 2H), 2.89-2.65 (m, 3H), 2.54 (s, 3H), 2.35-2.24 (m, 4H), 2.14-2.05 (m, 1H), 2.05-1.85 (m, 3H), 1.65 (t, J=12.9 Hz, 1H), 1.56-1.48 (m, 1H), 1.44 (s, 3H), 1.27 (d, J=10.0 Hz, 3H), 1.18-0.96 (m, 6H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 145.3 (q), 135.8 (q), 135.5 (q), 134.3 (t), 126.6 (t), 125.5 (t), 79.5 (q), 77.2 (t), 53.9 (t), 48.9 (s), 45.5 (d), 39.4 (q), 36.0 (d), 33.3 (t), 27.0 (s), 25.0 (s), 24.7 (s), 23.6 (s), 20.5 (s), 20.4 (s).</p><heading id="h-0103" level="1">Example 96: rac-(3aR,5R,7S,7aR)-1-ethyl-3,3,5,7-tetramethyl-5-phenyloctahydrobenzo[c]isoxazole</heading><p id="p-0380" num="0374">Following the general procedure described in Example 81b: 2,4,7-trimethyl-4-phenyloct-6-enal (1.03 g, 2.93 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-ethylhydroxylamine hydrochloride (0.43 g, 4.39 mmol), K<sub>2</sub>CO<sub>3 </sub>(0.32 g, 2.34 mmol) in toluene (50 mL) were reacted to give the title product (0.34 g, 40% yield) as a light yellow oil.</p><p id="p-0381" num="0375">GC/MS (EI): m/z (%): 287 (28) [M<sup>+</sup>], 272 (94), 171 (19), 157 (24), 140 (87), 129 (20), 118 (100), 105 (37), 91 (51). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 7.44-7.38 (m, 2H), 7.37-7.29 (m, 2H), 7.24-7.16 (m, 1H), 3.10-2.71 (m, 2H), 2.38-2.16 (m, 2H), 2.05-1.92 (m, 1H), 1.90-1.77 (m, 2H), 1.56 (t, J=12.4 Hz, 1H), 1.50-1.37 (m, 1H), 1.36 (s, 3H), 1.32-1.18 (m, 6H), 1.12 (s, 3H), 1.02 (d, J=6.4 Hz, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 151.3 (q), 128.3 (t), 125.9 (t), 125.1 (t), 79.4 (q), 75.3 (t), 56.5 (d), 53.2 (t), 46.2 (d), 38.6 (q), 37.1 (d), 33.7 (t), 26.7 (s), 26.6 (s), 24.7 (s), 20.4 (s), 13.9 (s).</p><heading id="h-0104" level="1">Example 97: rac-(3aR,5R,7S,7aR)-5-(3-chloro-2-methylphenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole</heading><p id="p-0382" num="0376">Following the general procedure described in Example 81b: 4-(3-chloro-2-methylphenyl)-2,4,7-trimethyloct-6-enal (289 mg, 0.83 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-methylhydroxylamine hydrochloride (104 mg, 1.24 mmol), K<sub>2</sub>CO<sub>3 </sub>(92 mg, 0.66 mmol) in toluene (50 mL) were reacted to give the title product (121 mg, 45% yield) as a light yellow oil.</p><p id="p-0383" num="0377">GC/MS (EI): m/z (%): 321 (10) [M<sup>+</sup>], 320(21), 306 (7), 234 (31), 195 (22), 180 (21), 166 (100), 126 (53), 115 (13), 96 (15), 68 (16). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 7.38-7.22 (m, 2H), 7.15-7.05 (m, 1H), 2.90-2.67 (m, 3H), 2.57 (s, 3H), 2.40-2.26 (m, 1H), 2.21-2.08 (m, 1H), 2.05-1.84 (m, 3H), 1.68 (t, J=12.9 Hz, 1H), 1.52-1.45 (m, 4H), 1.27 (s, 3H), 1.20-1.14 (m, 3H), 1.05 (d, J=6.2 Hz, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 150.2 (q), 137.4 (q), 134.2 (q), 127.5 (t), 126.4 (t), 123.9 (t), 79.4 (q), 76.9 (t), 53.8 (t), 48.9 (s), 45.6 (d), 40.0 (s), 36.3 (d), 33.3 (t), 27.0 (s), 26.9 (s), 25.1 (s), 25.0 (s), 20.3 (s), 20.2 (s).</p><heading id="h-0105" level="1">Example 98: rac-(3aR,5R,7S,7aR)-5-(2-fluorophenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole</heading><p id="p-0384" num="0378">Following the general procedure described in Example 81 b: 4-(2-fluorophenyl)-2,4,7-trimethyloct-6-enal (500 mg, 1.91 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-methylhydroxylamine hydrochloride (240 mg, 2.86 mmol), K<sub>2</sub>CO<sub>3 </sub>(211 mg, 1.53 mmol) in toluene (50 mL) were reacted to give the title product (120 mg, 22% yield) as a light yellow oil.</p><p id="p-0385" num="0379">GC/MS (EI): m/z (%): 291 (41) [M<sup>+</sup>], 276 (7), 136 (35), 126 (100), 123 (29), 109 (41), 98 (35), 87 (40). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 7.26 (td, J=8.2, 1.5 Hz, 1H), 7.18-7.08 (m, 1H), 7.06-6.88 (m, 2H), 2.85-2.56 (m, 3H), 2.34-2.14 (m, 1H), 2.04 (t, J=10.3 Hz, 1H), 1.85 (d, J=12.6 Hz, 3H), 1.59 (t, J=12.6 Hz, 1H), 1.52-1.41 (m, 1H), 1.36 (s, 3H), 1.26-1.16 (m, 3H), 1.14-1.03 (m, 3H), 0.96 (d, J=6.1 Hz, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 163.4 (q), 160.2 (q), 137.3 (q), 137.1 (q), 127.9 (t), 127.8 (t), 126.6 (t), 126.5 (t), 124.1 (t), 124.0 (t), 116.8 (t), 116.5 (t), 79.4 (q), 77.4 (t), 53.5 (t), 48.9 (s), 44.5 (d), 44.4 (d), 38.3 (q), 38.2 (q), 35.2 (d), 35.1 (d), 33.0 (t), 26.9 (s), 24.9 (s), 24.2 (s), 24.1 (s), 20.2 (s).</p><heading id="h-0106" level="1">Example 99: rac-(3aR,5R,7S,7aR)-1,3,3,5,7-pentamethyl-5-(p-tolyl)octahydrobenzo[c]isoxazole</heading><p id="p-0386" num="0380">Following the general procedure described in Example 81b: 2,4,7-trimethyl-4-(p-tolyl)oct-6-enal (284 mg, 1.01 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-methylhydroxylamine hydrochloride (127 mg, 1.52 mmol), K<sub>2</sub>CO<sub>3 </sub>(112 mg, 0.81 mmol) in toluene (50 mL) were reacted to give the title product (112 mg, 40% yield) as a light yellow oil.</p><p id="p-0387" num="0381">GC/MS (EI): m/z (%): 287 (1) [M<sup>+</sup>], 286(3), 195 (35), 180 (22), 171 (4), 132 (100), 126 (28), 117 (14), 105 (13), 98 (12), 91 (10). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 7.30 (d, J=8.2 Hz, 2H), 7.15 (d, J=8.2 Hz, 2H), 2.89-2.65 (m, 3H), 2.39-2.26 (m, 4H), 2.08 (t, J=10.3 Hz, 1H), 2.01-1.90 (m, 1H), 1.88-1.74 (m, 2H), 1.55 (t, J=12.9 Hz, 1H), 1.48-1.40 (s, 1H), 1.37 (d, J=12.9 Hz, 3H), 1.27 (s, 3H), 1.16-1.01 (m, 6H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 148.4 (q), 135.5 (q), 129.1 (t), 125.0 (t), 79.5 (q), 77.7 (t), 54.0 (t), 49.0 (s), 46.2 (d), 38.3 (q), 37.2 (d), 33.2 (t), 27.0 (s), 26.6 (s), 25.0 (s), 20.9 (s), 20.3 (s).</p><heading id="h-0107" level="1">Example 100: rac-(3aR,5R,7S,7aR)-1-isopropyl-3,3,5,7-tetramethyl-5-phenyloctahydrobenzo[c]isoxazole</heading><p id="p-0388" num="0382">Following the general procedure described in Example 81b: 2,4,7-trimethyl-4-phenyloct-6-enal (258 mg, 0.91 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-isopropylhydroxylamine (102 mg, 1.36 mmol) in xylene (50 mL) were reacted to give the title product rac-(3aR,5R,7S,7aR)-1-isopropyl-3,3,5,7-tetramethyl-5-phenyloctahydrobenzo[c]isoxazole (92 mg, 34% yield) as a light yellow oil.</p><p id="p-0389" num="0383">GC/MS (EI): m/z (%): 301 (35) [M<sup>+</sup>], 286 (100), 171 (11), 154 (71), 126 (28), 115 (24), 105 (20), 91 (23). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 7.45-7.37 (m, 2H), 7.33 (t, J=7.7 Hz, 2H), 7.24-7.16 (m, 1H), 3.32-3.08 (m, 1H), 2.48-2.26 (m, 2H), 2.05-1.90 (m, 1H), 1.87-1.72 (m, 2H), 1.62-1.41 (m, 2H), 1.36 (s, 3H), 1.31 (s, 3H), 1.26 (d, J=6.7 Hz, 3H), 1.13-0.97 (m, 9H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 151.4 (q), 128.3 (t), 125.9 (t), 125.1 (t), 78.0 (q), 69.0 (t), 55.0 (t), 53.1 (t), 46.5 (d), 38.5 (q), 37.0 (d), 33.6 (t), 27.2 (s), 26.7 (s), 24.3 (s), 22.6 (s), 20.4 (s).</p><p id="p-0390" num="0384">From the same reaction, additional isomers were also isolated: rac-(3aS,5R,7S,7aS)-1-isopropyl-3,3,5,7-tetramethyl-5-phenyloctahydrobenzo[c]isoxazole (19 mg, 6% yield) and rac-(3aS,5R,7R,7aS)-1-isopropyl-3,3,5,7-tetramethyl-5-phenyloctahydrobenzo[c]isoxazole (68 mg, 24% yield) as light yellow oils.</p><p id="p-0391" num="0385">rac-(3aS,5R,7S,7aS)-1-isopropyl-3,3,5,7-tetramethyl-5-phenyloctahydrobenzo[c]isoxazole: GC/MS (EI): m/z (%): 301 (24) [M<sup>+</sup>], 286 (38), 169 (14), 154 (80), 141 (37), 126 (100), 115 (25), 105 (38), 91 (44).</p><p id="p-0392" num="0386">rac-(3aS,5R,7R,7aS)-1-isopropyl-3,3,5,7-tetramethyl-5-phenyloctahydrobenzo[c]isoxazole: GC/MS (EI): m/z (%): 301 (35) [M<sup>+</sup>], 286 (100), 171 (11), 154 (71), 126 (28), 115 (24), 105 (20), 91 (23).</p><heading id="h-0108" level="1">Example 101: rac-(3aR,5R,7S,7aR)-1-isopropyl-5-(2-methoxyphenyl)-3,3,5,7-tetramethyloctahydrobenzo[c]isoxazole</heading><p id="p-0393" num="0387">Following the general procedure described in Example 81 b: 4-(2-methoxyphenyl)-2,4,7-trimethyloct-6-enal (700 mg, 2.55 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), propan-2-ol (460 mg, 7.65 mmol) in toluene (50 mL) were reacted to give the title product (183 mg, 22% yield) as a light yellow oil.</p><p id="p-0394" num="0388">GC/MS (EI): m/z (%): 331 (45) [M<sup>+</sup>], 316 (94), 257 (4), 201 (12), 154 (100), 135 (23), 126 (33), 115 (24), 91 (16). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 7.30 (d, J=7.7 Hz, 1H), 7.25-7.16 (m, 1H), 6.97-6.87 (m, 2H), 3.84 (s, 3H), 2.49-2.26 (m, 2H), 1.98 (d, J=12.1 Hz, 3H), 1.74-1.48 (m, 3H), 1.43 (s, 3H), 1.30 (s, 3H), 1.26 (d, J=6.7 Hz, 3H), 1.08 (d, J=7.2 Hz, 6H), 1.01 (d, J=6.2 Hz, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 158.4 (q), 138.6 (q), 127.3 (t), 126.0 (t), 120.6 (t), 112.0 (t), 78.2 (q), 68.9 (t), 55.1 (t), 54.9 (s), 52.8 (t), 44.6 (d), 38.7 (q), 34.7 (d), 27.2 (s), 27.0 (s), 24.3 (s), 23.6 (s), 22.6 (s), 20.5 (s), 13.7 (s).</p><heading id="h-0109" level="1">Example 102: rac-4-((3aR,5R,7S,7aR)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazol-5-yl)benzonitrile</heading><p id="p-0395" num="0389">Following the general procedure described in Example 81 b: 4-(2,4,7-trimethyl-1-oxooct-6-en-4-yl)benzonitrile (300 mg, 1.11 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-methylhydroxylamine hydrochloride (140 mg, 1.67 mmol), K<sub>2</sub>CO<sub>3 </sub>(123 mg, 0.89 mmol) in toluene (50 mL) were reacted to give the title product (75 mg, 23% yield) as a light yellow oil.</p><p id="p-0396" num="0390">GC/MS (EI): m/z (%): 298 (5) [M<sup>+</sup>], 297(20), 283 (6), 240 (13), 195 (21), 180 (18), 143(35), 126 (70), 116 (31), 98 (37), 68 (100). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 7.60 (d, J=8.4 Hz, 2H), 7.48 (d, J=8.4 Hz, 2H), 2.88-2.61 (m, 3H), 2.39-2.21 (m, 1H), 2.13-2.01 (m, 1H), 1.91-1.73 (m, 2H), 1.51 (t, J=12.9 Hz, 1H), 1.41 (d, J=12.2 Hz, 1H), 1.34 (s, 3H), 1.29-1.17 (m, 4H), 1.14 (d, J=9.7 Hz, 3H), 1.03 (d, J=6.0 Hz, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 156.5 (q), 132.2 (t), 126.1 (t), 119.0 (q), 109.8 (q), 79.3 (q), 77.3 (t), 53.6 (t), 48.9 (s), 45.6 (d), 39.2 (q), 36.6 (d), 33.1 (t), 26.9 (s), 26.3 (s), 24.9 (s), 20.2 (s).</p><heading id="h-0110" level="1">Example 103: rac-(3aR,5R,7S,7aR)-5-(3-methoxyphenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole</heading><p id="p-0397" num="0391">Following the general procedure described in Example 81 b: 4-(3-methoxyphenyl)-2,4,7-trimethyloct-6-enal (700 mg, 2.55 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-methylhydroxylamine hydrochloride (320 mg, 3.83 mmol), K<sub>2</sub>CO<sub>3 </sub>(282 mg, 2.04 mmol) in toluene (50 mL) were reacted to give the title product (238 mg, 31% yield) as a yellow oil.</p><p id="p-0398" num="0392">GC/MS (EI): m/z (%): 303 (5) [M<sup>+</sup>], 302 (8), 288 (3), 216(20), 195 (28), 180 (18), 148 (100), 126 (38), 98 (12), 96 (13). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 7.18 (t, J=8.0 Hz, 1H), 6.89 (dd, J=11.6, 5.0 Hz, 2H), 6.66 (dd, J=8.0, 2.2 Hz, 1H), 3.72 (s, 3H), 2.82-2.55 (m, 3H), 2.33-2.11 (m, 1H), 1.99 (t, J=10.2 Hz, 1H), 1.91-1.81 (m, 1H), 1.72 (dd, J=15.2, 7.1 Hz, 2H), 1.48 (t, J=12.9 Hz, 1H), 1.36 (dd, J=20.6, 8.2 Hz, 1H), 1.26 (s, 3H), 1.19 (d, J=8.7 Hz, 3H), 1.12-1.02 (m, 3H), 0.99-0.90 (m, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 159.5 (q), 153.0 (q), 129.2 (t), 117.5 (t), 112.1 (t), 110.0 (t), 79.3 (q), 77.6 (t), 55.1 (q), 53.8 (t), 48.9 (s), 46.0 (d), 38.6 (q), 36.9 (d), 33.1 (t), 26.9 (s), 26.5 (s), 24.9 (s), 20.2 (s).</p><heading id="h-0111" level="1">Example 104: rac-(3aR,5R,7S,7aR)-1,3,3,5,7-pentamethyl-5-(naphthalen-2-yl)octahydrobenzo[c]isoxazole</heading><p id="p-0399" num="0393">Following the general procedure described in Example 81b: 2,4,7-trimethyl-4-(naphthalen-2-yl)oct-6-enal (500 mg, 1.70 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-methylhydroxylamine hydrochloride (213 mg, 2.55 mmol), K<sub>2</sub>CO<sub>3 </sub>(188 mg, 1.36 mmol) in toluene (50 mL) were reacted to give the title product (160 mg, 29% yield) as a light yellow oil.</p><p id="p-0400" num="0394">GC/MS (EI): m/z (%): 323 (14) [M<sup>+</sup>], 308 (5), 236 (12), 195 (72), 180 (70), 168 (100), 126 (35), 98 (14), 96 (19). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 7.87-7.68 (m, 4H), 7.56 (dd, J=8.7, 1.5 Hz, 1H), 7.49-7.37 (m, 2H), 2.93-2.63 (m, 3H), 2.37 (dd, J=16.9, 6.5 Hz, 1H), 2.16-1.84 (m, 4H), 1.66 (s, 1H), 1.56 (d, J=12.4 Hz, 1H), 1.44 (s, 3H), 1.32 (s, 3H), 1.20-1.14 (m, 3H), 1.07 (d, J=5.8 Hz, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 148.5 (q), 133.4 (q), 131.8 (q), 128.0 (t), 127.9 (t), 127.4 (t), 126.0 (t), 125.6 (t), 124.4 (t), 122.8 (t), 79.5 (q), 77.7 (t), 53.6 (t), 48.9 (s), 46.1 (d), 38.7 (q), 37.0 (d), 33.2 (t), 27.0 (s), 26.4 (s), 25.0 (s), 20.3 (s).</p><heading id="h-0112" level="1">Example 105: rac-(3aR,5R,7S,7aR)-5-(2-ethylphenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole</heading><p id="p-0401" num="0395">Following the general procedure described in Example 81b: 4-(2-ethylphenyl)-2,4,7-trimethyloct-6-enal (500 mg, 1.84 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-methylhydroxylamine hydrochloride (230 mg, 2.75 mmol), K<sub>2</sub>CO<sub>3 </sub>(203 mg, 1.47 mmol) in toluene (50 mL) were reacted to give the title product (146 mg, 26% yield) as a light yellow oil.</p><p id="p-0402" num="0396">GC/MS (EI): m/z (%): 301 (82) [M<sup>+</sup>], 286 (5), 185 (10), 171 (13), 147 (20), 126 (100), 100 (47), 87 (52). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 7.45-7.33 (m, 1H), 7.28-7.09 (m, 3H), 3.00-2.67 (m, 5H), 2.35 (s, 1H), 2.14 (dd, J=13.8, 6.8 Hz, 1H), 1.94 (ddd, J=23.8, 8.1, 2.6 Hz, 3H), 1.72 (d, J=12.9 Hz, 1H), 1.56 (d, J=12.5 Hz, 1H), 1.47 (s, 3H), 1.29 (t, J=7.4 Hz, 6H), 1.17 (d, J=10.4 Hz, 3H), 1.05 (d, J=6.2 Hz, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 147.4 (q), 142.7 (q), 131.9 (t), 126.3 (t), 125.6 (t), 125.2 (t), 79.4 (q), 77.0 (t), 53.9 (t), 48.8 (s), 46.1 (d), 39.6 (q), 36.6 (d), 33.3 (t), 27.5 (d), 26.9 (s), 25.4 (s), 25.0 (s), 20.3 (s), 17.1 (s).</p><heading id="h-0113" level="1">Example 106: rac-(3aR,5R,7S,7aR)-5-(benzo[d][1,3]dioxol-5-yl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole</heading><p id="p-0403" num="0397">Following the general procedure described in Example 81b: 4-(benzo[d][1,3]dioxol-5-yl)-2,4,7-trimethyloct-6-enal (259 mg, 0.90 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-methylhydroxylamine hydrochloride (113 mg, 1.35 mmol), K<sub>2</sub>CO<sub>3 </sub>(99 mg, 0.72 mmol) in toluene (50 mL) were reacted to give the title product (87 mg, 31% yield) as a light yellow oil.</p><p id="p-0404" num="0398">GC/MS (EI): m/z (%): 317 (5) [M<sup>+</sup>], 302 (4), 258 (6), 230 (10), 195 (73), 180 (79), 162 (100), 138 (10), 126 (26), 98 (10), 96 (14). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 6.91 (d, J=1.4 Hz, 1H), 6.84 (dd, J=8.2, 1.6 Hz, 1H), 6.76 (d, J=8.2 Hz, 1H), 5.93 (s, 2H), 2.86-2.58 (m, 3H), 2.36-2.19 (m, 1H), 2.06 (t, J=10.3 Hz, 1H), 1.99-1.85 (m, 1H), 1.76 (t, J=11.3 Hz, 2H), 1.51 (t, J=12.9 Hz, 1H), 1.40 (d, J=12.7 Hz, 1H), 1.32 (d, J=7.6 Hz, 3H), 1.26 (d, J=8.6 Hz, 3H), 1.15 (s, 3H), 1.02 (d, J=6.2 Hz, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 147.7 (q), 145.6 (q), 145.5 (q), 117.8 (t), 107.9 (t), 106.2 (t), 101.0 (d), 79.4 (q), 77.7 (t), 54.0 (t), 49.0 (d), 46.5 (d), 38.6 (q), 37.4 (d), 33.2 (t), 27.0 (d), 26.9 (d), 25.0 (d), 20.3 (d).</p><heading id="h-0114" level="1">Example 107: rac-(3aR,5R,7S,7aR)-5-(3,5-dimethylphenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole</heading><p id="p-0405" num="0399">Following the general procedure described in Example 81 b: 4-(3,5-dimethylphenyl)-2,4,7-trimethyloct-6-enal (311 mg, 1.14 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-methylhydroxylamine hydrochloride (143 mg, 1.71 mmol), K<sub>2</sub>CO<sub>3 </sub>(126 mg, 0.91 mmol) in toluene (50 mL) were reacted to give the title product (124 mg, 36% yield) as a light yellow oil.</p><p id="p-0406" num="0400">GC/MS (EI): m/z (%): 301 (97) [M<sup>+</sup>], 286 (5), 255 (5), 185 (19), 171 (23), 126 (100), 119 (16), 100 (38), 87 (45), 70 (10). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 7.01 (s, 2H), 6.87 (s, 1H), 2.95-2.57 (m, 3H), 2.44-2.22 (m, 7H), 2.08 (t, J=10.3 Hz, 1H), 2.01-1.89 (m, 1H), 1.81 (dd, J=14.8, 7.1 Hz, 2H), 1.55 (t, J=12.9 Hz, 1H), 1.47 (d, J=12.1 Hz, 1H), 1.35 (s, 3H), 1.28 (d, J=11.5 Hz, 3H), 1.18-1.02 (m, 6H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 151.3 (q), 137.7 (q), 127.6 (t), 122.9 (t), 79.5 (q), 77.7 (t), 54.0 (t), 49.0 (s), 46.1 (d), 38.4 (q), 37.1 (d), 33.2 (t), 27.0 (s), 26.6 (s), 25.0 (s), 21.7 (s), 20.3 (s).</p><heading id="h-0115" level="1">Example 108: rac-(3aR,5R,7R,7aR)-1-ethyl-3,3,5,7-tetramethyl-5-(o-tolyl)octahydrobenzo[c]isoxazole</heading><p id="p-0407" num="0401">Following the general procedure described in Example 81b: 2,4,7-trimethyl-4-(o-tolyl)oct-6-enal (300 mg, 0.81 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-ethylhydroxylamine hydrochloride (120 mg, 1.21 mmol), K<sub>2</sub>CO<sub>3 </sub>(90 mg, 0.65 mmol) in toluene (50 mL) were reacted to give the title product (80 mg, 33% yield) as a light yellow oil.</p><p id="p-0408" num="0402">GC/MS (EI): m/z (%): 301 (27) [M<sup>+</sup>], 286 (100), 243 (10), 185 (10), 171 (10), 140 (25), 132 (38), 119 (14), 101 (18), 91 (10). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 7.17 (d, J=8.7 Hz, 1H), 7.00 (t, J=8.7 Hz, 3H), 2.99-2.62 (m, 2H), 2.61-2.48 (m, 1H), 2.40 (d, J=12.3 Hz, 3H), 2.24 (dd, J=14.2, 6.1 Hz, 1H), 2.13-1.93 (m, 1H), 1.90-1.59 (m, 2H), 1.41-0.69 (m, 17H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 143.6 (q), 135.6 (q), 133.6 (t), 127.9 (t), 126.2 (t), 126.0 (t), 78.8 (q), 75.8 (t), 56.2 (d), 53.4 (t), 47.7 (d), 41.8 (q), 37.0 (d), 33.8 (t), 30.4 (s), 26.5 (s), 24.5 (s), 24.0 (s), 20.2 (s), 13.7 (s).</p><heading id="h-0116" level="1">Example 109: rac-(3aR,5R,7S,7aR)-5-(3,5-dimethylphenyl)-1-isopropyl-3,3,5,7-tetramethyloctahydrobenzo[c]isoxazole</heading><p id="p-0409" num="0403">Following the general procedure described in Example 81 b: 4-(3,5-dimethylphenyl)-2,4,7-trimethyloct-6-enal (260 mg, 0.95 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-isopropylhydroxylamine (210 mg, 2.84 mmol), K<sub>2</sub>CO<sub>3 </sub>(90 mg, 0.65 mmol) in xylene (80 mL) were reacted to give the title product (220 mg, 69% yield) as a light yellow oil.</p><p id="p-0410" num="0404">GC/MS (EI): m/z (%): 329 (58) [M<sup>+</sup>], 314 (100), 199 (8), 185 (10), 171 (11), 154 (88), 126 (28), 115 (22), 112 (18), 91 (9). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 7.02 (s, 2H), 6.87 (s, 1H), 3.41-2.90 (m, 1H), 2.48-2.24 (m, 8H), 2.08-1.90 (m, 1H), 1.81 (ddd, J=12.2, 5.6, 2.7 Hz, 2H), 1.50 (dt, J=17.9, 12.7 Hz, 2H), 1.39-1.22 (m, 9H), 1.08 (dd, J=13.7, 5.8 Hz, 9H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 151.3 (q), 137.5 (q), 127.4 (t), 122.8 (t), 77.9 (q), 68.9 (t), 54.8 (t), 53.0 (t), 46.3 (d), 38.1, 36.9 (d), 33.4 (t), 27.1 (s), 26.6 (s), 24.2 (s), 22.5 (s), 21.5 (s), 20.4 (s), 13.6 (s).</p><heading id="h-0117" level="1">Example 110: rac-(3aR,5R,7S,7aR)-5-(4-methoxyphenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole</heading><p id="p-0411" num="0405">Following the general procedure described in Example 81b: 4-(4-methoxyphenyl)-2,4,7-trimethyloct-6-enal (500 mg, 1.82 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-methylhydroxylamine hydrochloride (230 mg, 2.73 mmol), K<sub>2</sub>CO<sub>3 </sub>(200 mg, 1.46 mmol) in toluene (50 mL) were reacted to give the title product (130 mg, 24% yield) as a light yellow oil.</p><p id="p-0412" num="0406">GC/MS (EI): m/z (%): 303 (1) [M<sup>+</sup>], 302 (3), 288 (5), 244 (5), 216 (6), 195 (61), 180 (53), 148 (100), 126 (20), 96 (10). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 7.32 (d, J=8.8 Hz, 2H), 6.87 (d, J=8.8 Hz, 2H), 3.79 (s, 3H), 2.88-2.64 (m, 3H), 2.42-2.20 (m, 1H), 2.07 (t, J=10.3 Hz, 1H), 2.00-1.89 (m, 1H), 1.79 (dd, J=14.9, 6.9 Hz, 2H), 1.55 (t, J=12.9 Hz, 1H), 1.48-1.39 (m, 1H), 1.38-1.23 (m, 6H), 1.20-1.11 (m, 3H), 1.04 (d, J=6.2 Hz, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 157.5 (q), 143.4 (q), 126.0 (t), 113.5 (t), 79.3 (q), 77.6 (t), 55.1 (s), 53.9 (t), 48.9 (s), 46.3 (d), 37.9 (q), 37.2 (d), 33.1 (t), 26.9 (s), 26.9 (s), 26.6 (s), 24.9 (s), 20.2 (s).</p><heading id="h-0118" level="1">Example 111: rac-(3aR,5R,7S,7aR)-1,3,3,5,7-pentamethyl-5-(naphthalen-1-yl)octahydrobenzo[c]isoxazole</heading><p id="p-0413" num="0407">Following the general procedure described in Example 81b: 2,4,7-trimethyl-4-(naphthalen-1-yl)oct-6-enal (500 mg, 1.70 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-methylhydroxylamine hydrochloride (210 mg, 2.55 mmol), K<sub>2</sub>CO<sub>3 </sub>(190 mg, 1.36 mmol) in toluene (50 mL) were reacted to give the title product (170 mg, 31% yield) as a light yellow oil.</p><p id="p-0414" num="0408">GC/MS (EI): m/z (%): 323 (2) [M<sup>+</sup>], 322 (5), 308 (4), 236 (6), 195 (82), 180 (100), 168 (64), 153 (49), 126 (19), 98 (12), 96 (11). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 8.44 (d, J=8.5 Hz, 1H), 7.90 (dd, J=7.9, 1.3 Hz, 1H), 7.75 (d, J=8.0 Hz, 1H), 7.62-7.36 (m, 4H), 3.01-2.68 (m, 3H), 2.49 (d, J=10.5 Hz, 1H), 2.32-2.12 (m, 3H), 1.92 (t, J=12.9 Hz, 1H), 1.76-1.69 (m, 3H), 1.39-1.26 (m, 5H), 1.20 (d, J=8.5 Hz, 3H), 1.14-1.06 (m, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 146.0 (q), 135.3 (q), 131.1 (q), 130.0 (t), 127.9 (t), 126.4 (t), 125.2 (t), 124.7 (t), 124.7 (t), 122.8 (t), 79.4 (q), 77.3 (t), 53.9 (t), 48.8 (s), 46.5 (d), 39.9 (q), 37.1 (d), 33.3 (t), 26.9 (s), 25.7 (s), 24.9 (s), 20.2 (s).</p><heading id="h-0119" level="1">Example 112: rac-(3aR,5R,7R,7aR)-5-(3-chloro-2-methylphenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole</heading><p id="p-0415" num="0409">Following the general procedure described in Example 81 b: 4-(3-chloro-2-methylphenyl)-2,4,7-trimethyloct-6-enal (290 mg, 0.83 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-methylhydroxylamine hydrochloride (100 mg, 1.24 mmol), K<sub>2</sub>CO<sub>3 </sub>(90 mg, 0.66 mmol) in toluene (50 mL) were reacted to give the title product (100 mg, 39% yield) as a light yellow oil.</p><p id="p-0416" num="0410">GC/MS (EI): m/z (%): 321 (12) [M<sup>+</sup>], 320 (44), 306 (7), 263 (44), 234 (20), 166 (100), 153 (14), 126 (23), 108 (21), 98 (18), 68 (12). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 7.30-7.21 (m, 1H), 7.18 (d, J=7.8 Hz, 1H), 7.05 (t, J=8.0 Hz, 1H), 2.92-2.65 (m, 3H), 2.59-2.49 (m, 3H), 2.47-2.34 (m, 1H), 2.16 (dd, J=12.1, 8.1 Hz, 1H), 1.81 (t, J=11.0 Hz, 2H), 1.36 (d, J=12.8 Hz, 3H), 1.30 (d, J=6.3 Hz, 1H), 1.26 (s, 1H), 1.23-1.09 (m, 6H), 1.03 (t, J=7.3 Hz, 4H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 145.7 (q), 137.4 (q), 133.9 (q), 127.5 (t), 126.6 (t), 126.4 (t), 79.0 (q), 78.1 (t), 54.2 (t), 48.7 (s), 48.2 (d), 42.0 (q), 37.2 (d), 33.4 (t), 30.6 (s), 26.8 (s), 24.7 (s), 20.1 (s), 19.9 (s).</p><heading id="h-0120" level="1">Example 113: rac-(3aR,5R,7S,7aR)-1-isopropyl-5-(4-methoxyphenyl)-3,3,5,7-tetramethyloctahydrobenzo[c]isoxazole</heading><p id="p-0417" num="0411">Following the general procedure described in Example 81 b: 4-(4-methoxyphenyl)-2,4,7-trimethyloct-6-enal (700 mg, 2.55 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-isopropylhydroxylamine (290 mg, 3.83 mmol), K<sub>2</sub>CO<sub>3 </sub>(280 mg, 2.04 mmol) in toluene (50 mL) were reacted to give the title product (150 mg, 18% yield) as a light yellow oil.</p><p id="p-0418" num="0412">GC/MS (EI): m/z (%): 331 (50) [M<sup>+</sup>], 316 (100), 208 (12), 187 (7), 154 (69), 126 (22), 115 (17). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 7.24 (d, J=8.8 Hz, 2H), 6.79 (d, J=8.8 Hz, 2H), 3.71 (s, 3H), 3.22-2.94 (m, 1H), 2.27 (dd, J=17.7, 5.9 Hz, 2H), 1.95-1.77 (m, 1H), 1.75-1.62 (m, 2H), 1.39 (dt, J=25.8, 12.7 Hz, 2H), 1.24 (d, J=8.6 Hz, 6H), 1.18 (d, J=6.7 Hz, 3H), 0.97 (dd, J=16.1, 6.3 Hz, 9H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 157.5 (q), 143.6 (q), 126.0 (t), 113.5 (t), 77.9 (q), 68.9 (t), 55.2, 54.9 (t), 53.0 (t), 46.7 (d), 37.8 (q), 37.1 (d), 33.5 (t), 27.1 (s), 26.6 (s), 24.2 (s), 22.5 (s), 20.3 (s), 13.6 (s).</p><heading id="h-0121" level="1">Example 114: rac-(3aR,5R,7S,7aR)-5-(3-isopropylphenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole</heading><p id="p-0419" num="0413">Following the general procedure described in Example 81b: 4-(3-isopropylphenyl)-2,4,7-trimethyloct-6-enal (500 mg, 1.75 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-methylhydroxylamine hydrochloride (220 mg, 2.62 mmol), K<sub>2</sub>CO<sub>3 </sub>(190 mg, 1.40 mmol) in toluene (50 mL) were reacted to give the title product (130 mg, 24% yield) as a light yellow oil.</p><p id="p-0420" num="0414">GC/MS (EI): m/z (%): 315 (62) [M<sup>+</sup>], 180 (13), 161 (14), 126 (100), 100 (38), 87 (40). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 7.23-7.08 (m, 3H), 7.00 (d, J=6.9 Hz, 1H), 2.91-2.78 (m, 1H), 2.77-2.57 (m, 3H), 2.34-2.17 (m, 1H), 2.08-1.67 (m, 4H), 1.49 (t, J=12.9 Hz, 1H), 1.37 (t, J=12.6 Hz, 1H), 1.28 (s, 3H), 1.23-1.10 (m, 9H), 1.09-0.91 (m, 6H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 151.1 (q), 148.6 (q), 128.1 (t), 123.6 (t), 123.3 (t), 122.5 (t), 79.3 (q), 77.6 (t), 53.9 (t), 48.9 (s), 46.0 (d), 38.5 (q), 37.0 (d), 34.4 (t), 33.1 (t), 26.9 (s), 26.6 (s), 24.9 (s), 24.1 (s), 24.1 (s), 20.2 (s).</p><heading id="h-0122" level="1">Example 115: rac-(3aR,5R,7R,7aR)-5-(4-methoxyphenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole</heading><p id="p-0421" num="0415">Following the general procedure described in Example 81 b: 4-(4-methoxyphenyl)-2,4,7-trimethyloct-6-enal (500 mg, 1.82 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-methylhydroxylamine hydrochloride (230 mg, 2.73 mmol), K<sub>2</sub>CO<sub>3 </sub>(200 mg, 1.46 mmol) in toluene (50 mL) were reacted to give the title product (120 mg, 21% yield) as a light yellow oil.</p><p id="p-0422" num="0416">GC/MS (EI): m/z (%): 303 (20) [M<sup>+</sup>], 302 (39), 288 (5), 245 (13), 216 (42), 195 (10), 180 (19), 148 (100), 126 (20), 98 (15). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 7.18 (d, J=8.7 Hz, 2H), 6.81 (d, J=8.7 Hz, 2H), 3.74 (s, 3H), 2.74 (s, 3H), 2.33 (d, J=12.7 Hz, 1H), 2.24-2.04 (m, 2H), 1.94 (dd, J=17.2, 6.4 Hz, 1H), 1.39-1.20 (m, 3H), 1.15 (dd, J=8.3, 4.0 Hz, 9H), 0.97 (d, J=6.4 Hz, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 157.3 (q), 138.8 (q), 126.7 (t), 113.9 (t), 78.9, 78.1 (t), 55.2 (t), 54.0 (s), 48.7 (s), 46.1 (d), 39.4, 36.9 (d), 34.6 (s), 33.1 (t), 26.6 (s), 24.8 (s), 20.1 (s).</p><heading id="h-0123" level="1">Example 116: rac-4-methoxy-3-((3aR,5R,7S,7aR)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazol-5-yl)benzonitrile</heading><p id="p-0423" num="0417">Following the general procedure described in Example 81 b: 4-methoxy-3-(2,4,7-trimethyl-1-oxooct-6-en-4-yl)benzonitrile (350 mg, 1.07 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-methylhydroxylamine hydrochloride (130 mg, 1.60 mmol), K<sub>2</sub>CO<sub>3 </sub>(120 mg, 0.85 mmol) in toluene (50 mL) were reacted to give the title product (100 mg, 28% yield) as a light yellow oil.</p><p id="p-0424" num="0418">GC/MS (EI): m/z (%): 328 (72) [M<sup>+</sup>], 282 (28), 241 (26), 226 (67), 160 (39), 126 (100), 100 (41), 87 (47). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 7.58-7.42 (m, 2H), 6.90 (d, J=8.4 Hz, 1H), 3.86 (s, 3H), 2.84-2.58 (m, 3H), 2.35-2.16 (m, 1H), 2.05-1.82 (m, 4H), 1.57 (t, J=12.7 Hz, 1H), 1.49-1.28 (m, 5H), 1.27-1.18 (m, 3H), 1.12-0.94 (m, 6H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 161.0 (q), 139.6 (q), 132.1 (t), 130.2 (t), 119.6 (q), 112.1 (t), 103.8 (q), 79.3 (q), 77.3 (t), 55.5 (s), 53.4 (t), 48.9 (s), 43.7 (d), 39.0 (q), 34.3 (d), 32.9 (t), 26.9 (s), 24.9 (s), 23.1 (s), 20.2 (s).</p><heading id="h-0124" level="1">Example 117: rac-(3aR,5R,7S,7aR)-5-(3,5-difluorophenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole</heading><p id="p-0425" num="0419">Following the general procedure described in Example 81b: 4-(3,5-difluorophenyl)-2,4,7-trimethyloct-6-enal (550 mg, 0.69 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-methylhydroxylamine hydrochloride (90 mg, 1.04 mmol), K<sub>2</sub>CO<sub>3 </sub>(80 mg, 0.55 mmol) in toluene (50 mL) were reacted to give the title product (90 mg, 40% yield) as a light yellow oil.</p><p id="p-0426" num="0420">GC/MS (EI): m/z (%): 309 (56) [M<sup>+</sup>], 294 (8), 207 (18), 193 (18), 179 (18), 141 (20), 126 (100), 113 (18), 100 (46), 87 (56). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 6.88 (d, J=7.7 Hz, 2H), 6.63 (tt, J=8.7, 2.2 Hz, 1H), 2.92-2.58 (m, 3H), 2.40-2.19 (m, 1H), 2.12-1.86 (m, 2H), 1.85-1.63 (m, 2H), 1.55-1.39 (m, 2H), 1.34-1.25 (m, 6H), 1.18-1.12 (m, 3H), 1.08-1.00 (m, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 164.8 (q), 164.6 (q), 161.5 (q), 161.4 (q), 155.6 (q), 108.5 (t), 108.2 (t), 101.7 (t), 101.3 (t), 101.0 (t), 79.3 (q), 77.5 (t), 53.8 (t), 49.0 (s), 45.9 (d), 39.1 (q), 36.9 (d), 33.2 (t), 27.1 (s), 27.0 (s), 26.5 (s), 25.0 (s), 20.2 (s).</p><heading id="h-0125" level="1">Example 118: rac-2-chloro-5-((3aR,5R,7S,7aR)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazol-5-yl)benzonitrile</heading><p id="p-0427" num="0421">Following the general procedure described in Example 81b: 2-chloro-5-(2,4,7-trimethyl-1-oxooct-6-en-4-yl)benzonitrile (400 mg, 1.32 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-methylhydroxylamine hydrochloride (170 mg, 1.98 mmol), K<sub>2</sub>CO<sub>3 </sub>(150 mg, 1.05 mmol) in toluene (50 mL) were reacted to give the title product (80 mg, 18% yield) as a light yellow oil.</p><p id="p-0428" num="0422">GC/MS (EI): m/z (%): 332 (23) [M<sup>+</sup>], 286 (9), 244 (5), 230 (8), 164 (13), 150 (11), 126 (100), 113 (16), 100 (46), 87 (55). Or GC/MS (EI): m/z (%): 331 (16) [M<sup>+</sup>], 274 (19), 195 (20), 177 (34), 150 (15), 126 (88), 98 (300), 68 (100). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 7.65 (s, 1H), 7.59-7.50 (m, 1H), 7.47-7.39 (m, 1H), 2.88-2.57 (m, 3H), 2.28 (t, J=11.7 Hz, 1H), 2.10-1.69 (m, 4H), 1.54-1.38 (m, 2H), 1.32 (s, 3H), 1.26 (s, 3H), 1.12 (s, 3H), 1.03 (s, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 150.9 (q), 134.2 (q), 131.2 (t), 130.9 (t), 129.8 (t), 116.3 (q), 113.1 (q), 79.2 (q), 77.3 (t), 53.6 (t), 48.9 (s), 45.7 (d), 38.7 (q), 36.8 (d), 33.1 (t), 26.9 (s), 26.4 (s), 24.9 (s), 20.1 (s).</p><heading id="h-0126" level="1">Example 119: rac-3-chloro-5-((3aR,5R,7S,7aR)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazol-5-yl)benzonitrile</heading><p id="p-0429" num="0423">Following the general procedure described in Example 81b: 3-chloro-5-(2,4,7-trimethyl-1-oxooct-6-en-4-yl)benzonitrile (200 mg, 0.66 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-methylhydroxylamine hydrochloride (82 mg, 0.99 mmol), K<sub>2</sub>CO<sub>3 </sub>(73 mg, 0.53 mmol) in toluene (50 mL) were reacted to give the title product (36 mg, 16% yield) as a light yellow oil.</p><p id="p-0430" num="0424">GC/MS (EI): m/z (%): 334 (16) [M<sup>+</sup>], 332 (48) [M<sup>+</sup>], 286 (24), 244 (20), 230 (33), 126 (100), 100 (49), 98 (36), 87 (66), 70 (22). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 7.56 (d, J=7.9 Hz, 2H), 7.48 (s, 1H), 2.88-2.63 (m, 3H), 2.41-2.23 (m, 1H), 2.13-1.92 (m, 2H), 1.86-1.72 (m, 2H), 1.55-1.41 (m, 2H), 1.34 (s, 3H), 1.28 (s, 3H), 1.15 (s, 3H), 1.05 (d, J=6.1 Hz, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 154.7 (q), 135.3 (q), 130.6 (t), 129.4 (t), 127.5 (t), 117.9 (q), 113.9 (q), 79.3 (q), 77.3 (t), 53.6 (t), 49.0 (s), 45.7 (d), 39.1 (q), 36.8 (d), 33.1 (s), 26.9 (s), 26.4 (s), 25.0 (s), 20.1 (s).</p><heading id="h-0127" level="1">Example 120: rac-(3aR,5R,7S,7aR)-5-(3,4-difluorophenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole</heading><p id="p-0431" num="0425">Following the general procedure described in Example 81b: 4-(3,4-difluorophenyl)-2,4,7-trimethyloct-6-enal (854 mg, 2.13 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-methylhydroxylamine hydrochloride (267 mg, 3.20 mmol), K<sub>2</sub>CO<sub>3 </sub>(236 mg, 1.71 mmol) in toluene (50 mL) were reacted to give the title product (189 mg, 29% yield) as a yellow oil.</p><p id="p-0432" num="0426">GC/MS (EI): m/z (%): 309 (40) [M<sup>+</sup>], 294 (5), 207 (14), 193 (10), 179 (8), 141 (28), 126 (100), 113 (15), 100 (45), 87 (54). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 7.22-7.13 (m, 1H), 7.12-7.05 (m, 2H), 2.88-2.63 (m, 3H), 2.37-2.22 (m, 1H), 2.12-1.86 (m, 2H), 1.84-1.69 (m, 2H), 1.57-1.39 (m, 2H), 1.34-1.25 (m, 6H), 1.19-1.11 (m, 3H), 1.08-1.01 (m, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 151.8 (q), 150.0 (q), 148.5 (q), 121.1 (t), 121.0 (t), 121.0 (t), 120.9 (t), 116.9 (t), 116.7 (t), 114.6 (t), 114.4 (t), 79.3 (q), 77.5 (t), 53.8 (t), 49.0 (s), 46.2 (d), 38.5 (q), 37.1 (d), 33.2 (t), 27.0 (s), 26.7 (s), 25.0 (s), 20.2 (s).</p><heading id="h-0128" level="1">Example 121: rac-2-methyl-5-((3aR,5R,7S,7aR)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazol-5-yl)benzonitrile</heading><p id="p-0433" num="0427">Following the general procedure described in Example 81b: 2-methyl-5-(2,4,7-trimethyl-1-oxooct-6-en-4-yl)benzonitrile (300 mg, 1.06 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-methylhydroxylamine hydrochloride (133 mg, 1.59 mmol), K<sub>2</sub>CO<sub>3 </sub>(117 mg, 0.85 mmol) in toluene (50 mL) were reacted to give the title product (135 mg, 41% yield) as a light yellow oil.</p><p id="p-0434" num="0428">GC/MS (EI): m/z (%): 312 (73) [M<sup>+</sup>], 266 (33), 207 (34), 157 (27), 144 (32), 126 (100), 100 (45), 98 (33), 87 (55), 70 (19). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 7.60 (s, 1H), 7.52 (d, J=8.1 Hz, 1H), 7.27 (d, J=8.3 Hz, 1H), 2.90-2.64 (m, 3H), 2.51 (s, 3H), 2.31 (t, J=10.7 Hz, 1H), 2.14-1.89 (m, 2H), 1.88-1.70 (m, 2H), 1.58-1.40 (m, 2H), 1.31 (d, J=15.1 Hz, 6H), 1.16 (d, J=8.5 Hz, 3H), 1.05 (d, J=5.9 Hz, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 149.6 (q), 139.3 (q), 130.2 (t), 129.8 (t), 129.2 (t), 118.5 (q), 112.6 (q), 79.2 (q), 77.4 (t), 53.7 (t), 49.4 (q), 48.9 (s), 45.9 (d), 38.4 (q), 36.8 (d), 33.1 (t), 27.0 (s), 26.9 (s), 26.4 (s), 24.9 (s), 20.1 (s), 19.8 (s).</p><heading id="h-0129" level="1">Example 122: rac-methyl 4-methyl-3-((3aR,5R,7S,7aR)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazol-5-yl)benzoate</heading><p id="p-0435" num="0429">Following the general procedure described in Example 81b: methyl (E)-4-methyl-3-(2,4,7-trimethyl-1-oxoocta-2,6-dien-4-yl)benzoate (1.40 g, 2.40 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-methylhydroxylamine hydrochloride (0.30 g, 3.61 mmol), K<sub>2</sub>CO<sub>3 </sub>(0.27 g, 1.92 mmol) in toluene (50 mL) were reacted to give the title product (0.25 g, 30% yield) as a light yellow oil.</p><p id="p-0436" num="0430">GC/MS (EI): m/z (%): 345 (68) [M<sup>+</sup>], 267 (47), 225 (29), 190 (30), 126 (100), 100 (47), 98 (32), 87 (68), 70 (17). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 8.02 (s, 1H), 7.70 (d, J=7.8 Hz, 1H), 7.13 (d, J=7.9 Hz, 1H), 3.82 (s, 3H), 2.81-2.58 (m, 3H), 2.54 (s, 3H), 2.31-2.16 (m, 1H), 2.10-1.85 (m, 4H), 1.64-1.44 (m, 2H), 1.39 (s, 3H), 1.21 (s, 3H), 1.09 (d, J=5.6 Hz, 3H), 0.99 (d, J=5.8 Hz, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 167.2 (q), 148.3 (q), 141.6 (q), 133.3 (t), 127.5 (t), 127.0 (t), 126.7 (t), 79.2 (q), 76.9 (t), 53.6 (t), 51.8 (s), 48.7 (s), 45.0 (d), 39.6 (q), 35.6 (d), 33.1 (t), 26.8 (s), 26.7 (s), 24.8 (s), 24.3 (s), 23.7 (s), 20.1 (s).</p><heading id="h-0130" level="1">Example 123: rac-(3aR,5R,7S,7aR)-1,3,3,5,7-pentamethyl-5-(2-(methylthio)phenyl)octahydrobenzo[c]isoxazole</heading><p id="p-0437" num="0431">Following the general procedure described in Example 81b: 2,4,7-trimethyl-4-(2-(methylthio)phenyl)oct-6-enal (792 mg, 0.76 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-methylhydroxylamine hydrochloride (96 mg, 1.15 mmol), K<sub>2</sub>CO<sub>3 </sub>(84 mg, 0.61 mmol) in toluene (50 mL) were reacted to give the title product (80 mg, 33% yield) as a light yellow oil.</p><p id="p-0438" num="0432">GC/MS (EI): m/z (%): 319 (46) [M<sup>+</sup>], 304 (9), 273 (13), 217 (8), 180 (11), 149 (35), 126 (100), 113 (16), 100 (36), 87 (56). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 7.47-7.32 (m, 2H), 7.24-7.10 (m, 2H), 2.92-2.71 (m, 3H), 2.50 (s, 3H), 2.36-2.24 (m, 2H), 2.08-1.91 (m, 4H), 1.90-1.77 (m, 1H), 1.56 (s, 3H), 1.27 (s, 3H), 1.17 (d, J=4.9 Hz, 3H), 1.03 (d, J=5.9 Hz, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 148.7 (q), 137.1 (q), 130.4 (t), 126.8 (t), 126.1 (t), 125.7 (t), 79.6 (q), 76.5 (t), 54.0 (t), 48.9 (s), 44.4 (d), 40.4 (q), 34.7 (d), 33.5 (t), 27.0 (s), 27.0 (s), 25.0 (s), 24.3 (s), 20.3 (s), 18.8 (s).</p><heading id="h-0131" level="1">Example 124: rac-(3aR,5R,7S,7aR)-5-(2,5-difluorophenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole</heading><p id="p-0439" num="0433">Following the general procedure described in Example 81b: 4-(2,5-difluorophenyl)-2,4,7-trimethyloct-6-enal (614 mg, 0.88 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-methylhydroxylamine hydrochloride (110 mg, 1.31 mmol), K<sub>2</sub>CO<sub>3 </sub>(97 mg, 0.70 mmol) in toluene (50 mL) were reacted to give the title product (108 mg, 38% yield) as a light yellow oil.</p><p id="p-0440" num="0434">GC/MS (EI): m/z (%): 309 (25) [M<sup>+</sup>], 294 (4), 263 (8), 207 (11), 153 (10), 141 (23), 126 (100), 113 (16), 100 (46), 87 (64). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 7.14-6.78 (m, 3H), 2.88-2.61 (m, 3H), 2.41-2.22 (m, 1H), 2.15-1.79 (m, 4H), 1.69-1.46 (m, 2H), 1.41 (s, 3H), 1.30-1.23 (m, 3H), 1.19-1.10 (m, 3H), 1.08-0.99 (m, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 160.3 (q), 159.3 (q), 157.1 (q), 117.8 (t), 117.6 (t), 117.4 (t), 117.3 (t), 113.9 (t), 113.8 (t), 113.6 (t), 113.6 (t), 113.5 (t), 79.4 (q), 77.4 (t), 53.5 (t), 49.0 (s), 44.3 (d), 44.2 (d), 38.6 (d), 38.5 (q), 35.1 (d), 35.0 (d), 33.1 (t), 27.0 (s), 25.0 (s), 24.0 (s), 23.9 (s), 20.2 (s).</p><heading id="h-0132" level="1">Example 125: rac-(3aR,5R,7S,7aR)-5-(2,3-dimethylphenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole</heading><p id="p-0441" num="0435">Following the general procedure described in Example 81b: 4-(2,3-dimethylphenyl)-2,4,7-trimethyloct-6-enal (420 mg, 1.54 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-methylhydroxylamine hydrochloride (193 mg, 2.31 mmol), K<sub>2</sub>CO<sub>3 </sub>(193 mg, 2.31 mmol) in toluene (50 mL) were reacted to give the title product (89 mg, 19% yield) as a light yellow oil.</p><p id="p-0442" num="0436">GC/MS (EI): m/z (%): 301 (100) [M<sup>+</sup>], 180 (22), 171 (28), 146 (37), 126 (93), 100 (48), 98 (34), 87 (69), 70 (17). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 7.33-7.27 (m, 1H), 7.11-7.06 (m, 2H), 2.89-2.65 (m, 3H), 2.46-2.40 (m, 3H), 2.29 (s, 3H), 2.21-2.10 (m, 1H), 2.08-1.89 (m, 4H), 1.78-1.66 (m, 1H), 1.63-1.54 (m, 1H), 1.51 (s, 3H), 1.33-1.27 (m, 3H), 1.16 (s, 3H), 1.08-1.03 (m, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 148.0 (q), 138.9 (q), 134.9 (q), 128.3 (t), 125.4 (t), 123.3 (t), 79.5 (q), 77.1 (t), 54.0 (t), 48.9 (s), 45.9 (d), 39.5 (q), 36.5 (d), 33.4 (t), 27.0 (s), 25.3 (s), 25.0 (s), 21.6 (s), 20.4 (s), 19.3 (s).</p><heading id="h-0133" level="1">Example 126: rac-(3aR,5R,7S,7aR)-1,3,3,5,7-pentamethyl-5-(2,4,5-trimethylphenyl)octahydrobenzo[c]isoxazole</heading><p id="p-0443" num="0437">Following the general procedure described in Example 81b: 2,4,7-trimethyl-4-(2,4,5-trimethylphenyl)oct-6-enal (458 mg, 1.47 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-methylhydroxylamine hydrochloride (184 mg, 2.21 mmol), K<sub>2</sub>CO<sub>3 </sub>(163 mg, 1.18 mmol) in toluene (50 mL) were reacted to give the title product (180 mg, 39% yield) as a light yellow oil.</p><p id="p-0444" num="0438">GC/MS (EI): m/z (%): 315 (53) [M<sup>+</sup>], 199 (9), 180 (24), 160 (15), 149 (36), 133 (23), 126 (100), 113 (16), 100 (41), 87 (59). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 7.15 (s, 1H), 6.95 (s, 1H), 2.91-2.65 (m, 3H), 2.51 (s, 3H), 2.38-2.29 (m, 1H), 2.23 (d, J=13.2 Hz, 6H), 2.15-2.05 (m, 1H), 2.03-1.82 (m, 3H), 1.72-1.48 (m, 2H), 1.45 (s, 3H), 1.28 (s, 3H), 1.20 (s, 1H), 1.15 (s, 2H), 1.06 (d, J=6.0 Hz, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 145.7 (q), 135.0 (t), 134.2 (q), 133.7 (q), 133.1 (q), 126.9 (t), 79.5 (q), 77.3 (t), 54.0 (t), 49.0 (s), 45.6 (d), 39.3 (q), 36.0 (d), 33.3 (t), 27.0 (s), 25.1 (s), 24.8 (s), 23.2 (s), 20.4 (s), 19.6 (s), 18.9 (s).</p><heading id="h-0134" level="1">Example 127: rac-(3aR,5R,7S,7aR)-1,3,3,5,7-pentamethyl-5-(4-(methylthio)phenyl)octahydrobenzo[c]isoxazole</heading><p id="p-0445" num="0439">Following the general procedure described in Example 81b: 2,4,7-trimethyl-4-(4-(methylthio)phenyl)oct-6-enal (350 mg, 1.21 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-methylhydroxylamine hydrochloride (151 mg, 1.81 mmol), K<sub>2</sub>CO<sub>3 </sub>(133 mg, 0.96 mmol) in toluene (50 mL) were reacted to give the title product (68 mg, 18% yield) as a yellow oil.</p><p id="p-0446" num="0440">GC/MS (EI): m/z (%): 319 (99) [M<sup>+</sup>], 195 (32), 180 (76), 165 (34), 164 (42), 137 (29), 126 (100), 100 (38), 98 (33), 87 (54). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 7.32 (d, J=8.5 Hz, 2H), 7.22 (d, J=8.5 Hz, 2H), 2.88-2.63 (m, 3H), 2.46 (s, 3H), 2.39-2.23 (m, 1H), 2.12-1.87 (m, 2H), 1.86-1.72 (m, 2H), 1.60-1.46 (m, 1H), 1.42 (d, J=12.3 Hz, 1H), 1.33 (s, 3H), 1.26 (s, 3H), 1.13 (s, 3H), 1.03 (d, J=6.1 Hz, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 148.4 (q), 135.6 (q), 126.9 (t), 125.7 (t), 79.4 (q), 77.6 (t), 53.9 (t), 48.9 (s), 46.1 (d), 38.3 (q), 37.0 (d), 33.1 (t), 27.0 (s), 26.5 (s), 25.0 (s), 20.2 (s), 16.1 (s).</p><heading id="h-0135" level="1">Example 128: rac-4-methoxy-3-((3aR,5R,7R,7aR)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazol-5-yl)benzonitrile</heading><p id="p-0447" num="0441">Following the general procedure described in Example 81b: 4-methoxy-3-(2,4,7-trimethyl-1-oxooct-6-en-4-yl)benzonitrile (351 mg, 1.07 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-methylhydroxylamine hydrochloride (134 mg, 1.60 mmol), K<sub>2</sub>CO<sub>3 </sub>(118 mg, 0.85 mmol) in toluene (50 mL) were reacted to give the title product (84 mg, 24% yield) as a light yellow oil.</p><p id="p-0448" num="0442">GC/MS (EI): m/z (%): 328 (100) [M<sup>+</sup>], 282 (33), 241 (37), 226 (87), 160 (45), 126 (98), 100 (38), 87 (80). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 7.59-7.35 (m, 2H), 6.91 (d, J=8.1 Hz, 1H), 3.87 (s, 3H), 2.70 (s, 4H), 2.47-2.29 (m, 1H), 2.20-2.05 (m, 1H), 1.85-1.62 (m, 2H), 1.34-0.95 (m, 14H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 161.7 (q), 135.4 (q), 132.9 (t), 132.1 (t), 119.5 (q), 112.4 (t), 104.1 (q), 78.9 (q), 78.1 (t), 55.4 (s), 54.7 (t), 48.7 (s), 46.5 (d), 40.9 (q), 35.6 (d), 33.4 (t), 29.5 (s), 26.6 (s), 24.7 (s), 20.2 (s).</p><heading id="h-0136" level="1">Example 129: rac-(3aR,5R,7S,7aR)-5-(3-fluoro-5-(trifluoromethyl)phenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole</heading><p id="p-0449" num="0443">Following the general procedure described in Example 81b: 4-(3-fluoro-5-(trifluoromethyl)phenyl)-2,4,7-trimethyloct-6-enal (400 mg, 1.21 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-methylhydroxylamine hydrochloride (152 mg, 1.82 mmol), K<sub>2</sub>CO<sub>3 </sub>(134 mg, 0.97 mmol) in toluene (50 mL) were reacted to give the title product (140 mg, 32% yield) as a light yellow oil.</p><p id="p-0450" num="0444">GC/MS (EI): m/z (%): 359 (52) [M<sup>+</sup>], 313 (25), 271 (17), 257 (39), 243 (23), 177 (17), 126 (100), 100 (46), 98 (36), 87 (58). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 7.44 (s, 1H), 7.30 (d, J=10.5 Hz, 1H), 7.18 (d, J=8.0 Hz, 1H), 2.92-2.66 (m, 3H), 2.45-2.27 (m, 1H), 2.18-1.93 (m, 2H), 1.91-1.77 (m, 2H), 1.61-1.42 (m, 2H), 1.38 (s, 3H), 1.29 (s, 3H), 1.17 (s, 3H), 1.08 (d, J=6.0 Hz, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 164.2 (q), 160.9 (q), 155.4 (q), 155.3 (q), 132.5 (q), 132.4 (q), 132.1 (q), 132.0 (q), 125.3 (q), 125.3 (q), 121.7 (q), 121.7 (q), 117.8 (t), 117.7 (t), 117.7 (t), 116.2 (t), 115.9 (t), 110.6 (t), 110.5 (t), 110.2 (t), 110.1 (t), 79.3 (q), 77.4 (t), 53.7 (t), 48.9 (s), 45.7 (d), 39.1 (q), 36.9 (d), 33.1 (t), 26.9 (s), 26.5 (s), 24.9 (s), 20.1 (s).</p><heading id="h-0137" level="1">Example 130: rac-(3aR,5R,7S,7aR)-1,3,3,5,7-pentamethyl-5-(2-methyl-5-(trifluoromethyl)phenyl)octahydrobenzo[c] isoxazole</heading><p id="p-0451" num="0445">Following the general procedure described in Example 81b: 2,4,7-trimethyl-4-(2-methyl-5-(trifluoromethyl)phenyl)oct-6-enal (300 mg, 0.92 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-methylhydroxylamine hydrochloride (115 mg, 1.38 mmol), K<sub>2</sub>CO<sub>3 </sub>(102 mg, 0.74 mmol) in toluene (50 mL) were reacted to give the title product (114 mg, 35% yield) as a yellow oil.</p><p id="p-0452" num="0446">GC/MS (EI): m/z (%): 355 (66) [M<sup>+</sup>], 309 (17), 253 (25), 187 (33), 173 (25), 126 (100), 100 (45), 98 (32), 87 (53). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 7.63 (s, 1H), 7.39 (d, J=7.8 Hz, 1H), 7.29 (s, 1H), 2.91-2.68 (m, 3H), 2.63 (s, 3H), 2.44-2.27 (m, 1H), 2.20-2.09 (m, 1H), 2.06-1.94 (m, 3H), 1.71-1.53 (m, 2H), 1.49 (s, 3H), 1.32 (s, 3H), 1.21 (s, 3H), 1.09 (d, J=6.0 Hz, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 149.0 (q), 140.3 (q), 133.7 (t), 128.3 (q), 127.9 (q), 126.4 (q), 122.9 (t), 122.8 (t), 122.4 (t), 122.3 (t), 118.2 (t), 79.4 (q), 77.0 (t), 53.8 (t), 48.9 (s), 45.1 (d), 39.9 (q), 35.7 (d), 33.3 (t), 27.0 (s), 26.9 (s), 25.0 (s), 24.5 (s), 23.7 (s), 20.3 (s).</p><heading id="h-0138" level="1">Example 131: rac-(3aR,5R,7S,7aR)-5-(2-ethoxyphenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole</heading><p id="p-0453" num="0447">Following the general procedure described in Example 81b: 4-(2-ethoxyphenyl)-2,4,7-trimethyloct-6-enal (600 mg, 1.66 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-methylhydroxylamine hydrochloride (208 mg, 2.50 mmol), K<sub>2</sub>CO<sub>3 </sub>(184 mg, 1.33 mmol) in toluene (50 mL) were reacted to give the title product (201 mg, 38% yield) as a light yellow oil.</p><p id="p-0454" num="0448">GC/MS (EI): m/z (%): 317 (94) [M<sup>+</sup>], 271 (15), 195 (16), 180 (33), 149 (45), 135 (35), 126 (100), 100 (41), 98 (29), 87 (52). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 7.31 (d, J=7.8 Hz, 1H), 7.23-7.13 (m, 1H), 6.95-6.83 (m, 2H), 4.15-3.97 (m, 2H), 2.89-2.63 (m, 3H), 2.44-2.24 (m, 1H), 2.15 (t, J=10.3 Hz, 1H), 2.02-1.73 (m, 5H), 1.51-1.43 (m, 6H), 1.26 (s, 3H), 1.14 (s, 3H), 1.05-0.99 (m, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 157.4 (q), 137.8 (q), 127.2 (t), 126.2 (t), 120.3 (t), 112.2 (t), 79.5 (q), 77.3 (t), 63.2 (d), 53.9 (t), 48.9 (s), 43.9 (d), 38.8 (q), 34.2 (d), 33.2 (t), 26.9 (s), 25.0 (s), 23.9 (s), 20.3 (s), 15.1 (s).</p><heading id="h-0139" level="1">Example 132: rac-(3aR,5R,7S,7aR)-1,3,3,5,7-pentamethyl-5-(5-methylthiophen-2-yl)octahydrobenzo[c]isoxazole</heading><p id="p-0455" num="0449">Following the general procedure described in Example 81b: 2,4,7-trimethyl-4-(5-methylthiophen-2-yl)oct-6-enal (854 mg, 1.55 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-methylhydroxylamine hydrochloride (194 mg, 2.33 mmol), K<sub>2</sub>CO<sub>3 </sub>(171 mg, 1.24 mmol) in toluene (50 mL) were reacted to give the title product (142 mg, 31% yield) as a light yellow oil.</p><p id="p-0456" num="0450">GC/MS (EI): m/z (%): 293 (23) [M<sup>+</sup>], 195 (35), 180 (100), 149 (13), 138 (14), 137 (15), 126 (15), 100 (8), 98 (13), 87 (18). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 6.64 (d, J=3.4 Hz, 1H), 6.60-6.52 (m, 1H), 2.86-2.63 (m, 3H), 2.44 (s, 3H), 2.35-2.20 (m, 1H), 2.14-2.03 (m, 1H), 1.79-1.71 (m, 2H), 1.68-1.60 (m, 2H), 1.54-1.46 (m, 1H), 1.41 (s, 3H), 1.29-1.25 (m, 3H), 1.14 (s, 3H), 1.01 (d, J=6.3 Hz, 3H). 13C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 155.3 (q), 136.9 (q), 124.4 (t), 120.8 (t), 79.4 (q), 77.7 (t), 54.0 (t), 49.0 (s), 48.1 (d), 39.0 (d), 38.5 (q), 33.3 (t), 27.3 (s), 27.0 (s), 25.0 (s), 20.1 (s), 15.3 (s).</p><heading id="h-0140" level="1">Example 133: rac-(3aR,5R,7R,7aR)-1,3,3,5,7-pentamethyl-5-(2-(methylthio)phenyl)octahydrobenzo[c]isoxazole</heading><p id="p-0457" num="0451">Following the general procedure described in Example 81b: 2,4,7-trimethyl-4-(2-(methylthio)phenyl)oct-6-enal (792 mg, 0.76 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-methylhydroxylamine hydrochloride (96 mg, 1.15 mmol), K<sub>2</sub>CO<sub>3 </sub>(84 mg, 0.61 mmol) in toluene (50 mL) were reacted to give the title product (90 mg, 37% yield) as a light yellow oil.</p><p id="p-0458" num="0452">GC/MS (EI): m/z (%): 319 (56) [M<sup>+</sup>], 304 (9), 273 (13), 217 (10), 180 (8), 161 (14), 149 (36), 126 (80), 113 (22), 87 (100). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 7.34-7.22 (m, 2H), 7.18-7.04 (m, 2H), 3.25-3.07 (m, 1H), 2.81-2.57 (m, 3H), 2.49 (s, 3H), 2.21-2.07 (m, 1H), 1.94-1.73 (m, 2H), 1.48 (s, 3H), 1.33-1.10 (m, 9H), 1.05-0.98 (m, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 144.3 (q), 136.9 (q), 130.1 (t), 128.6 (t), 126.7 (t), 125.5 (t), 79.2 (q), 78.3 (t), 54.4 (t), 48.8 (s), 47.7 (d), 42.2 (q), 36.6 (d), 33.5 (t), 29.4 (s), 26.9 (s), 24.8 (s), 20.2 (s), 18.7 (s).</p><heading id="h-0141" level="1">Example 134: rac-2-chloro-5-((3aR,5R,7R,7aR)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazol-5-yl)benzonitrile</heading><p id="p-0459" num="0453">Following the general procedure described in Example 81b: 2-chloro-5-(2,4,7-trimethyl-1-oxooct-6-en-4-yl)benzonitrile (400 mg, 1.32 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-methylhydroxylamine hydrochloride (165 mg, 1.98 mmol), K<sub>2</sub>CO<sub>3 </sub>(146 mg, 1.05 mmol) in toluene (50 mL) were reacted to give the title product (94 mg, 21% yield) as a light yellow oil.</p><p id="p-0460" num="0454">GC/MS (EI): m/z (%): 332 (25) [M<sup>+</sup>], 286 (7), 230 (8), 164 (14), 126 (96), 113 (32), 100 (41), 98 (51), 87 (100), 70 (20). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 7.58 (s, 1H), 7.52-7.40 (m, 2H), 2.78 (s, 3H), 2.16 (dd, J=20.7, 11.4 Hz, 2H), 1.75 (t, J=11.2 Hz, 1H), 1.66-1.56 (m, 1H), 1.49-1.36 (m, 1H), 1.31-1.12 (m, 11H), 1.02 (d, J=6.4 Hz, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 147.2 (q), 134.2 (q), 131.8 (t), 131.7 (t), 130.3 (t), 116.3 (q), 113.6 (q), 78.8 (q), 77.7 (t), 54.2 (t), 48.7 (s), 45.5 (d), 40.2 (q), 36.7 (d), 34.2 (s), 33.3 (t), 26.7 (s), 24.8 (s), 20.0 (s).</p><heading id="h-0142" level="1">Example 135: rac-3-methyl-4-((3aR,5R,7S,7aR)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazol-5-yl)benzonitrile</heading><p id="p-0461" num="0455">Following the general procedure described in Example 81 b: 3-methyl-4-(2,4,7-trimethyl-1-oxooct-6-en-4-yl)benzonitrile (1.26 g, 0.67 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-methylhydroxylamine hydrochloride (0.08 g, 0.100 mmol), K<sub>2</sub>CO<sub>3 </sub>(0.07 g, 0.53 mmol) in toluene (50 mL) were reacted to give the title product (0.045 g, 21% yield) as a colorless oil.</p><p id="p-0462" num="0456">GC/MS (EI): m/z (%): 312 (43) [M<sup>+</sup>], 297 (6), 266 (7), 210 (10), 182 (11), 144 (30), 126 (100), 100 (53), 98 (40), 87 (71), 70 (19). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 7.56 (d, J=7.8 Hz, 1H), 7.28 (s, 1H), 7.09 (d, J=7.8 Hz, 1H), 2.91-2.61 (m, 3H), 2.38 (s, 3H), 2.33-2.17 (m, 1H), 2.06-1.79 (m, 3H), 1.69 (t, J=12.8 Hz, 1H), 1.60-1.40 (m, 3H), 1.28-1.21 (m, 3H), 1.16 (s, 3H), 1.04 (d, J=6.2 Hz, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 153.8 (q), 137.6 (q), 136.5 (t), 129.8 (t), 126.5 (t), 119.0 (q), 110.1 (q), 79.4 (q), 77.3 (t), 53.7 (t), 48.9 (s), 45.0 (d), 40.4 (q), 35.7 (d), 33.3 (t), 27.0 (s), 25.0 (s), 24.4 (s), 23.7 (s), 20.3 (s).</p><heading id="h-0143" level="1">Example 136: rac-4-methyl-2-((3aR,5R,7S,7aR)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazol-5-yl)benzonitrile</heading><p id="p-0463" num="0457">Following the general procedure described in Example 81b: 4-methyl-2-(2,4,7-trimethyl-1-oxooct-6-en-4-yl)benzonitrile (271 mg, 0.96 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-methylhydroxylamine hydrochloride (120 mg, 1.43 mmol), K<sub>2</sub>CO<sub>3 </sub>(106 mg, 0.77 mmol) in toluene (40 mL) were reacted to give the title product (145 mg, 49% yield) as a light I5 yellow oil.</p><p id="p-0464" num="0458">GC/MS (EI): m/z (%): 312 (38) [M<sup>+</sup>], 297 (6), 281 (7), 266 (28), 249 (5), 207 (45), 126 (100), 100 (34), 87 (55), 70 (12). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 7.56 (d, J=7.8 Hz, 1H), 7.28 (s, 1H), 7.09 (d, J=7.8 Hz, 1H), 2.91-2.61 (m, 3H), 2.38 (s, 3H), 2.33-2.17 (m, 1H), 2.06-1.79 (m, 3H), 1.69 (t, J=12.8 Hz, 1H), 1.60-1.40 (m, 3H), 1.28-1.21 (m, 3H), 1.16 (s, 3H), 1.04 (d, J=6.2 Hz, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 153.3 (q), 143.6 (q), 136.0 (t), 127.2 (t), 127.1 (t), 120.6 (q), 107.6 (q), 79.5 (q), 76.6 (t), 53.8 (t), 48.9 (s), 44.9 (d), 39.5 (q), 35.5 (d), 33.4 (t), 27.0 (s), 26.9 (s), 24.9 (s), 24.6 (s), 22.2 (s), 20.0 (s).</p><heading id="h-0144" level="1">Example 137: rac-(3aR,5R,7S,7aR)-1,3,3,5,7-pentamethyl-5-(5-methylthiophen-3-yl)octahydrobenzo[c]isoxazole</heading><p id="p-0465" num="0459">Following the general procedure described in Example 81b: 2,4,7-trimethyl-4-(5-methylthiophen-3-yl)oct-6-enal (758 mg, 1.29 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-methylhydroxylamine hydrochloride (162 mg, 1.94 mmol), K<sub>2</sub>CO<sub>3 </sub>(143 mg, 1.03 mmol) in toluene (40 mL) were reacted to give the title product (83 mg, 22% yield) as a colorless oil.</p><p id="p-0466" num="0460">GC/MS (EI): m/z (%): 293 (44) [M<sup>+</sup>], 180 (27), 149 (27), 139 (44), 126 (100), 100 (29), 98 (51), 87 (80). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 6.72 (t, J=10.0 Hz, 2H), 2.88-2.61 (m, 3H), 2.46 (s, 3H), 2.35-2.19 (m, 1H), 2.07 (t, J=10.3 Hz, 1H), 1.99-1.82 (m, 1H), 1.78-1.63 (m, 2H), 1.61-1.34 (m, 4H), 1.34-1.21 (m, 7H), 1.15 (s, 3H), 1.01 (d, J=6.3 Hz, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 153.1 (q), 139.8 (q), 124.3 (t), 115.4 (t), 79.4 (q), 77.8 (t), 53.7 (t), 49.0 (s), 46.5 (d), 37.6 (q), 37.3 (d), 33.1 (t), 27.0 (s), 26.0 (s), 25.0 (s), 20.2 (s), 15.5 (s).</p><heading id="h-0145" level="1">Example 138: rac-(3aR,5R,7S,7aR)-5-(furan-3-yl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole</heading><p id="p-0467" num="0461">Following the general procedure described in Example 81b: 4-(furan-3-yl)-2,4,7-trimethyloct-6-enal (558 mg, 1.19 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-methylhydroxylamine hydrochloride (149 mg, 1.79 mmol), K<sub>2</sub>CO<sub>3 </sub>(132 mg, 0.95 mmol) in toluene (40 mL) were reacted to give the title product (100 mg, 32% yield) as a colorless oil.</p><p id="p-0468" num="0462">GC/MS (EI): m/z (%): 263 (46) [M<sup>+</sup>], 248 (8), 180 (18), 149 (10), 126 (100), 109 (21), 100 (41), 98 (35), 87 (60). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 7.37 (t, J=1.6 Hz, 1H), 7.22 (s, 1H), 6.36 (s, 1H), 2.90-2.70 (m, 3H), 2.33-2.18 (m, 1H), 2.08 (t, J=10.3 Hz, 1H), 1.91 (s, 1H), 1.72-1.60 (m, 2H), 1.54-1.36 (m, 2H), 1.28 (d, J=10.8 Hz, 6H), 1.13 (s, 3H), 1.00 (d, J=6.3 Hz, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 143.0 (t), 136.9 (t), 136.7 (q), 108.6 (t), 79.4 (q), 77.9 (t), 53.6 (t), 49.0 (s), 46.5 (d), 37.4 (d), 34.1 (q), 33.0 (t), 27.0 (s), 25.6 (s), 25.0 (s), 20.1 (s).</p><heading id="h-0146" level="1">Example 139: rac-(3aR,5R,7S,7aR)-5-(4-(tert-butyl)phenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole</heading><p id="p-0469" num="0463">Following the general procedure described in Example 81 b: 4-(4-(tert-butyl)phenyl)-2,4,7-trimethyloct-6-enal (658 mg, 1.97 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-methylhydroxylamine hydrochloride (247 mg, 2.96 mmol), K<sub>2</sub>CO<sub>3 </sub>(218 mg, 1.58 mmol) in toluene (40 mL) were reacted to give the title product (267 mg, 41% yield) as a colorless oil.</p><p id="p-0470" num="0464">GC/MS (EI): m/z (%): 329 (37) [M<sup>+</sup>], 180 (27), 159 (19), 126 (100), 100 (36), 98 (24), 87 (39), 57 (43). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 7.40-7.29 (m, 4H), 2.87-2.65 (m, 3H), 2.40-2.24 (m, 1H), 2.13-1.91 (m, 2H), 1.82 (t, J=11.2 Hz, 2H), 1.65-1.52 (m, 1H), 1.51-1.42 (m, 1H), 1.36 (s, 3H), 1.32 (s, 9H), 1.28 (s, 3H), 1.13 (s, 3H), 1.04 (d, J=6.0 Hz, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 148.6 (q), 148.2 (q), 125.1 (t), 124.7 (t), 79.4 (q), 77.7 (t), 53.9 (t), 49.0 (s), 46.2 (d), 38.2 (q), 37.1 (d), 34.3 (q), 33.2 (t), 31.4 (s), 27.1 (s), 27.0 (s), 26.6 (s), 25.0 (s), 20.3 (s).</p><heading id="h-0147" level="1">Example 140: rac-(3aS,5R,7S,7aS-5-(4-fluorophenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole</heading><p id="p-0471" num="0465">Following the general procedure described in Example 81b: 4-(4-fluorophenyl)-2,4,7-trimethyloct-6-enal (323 mg, 1.23 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-methylhydroxylamine hydrochloride (154 mg, 1.85 mmol), K<sub>2</sub>CO<sub>3 </sub>(136 mg, 0.98 mmol) in toluene (50 mL) were reacted to give the title product (44 mg, 12% yield) as a light yellow oil.</p><p id="p-0472" num="0466">GC/MS (EI): m/z (%): 291(34) [M<sup>+</sup>], 276 (4), 189 (4), 163 (4), 147 (5), 126 (100), 113 (29), 98 (66), 87 (13). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 7.32-7.22 (m, 2H), 6.99 (t, J=8.7 Hz, 2H), 2.86-2.68 (m, 3H), 2.44 (t, J=6.6 Hz, 1H), 2.25-2.12 (m, 1H), 2.05-1.94 (m, 1H), 1.85-1.59 (m, 4H), 1.30-1.23 (m, 9H), 0.85 (d, J=6.7 Hz, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 162.6 (q), 159.3 (q), 145.7 (q), 145.6 (q), 127.2 (t), 127.1 (t), 115.1 (t), 114.9 (t), 80.4 (q), 75.0 (t), 48.6 (t), 46.5 (s), 42.6 (d), 36.9 (q), 34.8 (s), 33.8 (d), 30.0 (s), 29.3 (t), 23.5 (s), 21.2 (s).</p><heading id="h-0148" level="1">Example 141: rac-(3aR,5R,7S,7aR)-5-(4-fluorophenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole</heading><p id="p-0473" num="0467">Following the general procedure described in Example 81b: 4-(4-fluorophenyl)-2,4,7-trimethyloct-6-enal (323 mg, 1.23 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-methylhydroxylamine hydrochloride (154 mg, 1.85 mmol), K<sub>2</sub>CO<sub>3 </sub>(136 mg, 0.98 mmol) in toluene (50 mL) were reacted to give the title product rac-(3aR,5R,7S,7aR)-5-(4-fluorophenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole (164 mg, 46% yield), as a light yellow oil.</p><p id="p-0474" num="0468">GC/MS (EI): m/z (%): 291 (50) [M<sup>+</sup>], 276 (5), 189 (8), 161 (8), 149 (10), 126 (100), 109 (30), 100 (41), 87 (42). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 7.40-7.28 (m, 2H), 6.99 (t, J=8.7 Hz, 2H), 2.89-2.60 (m, 3H), 2.40-2.21 (m, 1H), 2.14-1.87 (m, 2H), 1.85-1.69 (m, 2H), 1.52 (t, J=12.9 Hz, 1H), 1.39 (d, J=10.2 Hz, 1H), 1.35-1.30 (m, 3H), 1.29-1.22 (m, 3H), 1.13 (s, 3H), 1.02 (d, J=6.1 Hz, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 162.6 (q), 159.4 (q), 146.9 (q), 126.7 (t), 126.6 (t), 115.0 (t), 114.7 (t), 79.4 (q), 77.6 (t), 53.9 (t), 48.9 (s), 46.3 (d), 38.3 (q), 37.2 (d), 33.1 (t), 26.9 (s), 26.7 (s), 24.9 (s), 20.2 (s).</p><p id="p-0475" num="0469">In the same reaction, additional isomers were also obtained: rac-(3aS,5R,7S,7aS)-5-(4-fluorophenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole (48 mg, 12% yield) and rac-(3aS,5R,7R,7aS)-5-(4-fluorophenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole (79 mg, 20% yield) as light yellow oils.</p><p id="p-0476" num="0470">rac-(3aS,5R,7S,7aS)-5-(4-fluorophenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole: GC/MS (EI): m/z (%): 291 (33) [M<sup>+</sup>], 276 (4), 126 (100), 113 (30), 98 (73), 87 (14).</p><p id="p-0477" num="0471">rac-(3aS,5R,7R,7aS)-5-(4-fluorophenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole: GC/MS (EI): m/z (%): 291 (67) [M<sup>+</sup>], 276 (5), 189 (10), 161 (9), 149 (11), 126 (100), 109 (35), 100 (39), 98(40), 87 (71).</p><heading id="h-0149" level="1">Example 142: rac-(3aR,5R,7S,7aR)-5-(4-fluorophenyl)-1-isopropyl-3,3,5,7-tetramethyloctahydrobenzo[c]isoxazole</heading><p id="p-0478" num="0472">Following the general procedure described in Example 81b: 4-(4-fluorophenyl)-2,4,7-trimethyloct-6-enal (619 mg, 1.27 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-isopropylhydroxylamine (144 mg, 1.91 mmol) in toluene (40 mL) were reacted to give the title product (114 mg, 28% yield) as a light yellow oil.</p><p id="p-0479" num="0473">GC/MS (EI): m/z (%): 319 (30) [M<sup>+</sup>], 304 (100), 262 (2), 208 (3), 189 (11), 175 (8), 154 (78), 126 (30), 109 (33), 84 (9). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 7.32 (q, J=8.9, 5.3 Hz, 2H), 6.96 (t, J=8.7 Hz, 2H), 3.26-3.09 (m, 1H), 2.49-2.18 (m, 2H), 2.06-1.85 (m, 1H), 1.83-1.68 (m, 2H), 1.57-1.33 (m, 2H), 1.29 (d, J=7.3 Hz, 6H), 1.22 (d, J=6.7 Hz, 3H), 1.08-0.95 (m, 9H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 162.5 (q), 159.3 (q), 147.1 (q), 147.0 (q), 126.6 (t), 126.5 (t), 114.9 (t), 114.7 (t), 77.9 (q), 68.8 (t), 54.9 (t), 53.0 (t), 46.5 (d), 38.1 (q), 37.0 (d), 33.5 (t), 27.1 (s), 26.9 (s), 26.7 (s), 24.2 (s), 22.5 (s), 20.3 (s), 13.6 (s).</p><heading id="h-0150" level="1">Example 143: rac-(3aR,5R,7S,7aR)-5-(3-fluorophenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole</heading><p id="p-0480" num="0474">Following the general procedure described in Example 81b: 4-(3-fluorophenyl)-2,4,7-trimethyloct-6-enal (377 mg, 1.44 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-methylhydroxylamine hydrochloride (180 mg, 2.16 mmol), K<sub>2</sub>CO<sub>3 </sub>(159 mg, 1.15 mmol) in toluene (40 mL) were reacted to give the title product (184 mg, 44% yield) as a light yellow oil.</p><p id="p-0481" num="0475">GC/MS (EI): m/z (%): 291 (49) [M<sup>+</sup>], 276 (5), 189 (13), 161 (15), 147 (7), 126 (100), 109 (26), 100 (31), 87 (51). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 7.20 (q, J=14.4, 7.4 Hz, 1H), 7.09 (d, J=8.0 Hz, 1H), 7.00 (d, J=11.3 Hz, 1H), 6.80 (td, J=8.2, 1.6 Hz, 1H), 2.85-2.55 (m, 3H), 2.32-2.16 (m, 1H), 2.06-1.82 (m, 2H), 1.79-1.64 (m, 2H), 1.46 (t, J=12.9 Hz, 1H), 1.35 (d, J=12.3 Hz, 1H), 1.26 (s, 3H), 1.23-1.16 (m, 3H), 1.06 (s, 3H), 0.96 (d, J=6.1 Hz, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 164.5 (q), 161.2 (q), 154.0 (q), 154.0 (q), 129.6 (t), 129.5 (t), 120.7 (t), 120.6 (t), 112.7 (t), 112.5 (t), 112.4 (t), 112.1 (t), 79.2 (q), 77.5 (t), 53.7 (t), 48.8 (s), 45.9 (d), 38.6 (q), 36.8 (d), 33.0 (t), 26.9 (s), 26.5 (s), 24.9 (s), 20.1 (s).</p><heading id="h-0151" level="1">Example 144: rac-(3aR,5R,7S,7aR)-5-(2,4-difluorophenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole</heading><p id="p-0482" num="0476">Following the general procedure described in Example 81b: 4-(2,4-difluorophenyl)-2,4,7-trimethyloct-6-enal (401 mg, 0.14 mmol), N-methylhydroxylamine hydrochloride (18 mg, 0.22 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), K<sub>2</sub>CO<sub>3 </sub>(16 mg, 0.11 mmol) in toluene (50 mL) were reacted to give the title product (26 mg, 60% yield) as a light yellow oil.</p><p id="p-0483" num="0477">GC/MS (EI): m/z (%): 309 (38) [M<sup>+</sup>], 294 (5), 207 (12), 141 (33), 126 (100), 113 (14), 100 (43), 98 (36), 87 (51).</p><heading id="h-0152" level="1">Example 145: rac-1,3,3,5,7-pentamethyl-5-(4-methylpyridin-3-yl)octahydrobenzo[c]isoxazole</heading><p id="p-0484" num="0478">Following the general procedure described in Example 81b: 2,4,7-trimethyl-4-(4-methylpyridin-3-yl)oct-6-enal (654 mg, 0.71 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-methylhydroxylamine hydrochloride (88 mg, 1.06 mmol), K<sub>2</sub>CO<sub>3 </sub>(78 mg, 0.57 mmol) in toluene (50 mL) were reacted to give the title product (115 mg, 53% yield) as a light yellow oil.</p><p id="p-0485" num="0479">GC/MS (Isomer 1) (EI): m/z (%): 288 (52) [M<sup>+</sup>], 271 (32), 242 (13), 228 (24), 134 (100), 126 (21), 98 (22). And GC/MS (Isomer 2) (EI): m/z (%): 288 (51) [M<sup>+</sup>], 271 (31), 242 (36), 228 (5), 134 (100), 126 (58), 98 (28). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 8.60-8.36 (m, 1H), 8.33-8.15 (m, 1H), 7.06-6.89 (m, 1H), 2.76 (d, J=20.5 Hz, 2H), 2.56-2.41 (m, 3H), 2.40-2.20 (m, 1H), 2.20-1.89 (m, 2H), 1.86-1.58 (m, 2H), 1.57-1.35 (m, 3H), 1.33-1.06 (m, 9H), 1.04-0.93 (m, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 149.2 (t), 147.2 (t), 147.1 (t), 146.8 (t), 145.4 (q), 145.1 (q), 143.3 (q), 139.0 (q), 127.9 (t), 127.7 (t), 79.4 (q), 78.9 (q), 78.1 (t), 77.0 (t), 54.2 (t), 53.5 (t), 48.8 (s), 48.6 (s), 46.9 (d), 44.9 (d), 40.8 (q), 38.9 (q), 36.7 (d), 35.7 (d), 33.2 (t), 33.0 (t), 30.4 (s), 26.9 (s), 24.9 (s), 24.7 (s), 24.4 (s), 23.3 (s), 23.2 (s), 20.2 (s), 19.9 (s).</p><heading id="h-0153" level="1">Example 146: rac-2-(1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazol-5-yl)benzonitrile</heading><p id="p-0486" num="0480">Following the general procedure described in Example 81b: 2-(2,4,7-trimethyl-1-oxooct-6-en-4-yl)benzonitrile (389 mg, 1.44 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-methylhydroxylamine hydrochloride (181 mg, 2.17 mmol), K<sub>2</sub>CO<sub>3 </sub>(160 mg, 1.16 mmol) in toluene (50 mL) were reacted to give the title product (229 mg, 53% yield) as a light yellow oil.</p><p id="p-0487" num="0481">GC/MS (Isomer 1) (EI): m/z (%): 298 (29) [M<sup>+</sup>], 283 (3), 252 (21), 126 (50), 113 (19), 98 (36), 87 (100), 70 (18). And GC/MS (Isomer 2) (EI): m/z (%): 298 (14) [M<sup>+</sup>], 297 (62), 252 (40), 213 (100), 198 (71), 158 (50), 144 (44), 126 (64), 98 (49), 68 (52). And GC/MS (Isomer 3) (EI): m/z (%): 298 (6) [M<sup>+</sup>], 297 (24), 252 (16), 240 (19), 196 (33), 144 (28), 126 (100), 98 (30), 68 (43). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 7.74-7.65 (m, 1H), 7.58-7.40 (m, 2H), 7.36-7.27 (m, 1H), 2.98-2.75 (m, 3H), 2.72-2.52 (m, 1H), 2.43-2.20 (m, 1H), 2.17 (d, J=8.5 Hz, 2H), 2.02-1.92 (m, 1H), 1.78 (s, 1H), 1.57 (s, 1H), 1.49-1.39 (m, 2H), 1.36-1.24 (m, 3H), 1.20-1.14 (m, 4H), 1.06 (d, J=6.2 Hz, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 153.3 (q), 149.8 (q), 136.3 (t), 135.8 (t), 132.8 (t), 132.7 (t), 128.3 (t), 126.5 (t), 126.4 (t), 126.1 (t), 120.1 (q), 119.9 (q), 110.5 (q), 110.1 (q), 79.3 (q), 78.9 (q), 77.5 (t), 76.4 (t), 54.3 (t), 53.6 (t), 48.8 (q), 48.6 (q), 45.9, 44.7, 41.1 (q), 39.5 (q), 36.3 (d), 35.4 (d), 33.4 (s), 33.2 (s), 31.2 (s), 30.8 (s), 26.7 (s), 26.5 (s), 24.7 (s), 24.5 (s), 24.4 (s), 19.8 (s), 19.7 (s).</p><heading id="h-0154" level="1">Example 147: rac-5-(3-methoxypyridin-2-yl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole</heading><p id="p-0488" num="0482">Following the general procedure described in Example 81b: 4-(6-methoxypyridin-2-yl)-2,4,7-trimethyloct-6-enal (485 mg, 0.92 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-methylhydroxylamine hydrochloride (115 mg, 1.37 mmol), K<sub>2</sub>CO<sub>3 </sub>(101 mg, 0.73 mmol) in toluene (50 mL) were reacted to give the title product (234 mg, 84% yield) as a light yellow oil.</p><p id="p-0489" num="0483">GC/MS (Isomer 1) (EI): m/z (%): 304 (30) [M<sup>+</sup>], 258 (20), 244 (17), 150 (100), 123 (14), 98 (11). And GC/MS (Isomer 2) (EI): m/z (%): 304 (4) [M<sup>+</sup>], 303 (8), 258 (100), 242 (52), 218 (60), 150 (78), 123 (28), 98 (21). And GC/MS (Isomer 3) (EI): m/z (%): 304 (4) [M<sup>+</sup>], 258 (10), 247 (16), 231 (18), 150 (52), 123 (13), 97 (100). And GC/MS (Isomer 4) (EI): m/z (%): 304 (20) [M<sup>+</sup>], 258 (21), 217 (42), 202 (62), 150 (100), 123 (20), 98 (21). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 7.46 (q, J=8.0 Hz, 1H), 6.82 (t, J=6.8 Hz, 1H), 6.49 (dd, J=16.6, 8.2 Hz, 1H), 3.87 (d, J=11.3 Hz, 3H), 2.86-2.71 (m, 3H), 2.68-2.52 (m, 1H), 2.32 (d, J=19.4 Hz, 1H), 2.14-2.01 (m, 1H), 2.00-1.78 (m, 2H), 1.72 (d, J=12.9 Hz, 1H), 1.61 (d, J=19.4 Hz, 1H), 1.30 (d, J=30.5 Hz, 4H), 1.19 (d, J=6.8 Hz, 3H), 1.12 (t, J=9.5 Hz, 5H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 166.9 (q), 164.0 (q), 163.2 (q), 163.0 (q), 138.9 (t), 138.8 (t), 112.6 (t), 111.3 (t), 107.5 (t), 107.4 (t), 79.4 (q), 79.1 (q), 77.7 (t), 77.3 (t), 54.6 (t), 53.9 (t), 53.1 (s), 52.9 (s), 48.9 (s), 48.8 (s), 45.4 (d), 45.1 (d), 42.6 (q), 41.4 (q), 35.8 (d), 35.7 (d), 33.5 (t), 33.1 (t), 32.6 (s), 32.5 (s), 27.0 (s), 26.7 (s), 25.0 (s), 24.9 (s), 21.9 (s), 20.2 (s), 20.1 (s).</p><heading id="h-0155" level="1">Example 148: rac-(3aR,7aR)-1,3,3-trimethyl-6-phenyloctahydrobenzo[c]isoxazole</heading><p id="p-0490" num="0484">Following the general procedure described in Example 81b: 7-methyl-3-phenyloct-6-enal (500 mg, 2.31 mmol), N-methylhydroxylamine hydrochloride (290 mg, 3.47 mmol), K<sub>2</sub>CO<sub>3 </sub>(256 mg, 1.85 mmol) in toluene (50 mL) were reacted to give the title product (423 mg, 75% yield) as a yellow oil.</p><p id="p-0491" num="0485">GC/MS (EI): m/z (%): 245 (81) [M<sup>+</sup>], 230 (19), 199 (18), 162 (100), 143 (20), 104 (22), 91 (36). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 7.35-7.27 (m, 2H), 7.25-7.16 (m, 3H), 2.76-2.53 (m, 4H), 2.38 (td, J=10.9, 3.4 Hz, 1H), 2.10-1.76 (m, 4H), 1.65-1.39 (m, 3H), 1.39-1.30 (m, 3H), 1.18 (d, J=6.8 Hz, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 145.7 (q), 128.5 (t), 126.9 (t), 126.4 (t), 79.6 (q), 71.8 (t), 57.3 (t), 44.6 (q), 42.5 (t), 36.1 (d), 33.9 (d), 28.0 (s), 27.0 (s), 25.2 (s), 24.8 (d).</p><heading id="h-0156" level="1">Example 149: rac-(3aR,5R,7S,7aR)-1-isopropyl-3,3,7-trimethyl-5-phenyloctahydrobenzo[c]isoxazole</heading><p id="p-0492" num="0486">Following the general procedure described in Example 81 b: 2,7-dimethyl-4-phenyloct-6-enal (258 mg, 0.92 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-isopropylhydroxylamine (207 mg, 2.76 mmol) in xylene (80 mL) were reacted to give the title product (153 mg, 58% yield) as a light yellow oil.</p><p id="p-0493" num="0487">GC/MS (EI): m/z (%): 287 (31) [M<sup>+</sup>], 272 (100), 230 (5), 157 (12), 154 (43), 126 (21), 115 (18), 91 (27). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 7.48-6.99 (m, 5H), 3.35-3.08 (m, 1H), 2.69 (d, J=12.0 Hz, 1H), 2.51 (t, J=9.7 Hz, 1H), 2.13 (t, J=10.7 Hz, 1H), 1.86 (d, J=12.6 Hz, 3H), 1.43 (t, J=12.3 Hz, 1H), 1.35-1.19 (m, 7H), 1.07 (dd, J=24.9, 7.3 Hz, 9H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 146.0 (q), 128.5 (t), 126.9 (t), 126.3 (t), 78.0 (q), 68.4 (t), 57.7 (t), 54.9 (t), 44.0 (t), 42.5 (d), 37.4 (t), 32.9 (s), 27.3 (s), 24.4 (s), 22.7 (s), 20.2 (s), 13.7 (s).</p><heading id="h-0157" level="1">Example 150: rac-(3aR,5R,7S,7aR)-1,3,3,7-tetramethyl-5-phenyloctahydrobenzo[c]isoxazole</heading><p id="p-0494" num="0488">Following the general procedure described in Example 81b: 2,7-dimethyl-4-phenyloct-6-enal (301 mg, 1.07 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-methylhydroxylamine hydrochloride (134 mg, 1.61 mmol), K<sub>2</sub>CO<sub>3 </sub>(118 mg, 0.86 mmol) in toluene (50 mL) were reacted to give the title product (105 mg, 38% yield) as a light yellow oil.</p><p id="p-0495" num="0489">GC/MS (EI): m/z (%): 259 (13) [M<sup>+</sup>], 258 (32), 201 (23), 172 (24), 126 (100), 104 (84), 91 (31), 68 (13). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 7.35-7.27 (m, 2H), 7.22 (dd, J=7.6, 3.6 Hz, 3H), 2.85 (s, 3H), 2.73-2.60 (m, 1H), 2.16 (dt, J=12.2, 6.4 Hz, 2H), 2.00-1.71 (m, 3H), 1.52-1.33 (m, 2H), 1.25 (d, J=12.2 Hz, 3H), 1.21-0.96 (m, 6H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 145.8 (q), 128.5 (t), 126.8 (t), 126.3 (t), 79.3 (q), 77.0 (t), 58.5 (t), 48.9 (s), 44.0 (t), 42.2 (d), 37.0 (t), 32.9 (d), 27.0 (s), 25.1 (s), 20.0 (s).</p><heading id="h-0158" level="1">Example 151: rac-(3aR,5R,7S,7aR)-1,3,3,7-tetramethyl-5-(o-tolyl)octahydrobenzo[c]isoxazole</heading><p id="p-0496" num="0490">Following the general procedure described in Example 81b: 2,7-dimethyl-4-(o-tolyl)oct-6-enal (289 mg, 1.18 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-methylhydroxylamine hydrochloride (148 mg, 1.77 mmol), K<sub>2</sub>CO<sub>3 </sub>(131 mg, 0.95 mmol) in toluene (50 mL) were reacted to give the title product (114 mg, 35% yield) as a light yellow oil.</p><p id="p-0497" num="0491">GC/MS (EI): m/z (%): 273 (7) [M<sup>+</sup>], 272 (16), 215 (11), 186 (29), 126 (78), 118 (100), 105 (22), 98 (24), 91 (16). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 7.33-6.97 (m, 4H), 2.95-2.79 (m, 3H), 2.36 (s, 3H), 2.16 (dd, J=19.9, 5.6 Hz, 2H), 1.80 (d, J=13.2 Hz, 3H), 1.44 (dd, J=13.5, 10.3 Hz, 2H), 1.33-1.21 (m, 4H), 1.19-1.01 (m, 6H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 143.6 (q), 135.2 (q), 130.5 (t), 126.2 (t), 126.0 (t), 125.3 (t), 79.3 (q), 77.2 (t), 58.7 (t), 48.9 (s), 41.4 (d), 39.3 (t), 37.1 (t), 31.9 (d), 27.0 (s), 25.1 (s), 20.0 (s), 19.5 (s).</p><heading id="h-0159" level="1">Example 152: rac-(3aR,5R,7S,7aR)-5-(4-(tert-butyl)phenyl)-1,3,3,7-tetramethyloctahydrobenzo[c]isoxazole</heading><p id="p-0498" num="0492">Following the general procedure described in Example 81b: 4-(4-(tert-butyl)phenyl)-2,7-dimethyloct-6-enal (558 mg, 1.79 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-methylhydroxylamine hydrochloride (224 mg, 2.69 mmol), K<sub>2</sub>CO<sub>3 </sub>(198 mg, 1.43 mmol) in toluene (40 mL) were reacted to give the title product (224 mg, 40% yield) as a light yellow oil.</p><p id="p-0499" num="0493">GC/MS (EI): m/z (%): 315 (38) [M<sup>+</sup>], 300 (11), 145 (18), 126 (100), 100 (57), 98 (27), 87 (45), 57 (43). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 7.33 (d, J=8.1 Hz, 2H), 7.17 (d, J=8.1 Hz, 2H), 2.91-2.73 (m, 3H), 2.68 (d, J=13.3 Hz, 1H), 2.22-2.07 (m, 2H), 1.95-1.74 (m, 3H), 1.51-1.35 (m, 2H), 1.33-1.25 (m, 12H), 1.18 (d, J=7.1 Hz, 3H), 1.04 (d, J=6.3 Hz, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 149.1 (q), 142.8 (q), 126.5 (t), 125.4 (t), 79.4 (q), 77.1 (t), 58.6 (t), 49.0 (s), 43.5 (t), 42.2 (d), 37.0 (t), 34.4 (q), 33.1 (d), 31.4 (s), 27.1 (s), 27.0 (s), 25.2 (s), 20.1 (s).</p><heading id="h-0160" level="1">Example 153: rac-(3aR,5R,7S,7aR)-5-(4-(tert-butyl)phenyl)-1-isopropyl-3,3,7-trimethyloctahydrobenzo[c]isoxazole</heading><p id="p-0500" num="0494">Following the general procedure described in Example 81b: 4-(4-(tert-butyl)phenyl)-2,7-dimethyloct-6-enal (558 mg, 1.79 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-isopropylhydroxylamine (202 mg, 2.69 mmol) in toluene (40 mL) were reacted to give the title product (203 mg, 33% yield) as a light yellow oil.</p><p id="p-0501" num="0495">GC/MS (EI): m/z (%): 343 (30) [M<sup>+</sup>], 328 (100), 213 (5), 154 (65), 145 (15), 128 (21), 126 (20), 115 (16), 57 (26). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 7.33 (d, J=8.2 Hz, 2H), 7.17 (d, J=8.2 Hz, 2H), 3.28-3.20 (m, 1H), 2.77-2.60 (m, 1H), 2.51 (t, J=9.9 Hz, 1H), 2.21-2.06 (m, 1H), 1.92-1.69 (m, 3H), 1.48-1.36 (m, 1H), 1.33-1.24 (m, 16H), 1.15-1.07 (m, 6H), 1.01 (d, J=7.8 Hz, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 149.1 (q), 142.9 (q), 126.5 (t), 125.3 (t), 77.9 (q), 68.4 (t), 57.8 (t), 54.9 (t), 43.5 (t), 42.5 (d), 37.4 (t), 34.4 (q), 33.0 (d), 31.4 (s), 27.3 (s), 27.0 (s), 24.4 (s), 22.7 (s), 20.2 (s), 13.7 (s).</p><heading id="h-0161" level="1">Example 154: rac-3-((3aR,5R,7S,7aR)-1-isopropyl-3,3,7-trimethyloctahydrobenzo[c]isoxazol-5-yl)-4-methoxybenzonitrile</heading><p id="p-0502" num="0496">Following the general procedure described in Example 81b: 3-(2,7-dimethyl-1-oxooct-6-en-4-yl)-4-methoxybenzonitrile (528 mg, 1.57 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-isopropylhydroxylamine (177 mg, 2.36 mmol) in toluene (40 mL) were reacted to give the title product (233 mg, 43% yield) as a light yellow oil. GC/MS (EI): m/z (%): 342 (25) [M<sup>+</sup>], 327 (100), 212 (12), 154 (54), 146 (24), 128 (21), 126 (27), 116 (19), 84 (9). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 7.55-7.39 (m, 2H), 6.87 (d, J=8.3 Hz, 1H), 3.85 (s, 3H), 3.24-3.06 (m, 2H), 2.47 (t, J=9.9 Hz, 1H), 2.19-2.01 (m, 1H), 1.88-1.67 (m, 3H), 1.41-1.30 (m, 1H), 1.28-1.19 (m, 6H), 1.15 (t, J=6.7 Hz, 1H), 1.10-1.04 (m, 6H), 0.99 (d, J=6.3 Hz, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 160.2 (q), 135.5 (q), 131.9 (t), 130.5 (t), 119.5 (q), 110.8 (t), 103.8 (q), 77.9 (q), 68.4 (t), 57.5 (t), 55.7 (s), 54.9 (t), 40.7 (d), 37.3 (t), 35.9 (t), 30.9 (d), 27.2 (s), 27.0 (s), 24.4 (s), 22.6 (s), 20.1 (s).</p><heading id="h-0162" level="1">Example 155: rac-(3aR,5R,7S,7aR)-1-ethyl-5-(2-methoxyphenyl)-3,3,7-trimethyloctahydrobenzo[c]isoxazole</heading><p id="p-0503" num="0497">Following the general procedure described in Example 81b: 4-(2-methoxyphenyl)-2,7-dimethyloct-6-enal (558 mg, 1.82 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-ethylhydroxylamine (167 mg, 2.73 mmol) in toluene (40 mL) were reacted to give the title product (189 mg, 34% yield) as a light yellow oil.</p><p id="p-0504" num="0498">GC/MS (EI): m/z (%): 303 (36) [M<sup>+</sup>], 288 (24), 187 (7), 140 (100), 121 (28), 114 (44), 112 (36), 101 (39), 91 (26). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 7.23-7.12 (m, 2H), 6.97-6.80 (m, 2H), 3.82 (s, 3H), 3.26-3.09 (m, 1H), 3.07-2.93 (m, 1H), 2.91-2.68 (m, 1H), 2.33 (t, J=10.1 Hz, 1H), 2.18-2.04 (m, 1H), 1.92-1.74 (m, 3H), 1.51-1.34 (m, 2H), 1.30-1.19 (m, 6H), 1.18-0.95 (m, 6H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 156.7 (q), 133.9 (q), 127.0 (t), 126.5 (t), 120.5 (t), 110.4 (t), 79.3 (q), 74.8 (t), 57.9 (t), 56.5 (d), 55.3 (s), 40.8 (d), 37.6 (t), 36.2 (t), 31.3 (d), 26.6 (s), 24.9 (s), 20.0 (s), 13.8 (s).</p><heading id="h-0163" level="1">Example 156: rac-(3aR,5R,7S,7aR)-5-(2-ethylphenyl)-1,3,3,7-tetramethyloctahydrobenzo[c]isoxazole</heading><p id="p-0505" num="0499">Following the general procedure described in Example 81b: 4-(2-ethylphenyl)-2,7-dimethyloct-6-enal (658 mg, 1.91 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-methylhydroxylamine hydrochloride (239 mg, 2.86 mmol), K<sub>2</sub>CO<sub>3 </sub>(211 mg, 1.53 mmol) in toluene (40 mL) were reacted to give the title product (213 mg, 39% yield) as a light yellow oil.</p><p id="p-0506" num="0500">GC/MS (EI): m/z (%): 287 (38) [M<sup>+</sup>], 272 (11), 185 (6), 171 (10), 143 (9), 126 (100), 117 (19), 100 (65), 87 (41). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 7.25-7.11 (m, 4H), 3.01-2.83 (m, 3H), 2.70 (q, J=7.4 Hz, 3H), 2.27-2.07 (m, 2H), 1.75 (M, 3H), 1.57-1.37 (m, 2H), 1.33-1.15 (m, 9H), 1.05 (M, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 143.2 (q), 141.3 (q), 128.9 (t), 126.3 (t), 126.2 (t), 125.9 (t), 79.4 (q), 77.3 (t), 58.8 (t), 49.0 (s), 42.2 (d), 38.7 (t), 37.2 (t), 32.9 (d), 27.1 (s), 26.0 (d), 25.2 (s), 20.1 (s), 16.1 (s).</p><heading id="h-0164" level="1">Example 157: rac-(3aR,5R,7S,7aR)-5-(2-ethylphenyl)-1-isopropyl-3,3,7-trimethyloctahydrobenzo[c]isoxazole</heading><p id="p-0507" num="0501">Following the general procedure described in Example 81b: 4-(2-ethylphenyl)-2,7-dimethyloct-6-enal (528 mg, 1.53 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-isopropylhydroxylamine (173 mg, 2.30 mmol) in toluene (40 mL) were reacted to give the title product (165 mg, 34% yield) as a light yellow oil.</p><p id="p-0508" num="0502">GC/MS (EI): m/z (%): 315 (34) [M<sup>+</sup>], 300 (100), 258 (3), 185 (8), 171 (6), 154 (60), 128 (28), 115 (24), 91 (11). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 7.25-7.11 (m, 4H), 3.31-3.14 (m, 1H), 3.04-2.89 (m, 1H), 2.69 (q, J=7.5 Hz, 2H), 2.54 (t, J=9.9 Hz, 1H), 2.21-2.07 (m, 1H), 1.84-1.70 (m, 3H), 1.45 (q, J=24.8, 12.6 Hz, 1H), 1.32-1.19 (m, 10H), 1.15-1.07 (m, 6H), 1.06-1.00 (m, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 143.4 (q), 141.4 (q), 128.9 (t), 126.2 (t), 126.2 (t), 125.9 (t), 78.0 (q), 68.6 (t), 58.0 (t), 55.0 (t), 42.6 (d), 38.7 (t), 37.6 (t), 32.8 (d), 27.3 (s), 26.0 (d), 24.5 (s), 22.7 (s), 20.3 (s), 16.0 (s).</p><heading id="h-0165" level="1">Example 158: rac-(3aR,5R,7S,7aR)-5-(2,5-dimethylphenyl)-1,3,3,7-tetramethyloctahydrobenzo[c]isoxazole</heading><p id="p-0509" num="0503">Following the general procedure described in Example 81b: 4-(2,5-dimethylphenyl)-2,7-dimethyloct-6-enal (400 mg, 1.55 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-methylhydroxylamine hydrochloride (194 mg, 2.32 mmol), K<sub>2</sub>CO<sub>3 </sub>(0.171 mg, 1.238 mmol) in toluene (50 mL) were reacted to give the title product (125 mg, 28% yield) as a yellow oil.</p><p id="p-0510" num="0504">GC/MS (EI): m/z (%): 287 (100) [M<sup>+</sup>], 272 (20), 171 (17), 157 (15), 126 (75), 119 (20), 100 (50), 98 (27), 87 (52). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 7.09-7.02 (m, 2H), 6.97-6.90 (m, 1H), 3.01-2.62 (m, 4H), 2.33 (d, J=2.3 Hz, 6H), 2.27-2.03 (m, 2H), 1.93-1.72 (m, 3H), 1.55-1.32 (m, 2H), 1.31-1.26 (m, 3H), 1.17 (s, 3H), 1.12-1.02 (m, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 143.4 (q), 135.5 (q), 132.0 (q), 130.4 (t), 126.7 (t), 126.0 (t), 79.3 (q), 77.2 (t), 58.7 (t), 48.9 (s), 41.4 (d), 39.2 (t), 37.2 (t), 32.0 (d), 27.0 (s), 25.2 (s), 21.2 (s), 20.0 (s), 19.0 (s).</p><heading id="h-0166" level="1">Example 159: rac-(3aR,5R,7S,7aR)-5-(3-chloro-2-methylphenyl)-1-isopropyl-3,3,7-trimethyloctahydrobenzo[c]isoxazole</heading><p id="p-0511" num="0505">Following the general procedure described in Example 81b: 4-(3-chloro-2-methylphenyl)-2,7-dimethyloct-6-enal (300 mg, 1.08 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-isopropylhydroxylamine (121 mg, 1.61 mmol) in toluene (50 mL) were reacted to give the title product (90 mg, 25% yield) as a light yellow oil.</p><p id="p-0512" num="0506">GC/MS (EI): m/z (%): 337 (9) [M<sup>+</sup>], 335 (28) [M<sup>+</sup>], 322 (33), 320 (100), 154 (67), 141 (21), 139 (21), 126 (20), 115 (17). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 7.22 (d, J=7.5 Hz, 1H), 7.17-7.05 (m, 2H), 3.29-3.14 (m, 1H), 3.06-2.89 (m, 1H), 2.52 (t, J=9.9 Hz, 1H), 2.42-2.32 (m, 3H), 2.22-2.06 (m, 1H), 1.91-1.68 (m, 3H), 1.50-1.33 (m, 1H), 1.32-1.23 (m, 7H), 1.14-1.07 (m, 6H), 1.02 (d, J=6.3 Hz, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 145.8 (q), 135.2 (q), 133.5 (q), 127.1 (t), 126.7 (t), 123.9 (t), 77.9 (q), 68.5 (t), 57.8 (t), 54.9 (t), 41.8 (d), 40.2 (s), 37.5 (t), 31.9 (d), 27.3 (s), 24.5 (s), 22.7 (s), 20.2 (s), 15.7 (s), 13.7 (s).</p><heading id="h-0167" level="1">Example 160: rac-(3aR,5R,7S,7aR)-5-(2,4-dimethylphenyl)-1,3,3,7-tetramethyloctahydrobenzo[c]isoxazole</heading><p id="p-0513" num="0507">Following the general procedure described in Example 81b: 4-(2,4-dimethylphenyl)-2,7-dimethyloct-6-enal (400 mg, 1.55 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-methylhydroxylamine hydrochloride (194 mg, 2.32 mmol), K<sub>2</sub>CO<sub>3 </sub>(171 mg, 1.24 mmol) in toluene (50 mL) were reacted to give the title product (170 mg, 38% yield) as a yellow oil.</p><p id="p-0514" num="0508">GC/MS (EI): m/z (%): 287 (100) [M<sup>+</sup>], 288 (21), 171 (20), 126 (74), 119 (21), 100 (46), 98 (25), 87 (47). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 7.18-7.10 (m, 1H), 7.06-6.96 (m, 2H), 2.99-2.64 (m, 4H), 2.39-2.26 (m, 6H), 2.26-2.07 (m, 2H), 1.93-1.72 (m, 3H), 1.54-1.37 (m, 2H), 1.29 (s, 3H), 1.19 (s, 3H), 1.05 (d, J=6.3 Hz, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 140.6 (q), 135.3 (q), 135.0 (q), 131.2 (t), 126.8 (t), 125.2 (t), 79.3 (q), 77.2 (t), 58.7 (t), 48.9 (s), 41.5 (d), 38.9 (t), 37.1 (t), 32.0 (s), 27.0 (s), 25.1 (s), 20.8 (s), 19.9 (s), 19.3 (s).</p><heading id="h-0168" level="1">Example 161: rac-4-methyl-3-((3aR,5R,7S,7aR)-1,3,3,7-tetramethyloctahydrobenzo[c]isoxazol-5-yl)benzonitrile</heading><p id="p-0515" num="0509">Following the general procedure described in Example 81b: 3-(2,7-dimethyl-1-oxooct-6-en-4-yl)-4-methylbenzonitrile (492 mg, 1.08 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-methylhydroxylamine hydrochloride (135 mg, 1.62 mmol), K<sub>2</sub>CO<sub>3 </sub>(119 mg, 0.86 mmol) in toluene (50 mL) were reacted to give the title product (115 mg, 36% yield) as a light yellow oil.</p><p id="p-0516" num="0510">GC/MS (EI): m/z (%): 298 (50) [M<sup>+</sup>], 283 (24), 252 (10), 196 (10), 182 (10), 142 (10), 126 (100), 113 (18), 100 (79), 87 (63). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 7.54 (s, 1H), 7.47-7.39 (m, 1H), 7.29 (s, 1H), 3.05-2.64 (m, 4H), 2.45 (s, 3H), 2.30-2.03 (m, 2H), 1.92-1.76 (m, 3H), 1.57-1.38 (m, 2H), 1.34-1.28 (m, 3H), 1.23 (s, 3H), 1.08 (d, J=6.2 Hz, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 145.2 (q), 141.3 (q), 131.3 (t), 129.7 (t), 129.5 (t), 119.4 (q), 110.2 (q), 79.4 (q), 77.3 (t), 58.6 (t), 49.1 (s), 41.3 (d), 39.3 (t), 37.2 (t), 31.8 (d), 27.1 (s), 25.2 (s), 20.1 (s), 20.0 (s).</p><heading id="h-0169" level="1">Example 162: rac-(3aR,5R,7S,7aR)-5-(5-chloro-2-methylphenyl)-1-isopropyl-3,3,7-trimethyloctahydrobenzo[c]isoxazole</heading><p id="p-0517" num="0511">Following the general procedure described in Example 81 b: 4-(5-chloro-2-methylphenyl)-2,7-dimethyloct-6-enal (600 mg, 2.15 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-isopropylhydroxylamine (242 mg, 3.23 mmol) in xylene (50 mL) were reacted to give the title product (211 mg, 29% yield) as a light yellow oil.</p><p id="p-0518" num="0512">GC/MS (EI): m/z (%): 337 (9) [M<sup>+</sup>], 335 (27) [M<sup>+</sup>], 322 (33), 320 (100), 154 (68), 141 (19), 139 (21), 126 (18), 115 (15). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 7.16 (s, 1H), 7.02 (s, 2H), 3.26-3.11 (m, 1H), 2.85 (t, 1H), 2.56-2.42 (m, 1H), 2.26 (s, 3H), 2.18-1.95 (m, 2H), 1.85-1.62 (m, 3H), 1.44-1.28 (m, 1H), 1.26-1.19 (m, 6H), 1.12-1.04 (m, 6H), 0.99 (d, J=6.3 Hz, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 145.7 (q), 133.6 (q), 131.7 (q), 131.6 (t), 125.8 (t), 125.5 (t), 77.8 (q), 68.3 (t), 57.7 (t), 54.8 (t), 41.5 (d), 39.4 (t), 37.4 (t), 31.6 (d), 27.2 (s), 24.4 (s), 22.5 (s), 20.0 (s), 18.8 (s), 13.6 (s).</p><heading id="h-0170" level="1">Example 163: rac-(3aR,5R,7S,7aR)-5-(5-fluoro-2-methylphenyl)-1,3,3,7-tetramethyloctahydrobenzo[c]isoxazole</heading><p id="p-0519" num="0513">Following the general procedure described in Example 81 b: 4-(5-fluoro-2-methylphenyl)-2,7-dimethyloct-6-enal (300 mg, 1.14 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-methylhydroxylamine hydrochloride (143 mg, 1.72 mmol), K<sub>2</sub>CO<sub>3 </sub>(126 mg, 0.92 mmol) in toluene (50 mL) were reacted to give the title product (102 mg, 31% yield) as a yellow oil.</p><p id="p-0520" num="0514">GC/MS (EI): m/z (%): 291 (100) [M<sup>+</sup>], 276 (33), 175 (17), 136 (23), 126 (83), 100 (62), 98 (32), 87 (55). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 7.11-7.01 (m, 1H), 6.94-6.85 (m, 1H), 6.81-6.70 (m, 1H), 2.97-2.57 (m, 4H), 2.28 (s, 3H), 2.22-1.99 (m, 2H), 1.89-1.68 (m, 3H), 1.46-1.29 (m, 2H), 1.24 (s, 3H), 1.16 (s, 3H), 1.02 (d, J=6.3 Hz, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 163.2 (q), 160.0 (q), 145.8 (q), 145.7 (q), 131.6 (t), 131.5 (t), 130.6 (t), 112.7 (t), 112.4 (t), 112.4 (t), 112.1 (t), 79.3 (q), 77.1 (t), 58.6 (t), 48.9 (s), 41.2 (d), 39.5 (t), 37.1 (t), 31.8 (d), 27.1 (s), 25.1 (s), 19.9 (s), 18.7 (s).</p><heading id="h-0171" level="1">Example 164: rac-(3aR,5R,7S,7aR)-5-(4-fluoro-2-methylphenyl)-1,3,3,7-tetramethyloctahydrobenzo[c]isoxazole</heading><p id="p-0521" num="0515">Following the general procedure described in Example 81b: 4-(4-fluoro-2-methylphenyl)-2,7-dimethyloct-6-enal (300 mg, 1.14 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-methylhydroxylamine hydrochloride (143 mg, 1.72 mmol), K<sub>2</sub>CO<sub>3 </sub>(126 mg, 0.92 mmol) in toluene (50 mL) were reacted to give the title product (115 mg, 35% yield) as a yellow oil.</p><p id="p-0522" num="0516">GC/MS (EI): m/z (%): 291 (100) [M<sup>+</sup>], 276 (27), 136 (28), 126 (83), 123 (28), 100 (57), 98 (31), 87 (52), 70 (15). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 7.19-7.10 (m, 1H), 6.88-6.77 (m, 2H), 2.93-2.59 (m, 4H), 2.31 (s, 3H), 2.23-2.03 (m, 2H), 1.88-1.67 (m, 3H), 1.50-1.30 (m, 2H), 1.28-1.19 (m, 3H), 1.15 (s, 3H), 1.05-0.97 (m, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 162.4 (q), 159.2 (q), 139.3 (q), 139.3 (q), 137.5 (q), 137.4 (q), 126.8 (t), 126.6 (t), 117.0 (t), 116.7 (t), 112.8 (t), 112.5 (t), 79.3 (q), 79.1 (t), 58.7 (t), 48.9 (s), 41.6 (t), 38.8 (t), 37.1 (t), 32.1 (d), 27.0 (s), 25.1 (s), 19.9 (s), 19.5 (s).</p><heading id="h-0172" level="1">Example 165: rac-(3aR,5R,7S,7aR)-5-(4-chloro-2-methylphenyl)-1-isopropyl-3,3,7-trimethyloctahydrobenzo[c]isoxazole</heading><p id="p-0523" num="0517">Following the general procedure described in Example 81b: 4-(4-chloro-2-methylphenyl)-2,7-dimethyloct-6-enal (700 mg, 2.51 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-isopropylhydroxylaimine (283 mg, 3.77 mmol) in xylene (50 mL) were reacted to give the title product (288 mg, 34% yield) as a light yellow oil.</p><p id="p-0524" num="0518">GC/MS (EI): m/z (%): 337 (10) [M<sup>+</sup>], 335 (30) [M<sup>+</sup>], 322 (33), 320 (100), 154 (73), 141 (22), 139 (31), 126 (19), 115 (16). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 7.17-7.05 (m, 3H), 3.27-3.12 (m, 1H), 2.86 (t, J=12.0, 7.8, 3.3 Hz, 1H), 2.50 (t, J=9.9 Hz, 1H), 2.31 (s, 3H), 2.18-2.04 (m, 2H), 1.84-1.63 (m, 3H), 1.44-1.31 (m, 1H), 1.28-1.20 (m, 6H), 1.12-1.04 (m, 6H), 1.00 (d, J=6.4 Hz, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 142.3 (q), 137.2 (q), 131.2 (q), 130.1 (t), 126.7 (t), 126.1 (t), 77.9 (q), 68.4 (t), 57.8 (t), 54.9 (t), 41.7 (d), 38.9 (t), 37.4 (t), 31.8 (d), 27.2 (s), 24.4 (s), 22.6 (s), 20.1 (s), 19.3 (s), 13.6 (s).</p><heading id="h-0173" level="1">Example 166: rac-(3aR,5R,7S,7aR)-1-isopropyl-5-(2-methoxyphenyl)-3,3,7-trimethyloctahydrobenzo[c]isoxazole</heading><p id="p-0525" num="0519">Following the general procedure described in Example 81b: 4-(2-methoxyphenyl)-2,7-dimethyloct-6-enal (525 mg, 2.02 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-isopropylhydroxylamine (227 mg, 3.02 mmol) in toluene (40 mL) were reacted to give the title product (280 mg, 44% yield) as a colorless oil.</p><p id="p-0526" num="0520">GC/MS (EI): m/z (%): 317 (35) [M<sup>+</sup>], 302 (100), 187 (16), 154 (89), 141 (14), 128 (33), 126 (46), 121 (49), 112 (18), 91 (41). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 7.24-7.12 (m, 2H), 6.92 (t, J=7.4 Hz, 1H), 6.85 (d, J=8.2 Hz, 1H), 3.87-3.74 (m, 3H), 3.30-3.11 (m, 2H), 2.51 (t, J=9.8 Hz, 1H), 2.19-2.09 (m, 1H), 1.93-1.74 (m, 3H), 1.62-1.32 (m, 2H), 1.31-1.21 (m, 6H), 1.16-0.95 (m, 9H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 156.7 (q), 133.9 (q), 126.9 (t), 126.5 (t), 120.5 (t), 110.4 (t), 78.0 (q), 68.5 (t), 57.5 (t), 55.2 (s), 54.7 (t), 41.1 (d), 37.2 (t), 36.0 (t), 31.2 (d), 27.2 (s), 24.3 (s), 22.4 (s), 20.1 (s), 13.6 (s).</p><heading id="h-0174" level="1">Example 167: rac-(3aR,5R,7S,7aR)-5-(2-methoxyphenyl)-1,3,3,7-tetramethyloctahydrobenzo[c]isoxazole</heading><p id="p-0527" num="0521">Following the general procedure described in Example 81b: 4-(2-methoxyphenyl)-2,7-dimethyloct-6-enal (300 mg, 1.15 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-methylhydroxylamine hydrochloride (144 mg, 1.73 mmol), K<sub>2</sub>CO<sub>3 </sub>(127 mg, 0.92 mmol) in toluene (50 mL) were reacted to give the title product (155 mg, 47% yield) as a light yellow oil.</p><p id="p-0528" num="0522">GC/MS (EI): m/z (%): 289 (65) [M<sup>+</sup>], 274 (16), 243 (6), 187 (11), 126 (100), 121 (38), 100 (58), 91 (38), 87 (55), 70 (13). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 7.18 (t, J=8.0 Hz, 2H), 7.01-6.78 (m, 2H), 3.82 (s, 3H), 3.27-3.06 (m, 1H), 2.91-2.55 (m, 3H), 2.23-2.07 (m, 2H), 1.95-1.71 (m, 3H), 1.53-1.28 (m, 2H), 1.27-0.95 (m, 9H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 156.7 (q), 133.8 (q), 127.0 (t), 126.5 (t), 120.5 (t), 110.4 (t), 79.4 (q), 77.2 (t), 58.6 (t), 55.3 (s), 48.9 (s), 40.7 (d), 37.0 (t), 36.2 (t), 31.3 (d), 27.0 (s), 25.1 (s), 20.0 (s).</p><heading id="h-0175" level="1">Example 168: rac-(3aR,5R,7S,7aR)-1-isopropyl-3,3,7-trimethyl-5-(o-tolyl)octahydrobenzo[c]isoxazole</heading><p id="p-0529" num="0523">Following the general procedure described in Example 81b: 2,7-dimethyl-4-(o-tolyl)oct-6-enal (258 mg, 1.06 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-isopropylhydroxylamine (238 mg, 3.17 mmol) in xylene (80 mL) were reacted to give the title product (208 mg, 66% yield) as a light yellow oil.</p><p id="p-0530" num="0524">GC/MS (EI): m/z (%): 301(63) [M<sup>+</sup>], 286 (100), 244 (4), 171 (17), 154 (71), 126 (38), 115 (30), 105 (37), 91 (13). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 7.28-7.05 (m, 4H), 3.23 (dd, J=13.0, 6.5 Hz, 1H), 3.03-2.83 (m, 1H), 2.54 (t, J=9.9 Hz, 1H), 2.35 (s, 3H), 2.23-2.04 (m, 2H), 1.78 (d, J=12.4 Hz, 3H), 1.43 (dd, J=24.5, 12.3 Hz, 1H), 1.26 (dd, J=13.5, 6.7 Hz, 7H), 1.10 (t, J=7.5 Hz, 5H), 1.07-0.96 (m, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 143.9 (q), 135.3 (q), 130.5 (t), 126.3 (t), 126.0 (t), 125.4 (t), 78.1 (q), 68.5 (t), 57.9 (t), 54.9 (t), 41.8 (d), 39.3 (t), 37.5 (t), 31.9 (d), 27.3 (s), 24.5 (s), 22.6 (s), 20.2 (s), 19.5 (s), 13.6 (s).</p><heading id="h-0176" level="1">Example 169: rac-(3aR,7S,7aR)-5,5-diethyl-1,3,3,7-tetramethyloctahydrobenzo[c]isoxazole</heading><p id="p-0531" num="0525">Following the general procedure described in Example 81b: 4,4-diethyl-2,7-dimethyloct-6-enal (500 mg, 2.38 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-methylhydroxylamine hydrochloride (298 mg, 3.57 mmol), K<sub>2</sub>CO<sub>3 </sub>(263 mg, 1.90 mmol) in toluene (50 mL) were reacted to give the title product (236 mg, 42% yield) as a colorless oil.</p><p id="p-0532" num="0526">GC/MS (EI): m/z (%): 239 (44) [M<sup>+</sup>], 224 (36), 210 (20), 193 (14), 137 (17), 126 (100), 100 (50), 55 (16). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 2.77-2.52 (m, 3H), 1.97 (ddd, J=31.6, 17.0, 6.8 Hz, 2H), 1.76-1.63 (m, 1H), 1.34 (ddd, J=13.5, 10.2, 7.7 Hz, 4H), 1.14 (dd, J=26.2, 20.4 Hz, 7H), 0.98-0.81 (m, 5H), 0.80-0.59 (m, 7H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 79.2 (q), 78.1 (t), 53.1 (t), 48.8 (s), 43.9 (d), 36.5 (q), 33.4 (d), 32.9 (d), 32.4 (t), 26.9 (s), 25.4 (d), 24.8 (s), 20.2 (s), 7.6 (s), 7.5 (s).</p><heading id="h-0177" level="1">Example 170: rac-(3aR,5R,7aR)-5-ethyl-1-isopropyl-3,3-dimethyloctahydrobenzo[c]isoxazole</heading><p id="p-0533" num="0527">Following the general procedure described in Example 81b: 4-ethyl-7-methyloct-6-enal (1.00 g, 4.22 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-isopropylhydroxylamine hydrochloride (0.71 g, 6.33 mmol), K<sub>2</sub>CO<sub>3 </sub>(0.47 g, 3.38 mmol) in toluene (50 mL) were reacted to give the title product (0.47 g, 50% yield) as a light yellow oil. GC/MS (EI): m/z (%): 225 (18) [M<sup>+</sup>], 210 (100), 151 (7), 114 (21), 95 (29), 81 (11), 67 (8). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 3.06-2.80 (m, 1H), 2.48 (dd, J=10.8, 3.5 Hz, 1H), 1.96-1.85 (m, 1H), 1.82-1.73 (m, 1H), 1.70-1.62 (m, 1H), 1.55-1.15 (m, 8H), 1.13-0.99 (m, 9H), 0.93-0.75 (m, 5H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 78.5 (q), 66.4 (t), 57.8 (t), 57.2 (t), 39.0 (t), 31.3 (d), 31.2 (d), 30.9 (d), 29.5 (d), 26.9 (s), 24.6 (s), 20.6 (s), 19.3 (s), 11.7 (s).</p><heading id="h-0178" level="1">Example 171: rac-(3aR,7aS)-1,3,3,4,5,7-hexamethyloctahydrobenzo[c]isoxazole</heading><p id="p-0534" num="0528">Following the general procedure described in Example 81b: 2,4,5,7-tetramethyloct-6-enal (235 mg, 1.08 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-methylhydroxylamine hydrochloride (136 mg, 1.62 mmol), K<sub>2</sub>CO<sub>3 </sub>(120 mg, 0.87 mmol) in toluene (50 mL) were reacted to give the title product (77 mg, 34% yield) as a colorless oil.</p><p id="p-0535" num="0529">GC/MS (EI): m/z (%): 211 (63) [M<sup>+</sup>], 196 (91), 165 (10), 140 (100), 123 (19), 109 (25), 100 (80), 84 (29), 69 (16), 55 (33). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 2.71-2.57 (m, 3H), 2.50-2.39 (m, 1H), 1.91-1.73 (m, 2H), 1.70-1.55 (m, 2H), 1.39-1.25 (m, 8H), 0.99-0.85 (m, 9H). 13C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 81.1 (q), 74.7 (t), 57.2 (t), 46.2 (s), 37.4 (d), 34.8 (t), 32.8 (t), 30.6 (s), 29.4 (t), 23.7 (s), 20.6 (s), 19.9 (s), 19.2 (s).</p><heading id="h-0179" level="1">Example 172: rac-(3aR,7aR)-1,3,3,4,5,7-hexamethyloctahydrobenzo[c]isoxazole</heading><p id="p-0536" num="0530">Following the general procedure described in Example 81b: 2,4,5,7-tetramethyloct-6-enal (235 mg, 1.08 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-methylhydroxylamine hydrochloride (136 mg, 1.62 mmol), K<sub>2</sub>CO<sub>3 </sub>(120 mg, 0.87 mmol) in toluene (50 mL) were reacted to give the title product (77 mg, 34% yield) as a colorless oil.</p><p id="p-0537" num="0531">GC/MS (EI): m/z (%): 211 (55) [M<sup>+</sup>], 196 (61), 165 (14), 140 (55), 123 (19), 109 (28), 100 (100), 87 (24), 69 (16), 55 (25). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 2.85-2.51 (m, 3H), 2.17-1.98 (m, 1H), 1.78-1.56 (m, 3H), 1.49-1.39 (m, 1H), 1.36-1.23 (m, 3H), 1.21-1.07 (m, 5H), 1.02-0.88 (m, 9H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 79.8 (q), 77.8 (t), 63.3 (t), 49.0 (s), 44.2 (d), 39.0 (t), 38.7 (t), 36.6 (t), 29.1 (s), 24.7 (s), 20.1 (s), 19.1 (s), 16.2 (s).</p><heading id="h-0180" level="1">Example 173: rac-(3aR,5R,7aR)-1-ethyl-3,3-dimethyl-5-propyloctahydrobenzo[c]isoxazole</heading><p id="p-0538" num="0532">Following the general procedure described in Example 81b: 7-methyl-4-propyloct-6-enal (700 mg, 3.84 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-ethylhydroxylamine hydrochloride (562 mg, 5.76 mmol), K<sub>2</sub>CO<sub>3 </sub>(425 mg, 3.07 mmol) in toluene (50 mL) were reacted to give the title product (310 mg, 36% yield) as a colorless oil.</p><p id="p-0539" num="0533">GC/MS (EI): m/z (%): 225 (50) [M<sup>+</sup>], 210 (100), 165 (25), 123 (12), 109 (36), 100 (87), 95 (24), 81 (17), 74 (17), 67 (15). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 2.91 (dd, J=12.7, 7.1 Hz, 1H), 2.65 (dq, J=13.7, 6.9 Hz, 1H), 2.37-2.19 (m, 1H), 1.83 (t, J=10.2 Hz, 3H), 1.69 (d, J=12.3 Hz, 1H), 1.41-1.12 (m, 12H), 1.06 (s, 3H), 0.98-0.70 (m, 5H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 79.2 (q), 69.9 (t), 57.2 (t), 53.1 (d), 39.2 (d), 37.2 (t), 31.6 (d), 31.1 (d), 29.3 (d), 27.6 (s), 25.2 (s), 20.3, 14.4 (s), 13.1 (s).</p><heading id="h-0181" level="1">Example 174: rac-(3aR,5R,7S,7aR)-1,3,3,57-pentamethyl-5-propyloctahydrobenzo[c]isoxazole</heading><p id="p-0540" num="0534">Following the general procedure described in Example 81b: 2,4,7-trimethyl-4-propyloct-6-enal (842 mg, 3.12 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-methylhydroxylamine hydrochloride (391 mg, 4.68 mmol), K<sub>2</sub>CO<sub>3 </sub>(345 mg, 2.50 mmol) in toluene (50 mL) were reacted to give the title product (246 mg, 33% yield) as a colorless oil.</p><p id="p-0541" num="0535">GC/MS (EI): m/z (%): 239 (42) [M<sup>+</sup>], 224 (50), 193 (15), 137 (18), 126 (100), 109 (14), 100 (64), 81 (13), 69 (18), 55 (23). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 2.81-2.54 (m, 3H), 2.20-1.85 (m, 2H), 1.82-1.63 (m, 1H), 1.42-1.13 (m, 9H), 1.05 (d, J=13.8 Hz, 3H), 1.01-0.79 (m, 11H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 79.4 (q), 78.2 (t), 53.8 (t), 48.9 (t), 48.6 (d), 46.7 (d), 36.5 (d), 34.5 (q), 32.9 (t), 26.9 (s), 24.9 (s), 23.6 (s), 20.2 (s), 16.8 (d), 15.1 (s).</p><heading id="h-0182" level="1">Example 175: rac-(3aR,5R,7aR)-1,3,3-trimethyl-5-propyloctahydrobenzo[c]isoxazole</heading><p id="p-0542" num="0536">Following the general procedure described in Example 81 b: 7-methyl-4-propyloct-6-enal (859 mg, 4.50 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-methylhydroxylamine hydrochloride (564 mg, 6.76 mmol), K<sub>2</sub>CO<sub>3 </sub>(498 mg, 3.60 mmol) in toluene (50 mL) were reacted to give the title product (200 mg, 21% yield) as a colorless oil.</p><p id="p-0543" num="0537">GC/MS (EI): m/z (%): 211 (23) [M<sup>+</sup>], 210 (100), 196 (33), 165 (48), 153 (85), 126 (61), 109 (33), 96 (41), 82 (66), 67 (34), 55 (26). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 2.62 (s, 3H), 2.11 (td, J=10.9, 3.1 Hz, 1H), 1.78 (dd, J=15.9, 7.2 Hz, 3H), 1.66 (d, J=12.3 Hz, 1H), 1.38-1.13 (m, 9H), 1.05 (s, 3H), 0.95-0.73 (m, 5H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 79.4 (q), 72.0 (t), 57.6 (s), 44.8 (s), 39.1 (d), 37.1 (t), 31.5 (d), 30.9 (d), 28.5 (d), 27.9 (s), 25.2 (s), 20.3 (d), 14.4 (s).</p><heading id="h-0183" level="1">Example 176: rac-(3aR,5R,7S,7aR)-1-isopropyl-3,3,5,7-tetramethyl-5-propyloctahydrobenzo[c]isoxazole</heading><p id="p-0544" num="0538">Following the general procedure described in Example 81b: 2,4,7-trimethyl-4-propyloct-6-enal (748 mg, 2.77 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-isopropylhydroxylamine (312 mg, 4.16 mmol), K<sub>2</sub>CO<sub>3 </sub>(383 mg, 2.77 mmol) in toluene (50 mL) were reacted to give the title product (216 mg, 29% yield) as a colorless oil.</p><p id="p-0545" num="0539">GC/MS (EI): m/z (%): 267 (15) [M<sup>+</sup>], 252 (100), 210 (5), 154 (48), 137 (10), 128 (18), 95 (13), 81 (10), 69 (14), 55 (20). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 3.26-3.05 (m, 1H), 2.35-2.22 (m, 1H), 2.20-2.07 (m, 1H), 1.83-1.54 (m, 2H), 1.35-1.25 (m, 4H), 1.24 (d, J=7.2 Hz, 5H), 1.19 (dd, J=11.9, 2.8 Hz, 3H), 1.04 (d, J=6.2 Hz, 3H), 1.01 (s, 3H), 0.96-0.90 (m, 7H), 0.89-0.85 (m, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 78.1 (q), 69.5 (t), 54.8 (t), 52.7 (t), 48.6 (d), 47.0 (d), 36.4 (d), 34.4 (q), 33.0 (t), 27.1 (s), 24.2 (s), 23.6 (s), 22.5 (s), 20.4 (s), 16.8 (d), 15.1 (s), 13.6 (s).</p><heading id="h-0184" level="1">Example 177: rac-(3aR,5R,7S,7aR)-1,5,7-triethyl-3,3-dimethyloctahydrobenzo[c]isoxazole</heading><p id="p-0546" num="0540">Following the general procedure described in Example 81 b: 2,4-diethyl-7-methyloct-6-enal (2.01 g, 2.04 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-ethylhydroxylamine (0.19 g, 3.06 mmol), K<sub>2</sub>CO<sub>3 </sub>(0.23 g, 1.63 mmol) in toluene (50 mL) were reacted to give the title product (0.39 g, 78% yield) as a coloeless oil.</p><p id="p-0547" num="0541">GC/MS (EI): m/z (%): 239 (24) [M<sup>+</sup>], 224 (100), 179 (6), 140 (24), 128 (18), 112 (11), 74 (14). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 2.93-2.53 (m, 2H), 2.21 (t, J=10.0 Hz, 1H), 2.02-1.74 (m, 2H), 1.74-1.35 (m, 4H), 1.34-1.19 (m, 4H), 1.15 (dd, J=7.9, 5.6 Hz, 5H), 1.08-0.94 (m, 4H), 0.91-0.72 (m, 7H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 79.3 (q), 73.7 (t), 57.9 (t), 56.7 (d), 43.9 (t), 39.1 (t), 36.5 (d), 31.2 (d), 29.5 (d), 26.4 (s), 26.2 (d), 24.6 (s), 13.9 (s), 11.7 (s), 10.7 (s).</p><heading id="h-0185" level="1">Example 178: rac-(3aR,5R,7S,7aR)-1-ethyl-3,3,5,7-tetramethyloctahydrobenzo[c]isoxazole</heading><p id="p-0548" num="0542">Following the general procedure described in Example 81b: 2,4,7-trimethyloct-6-enal (400 mg, 2.38 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-ethylhydroxylamine hydrochloride (348 mg, 3.57 mmol), K<sub>2</sub>CO<sub>3 </sub>(263 mg, 1.90 mmol) in toluene (50 mL) were reacted to give the title product (123 mg, 24% yield) as a light yellow oil.</p><p id="p-0549" num="0543">GC/MS (EI): m/z (%): 211 (23) [M<sup>+</sup>], 196 (100), 151 (10), 140 (16), 114 (27), 109 (11), 95 (14). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 3.08-2.53 (m, 2H), 2.14 (t, J=10.1 Hz, 1H), 1.90 (t, J=10.8 Hz, 1H), 1.72-1.44 (m, 4H), 1.19 (dd, J=9.1, 4.8 Hz, 6H), 1.05 (d, J=16.4 Hz, 3H), 0.95 (t, J=8.4 Hz, 6H), 0.88-0.63 (m, 2H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 79.2 (q), 74.9 (t), 57.8 (t), 56.5 (d), 43.4 (d), 37.2 (t), 33.8 (d), 32.6 (t), 26.7 (s), 24.9 (s), 21.9 (s), 20.2 (s), 13.8 (s).</p><heading id="h-0186" level="1">Example 179: rac-(3aR,5R,7aR)-5-butyl-1-isopropyl-3,3-dimethyloctahydrobenzo[c]isoxazole</heading><p id="p-0550" num="0544">Following the general procedure described in Example 81b: 4-butyl-7-methyloct-6-enal (700 mg, 3.57 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-isopropylhydroxylamine hydrochloride (597 mg, 5.35 mmol), K<sub>2</sub>CO<sub>3 </sub>(394 mg, 2.85 mmol) in toluene (50 mL) were reacted to give the title product (42 mg, 5% yield) as a brown oil.</p><p id="p-0551" num="0545">GC/MS (EI): m/z (%): 253(15) [M<sup>+</sup>], 238 (100), 196 (3), 123 (8), 114 (16), 95 (8), 81 (9), 67 (7), 55 (6). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 3.07-2.79 (m, 1H), 2.51 (td, J=10.8, 3.2 Hz, 1H), 1.84 (ddd, J=25.2, 15.4, 7.9 Hz, 3H), 1.67 (d, J=14.1 Hz, 1H), 1.26 (dd, J=25.5, 6.2 Hz, 11H), 1.13-0.98 (m, 9H), 0.93-0.75 (m, 5H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 78.6 (q), 66.4 (t), 57.7 (t), 57.1 (t), 37.3 (t), 36.6 (d), 31.7 (d), 31.3 (d), 31.1 (d), 29.4 (d), 26.9 (s), 24.6 (s), 23.0 (d), 20.5 (s), 19.1 (s), 14.1 (s).</p><heading id="h-0187" level="1">Example 180: rac-(3aR,5R,7aR)-5-butyl-1-ethyl-3,3-dimethyloctahydrobenzo[c]isoxazole</heading><p id="p-0552" num="0546">Following the general procedure described in Example 81b: 4-butyl-7-methyloct-6-enal (812 mg, 4.14 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-ethylhydroxylamine hydrochloride (605 mg, 6.20 mmol), K<sub>2</sub>CO<sub>3 </sub>(457 mg, 3.31 mmol) in toluene (50 mL) were reacted to give the title product (519 mg, 52% yield) as a colorless oil.</p><p id="p-0553" num="0547">GC/MS (EI): m/z (%): 239 (44) [M<sup>+</sup>], 224 (100), 179 (17), 140 (8), 123 (20), 109 (21), 100 (82), 81 (20), 67 (16). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 2.90 (dd, J=12.7, 7.1 Hz, 1H), 2.64 (dd, J=12.7, 6.8 Hz, 1H), 2.35-2.19 (m, 1H), 1.90-1.75 (m, 3H), 1.68 (d, J=12.5 Hz, 1H), 1.39-1.19 (m, 12H), 1.16 (t, J=7.1 Hz, 3H), 1.05 (s, 3H), 0.91-0.81 (m, 4H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 79.1 (q), 69.9 (t), 57.2 (t), 53.1 (d), 37.5 (t), 36.6 (d), 31.6 (d), 31.1 (d), 29.5 (d), 29.3 (d), 27.5 (s), 25.2 (s), 23.0 (d), 14.1 (s), 13.1 (s).</p><heading id="h-0188" level="1">Example 181: 1,3,3-trimethyl-6-((R)-4-methylcyclohex-3-en-1-yl)octahydrobenzo[c]isoxazole</heading><p id="p-0554" num="0548">Following the general procedure described in Example 81 b: 7-methyl-3-((R)-4-methylcyclohex-3-en-1-yl)oct-6-enal (700 mg, 2.99 mmol), N-methylhydroxylamine hydrochloride (374 mg, 4.48 mmol), K<sub>2</sub>CO<sub>3 </sub>(330 mg, 2.39 mmol) in toluene (50 mL) were reacted to give the title product (648 mg, 82% yield) as a light yellow oil.</p><p id="p-0555" num="0549">GC/MS (EI): m/z (%): 263 (100) [M<sup>+</sup>], 248 (23), 217 (19), 166 (32), 121 (22), 112 (22), 95 (40), 81 (28), 67 (30), 55 (20). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 5.29 (s, 1H), 2.59 (s, 3H), 2.11 (d, J=9.2 Hz, 2H), 1.99-1.61 (m, 8H), 1.56 (s, 3H), 1.41-1.11 (m, 7H), 1.09-0.86 (m, 5H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 133.9 (q), 120.6 (t), 79.3 (q), 71.9 (t), 57.8 (t), 44.5 (s), 40.4 (t), 38.6 (t), 38.5 (t), 32.2 (d), 32.0 (d), 30.8 (t), 30.7 (d), 29.3 (d), 29.2 (d), 29.1 (d), 27.9 (s), 26.9 (d), 26.6 (d), 25.1 (s), 24.4 (d), 23.4 (s).</p><heading id="h-0189" level="1">Example 182: rac-(3aR,5R,7aR)-1,3,3-trimethyl-5-pentyloctahydrobenzo[c]isoxazole</heading><p id="p-0556" num="0550">Following the general procedure described in Example 81b: 4-(3-methylbut-2-en-1-yl)nonanal (412 mg, 1.74 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-methylhydroxylamine hydrochloride (218 mg, 2.61 mmol), K<sub>2</sub>CO<sub>3 </sub>(193 mg, 1.39 mmol) in toluene (50 mL) were reacted to give the title product (295 mg, 70% yield) as a colorless oil.</p><p id="p-0557" num="0551">GC/MS (EI): m/z (%): 239 (31) [M<sup>+</sup>], 224 (27), 193 (13), 137 (9), 123 (15), 109 (28), 86 (100), 67 (22), 55 (28). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 2.57 (s, 3H), 2.07 (td, J=11.0, 3.2 Hz, 1H), 1.74 (dd, J=15.6, 7.6 Hz, 3H), 1.63 (d, J=12.5 Hz, 1H), 1.31-1.09 (m, 13H), 1.01 (s, 3H), 0.91-0.67 (m, 5H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 79.4 (q), 71.9 (t), 57.5 (t), 44.6 (s), 37.3 (t), 36.7 (d), 32.1 (d), 31.4 (d), 30.8 (d), 28.4 (d), 27.8 (s), 26.9 (d), 25.1 (s), 22.6 (d), 14.1 (s).</p><heading id="h-0190" level="1">Example 183: rac-(3aR,5R,7S,7aR)-5,7-diethyl-1-isopropyl-3,3-dimethyloctahydrobenzo[c]isoxazole</heading><p id="p-0558" num="0552">Following the general procedure described in Example 81 b: 2,4-diethyl-7-methyloct-6-enal (1000 mg, 5.09 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-isopropylhydroxylamine hydrochloride (852 mg, 7.64 mmol), K<sub>2</sub>CO<sub>3 </sub>(563 mg, 4.07 mmol) in toluene (50 mL) were reacted to give the title product (125 mg, 10% yield) as a light yellow oil.</p><p id="p-0559" num="0553">GC/MS (EI): m/z (%): 253 (20) [M<sup>+</sup>], 238 (100), 196 (28), 179 (5), 154 (12), 123 (13), 109 (8), 95 (10), 81 (8), 69 (9), 55 (11). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 3.09 (dt, J=13.0, 6.5 Hz, 1H), 2.42 (t, J=9.8 Hz, 1H), 1.99-1.85 (m, 1H), 1.78 (d, J=13.2 Hz, 1H), 1.60 (dd, J=37.5, 28.7 Hz, 3H), 1.34-1.13 (m, 10H), 1.04 (dd, J=12.8, 6.4 Hz, 6H), 0.92-0.73 (m, 7H), 0.61 (dd, J=24.6, 11.6 Hz, 1H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 77.9 (q), 66.7 (t), 57.9 (t), 55.0 (t), 43.6 (t), 39.1 (t), 36.6 (d), 31.3 (d), 29.6 (d), 27.1 (s), 25.9 (d), 24.3 (s), 22.7 (s), 13.9 (s), 11.8 (s), 10.4 (s).</p><heading id="h-0191" level="1">Example 184: rac-(3aR,5R,7S,7aR)-1-isopropyl-3,3,7-trimethyl-5-(3-methylbut-2-en-1-yl)octahydrobenzo[c]isoxazole</heading><p id="p-0560" num="0554">Following the general procedure described in Example 81 b: 2,7-dimethyl-4-(3-methylbut-2-en-1-yl)oct-6-enal (853 mg, 3.64 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-isopropylhydroxylamine hydrochloride (610 mg, 5.47 mmol), K<sub>2</sub>CO<sub>3 </sub>(403 mg, 2.92 mmol) in toluene (50 mL) were reacted to give the title product (250 mg, 25% yield) as a light yellow oil.</p><p id="p-0561" num="0555">GC/MS (EI): m/z (%): 279 (23) [M<sup>+</sup>], 264 (100), 222 (4), 154 (6), 128 (4), 107 (4), 95 (7), 69 (13), 55 (5). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 5.08 (t, J=7.3 Hz, 1H), 3.19-2.99 (m, 1H), 2.28 (t, J=9.9 Hz, 1H), 1.86 (dd, J=17.2, 5.5 Hz, 3H), 1.69-1.46 (m, 9H), 1.38 (dd, J=7.2, 3.6 Hz, 1H), 1.24-1.10 (m, 6H), 1.00 (dd, J=10.3, 3.9 Hz, 6H), 0.90 (d, J=6.4 Hz, 3H), 0.73 (dd, J=25.1, 12.8 Hz, 2H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 132.2 (q), 122.8 (t), 77.8 (q), 68.7 (t), 57.4 (t), 54.7 (t), 41.3 (d), 38.3 (t), 36.9 (t), 35.1 (d), 31.4 (d), 27.2 (s), 25.8 (s), 24.3 (s), 22.6 (s), 20.2 (s), 17.8 (s), 13.6 (s).</p><heading id="h-0192" level="1">Example 185: rac-(3aR,5R,7S7aR)-1-ethyl-3,3,7-trimethyl-5-(3-methylbut-2-en-1-yl)octahydrobenzo[c]isoxazole</heading><p id="p-0562" num="0556">Following the general procedure described in Example 81b: 2,7-dimethyl-4-(3-methylbut-2-en-1-yl)oct-6-enal (2.00 g, 8.99 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-ethylhydroxylamine (0.82 g, 13.49 mmol), K<sub>2</sub>CO<sub>3 </sub>(0.99 g, 7.20 mmol) in toluene (50 mL) were reacted to give the title product (0.91 g, 38% yield) as a light yellow oil.</p><p id="p-0563" num="0557">GC/MS (EI): m/z (%): 265 (42) [M<sup>+</sup>], 250 (100), 222 (3), 194 (6), 140 (18), 114 (18), 95 (10), 81 (8), 69 (22). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 5.11 (t, J=7.3 Hz, 1H), 3.03-2.55 (m, 2H), 2.14 (t, J=10.1 Hz, 1H), 1.97-1.79 (m, 3H), 1.66 (d, J=8.6 Hz, 5H), 1.56 (s, 3H), 1.50-1.25 (m, 2H), 1.24-1.09 (m, 6H), 1.08-0.87 (m, 6H), 0.85-0.59 (m, 2H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 132.3 (q), 122.8 (t), 79.2 (q), 75.1 (t), 57.6 (t), 56.4 (d), 41.1 (d), 38.4 (t), 37.2 (t), 35.1 (d), 31.5 (d), 26.6 (s), 25.8 (s), 24.8 (s), 20.2 (s), 17.8 (s), 13.8 (s).</p><heading id="h-0193" level="1">Example 186: rac-(3aR,5R,7S,7aR)-1-ethyl-3,3,5,7-tetramethyl-5-(3-methylbut-2-en-1-yl)octahydrobenzo[c]isoxazole</heading><p id="p-0564" num="0558">Following the general procedure described in Example 81b: 2,4,7-trimethyl-4-(3-methylbut-2-en-1-yl)oct-6-enal (2.00 g, 7.95 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-ethylhydroxylamine hydrochloride (1.16 g, 11.93 mmol), K<sub>2</sub>CO<sub>3 </sub>(0.88 g, 6.36 mmol) in toluene (50 mL) were reacted to give the title product (1.03 g, 46% yield) as a light yellow oil.</p><p id="p-0565" num="0559">GC/MS (EI): m/z (%): 279 (55) [M<sup>+</sup>], 264 (80), 210 (7), 149 (11), 140 (100), 114 (42), 69 (35), 55 (20). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 5.19 (t, J=7.6 Hz, 1H), 3.08-2.60 (m, 2H), 2.18-2.00 (m, 2H), 1.91 (d, J=7.5 Hz, 2H), 1.72 (s, 4H), 1.58 (s, 3H), 1.48-1.26 (m, 3H), 1.26-1.14 (m, 6H), 1.12-0.99 (m, 4H), 0.91 (d, J=4.3 Hz, 6H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 133.5 (q), 120.4 (t), 79.3 (q), 75.7 (t), 56.4 (d), 53.0 (t), 46.2 (d), 43.6 (d), 36.2 (d), 35.8 (q), 33.4 (t), 26.6 (s), 26.2 (s), 24.7 (s), 24.0 (s), 20.3 (s), 18.0 (s), 13.9 (s).</p><p id="p-0566" num="0560">From the same reaction, an additional diastereomer was isolated: rac-(3aR,5R,7R,7aR)-1-ethyl-3,3,5,7-tetramethyl-5-(3-methylbut-2-en-1-yl)octahydrobenzo[c]isoxazole (320 mg, 14% yield) as a yellow oil. GC/MS (EI): m/z (%): 279 (63) [M<sup>+</sup>], 264 (90), 140 (100), 114 (47), 95 (19), 83 (21), 69 (41), 55 (27).</p><heading id="h-0194" level="1">Example 187: rac-(3aR,5R,7aR)-5-butyl-1,3,3-trimethyloctahydrobenzo[c]isoxazole</heading><p id="p-0567" num="0561">Following the general procedure described in Example 81b: 4-butyl-7-methyloct-6-enal (821 mg, 4.18 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-methylhydroxylamine hydrochloride (524 mg, 6.27 mmol), K<sub>2</sub>CO<sub>3 </sub>(462 mg, 3.35 mmol) in toluene (50 mL) were reacted to give the title product (675 mg, 72% yield) as a colorless oil.</p><p id="p-0568" num="0562">GC/MS (EI): m/z (%): 225 (39) [M<sup>+</sup>], 210 (29), 179 (21), 123 (24), 109 (26), 95 (27), 86 (100), 67 (21), 55 (26). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 2.65 (s, 3H), 2.12 (dd, J=10.9, 3.1 Hz, 1H), 1.95-1.77 (m, 3H), 1.70 (d, J=12.2 Hz, 1H), 1.31 (d, J=21.1 Hz, 11H), 1.09 (s, 3H), 0.98-0.75 (m, 5H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 79.5 (q), 72.1 (t), 57.7 (t), 44.8 (s), 37.4 (t), 36.6 (d), 31.6 (d), 31.0 (d), 29.5 (d), 28.6 (d), 28.0 (s), 25.3 (s), 23.0 (d), 14.2 (s).</p><heading id="h-0195" level="1">Example 188: rac-(3aR,5R,7aR)-1-isopropyl-3,3-dimethyl-5-propyloctahydrobenzo[c]isoxazole</heading><p id="p-0569" num="0563">Following the general procedure described in Example 81b: 7-methyl-4-propyloct-6-enal (1.50 g, 8.23 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-isopropylhydroxylamine (4.00 g, 53.30 mmol), K<sub>2</sub>CO<sub>3 </sub>(0.91 g, 6.58 mmol) in toluene (50 mL) were reacted to give the title product (1.02 g, 52% yield) as a colorless oil.</p><p id="p-0570" num="0564">GC/MS (EI): m/z (%): 239 (25) [M<sup>+</sup>], 224 (100), 182 (4), 165 (7), 114 (31), 109 (35), 95 (21), 81 (20), 67 (20), 55 (18). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 2.89 (dt, J=12.8, 6.4 Hz, 1H), 2.46 (td, J=10.8, 3.3 Hz, 1H), 1.93-1.53 (m, 4H), 1.40-1.10 (m, 9H), 1.09-0.94 (m, 9H), 0.93-0.67 (m, 5H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 78.5 (q), 66.3 (t), 57.7 (t), 57.0 (t), 39.1 (d), 36.9 (t), 31.6 (d), 31.2 (d), 26.8 (s), 24.5 (s), 20.5 (s), 20.2 (d), 19.1 (s), 14.3 (s).</p><heading id="h-0196" level="1">Example 189: 1-ethyl-3,3,5,7-tetramethyl-5-(3-methylbut-2-en-1-yl)octahydrobenzo[c]isoxazole</heading><p id="p-0571" num="0565">Following the general procedure described in Example 81b: 2,4,7-trimethyl-4-(3-methylbut-2-en-1-yl)oct-6-enal (2.00 g, 7.95 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-ethylhydroxylamine hydrochloride (1.16 g, 11.93 mmol), K<sub>2</sub>CO<sub>3 </sub>(0.88 g, 6.36 mmol) in toluene (50 mL) were reacted to give the title product (1.03 g, 46% yield) as a light yellow oil.</p><p id="p-0572" num="0566">GC/MS (EI): m/z (%): 279 (55) [M<sup>+</sup>], 264(80), 210 (7), 149 (11), 140 (100), 114 (42), 69 (35), 55 (20). And GC/MS (EI): m/z (%): 279 (50) [M<sup>+</sup>], 264(80), 208 (15), 152 (21), 140 (100), 114 (45), 69 (41), 55(22). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 5.09 (dt, J=24.7, 7.2 Hz, 1H), 3.00-2.52 (m, 2H), 2.07 (d, J=14.8 Hz, 2H), 1.83 (t, J=9.7 Hz, 2H), 1.75-1.61 (m, 4H), 1.52 (s, 3H), 1.40 (d, J=12.9 Hz, 1H), 1.33-1.09 (m, 7H), 1.07-0.76 (m, 11H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 133.3 (q), 133.1 (q), 120.4 (t), 120.2 (t), 79.1 (q), 75.6 (t), 56.4 (d), 56.3 (d), 52.9 (t), 46.9 (d), 46.1 (d), 43.5 (d), 36.1 (d), 35.7 (d), 35.6 (d), 35.3 (q), 33.3 (t), 33.2 (t), 29.2 (s), 26.5 (s), 26.0 (s), 24.5 (s), 23.8 (s), 20.2 (s), 18.0 (s), 17.9 (s), 13.7 (s).</p><heading id="h-0197" level="1">Example 190: 5-ethyl-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole</heading><p id="p-0573" num="0567">Following the general procedure described in Example 81 b: 4-ethyl-2,4,7-trimethyloct-6-enal (584 mg, 2.439 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-methylhydroxylamine hydrochloride (306 mg, 3.66 mmol), K<sub>2</sub>CO<sub>3 </sub>(270 mg, 1.951 mmol) in toluene (50 mL) were reacted to give the title product (342 mg, 62% yield) as a colorless oil.</p><p id="p-0574" num="0568">GC/MS (EI): m/z (%): 225 (26) [M<sup>+</sup>], 210 (38), 196 (7), 179 (12), 137 (9), 126 (100), 109 (20), 100 (68), 55 (28). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 2.86-2.46 (m, 3H), 2.16-1.82 (m, 2H), 1.69 (d, J=7.1 Hz, 1H), 1.49-1.13 (m, 7H), 1.10-0.64 (m, 14H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 79.2 (q), 79.1 (q), 78.2 (t), 78.0 (t), 53.8 (t), 53.5 (t), 48.9 (s), 46.5 (d), 46.2 (d), 38.0 (d), 35.9 (d), 35.2 (d), 34.4 (q), 34.2 (q), 32.8 (t), 32.5 (t), 29.5 (d), 28.5 (s), 26.9 (s), 24.9 (s), 24.8 (s), 23.0 (s), 20.2 (s), 7.9 (s).</p><heading id="h-0198" level="1">Example 191: 1,3,3,6-tetramethyloctahydrobenzo[c]isoxazole</heading><p id="p-0575" num="0569">Following the general procedure described in Example 81b: 3,7-dimethyloct-6-enal (3.125 g, 20.26 mmol), N-methylhydroxylamine hydrochloride (2.54 g, 30.40 mmol), K<sub>2</sub>CO<sub>3 </sub>(2.24 g, 16.21 mmol) in cyclohexane (80 mL) were reacted to give the title product (1.99 g, 54% yield) as a colorless oil.</p><p id="p-0576" num="0570">GC/MS (EI): m/z (%): 183 (71) [M<sup>+</sup>], 168 (54), 137 (94), 126 (9), 109 (15), 100 (100), 95 (43), 81 (44). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 2.58 (s, 3H), 2.14 (td, J=10.9, 3.5 Hz, 1H), 1.81-1.55 (m, 4H), 1.49-1.28 (m, 1H), 1.27-1.10 (m, 4H), 1.05 (d, J=9.8 Hz, 3H), 0.99-0.81 (m, 5H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 79.4 (q), 71.7 (t), 57.4 (t), 44.5 (s), 37.3 (d), 34.4 (d), 30.9 (t), 28.0, 25.2 (s), 24.5 (d), 21.9 (s).</p><heading id="h-0199" level="1">Example 192: 1,3,3,5,7-pentamethyl-5-(3-methylbut-2-en-1-yl)octahydrobenzo[c]isoxazole</heading><p id="p-0577" num="0571">Following the general procedure described in Example 81b: 2,4,7-trimethyl-4-(3-methylbut-2-en-1-yl)oct-6-enal (2.00 g, 5.84 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-methylhydroxylamine hydrochloride (0.73 g, 8.76 mmol), K<sub>2</sub>CO<sub>3 </sub>(0.65 g, 4.67 mmol) in toluene (50 mL) were reacted to give the title product (1.04 g, 67% yield) as a light yellow oil.</p><p id="p-0578" num="0572">GC/MS (EI): m/z (%): 265 (81) [M<sup>+</sup>], 250 (78), 194 (8), 149 (18), 138 (19), 126 (100), 100 (57), 69 (41), 55 (20). And GC/MS (EI): m/z (%): 265(66) [M<sup>+</sup>], 250 (79), 194 (27), 153 (27), 138 (31), 126 (100), 100 (63), 69 (52), 55 (28). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 5.10 (d, J=25.1 Hz, 1H), 2.90-2.44 (m, 3H), 2.06 (s, 1H), 1.88 (t, J=10.2 Hz, 2H), 1.66 (s, 4H), 1.54 (s, 3H), 1.48-0.62 (m, 17H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 133.4 (q), 133.1 (q), 120.4 (t), 120.2 (t), 79.2 (q), 79.1 (q), 78.1 (t), 77.9 (t), 53.7 (t), 48.8 (s), 46.8 (d), 46.1 (d), 43.5 (d), 36.1 (d), 35.7 (q), 35.6 (d), 35.5 (d), 35.3 (q), 32.8 (t), 29.2 (s), 26.9 (s), 26.1 (s), 24.8 (s), 23.8 (s), 20.1 (s), 18.0 (s), 17.9 (s).</p><heading id="h-0200" level="1">Example 193: 1-isopropyl-3,3,5,7-tetramethyloctahydrobenzo[c]isoxazole</heading><p id="p-0579" num="0573">Following the general procedure described in Example 81b: 2,4,7-trimethyloct-6-enal (2.83 g, 15.78 mmol), N-isopropylhydroxylamine hydrochloride (2.64 g, 23.67 mmol), K<sub>2</sub>CO<sub>3 </sub>(1.75 g, 12.62 mmol) in toluene (50 mL) were reacted to give the title product (1.63 g, 45% yield) as a colorless oil.</p><p id="p-0580" num="0574">GC/MS (EI): m/z (%): 225 (18) [M<sup>+</sup>], 210 (100), 168 (19), 151 (7), 128 (9), 109 (10), 95 (19). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 3.05 (dd, J=13.0, 6.5 Hz, 1H), 2.22 (t, J=9.9 Hz, 1H), 1.94-1.76 (m, 1H), 1.61-1.35 (m, 4H), 1.16-1.07 (m, 6H), 0.98-0.90 (m, 6H), 0.83 (dt, J=14.1, 7.0 Hz, 6H), 0.69 (dd, J=24.9, 12.7 Hz, 2H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 77.5 (q), 68.4 (t), 57.4 (t), 54.6 (t), 43.5 (d), 36.8 (t), 33.5 (d), 32.3 (t), 27.1 (s), 24.2 (s), 22.5 (s), 21.7 (s), 20.1 (s), 13.5 (s).</p><heading id="h-0201" level="1">Example 194: rac-(3aR,5R,7S,7aR)-1-isopropyl-3,3,5,7-tetramethyl-5-(3-methylbut-2-en-1-yl)octahydrobenzo[c]isoxazole</heading><p id="p-0581" num="0575">Following the general procedure described in Example 81b: 2,4,7-trimethyl-4-(3-methylbut-2-en-1-yl)oct-6-enal (2.02 g, 8.53 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-isopropylhydroxylamine hydrochloride (1.92 g, 25.6 mmol) in xylene (50 mL) were reacted to give the title product rac-(3aR,5R,7S,7aR)-1-isopropyl-3,3,5,7-tetramethyl-5-(3-methylbut-2-en-1-yl)octahydrobenzo[c]isoxazole (517 mg, 20% yield) as a light yellow oil.</p><p id="p-0582" num="0576">GC/MS (EI): m/z (%): 293 (24) [M<sup>+</sup>], 278 (100), 154 (38), 128 (13), 107 (13), 95 (9), 83 (8), 69 (23), 55 (11). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 5.15 (t, J=7.4 Hz, 1H), 3.12 (dt, J=12.9, 6.5 Hz, 1H), 2.24 (t, J=10.1 Hz, 1H), 2.16-2.01 (m, 1H), 1.87 (d, J=7.5 Hz, 2H), 1.78-1.60 (m, 4H), 1.55 (s, 3H), 1.34-1.11 (m, 8H), 1.05-0.94 (m, 7H), 0.93-0.76 (m, 7H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 133.4 (q), 120.4 (t), 77.8 (q), 69.4 (t), 54.8 (t), 52.8 (t), 46.5 (d), 43.6 (d), 36.1 (d), 35.7 (d), 33.2 (t), 27.1 (s), 26.1 (s), 24.2 (s), 23.8 (s), 22.6 (s), 20.3 (s), 18.0 (s), 13.7 (s).</p><p id="p-0583" num="0577">From the same reaction, two additional isomers were isolated: rac-(3aS,5R,7S,7aS)-1-isopropyl-3,3,5,7-tetramethyl-5-(3-methylbut-2-en-1-yl)octahydrobenzo[c]isoxazole (412 mg, 6% yield) and rac-(3aS,5R,7R,7aS)-1-isopropyl-3,3,5,7-tetramethyl-5-(3-methylbut-2-en-1-yl)octahydrobenzo[c]isoxazole (412 mg, 15% yield) as light yellow oils.</p><p id="p-0584" num="0578">rac-(3aS,5R,7S,7aS)-1-isopropyl-3,3,5,7-tetramethyl-5-(3-methylbut-2-en-1-yl)octahydrobenzo[c]isoxazole: GC/MS (EI): m/z (%): 293 (21) [M<sup>+</sup>], 278 (73), 154 (100), 126 (51), 107 (33), 95 (22), 84 (26), 69 (99), 55 (24).</p><p id="p-0585" num="0579">rac-(3aS,5R,7R,7aS)-1-isopropyl-3,3,5,7-tetramethyl-5-(3-methylbut-2-en-1-yl)octahydrobenzo[c]isoxazole: GC/MS (EI): m/z (%): 293 (20) [M<sup>+</sup>], 278 (100), 154 (60), 128 (18), 107 (22), 95 (22), 81 (18), 69 (79), 55 (22).</p><heading id="h-0202" level="1">Example 195: 1,3,3,7-tetramethyl-5-(3-methylbut-2-en-1-yl)octahydrobenzo[c]isoxazole</heading><p id="p-0586" num="0580">Following the general procedure described in Example 81b: 2,7-dimethyl-4-(3-methylbut-2-en-1-yl)oct-6-enal (7.13 g, 28.8 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-methylhydroxylamine hydrochloride (3.61 g, 43.3 mmol), K<sub>2</sub>CO<sub>3 </sub>(3.19 g, 23.08 mmol) in toluene (60 mL) were reacted to give the title product (5.75 g, 79% yield) as a colorless oil.</p><p id="p-0587" num="0581">GC/MS (EI): m/z (%): 251 (24) [M<sup>+</sup>], 236 (19), 193 (29), 180 (23), 149 (40), 126 (100), 108 (42), 93 (58), 69 (38), 55 (18). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 5.02 (t, J=7.3 Hz, 1H), 2.82-2.37 (m, 3H), 1.99-1.74 (m, 4H), 1.59 (s, 5H), 1.48 (s, 3H), 1.42-1.19 (m, 2H), 1.17-0.80 (m, 9H), 0.79-0.54 (m, 2H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 132.1 (q), 122.6 (t), 79.0 (q), 77.3 (t), 58.2 (t), 48.7 (s), 40.9 (d), 38.2 (t), 36.4 (t), 34.9 (d), 31.3 (d), 26.8 (s), 25.7 (s), 24.9 (s), 19.9 (s), 17.7 (s).</p><heading id="h-0203" level="1">Example 196: 1-isopropyl-5,7-dimethylhexahydro-1H-spiro[benzo[c]isoxazole-3,1&#x2032;-cyclopentane]</heading><p id="p-0588" num="0582">Following the general procedure described in Example 81b: 6-cyclopentylidene-2,4-dimethylhexanal (215 mg, 1.11 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-isopropylhydroxylamine hydrochloride (185 mg, 1.66 mmol), K<sub>2</sub>CO<sub>3 </sub>(122 mg, 0.89 mmol) in toluene (50 mL) were reacted to give the title product (93 mg, 33% yield) as a colorless oil.</p><p id="p-0589" num="0583">GC/MS (EI): m/z (%): 251 (34) [M<sup>+</sup>], 236 (100), 222 (31), 180 (26), 128 (41), 109 (22), 95 (28), 81 (18), 67 (14), 55 (19). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 3.13 (dt, J=12.9, 6.5 Hz, 1H), 2.33-2.19 (m, 1H), 2.17-2.03 (m, 1H), 1.83 (dd, J=11.9, 7.8 Hz, 1H), 1.75-1.34 (m, 11H), 1.27-1.14 (m, 3H), 1.04 (t, J=8.5 Hz, 3H), 0.95 (t, J=8.9 Hz, 6H), 0.90-0.68 (m, 2H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 88.9 (q), 69.4 (t), 55.5 (t), 55.0 (t), 43.8 (d), 37.1 (t), 36.6 (d), 34.5 (d), 33.9 (d), 32.5 (t), 24.9 (d), 23.7 (d), 22.7 (s), 22.0 (s), 20.3 (s), 14.1 (s).</p><heading id="h-0204" level="1">Example 197: 1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole</heading><p id="p-0590" num="0584">Following the general procedure described in Example 81b: 2,4,7-trimethyloct-6-enal (20.00 g, 102.00 mmol), N-methylhydroxylamine hydrochloride (12.78 g, 153.00 mmol), K<sub>2</sub>CO<sub>3 </sub>(11.28 g, 82.00 mmol) in toluene (300 ml) were reacted to give the title product (16.18 g, 80% yield) as a colorless oil.</p><p id="p-0591" num="0585">GC/MS (Isomer 1) (EI): m/z (%): 197 (32) [M<sup>+</sup>], 182 (100), 151 (17), 126 (22), 109 (18), 100 (47), 60 (19). And GC/MS (Isomer 2) (EI): m/z (%): 197 (31) [M<sup>+</sup>], 182 (100), 151 (20), 126 (20), 109 (18), 100 (44), 60 (19). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 2.91-2.50 (m, 3H), 2.01 (ddd, J=21.1, 15.3, 5.2 Hz, 3H), 1.55 (ddd, J=18.9, 17.9, 9.5 Hz, 3H), 1.40 (dd, J=10.7, 7.0 Hz, 1H), 1.30-1.05 (m, 5H), 1.04-0.64 (m, 8H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 79.2 (q), 79.1 (q), 77.9 (t), 77.2 (t), 58.4 (t), 51.9 (t), 48.9 (s), 43.2 (d), 40.1 (d), 36.6 (t), 33.7 (d), 32.5 (t), 31.9 (t), 30.9 (d), 27.7 (s), 26.9 (s), 26.8 (s), 25.0 (s), 24.8 (s), 21.8 (s), 20.1 (s), 20.0 (s), 19.2 (s).</p><heading id="h-0205" level="1">Example 198: 5,7-diethyl-1,3,3-trimethyloctahydrobenzo[c]isoxazole</heading><p id="p-0592" num="0586">Following the general procedure described in Example 81b: 2,4-diethyl-7-methyloct-6-enal (412 mg, 1.99 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-methylhydroxylamine hydrochloride (250 mg, 2.99 mmol), K<sub>2</sub>CO<sub>3 </sub>(220 mg, 1.60 mmol) in toluene (50 mL) were reacted to give the title product (0.30 mg, 66% yield) as a colorless oil.</p><p id="p-0593" num="0587">GC/MS (EI): m/z (%): 225 (25) [M<sup>+</sup>], 210 (100), 179 (7), 126 (23), 114 (20), 98(11), 81 (9). And GC/MS (EI): m/z (%): 225 (17) [M<sup>+</sup>], 210 (19), 179 (6), 126 (100), 109 (23), 96 (25). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 2.84-2.53 (m, 3H), 2.22-2.05 (m, 1H), 2.03-1.43 (m, 5H), 1.41-1.23 (m, 4H), 1.23-1.05 (m, 6H), 0.99 (s, 1H), 0.94-0.76 (m, 7H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 79.4 (q), 76.1 (t), 75.6 (t), 58.8 (t), 52.8 (t), 49.4 (s), 43.4 (t), 39.2 (t), 39.1 (t), 36.4 (d), 35.0 (t), 33.4 (d), 31.3 (d), 29.5 (d), 28.7 (d), 26.8 (s), 26.7 (s), 26.0 (d), 25.4 (d), 25.0 (s), 24.8 (s), 12.7 (s), 11.8 (s), 11.0 (s), 10.5 (s).</p><heading id="h-0206" level="1">Example 199: 1,5,7-trimethylhexahydro-1H-spiro[benzo[c]isoxazole-3,1&#x2032;-cyclopentane]</heading><p id="p-0594" num="0588">Following the general procedure described in Example 81b: 6-cyclopentylidene-2,4-dimethylhexanal (604 mg, 3.11 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-methylhydroxylamine hydrochloride (389 mg, 4.66 mmol), K<sub>2</sub>CO<sub>3 </sub>(344 mg, 2.49 mmol) in toluene (50 mL) were reacted to give the title product (303 mg, 44% yield) as a colorless oil.</p><p id="p-0595" num="0589">GC/MS (EI): m/z (%): 223 (40) [M<sup>+</sup>], 181 (28), 152 (100), 139 (23), 122 (27), 95 (39), 82 (32), 67 (23), 55 (35). And GC/MS (EI): m/z (%): 223 (32) [M<sup>+</sup>], 181 (19), 152 (100), 139 (14), 122 (24), 95 (29), 82 (21), 67 (19), 55 (28). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 2.84-2.52 (m, 3H), 2.38-1.82 (m, 3H), 1.78-1.41 (m, 11H), 1.30-0.85 (m, 7H), 0.84-0.58 (m, 1H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 90.2 (q), 78.8 (t), 78.1 (t), 56.0 (t), 49.5 (t), 49.2 (t), 43.4 (d), 40.2 (d), 36.8 (t), 36.3 (d), 36.2 (d), 35.7 (d), 35.5 (d), 33.9 (d), 32.5 (t), 32.0 (t), 31.1 (d), 27.8 (t), 25.1 (d), 23.9 (d), 21.9 (s), 20.2 (s), 20.1 (s), 19.3 (s).</p><heading id="h-0207" level="1">Example 200: 1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole hydrochloride</heading><p id="p-0596" num="0590">The flask was charged with 1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole (313 mg, 1.59 mmol) and acetone (40 mL). Then 2.7 mL 1M HCl was added dropwise at r.t. Stirred overnight to obtain the title product (304 mg, 1.29 mmol, 81% yield) as a white solid.</p><p id="p-0597" num="0591"><sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 14.92 (s, 1H), 3.15-2.86 (m, 3H), 2.83-2.59 (m, 1H), 2.56-2.31 (m, 1H), 2.27-1.90 (m, 1H), 1.88-1.68 (m, 2H), 1.66-1.31 (m, 5H), 1.20 (d, J=3.1 Hz, 3H), 1.15-1.07 (m, 3H), 1.00 (d, J=7.2 Hz, 1H), 0.92 (t, J=7.2 Hz, 2H), 0.85-0.67 (m, 1H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 88.9 (q), 87.7 (q), 87.5 (q), 78.4 (t), 77.8 (t), 73.2 (t), 72.8 (t), 54.7 (t), 51.1 (t), 48.8 (t), 44.7 (s), 42.8 (d), 42.3 (d), 40.0 (d), 39.3 (s), 33.0 (d), 32.9 (d), 32.8 (t), 31.9 (t), 31.4 (t), 31.3 (t), 30.5 (s), 28.4 (t), 26.9 (t), 26.9 (t), 26.2 (s), 26.1 (s), 23.5 (s), 23.4 (s), 22.5 (s), 21.2 (s), 21.1 (s), 20.5 (s), 19.5 (s), 19.4 (s), 19.3 (s), 19.2 (s), 18.8 (s), 18.5 (s).</p><heading id="h-0208" level="1">Example 201: 1-isopropyl-3,3,5,7-tetramethyloctahydrobenzo[c]isoxazole hydrochloride</heading><p id="p-0598" num="0592">A flask was charged with 1-isopropyl-3,3,5,7-tetramethyloctahydrobenzo[c]isoxazole (185 mg, 0.81 mmol) and acetone (40 mL). Then 1.4 mL 1M HCl was added dropwise at r.t. Stirred overnight to obtain the title product (180 mg, 0.69 mmol, 85% yield) as a light brown solid.</p><p id="p-0599" num="0593"><sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 14.36 (s, 1H), 3.90-3.47 (m, 1H), 2.92-2.35 (m, 3H), 1.75-1.53 (m, 3H), 1.46 (d, J=6.5 Hz, 3H), 1.39 (s, 3H), 1.19 (d, J=6.5 Hz, 3H), 1.12-1.00 (m, 6H), 0.84 (d, J=6.8 Hz, 3H), 0.79-0.60 (m, 2H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 86.0 (q), 70.9 (t), 56.7 (t), 53.1 (t), 43.1 (d), 32.9 (d), 32.1 (t), 31.0 (t), 26.4 (s), 23.0 (s), 21.2 (s), 19.2 (s), 18.7 (s), 13.6 (s).</p><heading id="h-0209" level="1">Example 202: 6-isopentyl-1,4,4,8-tetramethyloctahydro-2H-benzo[d][1,3]oxazine</heading><p id="p-0600" num="0594">A flask was charged with 40 mg Pd/C (10%), 1,3,3,7-tetramethyl-5-(3-methylbut-2-en-1-yl)octahydrobenzo[c]isoxazole (325 mg, 1.25 mmol) and methanol (50 mL), then the reaction mixture was stirred overnight at r.t. under hydrogen gas; after the reaction was filtered, washed with MTBE (50 mL*2), the filtrate was concentrated to give the crude product. Flash chromatography (hexane/MTBE=4:1-1:1) gave the title product (88 mg, 0.33 mmol, 26% yield) as a colorless oil.</p><p id="p-0601" num="0595">GC/MS (EI): m/z (%): 267 (8) [M<sup>+</sup>], 252 (7), 208 (2), 194 (2), 140 (100), 110 (14), 95 (6), 81 (3), 67 (3). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 4.65 (d, J=10.8 Hz, 1H), 4.22 (d, J=10.8 Hz, 1H), 2.49-2.22 (m, 4H), 1.79-1.54 (m, 3H), 1.52-1.36 (m, 2H), 1.28-1.06 (m, 11H), 0.97-0.79 (m, 9H), 0.76-0.47 (m, 2H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 81.2 (d), 74.6 (q), 63.8 (t), 41.6 (d), 40.5 (t), 37.1 (t), 36.3 (d), 34.9 (d), 34.0 (d), 33.9 (t), 32.8 (s), 29.1 (s), 28.4 (t), 22.8 (s), 22.7 (s), 18.6 (s), 18.6 (s).</p><p id="p-0602" num="0596">In the same reaction, an additional product was isolated: 2-(5-isopentyl-3-methyl-2-(methylamino)cyclohexyl)propan-2-ol (178 mg, 0.66 mmol, 52% yield) as colorless oil.</p><p id="p-0603" num="0597">GC/MS (EI): m/z (%): 255 (12) [M<sup>+</sup>], 240 (10), 128 (34), 110 (25), 84 (100), 70 (15), 59 (7).</p><heading id="h-0210" level="1">Example 203: 6-isopentyl-1, 4,4,8-tetramethyloctahydro-2H-benzo[d][1,3]oxazin-2-one</heading><p id="p-0604" num="0598">A mixture of 2-(5-isopentyl-3-methyl-2-(methylamino)cyclohexyl)propan-2-ol (556 mg, 2.18 mmol) and di(1H-imidazol-1-yl)methanone (459 mg, 2.83 mmol) in 1,2-dichloroethane (40 mL) was stirred under Ar atmosphere at r.t. for 5 minutes. The mixture was heated to 80&#xb0; C. in Ar atmosphere overnight, and the reaction was monitored by GC and GC-MS. After cooled to room temperature, the reaction mixture was filtered and the filter was washed with MTBE. The combined filtrates were concentrated in vacuo to give crude product, which was purified by flash chromatography (PE:MTBE=1:2) to afford 6-isopentyl-1,4,4,8-tetramethyloctahydro-2H-benzo[d][1,3]oxazin-2-one (485 mg, 75% yield) as a white solid.</p><p id="p-0605" num="0599">GC/MS (EI): m/z (%): 281 (13) [M<sup>+</sup>], 238 (2), 222 (22), 194 (7), 154 (40), 126 (3), 110 (100), 84 (25), 55 (9). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 2.98 (s, 3H), 2.52 (t, J=9.9 Hz, 1H), 1.78-1.50 (m, 4H), 1.48-1.29 (m, 2H), 1.24 (s, 3H), 1.19-1.00 (m, 10H), 0.83-0.73 (m, 7H), 0.72-0.56 (m, 1H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 155.5 (q), 79.2 (q), 65.0 (t), 49.1 (t), 42.9 (d), 40.0 (t), 38.2 (s), 37.1 (t), 36.1 (d), 34.3 (d), 33.4 (d), 28.1 (t), 27.2 (s), 22.5 (s), 22.4 (s), 22.3 (s), 20.4 (s).</p><heading id="h-0211" level="1">Example 204: rac-(3aR,5R,7S,7aR)-5-isopentyl-1-isopropyl-3,3,5,7-tetramethyloctahydrobenzo[c]isoxazole</heading><p id="p-0606" num="0600">Following the general procedure described in Example 81b: 4-isopentyl-2,4,7-trimethyloct-6-enal (1.317 g, 4.47 mmol), N-isopropylhydroxylamine (0.504 g, 6.71 mmol) in xylene (50 mL) were reacted at a reflux temperature to give the title product (438 mg, 31% yield) as a colorless oil.</p><p id="p-0607" num="0601">GC/MS (EI): m/z (%): 295 (12) [M<sup>+</sup>], 280 (100), 154 (53), 128 (14), 109 (11), 95 (11), 69 (10), 55 (10). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 3.31-3.00 (m, 1H), 2.35-2.20 (m, 1H), 2.18-2.05 (m, 1H), 1.92-1.49 (m, 3H), 1.47-1.35 (m, 1H), 1.33-1.24 (m, 2H), 1.23-1.09 (m, 9H), 1.09-0.95 (m, 7H), 0.94-0.78 (m, 12H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 78.1 (q), 69.5 (d), 54.8 (d), 52.7 (d), 47.1 (t), 43.7 (t), 36.4 (t), 34.2 (q), 33.0 (d), 32.6 (t), 28.9 (d), 27.1 (s), 26.2 (s), 24.2 (s), 23.6 (s), 22.8 (d), 22.4 (s), 20.4 (s).</p><heading id="h-0212" level="1">Example 205: rac-(3aR,5S,7aR)-1,3,3,5-tetramethyl-5-(3-methylbut-2-en-1-yl)octahydrobenzo[c]isoxazole</heading><p id="p-0608" num="0602">Following the general procedure described in Example 81b: 4,7-dimethyl-4-(3-methylbut-2-en-1-yl)oct-6-enal (0.589 g, 2.145 mmol) (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-methylhydroxylamine hydrochloride (0.269 g, 3.22 mmol), K<sub>2</sub>CO<sub>3 </sub>(0.237 g, 1.716 mmol) in toluene (50 mL) were reacted to give the title product (165 mg, 28% yield) as a light yellow oil.</p><p id="p-0609" num="0603">GC/MS (EI): m/z (%): 251 (55) [M<sup>+</sup>], 236 (100), 180 (18), 166 (23), 139 (21), 124 (56), 86 (69), 69 (26), 55 (17). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) &#x3b4; 5.14 (t, J=7.2 Hz, 1H), 2.59 (s, 3H), 2.15-1.92 (m, 2H), 1.88 (d, J=7.5 Hz, 2H), 1.72-1.58 (m, 4H), 1.54 (s, 3H), 1.48-1.35 (m, 2H), 1.32-1.08 (m, 6H), 1.02 (s, 3H), 0.83 (s, 3H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) &#x3b4; 133.4 (q), 120.3 (d), 79.4 (q), 72.4 (d), 52.7 (d), 44.7 (q), 43.6 (t), 35.9 (t), 35.4 (t), 27.81 (s), 26.11 (s), 25.02 (s), 24.9 (t), 22.97 (s), 17.93 (s).</p><heading id="h-0213" level="1">Example 206: 5-(2,5-dimethoxyphenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole</heading><p id="p-0610" num="0604">The title compound was prepared following the general procedure described in Example 81b: 4-(2,5-dimethoxyphenyl)-2,4,7-trimethyloct-6-enal (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-methylhydroxylamine hydrochloride and K<sub>2</sub>CO<sub>3 </sub>in toluene were reacted to give the title product (mixture of two diastereomers) as a light yellow oil.</p><p id="p-0611" num="0605">GC/MS (Isomer 1) (EI): m/z (%): 333 (55) [M<sup>+</sup>], 246 (75), 178 (100), 163 (21), 151 (17), 138 (25), 126 (23), 96 (8). GC/MS (Isomer 2) (EI): m/z (%): 333 (30) [M<sup>+</sup>], 246 (36), 178 (100), 163 (25), 151 (19), 138 (15), 126 (45), 96 (20).</p><heading id="h-0214" level="1">Example 207: rac-(3aR,5R,7S,7aR)-1,3,3,5,7-pentamethyl-5-(m-tolyl)octahydrobenzo[c]isoxazole</heading><p id="p-0612" num="0606">The title compound was prepared following the general procedure described in Example 81b: 2,4,7-trimethyl-4-(m-tolyl)oct-6-enal (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-methylhydroxylamine hydrochloride and K<sub>2</sub>CO<sub>3 </sub>in toluene were reacted to give the title product as a light yellow oil.</p><p id="p-0613" num="0607">GC/MS (EI): m/z (%): 287 (1) [M<sup>+</sup>], 195 (35), 180 (44), 184 (20), 157 (12), 132 (100), 126 (35), 117 (22), 105 (20), 91 (23).</p><heading id="h-0215" level="1">Example 208: rac-(3aR,5R,7S,7aR)-1-isopropyl-5-(6-methoxypyridin-2-yl)-3,3,5,7-tetramethyloctahydrobenzo[c]isoxazole</heading><p id="p-0614" num="0608">The title compound was prepared following the general procedure described in Example 81b: 4-(6-methoxypyrdin-2-yl)-2,4,7-trimethyloct-6-enal (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a) and N-isopropylhydroxylamine in toluene were reacted to give the title product as a light yellow oil.</p><p id="p-0615" num="0609">GC/MS (EI): m/z (%): 332 (16) [M<sup>+</sup>], 317 (28), 259 (29), 231 (52), 150 (89), 125 (100), 110 (82), 84 (20).</p><heading id="h-0216" level="1">Example 209: 5-(2,4-dimethoxyphenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole</heading><p id="p-0616" num="0610">The title compound was prepared following the general procedure described in Example 81b: 4-(2,4-dimethoxyphenyl)-2,4,7-trimethyloct-6-enal (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-methylhydroxylamine hydrochloride and K<sub>2</sub>CO<sub>3 </sub>in toluene were reacted to give the title product (mixture of two diastereomers) as a light yellow oil.</p><p id="p-0617" num="0611">GC/MS (Isomer 1) (EI): m/z (%): 333 (52) [M<sup>+</sup>], 246 (50), 178 (100), 163 (53), 151 (27), 138 (55), 126 (15), 108 (42). GC/MS (Isomer 2) (EI): m/z (%): 333 (2) [M<sup>+</sup>], 195 (90), 180 (100), 178 (60), 163 (40), 151 (23), 138 (19), 126 (12).</p><heading id="h-0217" level="1">Example 210: 2-methyl-3-(1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazol-5-yl)benzonitrile</heading><p id="p-0618" num="0612">The title compound was prepared following the general procedure described in Example 81 b: 2-methyl-3-(2,4,7-trimethyl-1-oxooct-6-en-4-yl)benzonitrile (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-methylhydroxylamine hydrochloride and K<sub>2</sub>CO<sub>3 </sub>in toluene were reacted to give the title product (mixture of two diastereomers) as a light yellow oil.</p><p id="p-0619" num="0613">GC/MS (Isomer 1) (EI): m/z (%): 312 (56) [M<sup>+</sup>], 210 (20), 144 (32), 126 (100), 113 (32), 98 (55), 87 (95), 68 (27). GC/MS (Isomer 2) (EI): m/z (%): 312 (52) [M<sup>+</sup>], 210 (14), 144 (25), 126 (100), 113 (18), 98 (35), 87 (56), 68 (25).</p><heading id="h-0218" level="1">Example 211: rac-(3aR,5R,7S,7aR)-5-(3,5-dimethoxyphenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole</heading><p id="p-0620" num="0614">The title compound was prepared following the general procedure described in Example 81 b: 4-(3,5-dimethoxyphenyl)-2,4,7-trimethyloct-6-enal (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-methylhydroxylamine hydrochloride and K<sub>2</sub>CO<sub>3 </sub>in toluene were reacted to give the title product as a light yellow oil</p><p id="p-0621" num="0615">GC/MS (EI): m/z (%): 333 (42) [M<sup>+</sup>], 246 (100), 231 (32), 204 (44), 178 (83), 165 (15), 139 (22), 126 (28).</p><heading id="h-0219" level="1">Example 212: 1,3,3,5,7-pentamethyl-5-(pyridin-3-yl)octahydrobenzo[c]isoxazole</heading><p id="p-0622" num="0616">The title compound was prepared following the general procedure described in Example 81 b: 2,4,7-trimethyl-4-(pyridin-3-yl)oct-6-enal (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-methylhydroxylamine hydrochloride and K<sub>2</sub>CO<sub>3 </sub>in toluene were reacted to give the title product (mixture of three diastereomers) as a light yellow oil.</p><p id="p-0623" num="0617">GC/MS (Isomer 1) (EI): m/z (%): 274 (55) [M<sup>+</sup>], 257 (45), 228 (14), 120 (100), 98 (37), 87 (14), 70 (12). GC/MS (Isomer 2) (EI): m/z (%): 274 (15) [M<sup>+</sup>], 273 (69), 228 (12), 120 (100), 98 (18), 91 (12), 68 (22). GC/MS (Isomer 3) (EI): m/z (%): 274 (5) [M<sup>+</sup>], 273 (30), 228 (12), 187 (65), 149 (32), 120 (100), 98 (20).</p><heading id="h-0220" level="1">Example 213: rac-(3aR,5R,7S,7aR)-5-(4-fluoro-2-methoxyphenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole</heading><p id="p-0624" num="0618">The title compound was prepared following the general procedure described in Example 81 b: 4-(4-fluoro-2-methoxyphenyl)-2,4,7-trimethyloct-6-enal (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-methylhydroxylamine hydrochloride and K<sub>2</sub>CO<sub>3 </sub>in toluene were reacted to give the title product (mixture of three diastereomers) as a white solid.</p><p id="p-0625" num="0619">GC/MS (EI): m/z (%): 321 (70) [M<sup>+</sup>], 219 (14), 180 (18), 153 (32), 139 (30), 126 (100), 100 (40), 87 (45).</p><heading id="h-0221" level="1">Example 214: rac-(3aR,5R,7S,7aR)-5-(2,6-dimethylphenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole</heading><p id="p-0626" num="0620">The title compound was prepared following the general procedure described in Example 81 b: 4-(2,6-dimethylphenyl)-2,4,7-trimethyloct-6-enal (obtained from the corresponding &#x3b1;,&#x3b2;-unsaturated aldehyde using the general procedure described in Example 81a), N-methylhydroxylamine hydrochloride and K<sub>2</sub>CO<sub>3 </sub>in toluene were reacted to give the title product as a yellow oil.</p><p id="p-0627" num="0621">GC/MS (EI): m/z (%): 301 (1) [M<sup>+</sup>], 300 (10), 214 (18), 195 (49), 180 (28), 146 (100), 126 (36), 96 (15).</p><heading id="h-0222" level="1">Example 4: Assay on TRPM8 Modulators</heading><p id="p-0628" num="0622">A HEK293 cell line stably expressing hTRPM8 was generated according to Klein et al., (Chem. Senses 36: 649-658, 2011) and receptor activation was monitored by calcium imaging in a Flexstation. For Ca-imaging assays of TRPM8 channel activation, cells were seeded on day 0 at a density of 12000 cells per well in Dulbecco's modified Eagle medium (DMEM) containing 9% foetal bovine serum in black, clear bottom 96-well plates that had been coated with 0.001% polyethyleneimine (molecular weight=60 000, Acros Organics). On day 2, agonists were evaluated via calcium imaging using Fluo-4. Briefly, growth medium was discarded, and the cells were incubated in the dark for 1 h at 37&#xb0; C. in 50 &#x3bc;L loading buffer consisting of 2.7 &#x3bc;M Fluo-4 AM (Invitrogen) and 2.5 &#x3bc;M probenecid (Sigma-Aldrich) in DMEM (without serum). After incubation, the plates were washed five times with 100 &#x3bc;L of assay buffer (in mM: 130 NaCl, 5 KCl, 10 HEPES, 2 CaCl<sub>2</sub>, and 10 glucose, pH7.4.) and further incubated in the dark at room temperature for 30 min. The cells were then washed five times with 100 &#x3bc;L assay buffer and then calcium influx to serial dilutions of inventive compounds were measured in a Flexstation 3 (Molecular Devices). Receptor activation was initiated following addition of 20 &#x3bc;l of a 10-fold concentrated ligand stock solution, which is also prepared in assay buffer. Fluorescence was continuously monitored for 15 seconds prior to ligand addition and for 105 seconds after ligand addition, for a total of 120 seconds. Maximal receptor activation in relation to solvent control and relative to 31.6 &#x3bc;M menthol is determined. Data from serial dilutions were processed with a KNIME workflow to fit a sigmoidal dose-response curve and to extrapolate EC50 values.</p><p id="p-0629" num="0623">TRPM8 agonist exhibiting an EC50 value below 35 &#x3bc;M are presented in Table 1 below.</p><p id="p-0630" num="0000"><tables id="TABLE-US-00001" num="00001"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="1" colwidth="28pt" align="center"/><colspec colname="2" colwidth="175pt" align="left"/><colspec colname="3" colwidth="14pt" align="left"/><thead><row><entry namest="1" nameend="3" rowsep="1">TABLE 1</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row><row><entry>Comp.</entry><entry/><entry/></row><row><entry>No.</entry><entry>Chemical Name</entry><entry>EC50</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row></thead><tbody valign="top"><row><entry/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="1" colwidth="28pt" align="char" char="."/><colspec colname="2" colwidth="175pt" align="left"/><colspec colname="3" colwidth="14pt" align="center"/><tbody valign="top"><row><entry>1</entry><entry>1,3,3,5,7-pentamethyl-5-(3-methylbut-2-en-1-</entry><entry>++</entry></row><row><entry/><entry>yl)octahydrobenzo[c]isoxazole</entry><entry/></row><row><entry>2</entry><entry>1,3,3,5,7-pentamethyl-5-(4-methylpyridin-3-</entry><entry>++</entry></row><row><entry/><entry>yl)octahydrobenzo[c]isoxazole</entry><entry/></row><row><entry>3</entry><entry>1,3,3,5,7-pentamethyl-5-(pyridin-3-yl)octahydrobenzo[c]</entry><entry>+</entry></row><row><entry/><entry>isoxazole</entry><entry/></row><row><entry>4</entry><entry>1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole</entry><entry>+</entry></row><row><entry>5</entry><entry>1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole </entry><entry>+</entry></row><row><entry/><entry>hydrochloride</entry><entry/></row><row><entry>6</entry><entry>1,3,3,6-tetramethyloctahydrobenzo[c]isoxazole</entry><entry>+</entry></row><row><entry>7</entry><entry>1,3,3-trimethyl-6-((R)-4-methylcyclohex-3-en-1-</entry><entry>++</entry></row><row><entry/><entry>yl)octahydrobenzo[c]isoxazole</entry><entry/></row><row><entry>8</entry><entry>1,5,7-trimethylhexahydro-1H-spiro[benzo[c]isoxazole-3,1&#x2032;-</entry><entry>+</entry></row><row><entry/><entry>cyclopentane]</entry><entry/></row><row><entry>9</entry><entry>1-ethyl-3,3,5,7-tetramethyl-5-(3-methylbut-2-en-1-</entry><entry>+++</entry></row><row><entry/><entry>yl)octahydrobenzo[c]isoxazole</entry><entry/></row><row><entry>10</entry><entry>1-isopropyl-3,3,5,7-tetramethyl-5-(3-methylbut-2-en-1-</entry><entry>++</entry></row><row><entry/><entry>yl)octahydrobenzo[c]isoxazole</entry><entry/></row><row><entry>11</entry><entry>1-isopropyl-3,3,5,7-tetramethyloctahydrobenzo[c]isoxazol-</entry><entry>++</entry></row><row><entry/><entry>1-ium chloride</entry><entry/></row><row><entry>12</entry><entry>1-isopropyl-3,3,5,7-tetramethyloctahydrobenzo[c]isoxazole</entry><entry>++</entry></row><row><entry>13</entry><entry>1-isopropyl-5,7-dimethylhexahydro-1H-spiro[benzo[c]</entry><entry>+</entry></row><row><entry/><entry>isoxazole-3,1-cyclopentane]</entry><entry/></row><row><entry>14</entry><entry>2-(1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazol-5-</entry><entry>+++</entry></row><row><entry/><entry>yl)benzonitrile</entry><entry/></row><row><entry>15</entry><entry>2-methyl-3-(1,3,3,5,7-pentamethyloctahydrobenzo[c]</entry><entry>++</entry></row><row><entry/><entry>isoxazol-5-yl)benzonitrile</entry><entry/></row><row><entry>16</entry><entry>5-(2,4-dimethoxyphenyl)-1,3,3,5,7-</entry><entry>++</entry></row><row><entry/><entry>pentamethyloctahydrobenzo[c]isoxazole</entry><entry/></row><row><entry>17</entry><entry>5-(2,5-dimethoxyphenyl)-1,3,3,5,7-</entry><entry>+++</entry></row><row><entry/><entry>pentamethyloctahydrobenzo[c]isoxazole</entry><entry/></row><row><entry>18</entry><entry>5-(6-methoxypyridin-2-yl)-1,3,3,5,7-</entry><entry>++</entry></row><row><entry/><entry>pentamethyloctahydrobenzo[c]isoxazole</entry><entry/></row><row><entry>19</entry><entry>5,7-diethyl-1,3,3-trimethyloctahydrobenzo[c]isoxazole</entry><entry>+</entry></row><row><entry>20</entry><entry>5-ethyl-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole</entry><entry>+</entry></row><row><entry>21</entry><entry>6-isopentyl-1,4,4,8-tetramethyloctahydro-2H-benzo[d][1,3]</entry><entry>+</entry></row><row><entry/><entry>oxazin-2-one</entry><entry/></row><row><entry>22</entry><entry>6-isopentyl-1,4,4,8-tetramethyloctahydro-2H-benzo[d][1,3]</entry><entry>+</entry></row><row><entry/><entry>oxazine</entry><entry/></row><row><entry>23</entry><entry>rac-(3aR,5R,7aR)-1,3,3-trimethyl-5-</entry><entry>++</entry></row><row><entry/><entry>pentyloctahydrobenzo[c]isoxazole</entry><entry/></row><row><entry>24</entry><entry>rac-(3aR,5R,7aR)-1,3,3-trimethyl-5-</entry><entry>++</entry></row><row><entry/><entry>propyloctahydrobenzo[c]isoxazole</entry><entry/></row><row><entry>25</entry><entry>rac-(3aR,5R,7aR)-1-ethyl-3,3-dimethyl-5-</entry><entry>++</entry></row><row><entry/><entry>propyloctahydrobenzo[c]isoxazole</entry><entry/></row><row><entry>26</entry><entry>rac-(3aR,5R,7aR)-1-isopropyl-3,3-dimethyl-5-</entry><entry>++</entry></row><row><entry/><entry>propyloctahydrobenzo[c]isoxazole</entry><entry/></row><row><entry>27</entry><entry>rac-(3aR,5R,7aR)-5-butyl-1,3,3-</entry><entry>++</entry></row><row><entry/><entry>trimethyloctahydrobenzo[c]isoxazole</entry><entry/></row><row><entry>28</entry><entry>rac-(3aR,5R,7aR)-5-butyl-1-ethyl-3,3-</entry><entry>++</entry></row><row><entry/><entry>dimethyloctahydrobenzo[c]isoxazole</entry><entry/></row><row><entry>29</entry><entry>rac-(3aR,5R,7aR)-5-butyl-1-isopropyl-3,3-</entry><entry>+</entry></row><row><entry/><entry>dimethyloctahydrobenzo[c]isoxazole</entry><entry/></row><row><entry>30</entry><entry>rac-(3aR,5R,7aR)-5-ethyl-1-isopropyl-3,3-</entry><entry>+</entry></row><row><entry/><entry>dimethyloctahydrobenzo[c]isoxazole</entry><entry/></row><row><entry>31</entry><entry>rac-(3aR,5R,7R,7aR)-1,3,3,5,7-pentamethyl-5-(2-</entry><entry>+</entry></row><row><entry/><entry>(methylthio)phenyl)octahydrobenzo[c]isoxazole</entry><entry/></row><row><entry>32</entry><entry>rac-(3aR,5R,7R,7aR)-1-ethyl-3,3,5,7-tetramethyl-5-(3-</entry><entry>+</entry></row><row><entry/><entry>methylbut-2-en-1-yl)octahydrobenzo[c]isoxazole</entry><entry/></row><row><entry>33</entry><entry>rac-(3aR,5R,7R,7aR)-1-ethyl-3,3,5,7-tetramethyl-5-(o-</entry><entry>++</entry></row><row><entry/><entry>tolyl)octahydrobenzo[c]isoxazole</entry><entry/></row><row><entry>34</entry><entry>rac-(3aR,5R,7R,7aR)-5-(3-chloro-2-methylphenyl)-</entry><entry>++</entry></row><row><entry/><entry>1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole</entry><entry/></row><row><entry>35</entry><entry>rac-(3aR,5R,7R,7aR)-5-(4-fluoro-2-methylphenyl)-</entry><entry>+</entry></row><row><entry/><entry>1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole</entry><entry/></row><row><entry>36</entry><entry>rac-(3aR,5R,7R,7aR)-5-(4-methoxyphenyl)-1,3,3,5,7-</entry><entry>+</entry></row><row><entry/><entry>pentamethyloctahydrobenzo[c]isoxazole</entry><entry/></row><row><entry>37</entry><entry>rac-(3aR,5R,7S,7aR)-1,3,3,5,7-pentamethyl-5-(2-</entry><entry>+++</entry></row><row><entry/><entry>(methylthio)phenyl)octahydrobenzo[c]isoxazole</entry><entry/></row><row><entry>38</entry><entry>rac-(3aR,5R,7S,7aR)-1,3,3,5,7-pentamethyl-5-(2,4,5-</entry><entry>+++</entry></row><row><entry/><entry>trimethylphenyl)octahydrobenzo[c]isoxazole</entry><entry/></row><row><entry>39</entry><entry>rac-(3aR,5R,7S,7aR)-1,3,3,5,7-pentamethyl-5-(2-methyl-5-</entry><entry>++</entry></row><row><entry/><entry>(trifluoromethyl)phenyl)octahydrobenzo[c]isoxazole</entry><entry/></row><row><entry>40</entry><entry>rac-(3aR,5R,7S,7aR)-1,3,3,5,7-pentamethyl-5-(4-</entry><entry>+++</entry></row><row><entry/><entry>(methylthio)phenyl)octahydrobenzo[c]isoxazole</entry><entry/></row><row><entry>41</entry><entry>rac-(3aR,5R,7S,7aR)-1,3,3,5,7-pentamethyl-5-(5-</entry><entry>++</entry></row><row><entry/><entry>methylthiophen-2-yl)octahydrobenzo[c]isoxazole</entry><entry/></row><row><entry>42</entry><entry>rac-(3aR,5R,7S,7aR)-1,3,3,5,7-pentamethyl-5-(5-</entry><entry>+++</entry></row><row><entry/><entry>methylthiophen-3-yl)octahydrobenzo[c]isoxazole</entry><entry/></row><row><entry>43</entry><entry>rac-(3aR,5R,7S,7aR)-1,3,3,5,7-pentamethyl-5-(m-</entry><entry>+++</entry></row><row><entry/><entry>tolyl)octahydrobenzo[c]isoxazole</entry><entry/></row><row><entry>44</entry><entry>rac-(3aR,5R,7S,7aR)-1,3,3,5,7-pentamethyl-5-</entry><entry>++</entry></row><row><entry/><entry>(naphthalen-1-yl)octahydrobenzo[c]isoxazole</entry><entry/></row><row><entry>45</entry><entry>rac-(3aR,5R,7S,7aR)-1,3,3,5,7-pentamethyl-5-</entry><entry>+++</entry></row><row><entry/><entry>(naphthalen-2-yl)octahydrobenzo[c]isoxazole</entry><entry/></row><row><entry>46</entry><entry>rac-(3aR,5R,7S,7aR)-1,3,3,5,7-pentamethyl-5-(o-</entry><entry>++++</entry></row><row><entry/><entry>tolyl)octahydrobenzo[c]isoxazole</entry><entry/></row><row><entry>47</entry><entry>rac-(3aR,5R,7S,7aR)-1,3,3,5,7-pentamethyl-5-(p-</entry><entry>+++</entry></row><row><entry/><entry>tolyl)octahydrobenzo[c]isoxazole</entry><entry/></row><row><entry>48</entry><entry>rac-(3aR,5R,7S,7aR)-1,3,3,5,7-pentamethyl-5-</entry><entry>+++</entry></row><row><entry/><entry>phenyloctahydrobenzo[c]isoxazole</entry><entry/></row><row><entry>49</entry><entry>rac-(3aR,5R,7S,7aR)-1,3,3,5,7-pentamethyl-5-</entry><entry>++</entry></row><row><entry/><entry>propyloctahydrobenzo[c]isoxazole</entry><entry/></row><row><entry>50</entry><entry>rac-(3aR,5R,7S,7aR)-1,3,3,7-tetramethyl-5-(3-methylbut-</entry><entry>+++</entry></row><row><entry/><entry>2-en-1-yl)octahydrobenzo[c]isoxazole</entry><entry/></row><row><entry>51</entry><entry>rac-(3aR,5R,7S,7aR)-1,3,3,7-tetramethyl-5-(o-</entry><entry>++</entry></row><row><entry/><entry>tolyl)octahydrobenzo[c]isoxazole</entry><entry/></row><row><entry>52</entry><entry>rac-(3aR,5R,7S,7aR)-1,3,3,7-tetramethyl-5-</entry><entry>+++</entry></row><row><entry/><entry>phenyloctahydrobenzo[c]isoxazole</entry><entry/></row><row><entry>53</entry><entry>rac-(3aR,5R,7S,7aR)-1-ethyl-3,3,5,7-tetramethyl-5-(3-</entry><entry>+++</entry></row><row><entry/><entry>methylbut-2-en-1-yl)octahydrobenzo[c]isoxazole</entry><entry/></row><row><entry>54</entry><entry>rac-(3aR,5R,7S,7aR)-1-ethyl-3,3,5,7-tetramethyl-5-(o-</entry><entry>++++</entry></row><row><entry/><entry>tolyl)octahydrobenzo[c]isoxazole</entry><entry/></row><row><entry>55</entry><entry>rac-(3aR,5R,7S,7aR)-1-ethyl-3,3,5,7-tetramethyl-5-</entry><entry>+++</entry></row><row><entry/><entry>phenyloctahydrobenzo[c]isoxazole</entry><entry/></row><row><entry>56</entry><entry>rac-(3aR,5R,7S,7aR)-1-ethyl-3,3,5,7-</entry><entry>+</entry></row><row><entry/><entry>tetramethyloctahydrobenzo[c]isoxazole</entry><entry/></row><row><entry>57</entry><entry>rac-(3aR,5R,7S,7aR)-1-ethyl-5-(2-methoxyphenyl)-3,3,7-</entry><entry>++++</entry></row><row><entry/><entry>trimethyloctahydrobenzo[c]isoxazole</entry><entry/></row><row><entry>58</entry><entry>rac-(3aR,5R,7S,7aR)-1-isopropyl-3,3,5,7-tetramethyl-5-(3-</entry><entry>+++</entry></row><row><entry/><entry>methylbut-2-en-1-yl)octahydrobenzo[c]isoxazole</entry><entry/></row><row><entry>59</entry><entry>rac-(3aR,5R,7S,7aR)-1-isopropyl-3,3,5,7-tetramethyl-5-(o-</entry><entry>+++</entry></row><row><entry/><entry>tolyl)octahydrobenzo[c]isoxazole</entry><entry/></row><row><entry>60</entry><entry>rac-(3aR,5R,7S,7aR)-1-isopropyl-3,3,5,7-tetramethyl-5-</entry><entry>+++</entry></row><row><entry/><entry>phenyloctahydrobenzo[c]isoxazole</entry><entry/></row><row><entry>61</entry><entry>rac-(3aR,5R,7S,7aR)-1-isopropyl-3,3,5,7-tetramethyl-5-</entry><entry>+</entry></row><row><entry/><entry>propyloctahydrobenzo[c]isoxazole</entry><entry/></row><row><entry>62</entry><entry>rac-(3aR,5R,7S,7aR)-1-isopropyl-3,3,7-trimethyl-5-(3-</entry><entry>++</entry></row><row><entry/><entry>methylbut-2-en-1-yl)octahydrobenzo[c]isoxazole</entry><entry/></row><row><entry>63</entry><entry>rac-(3aR,5R,7S,7aR)-1-isopropyl-3,3,7-trimethyl-5-(o-</entry><entry>++</entry></row><row><entry/><entry>tolyl)octahydrobenzo[c]isoxazole</entry><entry/></row><row><entry>64</entry><entry>rac-(3aR,5R,7S,7aR)-1-isopropyl-3,3,7-trimethyl-5-</entry><entry>+++</entry></row><row><entry/><entry>phenyloctahydrobenzo[c]isoxazole</entry><entry/></row><row><entry>65</entry><entry>rac-(3aR,5R,7S,7aR)-1-isopropyl-5-(2-methoxyphenyl)-</entry><entry>+++</entry></row><row><entry/><entry>3,3,5,7-tetramethyloctahydrobenzo[c]isoxazole</entry><entry/></row><row><entry>66</entry><entry>rac-(3aR,5R,7S,7aR)-1-isopropyl-5-(2-methoxyphenyl)-</entry><entry>++++</entry></row><row><entry/><entry>3,3,7-trimethyloctahydrobenzo[c]isoxazole</entry><entry/></row><row><entry>67</entry><entry>rac-(3aR,5R,7S,7aR)-1-isopropyl-5-(4-methoxyphenyl)-</entry><entry>+</entry></row><row><entry/><entry>3,3,5,7-tetramethyloctahydrobenzo[c]isoxazole</entry><entry/></row><row><entry>68</entry><entry>rac-(3aR,5R,7S,7aR)-1-isopropyl-5-(6-methoxypyridin-</entry><entry>++</entry></row><row><entry/><entry>2-yl)-3,3,5,7-tetramethyloctahydrobenzo[c]isoxazole</entry><entry/></row><row><entry>69</entry><entry>rac-(3aR,5R,7S,7aR)-5-(2,3-dimethylphenyl)-1,3,3,5,7-</entry><entry>+++</entry></row><row><entry/><entry>pentamethyloctahydrobenzo[c]isoxazole</entry><entry/></row><row><entry>70</entry><entry>rac-(3aR,5R,7S,7aR)-5-(2,4-difluorophenyl)-1,3,3,5,7-</entry><entry>+++</entry></row><row><entry/><entry>pentamethyloctahydrobenzo[c]isoxazole</entry><entry/></row><row><entry>71</entry><entry>rac-(3aR,5R,7S,7aR)-5-(2,4-dimethylphenyl)-1,3,3,5,7-</entry><entry>+++</entry></row><row><entry/><entry>pentamethyloctahydrobenzo[c]isoxazole</entry><entry/></row><row><entry>72</entry><entry>rac-(3aR,5R,7S,7aR)-5-(2,4-dimethylphenyl)-1,3,3,7-</entry><entry>+++</entry></row><row><entry/><entry>tetramethyloctahydrobenzo[c]isoxazole</entry><entry/></row><row><entry>73</entry><entry>rac-(3aR,5R,7S,7aR)-5-(2,5-difluorophenyl)-1,3,3,5,7-</entry><entry>+++</entry></row><row><entry/><entry>pentamethyloctahydrobenzo[c]isoxazole</entry><entry/></row><row><entry>74</entry><entry>rac-(3aR,5R,7S,7aR)-5-(2,5-dimethylphenyl)-1,3,3,5,7-</entry><entry>++++</entry></row><row><entry/><entry>pentamethyloctahydrobenzo[c]isoxazole</entry><entry/></row><row><entry>75</entry><entry>rac-(3aR,5R,7S,7aR)-5-(2,5-dimethylphenyl)-1,3,3,7-</entry><entry>++</entry></row><row><entry/><entry>tetramethyloctahydrobenzo[c]isoxazole</entry><entry/></row><row><entry>76</entry><entry>rac-(3aR,5R,7S,7aR)-5-(2,6-dimethylphenyl)-1,3,3,5,7-</entry><entry>++</entry></row><row><entry/><entry>pentamethyloctahydrobenzo[c]isoxazole</entry><entry/></row><row><entry>77</entry><entry>rac-(3aR,5R,7S,7aR)-5-(2-ethoxyphenyl)-1,3,3,5,7-</entry><entry>++</entry></row><row><entry/><entry>pentamethyloctahydrobenzo[c]isoxazole</entry><entry/></row><row><entry>78</entry><entry>rac-(3aR,5R,7S,7aR)-5-(2-ethylphenyl)-1,3,3,5,7-</entry><entry>+++</entry></row><row><entry/><entry>pentamethyloctahydrobenzo[c]isoxazole</entry><entry/></row><row><entry>79</entry><entry>rac-(3aR,5R,7S,7aR)-5-(2-ethylphenyl)-1,3,3,7-</entry><entry>+</entry></row><row><entry/><entry>tetramethyloctahydrobenzo[c]isoxazole</entry><entry/></row><row><entry>80</entry><entry>rac-(3aR,5R,7S,7aR)-5-(2-ethylphenyl)-1-isopropyl-3,3,7-</entry><entry>++</entry></row><row><entry/><entry>trimethyloctahydrobenzo[c]isoxazole</entry><entry/></row><row><entry>81</entry><entry>rac-(3aR,5R,7S,7aR)-5-(2-fluorophenyl)-1,3,3,5,7-</entry><entry>+++</entry></row><row><entry/><entry>pentamethyloctahydrobenzo[c]isoxazole</entry><entry/></row><row><entry>82</entry><entry>rac-(3aR,5R,7S,7aR)-5-(2-methoxyphenyl)-1,3,3,5,7-</entry><entry>+++</entry></row><row><entry/><entry>pentamethyloctahydrobenzo[c]isoxazole</entry><entry/></row><row><entry>83</entry><entry>rac-(3aR,5R,7S,7aR)-5-(2-methoxyphenyl)-1,3,3,7-</entry><entry>++++</entry></row><row><entry/><entry>tetramethyloctahydrobenzo[c]isoxazole</entry><entry/></row><row><entry>84</entry><entry>rac-(3aR,5R,7S,7aR)-5-(3,4-difluorophenyl)-1,3,3,5,7-</entry><entry>+++</entry></row><row><entry/><entry>pentamethyloctahydrobenzo[c]isoxazole</entry><entry/></row><row><entry>85</entry><entry>rac-(3aR,5R,7S,7aR)-5-(3,5-difluorophenyl)-1,3,3,5,7-</entry><entry>++++</entry></row><row><entry/><entry>pentamethyloctahydrobenzo[c]isoxazole</entry><entry/></row><row><entry>86</entry><entry>rac-(3aR,5R,7S,7aR)-5-(3,5-dimethoxyphenyl)-1,3,3,5,7-</entry><entry>+</entry></row><row><entry/><entry>pentamethyloctahydrobenzo[c]isoxazole</entry><entry/></row><row><entry>87</entry><entry>rac-(3aR,5R,7S,7aR)-5-(3,5-dimethylphenyl)-1,3,3,5,7-</entry><entry>++</entry></row><row><entry/><entry>pentamethyloctahydrobenzo[c]isoxazole</entry><entry/></row><row><entry>88</entry><entry>rac-(3aR,5R,7S,7aR)-5-(3,5-dimethylphenyl)-1-isopropyl-</entry><entry>++</entry></row><row><entry/><entry>3,3,5,7-tetramethyloctahydrobenzo[c]isoxazole</entry><entry/></row><row><entry>89</entry><entry>rac-(3aR,5R,7S,7aR)-5-(3-chloro-2-methylphenyl)-</entry><entry>+++</entry></row><row><entry/><entry>1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole</entry><entry/></row><row><entry>90</entry><entry>rac-(3aR,5R,7S,7aR)-5-(3-chloro-2-methylphenyl)-1-</entry><entry>+++</entry></row><row><entry/><entry>isopropyl-3,3,7-trimethyloctahydrobenzo[c]isoxazole</entry><entry/></row><row><entry>91</entry><entry>rac-(3aR,5R,7S,7aR)-5-(3-fluoro-5-(trifluoromethyl)</entry><entry>++</entry></row><row><entry/><entry>phenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole</entry><entry/></row><row><entry>92</entry><entry>rac-(3aR,5R,7S,7aR)-5-(3-fluorophenyl)-1,3,3,5,7-</entry><entry>+++</entry></row><row><entry/><entry>pentamethyloctahydrobenzo[c]isoxazole</entry><entry/></row><row><entry>93</entry><entry>rac-(3aR,5R,7S,7aR)-5-(3-isopropylphenyl)-1,3,3,5,7-</entry><entry>+</entry></row><row><entry/><entry>pentamethyloctahydrobenzo[c]isoxazole</entry><entry/></row><row><entry>94</entry><entry>rac-(3aR,5R,7S,7aR)-5-(3-methoxyphenyl)-1,3,3,5,7-</entry><entry>+++</entry></row><row><entry/><entry>pentamethyloctahydrobenzo[c]isoxazole</entry><entry/></row><row><entry>95</entry><entry>rac-(3aR,5R,7S,7aR)-5-(4-(tert-butyl)phenyl)-1,3,3,5,7-</entry><entry>+</entry></row><row><entry/><entry>pentamethyloctahydrobenzo[c]isoxazole</entry><entry/></row><row><entry>96</entry><entry>rac-(3aR,5R,7S,7aR)-5-(4-(tert-butyl)phenyl)-1,3,3,7-</entry><entry>+</entry></row><row><entry/><entry>tetramethyloctahydrobenzo[c]isoxazole</entry><entry/></row><row><entry>97</entry><entry>rac-(3aR,5R,7S,7aR)-5-(4-(tert-butyl)phenyl)-1-isopropyl-</entry><entry>+</entry></row><row><entry/><entry>3,3,7-trimethyloctahydrobenzo[c]isoxazole</entry><entry/></row><row><entry>98</entry><entry>rac-(3aR,5R,7S,7aR)-5-(4-chloro-2-methylphenyl)-1-</entry><entry>+++</entry></row><row><entry/><entry>isopropyl-3,3,7-trimethyloctahydrobenzo[c]isoxazole</entry><entry/></row><row><entry>99</entry><entry>rac-(3aR,5R,7S,7aR)-5-(4-fluoro-2-methoxyphenyl)-1,3,</entry><entry>++++</entry></row><row><entry/><entry>3,5,7-pentamethyloctahydrobenzo[c]isoxazole</entry><entry/></row><row><entry>100</entry><entry>rac-(3aR,5R,7S,7aR)-5-(4-fluoro-2-methylphenyl)-1,3,3,</entry><entry>++++</entry></row><row><entry/><entry>5,7-pentamethyloctahydrobenzo[c]isoxazole</entry><entry/></row><row><entry>101</entry><entry>rac-(3aR,5R,7S,7aR)-5-(4-fluoro-2-methylphenyl)-1,3,3,7-</entry><entry>+++</entry></row><row><entry/><entry>tetramethyloctahydrobenzo[c]isoxazole</entry><entry/></row><row><entry>102</entry><entry>rac-(3aR,5R,7S,7aR)-5-(4-fluorophenyl)-1,3,3,5,7-</entry><entry>++++</entry></row><row><entry/><entry>pentamethyloctahydrobenzo[c]isoxazole</entry><entry/></row><row><entry>103</entry><entry>rac-(3aR,5R,7S,7aR)-5-(4-fluorophenyl)-1-isopropyl-3,3,</entry><entry>++++</entry></row><row><entry/><entry>5,7-tetramethyloctahydrobenzo[c]isoxazole</entry><entry/></row><row><entry>104</entry><entry>rac-(3aR,5R,7S,7aR)-5-(4-methoxyphenyl)-1,3,3,5,7-</entry><entry>++</entry></row><row><entry/><entry>pentamethyloctahydrobenzo[c]isoxazole</entry><entry/></row><row><entry>105</entry><entry>rac-(3aR,5R,7S,7aR)-5-(5-chloro-2-methylphenyl)-1,3,3,</entry><entry>++++</entry></row><row><entry/><entry>5,7-pentamethyloctahydrobenzo[c]isoxazole</entry><entry/></row><row><entry>106</entry><entry>rac-(3aR,5R,7S,7aR)-5-(5-chloro-2-methylphenyl)-1-</entry><entry>++</entry></row><row><entry/><entry>isopropyl-3,3,7-trimethyloctahydrobenzo[c]isoxazole</entry><entry/></row><row><entry>107</entry><entry>rac-(3aR,5R,7S,7aR)-5-(5-fluoro-2-methylphenyl)-1,3,3,</entry><entry>++++</entry></row><row><entry/><entry>5,7-pentamethyloctahydrobenzo[c]isoxazole</entry><entry/></row><row><entry>108</entry><entry>rac-(3aR,5R,7S,7aR)-5-(5-fluoro-2-methylphenyl)-1,3,3,7-</entry><entry>++</entry></row><row><entry/><entry>tetramethyloctahydrobenzo[c]isoxazole</entry><entry/></row><row><entry>109</entry><entry>rac-(3aR,5R,7S,7aR)-5-(benzo[d][1,3]dioxol-5-yl)-1,3,3,</entry><entry>++</entry></row><row><entry/><entry>5,7-pentamethyloctahydrobenzo[c]isoxazole</entry><entry/></row><row><entry>110</entry><entry>rac-(3aR,5R,7S,7aR)-5-(furan-3-yl)-1,3,3,5,7-</entry><entry>++</entry></row><row><entry/><entry>pentamethyloctahydrobenzo[c]isoxazole</entry><entry/></row><row><entry>111</entry><entry>rac-(3aR,5R,7S,7aR)-5,7-diethyl-1-isopropyl-3,3-</entry><entry>++</entry></row><row><entry/><entry>dimethyloctahydrobenzo[c]isoxazole</entry><entry/></row><row><entry>112</entry><entry>rac-(3aR,5R,S,7aR)-5-isopentyl-1-isopropyl-3,3,5,7-</entry><entry>+++</entry></row><row><entry/><entry>tetramethyloctahydrobenzo[c]isoxazole</entry><entry/></row><row><entry>113</entry><entry>rac-(3aR,5S,7aR)-1,3,3,5-tetramethyl-5-(3-methylbut-2-</entry><entry>++</entry></row><row><entry/><entry>en-1-yl)octahydrobenzo[c]isoxazole</entry><entry/></row><row><entry>114</entry><entry>rac-(3aR,7aR)-1,3,3,4,5,7-hexamethyloctahydrobenzo[c]</entry><entry>+</entry></row><row><entry/><entry>isoxazole</entry><entry/></row><row><entry>115</entry><entry>rac-(3aR,7aR)-1,3,3-trimethyl-6-phenyloctahydrobenzo</entry><entry>+</entry></row><row><entry/><entry>[c]isoxazole</entry><entry/></row><row><entry>116</entry><entry>rac-(3aR,7aR)-1,5,7-triethyl-3,3-</entry><entry>+</entry></row><row><entry/><entry>dimethyloctahydrobenzo[c]isoxazole</entry><entry/></row><row><entry>117</entry><entry>rac-(3aR,7aS)-1,3,3,4,5,7-hexamethyloctahydrobenzo[c]</entry><entry>+</entry></row><row><entry/><entry>isoxazole</entry><entry/></row><row><entry>118</entry><entry>rac-(3aR,7S,7aR)-5,5-diethyl-1,3,3,7-</entry><entry>+</entry></row><row><entry/><entry>tetramethyloctahydrobenzo[c]isoxazole</entry><entry/></row><row><entry>119</entry><entry>rac-(3aS,5R,7S,7aS)-5-(4-fluorophenyl)-1,3,3,5,7-</entry><entry>++</entry></row><row><entry/><entry>pentamethyloctahydrobenzo[c]isoxazole</entry><entry/></row><row><entry>120</entry><entry>rac-(3aS,5S,7S,7aS)-1-ethyl-3,3,7-trimethy)-5-(3-methylbut-</entry><entry>++</entry></row><row><entry/><entry>2-en-1-yl)octahydrobenzo[c]isoxazole</entry><entry/></row><row><entry>121</entry><entry>rac-2-chloro-5-((3aR,5R,7S,7aR)-1,3,3,5,7-</entry><entry>++++</entry></row><row><entry/><entry>pentamethyloctahydrobenzo[c]isoxazol-5-yl)benzonitrile</entry><entry/></row><row><entry>122</entry><entry>rac-2-chloro-5-((3aS,5R,7R,7aS)-1,3,3,5,7-</entry><entry>+</entry></row><row><entry/><entry>pentamethyloctahydrobenzo[c]isoxazol-5-yl)benzonitrile</entry><entry/></row><row><entry>123</entry><entry>rac-2-methyl-5-((3aR,5R,7S,7aR)-1,3,3,5,7-</entry><entry>+++</entry></row><row><entry/><entry>pentamethyloctahydrobenzo[c]isoxazol-5-yl)benzonitrile</entry><entry/></row><row><entry>124</entry><entry>rac-3-((3aR,5R,7S,7aR)-1,3,3,5,7-</entry><entry>++++</entry></row><row><entry/><entry>pentamethyloctahydrobenzo[c]isoxazol-5-yl)benzonitrile</entry><entry/></row><row><entry>125</entry><entry>rac-3-((3aR,5R,7S,7aR)-1-ethyl-3,3,5,7-</entry><entry>++++</entry></row><row><entry/><entry>tetramethyloctahydrobenzo[c]isoxazol-5-yl)-4-</entry><entry/></row><row><entry/><entry>methylbenzonitrile</entry><entry/></row><row><entry>126</entry><entry>rac-3-((3aR,5R,7S,7aR)-1-isopropyl-3,3,5,7-</entry><entry>+++</entry></row><row><entry/><entry>tetramethyloctahydrobenzo[c]isoxazol-5-yl)-4-</entry><entry/></row><row><entry/><entry>methylbenzonitrile</entry><entry/></row><row><entry>127</entry><entry>rac-3-((3aR,5R,7S,7aR)-1-isopropyl-3,3,5,7-</entry><entry>++++</entry></row><row><entry/><entry>tetramethyloctahydrobenzo[c]isoxazol-5-yl)benzonitrile</entry><entry/></row><row><entry>128</entry><entry>rac-3-((3aR,5R,7S,7aR)-1-isopropyl-3,3,7-</entry><entry>++++</entry></row><row><entry/><entry>trimethyloctahydrobenzo[c]isoxazol-5-yl)-4-</entry><entry/></row><row><entry/><entry>methoxybenzonitrile</entry><entry/></row><row><entry>129</entry><entry>rac-3-chloro-5-((3aR,5R,7S,7aR)-1,3,3,5,7-</entry><entry>++++</entry></row><row><entry/><entry>pentamethyloctahydrobenzo[c]isoxazol-5-yl)benzonitrile</entry><entry/></row><row><entry>130</entry><entry>rac-3-methyl-4-((3aR,5R,7S,7aR)-1,3,3,5,7-</entry><entry>+++</entry></row><row><entry/><entry>pentamethyloctahydrobenzo[c]isoxazol-5-yl)benzonitrile</entry><entry/></row><row><entry>131</entry><entry>rac-4-((3aR,5R,7S,7aR)-1,3,3,5,7-</entry><entry>+++</entry></row><row><entry/><entry>pentamethyloctahydrobenzo[c]isoxazol-5-yl)benzonitrile</entry><entry/></row><row><entry>132</entry><entry>rac-4-methoxy-3-((3aR,5R,7R,7aR)-1,3,3,5,7-</entry><entry>++</entry></row><row><entry/><entry>pentamethyloctahydrobenzo[c]isoxazol-5-yl)benzonitrile</entry><entry/></row><row><entry>133</entry><entry>rac-4-methoxy-3-((3aR,5R,7S,7aR)-1,3,3,5,7-</entry><entry>++++</entry></row><row><entry/><entry>pentamethyloctahydrobenzo[c]isoxazol-5-yl)benzonitrile</entry><entry/></row><row><entry>134</entry><entry>rac-4-methyl-2-((3aR,5R,7S,7aR)-1,3,3,5,7-</entry><entry>+++</entry></row><row><entry/><entry>pentamethyloctahydrobenzo[c]isoxazol-5-yl)benzonitrile</entry><entry/></row><row><entry>135</entry><entry>rac-4-methyl-3-((3aR,5R,7S,7aR)-1,3,3,5,7-</entry><entry>++++</entry></row><row><entry/><entry>pentamethyloctahydrobenzo[c]isoxazol-5-yl)benzonitrile</entry><entry/></row><row><entry>136</entry><entry>rac-4-methyl-3-((3aR,5R,7S,7aR)-1,3,3,7-</entry><entry>+++</entry></row><row><entry/><entry>tetramethyloctahydrobenzo[c]isoxazol-5-yl)benzonitrile</entry><entry/></row><row><entry>137</entry><entry>rac-methyl 4-methyl-3-((3aR,5R,7S,7aR)-1,3,3,5,7-</entry><entry>+++</entry></row><row><entry/><entry>pentamethyloctahydrobenzo[c]isoxazol-5-yl)benzoate</entry><entry/></row><row><entry>138</entry><entry>rel-4-methyl-3-((3aR,5R,7S,7aR)-1,3,3,5,7-</entry><entry>++++</entry></row><row><entry/><entry>pentamethyloctahydrobenzo[c]isoxazol-5-yl)benzonitrile</entry><entry/></row><row><entry>139</entry><entry>rel-4-methyl-3-((3aS,5S,7R,7aS)-1,3,3,5,7-</entry><entry>+++</entry></row><row><entry/><entry>pentamethyloctahydrobenzo[c]isoxazol-5-yl)benzonitrile</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row><row><entry namest="1" nameend="3" align="left" id="FOO-00001">++++ EC<sub>50 </sub>Value in the range of 0.05 &#x3bc;M and lower</entry></row><row><entry namest="1" nameend="3" align="left" id="FOO-00002">+++ EC<sub>50 </sub>value in the range of 0.05-0.3 &#x3bc;M</entry></row><row><entry namest="1" nameend="3" align="left" id="FOO-00003">++ EC<sub>50 </sub>value in the range of 0.3-1.00 &#x3bc;M</entry></row><row><entry namest="1" nameend="3" align="left" id="FOO-00004">+ EC<sub>50 </sub>value in the range of 1.00-35 &#x3bc;M</entry></row></tbody></tgroup></table></tables></p><heading id="h-0223" level="1">Example 5: Sensory Studies in Aqueous Solution</heading><p id="p-0631" num="0624">The compounds as listed below in Table 2 were dissolved at a concenteration of 1 wt-% in propylene glycol. These solutions were then dispensed in appropriate quantities into deionized water containing 0.5 wt-% Poloxamer 407 (which is a hydrophilic non-ionic surfactant, e.g., commercially available from SigmaAldrich) and 0.25 wt-% Cremaphor&#xae; RH40 (obtained from BASF) as solubilizer, to obtain the desired final concentration of 40 ppm (parts per milion) of the respective compound.</p><p id="p-0632" num="0625">A trained group of panelists evaluated the aqueous solutions containing test compound by swilling 20 mL of the solution in the mouth for 60 seconds, followed by spitting, without rinsing the mouth afterwards for the duration of the evaluation. Panelists evaluated and recorded the cooling performance as well as other sensorial and organoleptic attributes at different timepoints over a period of two hours. Cooling performance was rated on a scale from 0 to 10 with 0 being no effect and 10 being freezing. Scores were averaged for all panelists and the cooling intensity qualified as &#x201c;N&#x201d; for &#x201c;none&#x201d; (score of 0), &#x201c;L&#x201d; for &#x201c;low&#x201d; (score above 0, up to 1), &#x201c;M&#x201d; for &#x201c;medium&#x201d; (score above 1, up to 4), &#x201c;S&#x201d; for &#x201c;strong&#x201d; (score above 4, up to 8) and &#x201c;E&#x201d; for &#x201c;extreme&#x201d; (score above 8), which are provided in Table 2. None of the tested compounds showed any statistically significant bitterness or negative organoleptic features. All tasted samples developed cooling sensation starting during swilling (almost immediately upon contact with the mucosa) and before expectorating.</p><p id="p-0633" num="0000"><tables id="TABLE-US-00002" num="00002"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="1" colwidth="28pt" align="left"/><colspec colname="2" colwidth="126pt" align="left"/><colspec colname="3" colwidth="42pt" align="center"/><colspec colname="4" colwidth="21pt" align="center"/><thead><row><entry namest="1" nameend="4" rowsep="1">TABLE 2</entry></row><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row><row><entry/><entry/><entry>Max. cooling</entry><entry>Cool-</entry></row><row><entry/><entry/><entry>(time of max</entry><entry>ing</entry></row><row><entry>Comp.</entry><entry/><entry>cooling in</entry><entry>after</entry></row><row><entry>No.</entry><entry>Chemical Name</entry><entry>minutes)</entry><entry>1 h</entry></row><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row></thead><tbody valign="top"><row><entry/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="1" colwidth="28pt" align="char" char="."/><colspec colname="2" colwidth="126pt" align="left"/><colspec colname="3" colwidth="42pt" align="center"/><colspec colname="4" colwidth="21pt" align="center"/><tbody valign="top"><row><entry>12</entry><entry>1-isopropyl-3,3,5,7-</entry><entry>M (5)&#x2002;</entry><entry>L</entry></row><row><entry/><entry>tetramethyloctahydrobenzo[c]isoxazole</entry><entry/><entry/></row><row><entry>4</entry><entry>1,3,3,5,7-</entry><entry>M (3)&#x2002;</entry><entry>L</entry></row><row><entry/><entry>pentamethyloctahydrobenzo[c]isoxazole</entry><entry/><entry/></row><row><entry>50</entry><entry>rac-(3aR,5R,7S,7aR)-1,3,3,7-tetramethyl-</entry><entry>M (10)</entry><entry>M</entry></row><row><entry/><entry>5-(3-methylbut-2-en-1-</entry><entry/><entry/></row><row><entry/><entry>yl)octahydrobenzo[c]isoxazole</entry><entry/><entry/></row><row><entry>26</entry><entry>rac-(3aR,5R,7aR)-1-isopropyl-3,3-</entry><entry>S (10)</entry><entry>M</entry></row><row><entry/><entry>dimethyl-5-propyloctahydrobenzo[c]</entry><entry/><entry/></row><row><entry/><entry>isoxazole</entry><entry/><entry/></row><row><entry>1</entry><entry>1,3,3,5,7-pentamethyl-5-(3-methylbut-2-</entry><entry>M (20)</entry><entry>M</entry></row><row><entry/><entry>en-1-yl)octahydrobenzo[c]isoxazole</entry><entry/><entry/></row><row><entry>9</entry><entry>1-ethyl-3,3,5,7-tetramethyl-5-(3-methylbut-</entry><entry>M (10)</entry><entry>M</entry></row><row><entry/><entry>2-en-1-yl)octahydrobenzo[c]isoxazole</entry><entry/><entry/></row><row><entry>64</entry><entry>rac-(3aR,5R,7S,7aR)-1-isopropyl-3,3,7-</entry><entry>M (10)</entry><entry>M</entry></row><row><entry/><entry>trimethyl-5-phenyloctahydrobenzo[c]</entry><entry/><entry/></row><row><entry/><entry>isoxazole</entry><entry/><entry/></row><row><entry>48</entry><entry>rac-(3aR,5R,7S,7aR)-1,3,3,5,7-</entry><entry>S (10)</entry><entry>M</entry></row><row><entry/><entry>pentamethyl-5-phenyloctahydrobenzo[c]</entry><entry/><entry/></row><row><entry/><entry>isoxazole</entry><entry/><entry/></row><row><entry>46</entry><entry>rac-(3aR,5R,7S,7aR)-1,3,3,5,7-</entry><entry>S (10)</entry><entry>M</entry></row><row><entry/><entry>pentamethyl-5-(o-tolyl)octahydrobenzo[c]</entry><entry/><entry/></row><row><entry/><entry>isoxazole</entry><entry/><entry/></row><row><entry>135</entry><entry>rac-4-methyl-3-((3aR,5R,7S,7aR)-</entry><entry>E (10)</entry><entry>M</entry></row><row><entry/><entry>1,3,3,5,7-pentamethyloctahydrobenzo[c]</entry><entry/><entry/></row><row><entry/><entry>isoxazol-5-yl)benzonitrile</entry><entry/><entry/></row><row><entry>124</entry><entry>rac-3-((3aR,5R,7S,7aR)-1,3,3,5,7-</entry><entry>S (5)&#x2002;</entry><entry>M</entry></row><row><entry/><entry>pentamethyloctahydrobenzo[c]isoxazol-5-</entry><entry/><entry/></row><row><entry/><entry>yl)benzonitrile</entry><entry/><entry/></row><row><entry>120</entry><entry>rac-(3aS,5S,7S,7aS)-1-ethyl-3,3,7-</entry><entry>M (10)</entry><entry>L</entry></row><row><entry/><entry>trimethyl-5-(3-methylbut-2-en-1-</entry><entry/><entry/></row><row><entry/><entry>yl)octahydrobenzo[c]isoxazole</entry><entry/><entry/></row><row><entry>111</entry><entry>rac-(3aR,5R,7S,7aR)-5,7-diethyl-1-</entry><entry>M (10)</entry><entry>L</entry></row><row><entry/><entry>isopropyl-3,3-dimethyloctahydrobenzo[c]</entry><entry/><entry/></row><row><entry/><entry>isoxazole</entry><entry/><entry/></row><row><entry>85</entry><entry>rac-(3aR,5R,7S,7aR)-5-(3,5-</entry><entry>M (10)</entry><entry>M</entry></row><row><entry/><entry>difluorophenyl)-1,3,3,5,7-</entry><entry/><entry/></row><row><entry/><entry>pentamethyloctahydrobenzo[c]isoxazole</entry><entry/><entry/></row><row><entry>83</entry><entry>rac-(3aR,5R,7S,7aR)-5-(2-methoxy-</entry><entry>S (10)</entry><entry>L</entry></row><row><entry/><entry>phenyl)-1,3,3,7-tetramethyloctahydrobenzo</entry><entry/><entry/></row><row><entry/><entry>[c]isoxazole</entry><entry/><entry/></row><row><entry>66</entry><entry>rac-(3aR,5R,7S,7aR)-1-isopropyl-5-(2-</entry><entry>M (20)</entry><entry>M</entry></row><row><entry/><entry>methoxyphenyl)-3,3,7-</entry><entry/><entry/></row><row><entry/><entry>trimethyloctahydrobenzo[c]isoxazole</entry><entry/><entry/></row><row><entry>102</entry><entry>rac-(3aR,5R,7S,7aR)-5-(4-fluorophenyl)-</entry><entry>S (10)</entry><entry>M</entry></row><row><entry/><entry>1,3,3,5,7-</entry><entry/><entry/></row><row><entry/><entry>pentamethyloctahydrobenzo[c]isoxazole</entry><entry/><entry/></row><row><entry>7</entry><entry>1,3,3-trimethyl-6-(4-methylcyclohex-3-</entry><entry>M (10)</entry><entry>L</entry></row><row><entry/><entry>en-1-yl)octahydrobenzo[c]isoxazole</entry></row><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><heading id="h-0224" level="1">Example 6: Sensory Studies in Model Dentifrice</heading><p id="p-0634" num="0626">The compounds listed in Table 3 were dissolved at a concenteration of 1 wt-% in propylene glycol. These solutions were then dispersed in appropriate quantities to obtain the desired final concentration of 100 ppm (parts per milion) of the test compound into a model, unflavored dentifrice, the formula of which is given below (ingredients obtained from the suppliers respectively indicated in parenthesis).</p><p id="p-0635" num="0000"><tables id="TABLE-US-00003" num="00003"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="offset" colwidth="14pt" align="left"/><colspec colname="1" colwidth="161pt" align="center"/><colspec colname="2" colwidth="42pt" align="center"/><thead><row><entry/><entry namest="offset" nameend="2" align="center" rowsep="1"/></row><row><entry/><entry/><entry>wt %</entry></row><row><entry/><entry namest="offset" nameend="2" align="center" rowsep="1"/></row></thead><tbody valign="top"><row><entry/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="offset" colwidth="14pt" align="left"/><colspec colname="1" colwidth="161pt" align="left"/><colspec colname="2" colwidth="42pt" align="char" char="."/><tbody valign="top"><row><entry/><entry>Trisodium Phosphate dodecahydrate</entry><entry>0.2</entry></row><row><entry/><entry>Sorbitol</entry><entry>50.0</entry></row><row><entry/><entry>Precipitated Silica-Sorbosil&#x2009;&#x2122; AC77 (Surfachem)</entry><entry>8.0</entry></row><row><entry/><entry>Precipitated Silica-Sorbosil&#x2009;&#x2122; TC15 (Surfachem)</entry><entry>9.0</entry></row><row><entry/><entry>Sodium Carboxy Methyl Cellulose 9M31XF (Ashland)</entry><entry>0.8</entry></row><row><entry/><entry>Titanium Dioxide</entry><entry>1.0</entry></row><row><entry/><entry>Sodium Lauryl Sulphate</entry><entry>1.5</entry></row><row><entry/><entry>PEG 1500 (Kilo)</entry><entry>5.0</entry></row><row><entry/><entry>Demin Water</entry><entry>24.5</entry></row><row><entry/><entry namest="offset" nameend="2" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0636" num="0627">A trained group of panelists evaluated the dentifrice containing a compound of formula (I), by brushing their teeth with 1 g of the dentifrice using a toothbrush for 60 seconds, followed by spitting, without rinsing the mouth afterwards for the duration of the evaluation. Panelists evaluated and recorded the cooling performance as well as other sensorial and organoleptic attributes at different timepoints over a period of two hours. Cooling performance was rated on a scale from 0 to 10 with 0 being no effect and 10 being freezing. Scores were averaged for all panelists and the cooling intensity qualified as &#x201c;N&#x201d; for &#x201c;none&#x201d; (score of 0), &#x201c;L&#x201d; for &#x201c;low&#x201d; (score above 0, up to 1), &#x201c;M&#x201d; for &#x201c;medium&#x201d; (score above 1, up to 4), &#x201c;S&#x201d; for &#x201c;strong&#x201d; (score above 4, up to 8) and &#x201c;E&#x201d; for &#x201c;extreme&#x201d; (score above 8), which are summarized below in Table 3. None of the tested compounds showed any statistically significant bitterness or negative organoleptic features. All tasted samples developed cooling sensation starting during brushing, before expectorating.</p><p id="p-0637" num="0000"><tables id="TABLE-US-00004" num="00004"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="1" colwidth="35pt" align="left"/><colspec colname="2" colwidth="119pt" align="left"/><colspec colname="3" colwidth="42pt" align="center"/><colspec colname="4" colwidth="21pt" align="center"/><thead><row><entry namest="1" nameend="4" rowsep="1">TABLE 3</entry></row><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row><row><entry/><entry/><entry>Max. cooling</entry><entry>Cool-</entry></row><row><entry/><entry/><entry>(time of max</entry><entry>ing</entry></row><row><entry>Comp.</entry><entry/><entry>cooling in</entry><entry>after</entry></row><row><entry>No.</entry><entry>Chemical Name</entry><entry>minutes)</entry><entry>1 h</entry></row><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row></thead><tbody valign="top"><row><entry/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="1" colwidth="35pt" align="char" char="."/><colspec colname="2" colwidth="119pt" align="left"/><colspec colname="3" colwidth="42pt" align="center"/><colspec colname="4" colwidth="21pt" align="center"/><tbody valign="top"><row><entry>48</entry><entry>rac-(3aR,5R,7S,7aR)-1,3,3,5,7-</entry><entry>M (5)&#x2002;</entry><entry>L</entry></row><row><entry/><entry>pentamethyl-5-phenyloctahydrobenzo</entry><entry/><entry/></row><row><entry/><entry>[c]isoxazole</entry><entry/><entry/></row><row><entry>46</entry><entry>rac-(3aR,5R,7S,7aR)-1,3,3,5,7-</entry><entry>S (20)</entry><entry>M</entry></row><row><entry/><entry>pentamethyl-5-(o-tolyl)octahydrobenzo</entry><entry/><entry/></row><row><entry/><entry>[c]isoxazole</entry><entry/><entry/></row><row><entry>135</entry><entry>rac-4-methyl-3-((3aR,5R,7S,7aR)-</entry><entry>S (5)&#x2002;</entry><entry>M</entry></row><row><entry/><entry>1,3,3,5,7-pentamethyloctahydrobenzo[c]</entry><entry/><entry/></row><row><entry/><entry>isoxazol-5-yl)benzonitrile</entry><entry/><entry/></row><row><entry>102</entry><entry>rac-(3aR,5R,7S,7aR)-5-(4-fluorophenyl)-</entry><entry>M (10)</entry><entry>M</entry></row><row><entry/><entry>1,3,3,5,7-</entry><entry/><entry/></row><row><entry/><entry>pentamethyloctahydrobenzo[c]isoxazole</entry></row><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><?detailed-description description="Detailed Description" end="tail"?></description><us-chemistry idref="CHEM-US-00001" cdx-file="US20230002334A1-20230105-C00001.CDX" mol-file="US20230002334A1-20230105-C00001.MOL"/><us-chemistry idref="CHEM-US-00002" cdx-file="US20230002334A1-20230105-C00002.CDX" mol-file="US20230002334A1-20230105-C00002.MOL"/><us-chemistry idref="CHEM-US-00003" cdx-file="US20230002334A1-20230105-C00003.CDX" mol-file="US20230002334A1-20230105-C00003.MOL"/><us-chemistry idref="CHEM-US-00004" cdx-file="US20230002334A1-20230105-C00004.CDX" mol-file="US20230002334A1-20230105-C00004.MOL"/><us-chemistry idref="CHEM-US-00005" cdx-file="US20230002334A1-20230105-C00005.CDX" mol-file="US20230002334A1-20230105-C00005.MOL"/><us-chemistry idref="CHEM-US-00006" cdx-file="US20230002334A1-20230105-C00006.CDX" mol-file="US20230002334A1-20230105-C00006.MOL"/><us-chemistry idref="CHEM-US-00007" cdx-file="US20230002334A1-20230105-C00007.CDX" mol-file="US20230002334A1-20230105-C00007.MOL"/><us-chemistry idref="CHEM-US-00008" cdx-file="US20230002334A1-20230105-C00008.CDX" mol-file="US20230002334A1-20230105-C00008.MOL"/><us-chemistry idref="CHEM-US-00009" cdx-file="US20230002334A1-20230105-C00009.CDX" mol-file="US20230002334A1-20230105-C00009.MOL"/><us-chemistry idref="CHEM-US-00010" cdx-file="US20230002334A1-20230105-C00010.CDX" mol-file="US20230002334A1-20230105-C00010.MOL"/><us-chemistry idref="CHEM-US-00011" cdx-file="US20230002334A1-20230105-C00011.CDX" mol-file="US20230002334A1-20230105-C00011.MOL"/><us-chemistry idref="CHEM-US-00012" cdx-file="US20230002334A1-20230105-C00012.CDX" mol-file="US20230002334A1-20230105-C00012.MOL"/><us-chemistry idref="CHEM-US-00013" cdx-file="US20230002334A1-20230105-C00013.CDX" mol-file="US20230002334A1-20230105-C00013.MOL"/><claims id="claims"><claim id="CLM-00001" num="00001"><claim-text><b>1</b>. A method of modulating of transient receptor potential channel melastatin member 8 (TRPM8) comprising bringing the receptor into contact with a compound of formula (I), a salt or solvate thereof</claim-text><claim-text><chemistry id="CHEM-US-00008" num="00008"><img id="EMI-C00008" he="28.36mm" wi="56.39mm" file="US20230002334A1-20230105-C00008.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry><claim-text>wherein</claim-text><claim-text>X is O and the dotted line represents a single bond;</claim-text><claim-text>or</claim-text><claim-text>X is selected from CR<sup>3 </sup>and NR<sup>3</sup>,</claim-text><claim-text>wherein R<sup>3 </sup>is selected from hydrogen, C<sub>1</sub>-C<sub>6 </sub>alkyl, C<sub>1</sub>-C<sub>7 </sub>alkyl substituted with one or two OH groups, C<sub>3</sub>-C<sub>7 </sub>cycloalkyl, C<sub>3</sub>-C<sub>7 </sub>cycloalkyl substituted with one or two OH groups, C<sub>5</sub>-C<sub>7 </sub>cycloalkenyl, C<sub>5</sub>-C<sub>7 </sub>cycloalkenyl substituted with one, two or three C<sub>1</sub>-C<sub>3 </sub>alkyl groups, and phenyl,</claim-text><claim-text>and the dotted line represents a single bond or a double bond;</claim-text><claim-text>R<sup>1 </sup>is selected from hydrogen,</claim-text><claim-text>C<sub>1</sub>-C<sub>6 </sub>alkyl,</claim-text><claim-text>C<sub>1</sub>-C<sub>7 </sub>alkyl substituted with one or two OH groups,</claim-text><claim-text>C<sub>3</sub>-C<sub>7 </sub>alkenyl,</claim-text><claim-text>phenyl optionally substituted with up to five substituents selected from the group consisting of halogen, C&#x2261;N, NO<sub>2</sub>, C<sub>1</sub>-C6 alkyl, C<sub>1</sub>-C<sub>6 </sub>alkyl comprising up to 5 halogen atoms, C<sub>1</sub>-C<sub>6 </sub>alkyloxy, C<sub>1</sub>-C<sub>6 </sub>alkyloxy comprising up to 5 halogen atoms, C<sub>3</sub>-C<sub>7 </sub>cycloalkyl, &#x2014;C(O)O&#x2014;R<sup>10 </sup>wherein R<sup>10 </sup>is selected from hydrogen and C<sub>1</sub>-C<sub>3 </sub>alkyl, and &#x2014;SR<sup>11 </sup>wherein R<sup>11 </sup>is selected from hydrogen and C<sub>1</sub>-C<sub>3 </sub>alkyl,</claim-text><claim-text>naphthyl optionally substituted with up to five substituents selected from the group consisting of halogen, C&#x2261;N, NO<sub>2</sub>, C<sub>1</sub>-C<sub>6 </sub>alkyl, C<sub>1</sub>-C<sub>6 </sub>alkyl comprising up to 5 halogen atoms, C<sub>1</sub>-C<sub>6 </sub>alkyloxy, C<sub>1</sub>-C<sub>6 </sub>alkyloxy comprising up to 5 halogen atoms, C<sub>3</sub>-C<sub>7 </sub>cycloalkyl, &#x2014;C(O)O&#x2014;R<sup>10 </sup>wherein R<sup>10 </sup>is selected from hydrogen and C<sub>1</sub>-C<sub>3 </sub>alkyl, and &#x2014;SR<sup>11 </sup>wherein R<sup>11 </sup>is selected from hydrogen and C<sub>1</sub>-C<sub>3 </sub>alkyl, and</claim-text><claim-text>C<sub>5</sub>-C<sub>10 </sub>mono- or bicyclic aryl wherein 1 or 2 C-atoms are replaced by a hetero atom independently selected from sulfur, nitrogen, and oxygen, optionally substituted with up to three substituents selected from the group consisting of halogen, C&#x2261;N, NO<sub>2</sub>, C<sub>1</sub>-C<sub>6 </sub>alkyl, C<sub>1</sub>-C<sub>6 </sub>alkyl comprising up to 5 halogen atoms, C<sub>1</sub>-C<sub>6 </sub>alkyloxy, C<sub>1</sub>-C<sub>6 </sub>alkyloxy comprising up to 5 halogen atoms, C<sub>3</sub>-C<sub>7 </sub>cycloalkyl, &#x2014;C(O)O&#x2014;R<sup>10 </sup>wherein R<sup>10 </sup>is selected from hydrogen and C<sub>1</sub>-C<sub>3 </sub>alkyl, and &#x2014;SR<sup>11 </sup>wherein R<sup>11 </sup>is selected from hydrogen and C<sub>1</sub>-C<sub>3 </sub>alkyl;</claim-text><claim-text>R<sup>2</sup>, R<sup>4</sup>, R<sup>5</sup>, and R<sup>7 </sup>are independently selected from hydrogen and C<sub>1</sub>-C<sub>6 </sub>alkyl;</claim-text><claim-text>R<sup>6 </sup>is selected from hydrogen, C<sub>1</sub>-C<sub>6 </sub>alkyl, and C<sub>3</sub>-C<sub>7 </sub>cycloalkyl;</claim-text><claim-text>R<sup>8 </sup>and R<sup>9 </sup>are independently selected from hydrogen, and C<sub>1</sub>-C<sub>6 </sub>alkly, or</claim-text><claim-text>R<sup>8 </sup>and R<sup>9 </sup>form together with the C-atom to which they are attached a 3, 4, 5, 6, or 7-membered cycloalkyl ring;</claim-text><claim-text>and</claim-text><claim-text>n is 0, or n is 1 and R&#x2032; is selected from hydrogen, C<sub>1</sub>-C<sub>6 </sub>alkyl, C<sub>2</sub>-C<sub>6 </sub>alkyl substituted with one or two OH groups, C<sub>2</sub>-C<sub>6 </sub>alkenyl, or R&#x2032; forms together with the C-atom to which it is attached a carbonyl group (C&#x2550;O).</claim-text></claim-text></claim><claim id="CLM-00002" num="00002"><claim-text><b>2</b>. The method according to <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the compound of formula (I), a salt or solvate thereof is a compound, wherein X is selected from CR<sup>3 </sup>and NR<sup>3 </sup>wherein R<sup>3 </sup>is selected from hydrogen, C<sub>1</sub>-C<sub>6 </sub>alkyl, C<sub>1</sub>-C<sub>7 </sub>alkyl substituted with one or two OH groups, C<sub>3</sub>-C<sub>7 </sub>cycloalkyl, C<sub>3</sub>-C<sub>7 </sub>cycloalkyl substituted with one or two OH groups, C<sub>5</sub>-C<sub>7 </sub>cycloalkenyl, C<sub>5</sub>-C<sub>7 </sub>cycloalkenyl substituted with one, two or three C<sub>1</sub>-C<sub>3 </sub>alkyl groups, and phenyl; and the dotted line represents a single bond or a double bond.</claim-text></claim><claim id="CLM-00003" num="00003"><claim-text><b>3</b>. The method according to <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the compound of formula (I) is selected from the group consisting of 4-methyl-3-(1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazol-5-yl)benzonitrile; 4-methoxy-3-(1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazol-5-yl)benzonitrile; 1-ethyl-5-(2-methoxyphenyl)-3,3,7-trimethyloctahydrobenzo[c]isoxazole; 5-(2-methoxyphenyl)-1,3,3,7-tetramethyloctahydrobenzo[c]isoxazole; 5-(3,5-difluorophenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole; 1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazol-5-yl)benzonitrile; 1,3,3,5,7-pentamethyl-5-(o-tolyl)octahydrobenzo[c]isoxazole; 5-(5-chloro-2-methylphenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole; 3-(1-isopropyl-3,3,7-trimethyloctahydrobenzo[c]isoxazol-5-yl)-4-methoxybenzonitrile; 5-(2,5-dimethylphenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole; 3-(1-ethyl-3,3,5,7-tetramethyloctahydrobenzo[c]isoxazol-5-yl)-4-methylbenzonitrile; 5-(5-fluoro-2-methylphenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole; 1-isopropyl-5-(2-methoxyphenyl)-3,3,7-trimethyloctahydrobenzo[c]isoxazole; 3-chloro-5-(1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazol-5-yl)benzonitrile; 3-(1-isopropyl-3,3, 5,7-tetramethyloctahydrobenzo[c]isoxazol-5-yl)benzonitrile; 5-(3,4-difluorophenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole; 3-(1-isopropyl-3,3, 5,7-tetramethyloctahydrobenzo[c]isoxazol-5-yl)-4-methylbenzonitrile; 5-(2-methoxyphenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole; 2-methyl-5-(1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazol-5-yl)benzonitrile; methyl 4-methyl-3-(1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazol-5-yl)benzoate; 1-isopropyl-3,3,5,7-tetramethyl-5-(o-tolyl)octahydrobenzo[c]isoxazole; 5-(3-fluorophenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole; 1,3,3,5,7-pentamethyl-5-phenyloctahydrobenzo[c]isoxazole; 1-isopropyl-3,3,7-trimethyl-5-phenyloctahydrobenzo[c]isoxazole; 5-(4-chloro-2-methylphenyl)-1-isopropyl-3,3,7-trimethyloctahydrobenzo[c]isoxazole; 5-(2,4-dimethylphenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole; 5-(4-fluoro-2-methylphenyl)-1,3,3,7-tetramethyloctahydrobenzo[c]isoxazole; 5-(2,5-difluorophenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole; 1-ethyl-3,3,5,7-tetramethyl-5-phenyloctahydrobenzo[c]isoxazole; 1,3,3,5,7-pentamethyl-5-(p-tolyl)octahydrobenzo[c]isoxazole; 1-isopropyl-3,3,5,7-tetramethyl-5-phenyloctahydrobenzo[c]isoxazole; 1,3,3,7-tetramethyl-5-phenyloctahydrobenzo[c]isoxazole; 1-isopropyl-5-(2-methoxyphenyl)-3,3,5,7-tetramethyloctahydrobenzo[c]isoxazole; 5-(2-fluorophenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole; 4-(1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazol-5-yl)benzonitrile; 3-methyl-4-(1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazol-5-yl)benzonitrile; 5-(2,4-difluorophenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole; 5-(2,5-dimethoxyphenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole; 5-(2,3-dimethylphenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole; 1,3,3,5,7-pentamethyl-5-(2,4,5-trimethylphenyl)octahydrobenzo[c]isoxazole; 1,3,3,5,7-pentamethyl-5-(4-(methylthio)phenyl)octahydrobenzo[c]isoxazole; 2-(1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazol-5-yl)benzonitrile; 5-(3-methoxyphenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole; 5-(3-chloro-2-methylphenyl)-1-isopropyl-3,3,7-trimethyloctahydrobenzo[c]isoxazole; 1,3,3,5,7-pentamethyl-5-(naphthalen-2-yl)octahydrobenzo[c]isoxazole; 5-(2,4-dimethylphenyl)-1,3,3,7-tetramethyloctahydrobenzo[c]isoxazole; 4-methyl-3-(1,3,3,7-tetramethyloctahydrobenzo[c]isoxazol-5-yl)benzonitrile; 1,3,3,7-tetramethyl-5-(3-methylbut-2-en-1-yl)octahydrobenzo[c]isoxazole; 5-(2-ethylphenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole; 1,3,3,5,7-pentamethyl-5-(m-tolyl)octahydrobenzo[c]isoxazole; 1,3,3,5,7-pentamethyl-5-(5-methylthiophen-3-yl)octahydrobenzo[c]isoxazole; 1-ethyl-3,3,7-trimethyl-5-(3-methylbut-2-en-1-yl)octahydrobenzo[c]isoxazole; 5-(2-ethylphenyl)-1-isopropyl-3,3,7-trimethyloctahydrobenzo[c]isoxazole; 1,3,3,5,7-pentamethyl-5-(3-methylbut-2-en-1-yl)octahydrobenzo[c]isoxazole; 5-(2,6-dimethylphenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole; 5-(benzo[d][1,3]dioxol-5-yl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole; 1-isopropyl-5-(6-methoxypyridin-2-yl)-3,3,5,7-tetramethyloctahydrobenzo[c]isoxazole; 5-(5-chloro-2-methylphenyl)-1-isopropyl-3,3,7-trimethyloctahydrobenzo[c]isoxazole; 5-butyl-1,3,3-trimethyloctahydrobenzo[c]isoxazole; 5-(2,4-dimethoxyphenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole; 1-isopropyl-3,3,7-trimethyl-5-(o-tolyl)octahydrobenzo[c]isoxazole; 1-isopropyl-3,3,7-trimethyl-5-(3-methylbut-2-en-1-yl)octahydrobenzo[c]isoxazole; 5-(5-fluoro-2-methylphenyl)-1,3,3,7-tetramethyloctahydrobenzo[c]isoxazole; 5-(3,5-dimethylphenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole; 1-isopropyl-3,3,5,7-tetramethyloctahydrobenzo[c]isoxazole; 1,3,3-trimethyl-6-(4-methylcyclohex-3-en-1-yl)octahydrobenzo[c]isoxazole; 5-(3-fluoro-5-(trifluoromethyl)phenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole; 1-isopropyl-3,3-dimethyl-5-propyloctahydrobenzo[c]isoxazole; 1,3,3-trimethyl-5-pentyloctahydrobenzo[c]isoxazole; 1-ethyl-3,3,5,7-tetramethyl-5-(o-tolyl)octahydrobenzo[c]isoxazole; 5-(3,5-dimethylphenyl)-1-isopropyl-3,3,5,7-tetramethyloctahydrobenzo[c]isoxazole; 5-(2,5-dimethylphenyl)-1,3,3,7-tetramethyloctahydrobenzo[c]isoxazole; 5,7-diethyl-1-isopropyl-3,3-dimethyloctahydrobenzo[c]isoxazole; 1,3,3,5,7-pentamethyl-5-(2-methyl-5-(trifluoromethyl)phenyl)octahydrobenzo[c]isoxazole; 1-ethyl-3,3-dimethyl-5-propyloctahydrobenzo[c]isoxazole; 1,3,3,5,7-pentamethyl-5-propyloctahydrobenzo[c]isoxazole; 1,3,3-trimethyl-5-propyloctahydrobenzo[c]isoxazole; 2-methyl-3-(1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazol-5-yl)benzonitrile; 1,3,3,7-tetramethyl-5-(o-tolyl)octahydrobenzo[c]isoxazole; 5-butyl-1-ethyl-3,3-dimethyloctahydrobenzo[c]isoxazole; 5-(4-fluorophenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole; 5-(furan-3-yl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole; 1-isopropyl-3,3,5,7-tetramethyloctahydrobenzo[c]isoxazol-1-ium chloride; 1,3,3,5,7-pentamethyl-5-(naphthalen-1-yl)octahydrobenzo[c]isoxazole; 5-(2-ethoxyphenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole; 5-(3-chloro-2-methylphenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole; 5-(6-methoxypyridin-2-yl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole; 1,3,3,5,7-pentamethyl-5-(5-methylthiophen-2-yl)octahydrobenzo[c]isoxazole; 1,3,3,5,7-pentamethyl-5-(4-methylpyridin-3-yl)octahydrobenzo[c]isoxazole; 1-ethyl-3,3,5,7-tetramethyloctahydrobenzo[c]isoxazole; 5-(2-ethylphenyl)-1,3,3,7-tetramethyloctahydrobenzo[c]isoxazole; 5-butyl-1-isopropyl-3,3-dimethyloctahydrobenzo[c]isoxazole; 1-ethyl-3,3,5,7-tetramethyl-5-(3-methylbut-2-en-1-yl)octahydrobenzo[c]isoxazole; 5-(4-fluoro-2-methylphenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole; 1-isopropyl-5,7-dimethylhexahydro-1H-spiro[benzo[c]isoxazole-3,1&#x2032;-cyclopentane]; 1,5,7-triethyl-3,3-dimethyloctahydrobenzo[c]isoxazole; 1-isopropyl-3,3,5,7-tetramethyl-5-propyloctahydrobenzo[c]isoxazole; 6-isopentyl-1,4,4,8-tetramethyloctahydro-2H-benzo[d][1,3]oxazine; 5-(3,5-dimethoxyphenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole; 5,7-diethyl-1,3,3-trimethyloctahydrobenzo[c]isoxazole; 1-isopropyl-5-(4-methoxyphenyl)-3,3,5,7-tetramethyloctahydrobenzo[c]isoxazole; 5-(3-isopropylphenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole; 1,3,3-trimethyl-6-phenyloctahydrobenzo[c]isoxazole; 5-ethyl-1-isopropyl-3,3-dimethyloctahydrobenzo[c]isoxazole; 5,5-diethyl-1,3,3,7-tetramethyloctahydrobenzo[c]isoxazole; 1,3,3,5,7-pentamethyl-5-(2-(methylthio)phenyl)octahydrobenzo[c]isoxazole; 1,5,7-trimethylhexahydro-1H-spiro[benzo[c]isoxazole-3,1&#x2032;-cyclopentane]; 5-ethyl-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole; 5-(4-methoxyphenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole; 1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole; 1,3,3,4,5,7-hexamethyloctahydrobenzo[c]isoxazole; 1,3,3,5,7-pentamethyl-5-(pyridin-3-yl)octahydrobenzo[c]isoxazole; 1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole hydrochloride; 5-(4-fluoro-2-methoxyphenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole; 5-(4-fluorophenyl)-1-isopropyl-3,3,5,7-tetramethyloctahydrobenzo[c]isoxazole; 4-methyl-2-(1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazol-5-yl)benzonitrile; 1,3,3,5-tetramethyl-5-(3-methylbut-2-en-1-yl)octahydrobenzo[c]isoxazole; 6-isopentyl-1,4,4,8-tetramethyloctahydro-2H-benzo[d][1,3]oxazin-2-one; 1-isopropyl-3,3,5,7-tetramethyl-5-(3-methylbut-2-en-1-yl)octahydrobenzo[c]isoxazole; 5-isopentyl-1-isopropyl-3,3,5,7-tetramethyloctahydrobenzo[c]isoxazole; 2-chloro-5-(1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazol-5-yl)benzonitrile; 5-(4-(tert-butyl)phenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole; 5-(4-(tert-butyl)phenyl)-1,3,3,7-tetramethyloctahydrobenzo[c]isoxazole; 5-(4-(tert-butyl)phenyl)-1-isopropyl-3,3,7-trimethyloctahydrobenzo[c]isoxazole; and 1,3,3,6-tetramethyloctahydrobenzo[c]isoxazole, or a salt or solvate thereof.</claim-text></claim><claim id="CLM-00004" num="00004"><claim-text><b>4</b>. A non-medical method of inducing a cooling sensation in a human or animal comprising contacting the human or animal with a compound of formula (I), or a salt or solvate thereof, as defined in <claim-ref idref="CLM-00001">claim 1</claim-ref>.</claim-text></claim><claim id="CLM-00005" num="00005"><claim-text><b>5</b>. A method of achieving a cooling effect or sensation on the skin or mucosa comprising contacting the skin or mucosa with a product comprising one or more compounds of formula (I) as defined in <claim-ref idref="CLM-00001">claim 1</claim-ref>.</claim-text></claim><claim id="CLM-00006" num="00006"><claim-text><b>6</b>. A consumer product comprising one or more compounds of formula (I) as defined in <claim-ref idref="CLM-00001">claim 1</claim-ref>.</claim-text></claim><claim id="CLM-00007" num="00007"><claim-text><b>7</b>. A pharmaceutical composition or medicament comprising one or more compounds of formula (I) as defined in <claim-ref idref="CLM-00001">claim 1</claim-ref>.</claim-text></claim><claim id="CLM-00008" num="00008"><claim-text><b>8</b>. A method of using the compound of formula (I) as defined in <claim-ref idref="CLM-00001">claim 1</claim-ref> to provide a cooling effect or sensation.</claim-text></claim><claim id="CLM-00009" num="00009"><claim-text><b>9</b>. A method of using the compound of formula (I) as defined in <claim-ref idref="CLM-00001">claim 1</claim-ref> as medicament.</claim-text></claim><claim id="CLM-00010" num="00010"><claim-text><b>10</b>. A composition comprising a cool sensation wherein the composition comprises a compound of formula (I)</claim-text><claim-text><chemistry id="CHEM-US-00009" num="00009"><img id="EMI-C00009" he="28.36mm" wi="56.39mm" file="US20230002334A1-20230105-C00009.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry><claim-text>wherein</claim-text><claim-text>X is O and the dotted line represents a single bond;</claim-text><claim-text>or</claim-text><claim-text>X is selected from CR<sup>3 </sup>and NR<sup>3</sup>,</claim-text><claim-text>wherein R<sup>3 </sup>is selected from hydrogen, C<sub>1</sub>-C<sub>6 </sub>alkyl, C<sub>1</sub>-C<sub>7 </sub>alkyl substituted with one or two OH groups, C<sub>3</sub>-C<sub>7 </sub>cycloalkyl, C<sub>3</sub>-C<sub>7 </sub>cycloalkyl substituted with one or two OH groups, C<sub>5</sub>-C<sub>7 </sub>cycloalkenyl, C<sub>5</sub>-C<sub>7 </sub>cycloalkenyl substituted with one, two or three C<sub>1</sub>-C<sub>3 </sub>alkyl groups, and phenyl,</claim-text><claim-text>and the dotted line represents a single bond or a double bond;</claim-text><claim-text>R<sup>1 </sup>is selected from hydrogen,</claim-text><claim-text>C<sub>1</sub>-C<sub>6 </sub>alkyl,</claim-text><claim-text>C<sub>1</sub>-C<sub>7 </sub>alkyl substituted with one or two OH groups,</claim-text><claim-text>C<sub>3</sub>-C<sub>7 </sub>alkenyl,</claim-text><claim-text>phenyl optionally substituted with up to five substituents selected from the group consisting of halogen, C&#x2261;N, NO<sub>2</sub>, C<sub>1</sub>-C<sub>6 </sub>alkyl, C<sub>1</sub>-C<sub>6 </sub>alkyl comprising up to 5 halogen atoms, C<sub>1</sub>-C<sub>6 </sub>alkyloxy, C<sub>1</sub>-C<sub>6 </sub>alkyloxy comprising up to 5 halogen atoms, C<sub>3</sub>-C<sub>7 </sub>cycloalkyl, &#x2014;C(O)O&#x2014;R<sup>10 </sup>wherein R<sup>10 </sup>is selected from hydrogen and C<sub>1</sub>-C<sub>3 </sub>alkyl, and &#x2014;SR<sup>11 </sup>wherein R<sup>11 </sup>is selected from hydrogen and C<sub>1</sub>-C<sub>3 </sub>alkyl,</claim-text><claim-text>naphthyl optionally substituted with up to five substituents selected from the group consisting of halogen, C&#x2261;N, NO<sub>2</sub>, C<sub>1</sub>-C<sub>6 </sub>alkyl, C<sub>1</sub>-C<sub>6 </sub>alkyl comprising up to 5 halogen atoms, C<sub>1</sub>-C<sub>6 </sub>alkyloxy, C<sub>1</sub>-C<sub>6 </sub>alkyloxy comprising up to 5 halogen atoms, C<sub>3</sub>-C<sub>7 </sub>cycloalkyl, &#x2014;C(O)O&#x2014;R<sup>10 </sup>wherein R<sup>10 </sup>is selected from hydrogen and C<sub>1</sub>-C<sub>3 </sub>alkyl, and &#x2014;SR<sup>11 </sup>wherein R<sup>11 </sup>is selected from hydrogen and C<sub>1</sub>-C<sub>3 </sub>alkyl, and</claim-text><claim-text>C<sub>5</sub>-C<sub>10 </sub>mono- or bicyclic aryl wherein 1 or 2 C-atoms are replaced by a hetero atom independently selected from sulfur, nitrogen, and oxygen, optionally substituted with up to three substituents selected from the group consisting of halogen, C&#x2261;N, NO<sub>2</sub>, C<sub>1</sub>-C<sub>6 </sub>alkyl, C<sub>1</sub>-C<sub>6 </sub>alkyl comprising up to 5 halogen atoms, C<sub>1</sub>-C<sub>6 </sub>alkyloxy, C<sub>1</sub>-C<sub>6 </sub>alkyloxy comprising up to 5 halogen atoms, C<sub>3</sub>-C<sub>7 </sub>cycloalkyl, &#x2014;C(O)O&#x2014;R<sup>10 </sup>wherein R<sup>10 </sup>is selected from hydrogen and C<sub>1</sub>-C<sub>3 </sub>alkyl, and &#x2014;SR<sup>11 </sup>wherein R<sup>11 </sup>is selected from hydrogen and C<sub>1</sub>-C<sub>3 </sub>alkyl;</claim-text><claim-text>R<sup>2</sup>, R<sup>4</sup>, R<sup>5</sup>, and R<sup>7 </sup>are independently selected from hydrogen and C<sub>1</sub>-C<sub>6 </sub>alkyl;</claim-text><claim-text>R<sup>6 </sup>is selected from hydrogen, C<sub>1</sub>-C<sub>6 </sub>alkyl, and C<sub>3</sub>-C<sub>7 </sub>cycloalkyl;</claim-text><claim-text>R<sup>8 </sup>and R<sup>9 </sup>are independently selected from hydrogen, and C<sub>1</sub>-C<sub>6 </sub>alkyl, or</claim-text><claim-text>R<sup>8 </sup>and R<sup>9 </sup>form together with the C-atom to which they are attached a 3, 4, 5, 6, or 7-membered cycloalkyl ring;</claim-text><claim-text>and</claim-text><claim-text>n is 0, or n is 1 and R&#x2032; is selected from hydrogen, C<sub>1</sub>-C<sub>6 </sub>alkyl, C<sub>2</sub>-C<sub>6 </sub>alkyl substituted with one or two OH groups, C<sub>2</sub>-C<sub>6 </sub>alkenyl, or R&#x2032; forms together with the C-atom to which it is attached a carbonyl group (C&#x2550;O).</claim-text></claim-text></claim><claim id="CLM-00011" num="00011"><claim-text><b>11</b>. (canceled)</claim-text></claim><claim id="CLM-00012" num="00012"><claim-text><b>12</b>. The compound according to <claim-ref idref="CLM-00014">claim 14</claim-ref> wherein R<sup>1 </sup>is not hydrogen.</claim-text></claim><claim id="CLM-00013" num="00013"><claim-text><b>13</b>. The compound according to <claim-ref idref="CLM-00014">claim 14</claim-ref> selected from the group consisting of 4-methyl-3-(1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazol-5-yl)benzonitrile; 4-methoxy-3-(1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazol-5-yl)benzonitrile; 1-ethyl-5-(2-methoxyphenyl)-3,3,7-trimethyloctahydrobenzo[c]isoxazole; 5-(2-methoxyphenyl)-1,3,3,7-tetramethyloctahydrobenzo[c]isoxazole; 5-(3,5-difluorophenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole; 1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazol-5-yl)benzonitrile; 1,3,3,5,7-pentamethyl-5-(o-tolyl)octahydrobenzo[c]isoxazole; 5-(5-chloro-2-methylphenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole; 3-(1-isopropyl-3,3,7-trimethyloctahydrobenzo[c]isoxazol-5-yl)-4-methoxybenzonitrile; 5-(2,5-dimethylphenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole; 3-(1-ethyl-3,3,5,7-tetramethyloctahydrobenzo[c]isoxazol-5-yl)-4-methylbenzonitrile; 5-(5-fluoro-2-methylphenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole; 1-isopropyl-5-(2-methoxyphenyl)-3,3,7-trimethyloctahydrobenzo[c]isoxazole; 3-chloro-5-(1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazol-5-yl)benzonitrile; 3-(1-isopropyl-3,3, 5,7-tetramethyloctahydrobenzo[c]isoxazol-5-yl)benzonitrile; 5-(3,4-difluorophenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole; 3-(1-isopropyl-3,3, 5,7-tetramethyloctahydrobenzo[c]isoxazol-5-yl)-4-methylbenzonitrile; 5-(2-methoxyphenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole; 2-methyl-5-(1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazol-5-yl)benzonitrile; methyl 4-methyl-3-(1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazol-5-yl)benzoate; 1-isopropyl-3,3,5,7-tetramethyl-5-(o-tolyl)octahydrobenzo[c]isoxazole; 5-(3-fluorophenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole; 1,3,3,5,7-pentamethyl-5-phenyloctahydrobenzo[c]isoxazole; 1-isopropyl-3,3,7-trimethyl-5-phenyloctahydrobenzo[c]isoxazole; 5-(4-chloro-2-methylphenyl)-1-isopropyl-3,3,7-trimethyloctahydrobenzo[c]isoxazole; 5-(2,4-dimethylphenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole; 5-(4-fluoro-2-methylphenyl)-1,3,3,7-tetramethyloctahydrobenzo[c]isoxazole; 5-(2,5-difluorophenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole; 1-ethyl-3,3,5,7-tetramethyl-5-phenyloctahydrobenzo[c]isoxazole; 1,3,3,5,7-pentamethyl-5-(p-tolyl)octahydrobenzo[c]isoxazole; 1-isopropyl-3,3,5,7-tetramethyl-5-phenyloctahydrobenzo[c]isoxazole; 1,3,3,7-tetramethyl-5-phenyloctahydrobenzo[c]isoxazole; 1-isopropyl-5-(2-methoxyphenyl)-3,3,5,7-tetramethyloctahydrobenzo[c]isoxazole; 5-(2-fluorophenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole; 4-(1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazol-5-yl)benzonitrile; 3-methyl-4-(1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazol-5-yl)benzonitrile; 5-(2,4-difluorophenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole; 5-(2,5-dimethoxyphenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole; 5-(2,3-dimethylphenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole; 1,3,3,5,7-pentamethyl-5-(2,4,5-trimethylphenyl)octahydrobenzo[c]isoxazole; 1,3,3,5,7-pentamethyl-5-(4-(methylthio)phenyl)octahydrobenzo[c]isoxazole; 2-(1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazol-5-yl)benzonitrile; 5-(3-methoxyphenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole; 5-(3-chloro-2-methylphenyl)-1-isopropyl-3,3,7-trimethyloctahydrobenzo[c]isoxazole; 1,3,3,5,7-pentamethyl-5-(naphthalen-2-yl)octahydrobenzo[c]isoxazole; 5-(2,4-dimethylphenyl)-1,3,3,7-tetramethyloctahydrobenzo[c]isoxazole; 4-methyl-3-(1,3,3,7-tetramethyloctahydrobenzo[c]isoxazol-5-yl)benzonitrile; 1,3,3,7-tetramethyl-5-(3-methylbut-2-en-1-yl)octahydrobenzo[c]isoxazole; 5-(2-ethylphenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole; 1,3,3,5,7-pentamethyl-5-(m-tolyl)octahydrobenzo[c]isoxazole; 1,3,3,5,7-pentamethyl-5-(5-methylthiophen-3-yl)octahydrobenzo[c]isoxazole; 1-ethyl-3,3,7-trimethyl-5-(3-methylbut-2-en-1-yl)octahydrobenzo[c]isoxazole; 5-(2-ethylphenyl)-1-isopropyl-3,3,7-trimethyloctahydrobenzo[c]isoxazole; 1,3,3,5,7-pentamethyl-5-(3-methylbut-2-en-1-yl)octahydrobenzo[c]isoxazole; 5-(2,6-dimethylphenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole; 5-(benzo[d][1,3]dioxol-5-yl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole; 1-isopropyl-5-(6-methoxypyridin-2-yl)-3,3,5,7-tetramethyloctahydrobenzo[c]isoxazole; 5-(5-chloro-2-methylphenyl)-1-isopropyl-3,3,7-trimethyloctahydrobenzo[c]isoxazole; 5-butyl-1,3,3-trimethyloctahydrobenzo[c]isoxazole; 5-(2,4-dimethoxyphenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole; 1-isopropyl-3,3,7-trimethyl-5-(o-tolyl)octahydrobenzo[c]isoxazole; 1-isopropyl-3,3,7-trimethyl-5-(3-methylbut-2-en-1-yl)octahydrobenzo[c]isoxazole; 5-(5-fluoro-2-methylphenyl)-1,3,3,7-tetramethyloctahydrobenzo[c]isoxazole; 5-(3,5-dimethylphenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole; 1-isopropyl-3,3,5,7-tetramethyloctahydrobenzo[c]isoxazole; 1,3,3-trimethyl-6-(4-methylcyclohex-3-en-1-yl)octahydrobenzo[c]isoxazole; 5-(3-fluoro-5-(trifluoromethyl)phenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole; 1-isopropyl-3,3-dimethyl-5-propyloctahydrobenzo[c]isoxazole; 1,3,3-trimethyl-5-pentyloctahydrobenzo[c]isoxazole; 1-ethyl-3,3,5,7-tetramethyl-5-(o-tolyl)octahydrobenzo[c]isoxazole; 5-(3,5-dimethylphenyl)-1-isopropyl-3,3,5,7-tetramethyloctahydrobenzo[c]isoxazole; 5-(2,5-dimethylphenyl)-1,3,3,7-tetramethyloctahydrobenzo[c]isoxazole; 5,7-diethyl-1-isopropyl-3,3-dimethyloctahydrobenzo[c]isoxazole; 1,3,3,5,7-pentamethyl-5-(2-methyl-5-(trifluoromethyl)phenyl)octahydrobenzo[c]isoxazole; 1-ethyl-3,3-dimethyl-5-propyloctahydrobenzo[c]isoxazole; 1,3,3,5,7-pentamethyl-5-propyloctahydrobenzo[c]isoxazole; 1,3,3-trimethyl-5-propyloctahydrobenzo[c]isoxazole; 2-methyl-3-(1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazol-5-yl)benzonitrile; 1,3,3,7-tetramethyl-5-(o-tolyl)octahydrobenzo[c]isoxazole; 5-butyl-1-ethyl-3,3-dimethyloctahydrobenzo[c]isoxazole; 5-(4-fluorophenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole; 5-(furan-3-yl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole; 1-isopropyl-3,3,5,7-tetramethyloctahydrobenzo[c]isoxazol-1-ium chloride; 1,3,3,5,7-pentamethyl-5-(naphthalen-1-yl)octahydrobenzo[c]isoxazole; 5-(2-ethoxyphenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole; 5-(3-chloro-2-methylphenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole; 5-(6-methoxypyridin-2-yl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole; 1,3,3,5,7-pentamethyl-5-(5-methylthiophen-2-yl)octahydrobenzo[c]isoxazole; 1,3,3,5,7-pentamethyl-5-(4-methylpyridin-3-yl)octahydrobenzo[c]isoxazole; 1-ethyl-3,3,5,7-tetramethyloctahydrobenzo[c]isoxazole; 5-(2-ethylphenyl)-1,3,3,7-tetramethyloctahydrobenzo[c]isoxazole; 5-butyl-1-isopropyl-3,3-dimethyloctahydrobenzo[c]isoxazole; 1-ethyl-3,3,5,7-tetramethyl-5-(3-methylbut-2-en-1-yl)octahydrobenzo[c]isoxazole; 5-(4-fluoro-2-methylphenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole; 1-isopropyl-5,7-dimethylhexahydro-1H-spiro[benzo[c]isoxazole-3,1&#x2032;-cyclopentane]; 1,5,7-triethyl-3,3-dimethyloctahydrobenzo[c]isoxazole; 1-isopropyl-3,3,5,7-tetramethyl-5-propyloctahydrobenzo[c]isoxazole; 6-isopentyl-1,4,4,8-tetramethyloctahydro-2H-benzo[d][1,3]oxazine; 5-(3,5-dimethoxyphenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole; 5,7-diethyl-1,3,3-trimethyloctahydrobenzo[c]isoxazole; 1-isopropyl-5-(4-methoxyphenyl)-3,3,5,7-tetramethyloctahydrobenzo[c]isoxazole; 5-(3-isopropylphenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole; 1,3,3-trimethyl-6-phenyloctahydrobenzo[c]isoxazole; 5-ethyl-1-isopropyl-3,3-dimethyloctahydrobenzo[c]isoxazole; 1,3,3,5,7-pentamethyl-5-(2-(methylthio)phenyl)octahydrobenzo[c]isoxazole; 1,5,7-trimethylhexahydro-1H-spiro[benzo[c]isoxazole-3,1&#x2032;-cyclopentane]; 5-ethyl-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole; 5-(4-methoxyphenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole; 1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole; 1,3,3,4,5,7-hexamethyloctahydrobenzo[c]isoxazole; 1,3,3,5,7-pentamethyl-5-(pyridin-3-yl)octahydrobenzo[c]isoxazole; 1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole hydrochloride; 5-(4-fluoro-2-methoxyphenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole; 5-(4-fluorophenyl)-1-isopropyl-3,3,5,7-tetramethyloctahydrobenzo[c]isoxazole; 4-methyl-2-(1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazol-5-yl)benzonitrile; 1,3,3,5-tetramethyl-5-(3-methylbut-2-en-1-yl)octahydrobenzo[c]isoxazole; 6-isopentyl-1,4,4,8-tetramethyloctahydro-2H-benzo[d][1,3]oxazin-2-one; 1-isopropyl-3,3,5,7-tetramethyl-5-(3-methylbut-2-en-1-yl)octahydrobenzo[c]isoxazole; 5-isopentyl-1-isopropyl-3,3,5,7-tetramethyloctahydrobenzo[c]isoxazole; 2-chloro-5-(1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazol-5-yl)benzonitrile; 5-(4-(tert-butyl)phenyl)-1,3,3,5,7-pentamethyloctahydrobenzo[c]isoxazole; 5-(4-(tert-butyl)phenyl)-1,3,3,7-tetramethyloctahydrobenzo[c]isoxazole; 5-(4-(tert-butyl)phenyl)-1-isopropyl-3,3,7-trimethyloctahydrobenzo[c]isoxazole; and 1,3,3,6-tetramethyloctahydrobenzo[c]isoxazole, or a salt or solvate thereof.</claim-text></claim><claim id="CLM-00014" num="00014"><claim-text><b>14</b>. A compound having formula (Ia), a salt, or solvate thereof</claim-text><claim-text><chemistry id="CHEM-US-00010" num="00010"><img id="EMI-C00010" he="27.01mm" wi="53.85mm" file="US20230002334A1-20230105-C00010.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry><claim-text>wherein</claim-text><claim-text>X is C;</claim-text><claim-text>R<sup>3 </sup>is selected from hydrogen, C<sub>1</sub>-C<sub>6 </sub>alkyl, C<sub>1</sub>-C<sub>7 </sub>alkyl substituted with one or two OH groups, C<sub>3</sub>-C<sub>7 </sub>cycloalkyl, C<sub>3</sub>-C<sub>7 </sub>cycloalkyl substituted with one or two OH groups, C<sub>5</sub>-C<sub>7 </sub>cycloalkenyl, C<sub>5</sub>-C<sub>7 </sub>cycloalkenyl substituted with one, two or three C<sub>1</sub>-C<sub>3 </sub>alkyl groups, and phenyl;</claim-text><claim-text>R<sup>1 </sup>is selected from hydrogen,</claim-text><claim-text>C<sub>1</sub>-C<sub>6 </sub>alkyl,</claim-text><claim-text>C<sub>1</sub>-C<sub>7 </sub>alkyl substituted with one or two OH groups,</claim-text><claim-text>C<sub>3</sub>-C<sub>7 </sub>alkenyl,</claim-text><claim-text>phenyl optionally substituted with up to five (e.g. one, two or three) substituents selected from the group consisting of halogen (including Br, Cl, and F), C&#x2261;N, NO<sub>2</sub>, C<sub>1</sub>-C<sub>6 </sub>alkyl, C<sub>1</sub>-C<sub>6 </sub>alkyl comprising up to 5 halogen atoms (including Br, Cl, and F), C<sub>1</sub>-C<sub>6 </sub>alkyloxy, C<sub>1</sub>-C<sub>6 </sub>alkyloxy comprising up to 5 halogen atoms (including Br, Cl, and F), C<sub>3</sub>-C<sub>7 </sub>cycloalkyl, &#x2014;C(O)O&#x2014;R<sup>10 </sup>wherein R<sup>10 </sup>is selected from hydrogen and C<sub>1</sub>-C<sub>3 </sub>alkyl, and &#x2014;SR<sup>11 </sup>wherein R<sup>11 </sup>is selected from hydrogen and C<sub>1</sub>-C<sub>3 </sub>alkyl (including ethyl and isopropyl),</claim-text><claim-text>naphthyl optionally substituted with up to five (e.g. one, two or three) substituents selected from the group consisting of halogen (including Br, Cl, and F), C&#x2261;N, NO<sub>2</sub>, C<sub>1</sub>-C<sub>6 </sub>alkyl, C<sub>1</sub>-C<sub>6 </sub>alkyl comprising up to 5 halogen atoms (including Br, Cl, and F), C<sub>1</sub>-C<sub>6 </sub>alkyloxy, C<sub>1</sub>-C<sub>6 </sub>alkyloxy comprising up to 5 halogen atoms (including Br, Cl, and F), C<sub>3</sub>-C<sub>7 </sub>cycloalkyl, &#x2014;C(O)O&#x2014;R<sup>10 </sup>wherein R<sup>10 </sup>is selected from hydrogen and C<sub>1</sub>-C<sub>3 </sub>alkyl, and &#x2014;SR<sup>11 </sup>wherein R<sup>11 </sup>is selected from hydrogen and C<sub>1</sub>-C<sub>3 </sub>alkyl (including ethyl and isopropyl), and</claim-text><claim-text>C<sub>5</sub>-C<sub>10 </sub>mono- or bicyclic aryl wherein 1 or 2 C-atoms are replaced by a hetero atom independently selected from sulfur, nitrogen, and oxygen, optionally substituted with up to three (e.g. 1 or 2) substituents selected from the group consisting of halogen (including Br, Cl, and F), C&#x2261;N, NO<sub>2</sub>, C<sub>1</sub>-C<sub>6 </sub>alkyl, C<sub>1</sub>-C<sub>6 </sub>alkyl comprising up to 5 halogen atoms (including Br, Cl, and F), C<sub>1</sub>-C<sub>6 </sub>alkyloxy, C<sub>1</sub>-C<sub>6 </sub>alkyloxy comprising up to 5 halogen atoms (including Br, Cl, and F), C<sub>3</sub>-C<sub>7 </sub>cycloalkyl, &#x2014;C(O)O&#x2014;R<sup>10 </sup>wherein R<sup>10 </sup>is selected from hydrogen and C<sub>1</sub>-C<sub>3 </sub>alkyl, and &#x2014;SR<sup>11 </sup>wherein R<sup>11 </sup>is selected from hydrogen and C<sub>1</sub>-C<sub>3 </sub>alkyl (including ethyl and isopropyl);</claim-text><claim-text>R<sup>2 </sup>is H or methyl;</claim-text><claim-text>R<sup>4</sup>, R<sup>5</sup>, and R<sup>7 </sup>are independently selected from hydrogen and C<sub>1</sub>-C<sub>6 </sub>alkyl;</claim-text><claim-text>R<sup>6 </sup>is selected from hydrogen, C<sub>1</sub>-C<sub>6 </sub>alkyl (e.g. ethyl, isopropyl), and C<sub>3</sub>-C<sub>7 </sub>cycloalkyl;</claim-text><claim-text>R<sup>8 </sup>and R<sup>9 </sup>are independently selected from hydrogen, and C<sub>1</sub>-C<sub>6 </sub>alkyl, or</claim-text><claim-text>R<sup>8 </sup>and R<sup>9 </sup>form together with the C-atom to which they are attached a 3, 4, 5, 6, or 7-membered cycloalkyl ring.</claim-text></claim-text></claim><claim id="CLM-00015" num="00015"><claim-text><b>15</b>. A non-medical method of inducing a cooling sensation in a human or animal comprising contacting the human or animal with a compound of formula (I), or a salt or solvate thereof, as defined in <claim-ref idref="CLM-00003">claim 3</claim-ref>.</claim-text></claim><claim id="CLM-00016" num="00016"><claim-text><b>16</b>. A method of achieving a cooling effect or sensation on the skin or mucosa comprising contacting the skin or mucosa with a product comprising one or more compounds of formula (I) as defined in <claim-ref idref="CLM-00003">claim 3</claim-ref>.</claim-text></claim><claim id="CLM-00017" num="00017"><claim-text><b>17</b>. A consumer product comprising one or more compounds of formula (I) as defined in <claim-ref idref="CLM-00003">claim 3</claim-ref>.</claim-text></claim><claim id="CLM-00018" num="00018"><claim-text><b>18</b>. The consumer product of <claim-ref idref="CLM-00017">claim 17</claim-ref>, wherein the consumer product is selected from dental care products, food products, and chewing gum.</claim-text></claim><claim id="CLM-00019" num="00019"><claim-text><b>19</b>. A pharmaceutical composition or medicament comprising one or more compounds of formula (I) as defined in <claim-ref idref="CLM-00003">claim 3</claim-ref>.</claim-text></claim><claim id="CLM-00020" num="00020"><claim-text><b>20</b>. The consumer product of <claim-ref idref="CLM-00003">claim 3</claim-ref>, wherein the consumer product is selected from dental care products, food products, and chewing gum.</claim-text></claim><claim id="CLM-00021" num="00021"><claim-text><b>21</b>. The method according to <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the compound comprises formula (Ia), a salt, or solvate thereof</claim-text><claim-text><chemistry id="CHEM-US-00011" num="00011"><img id="EMI-C00011" he="27.01mm" wi="53.85mm" file="US20230002334A1-20230105-C00011.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry><claim-text>wherein</claim-text><claim-text>X is C;</claim-text><claim-text>R<sup>3 </sup>is selected from hydrogen, C<sub>1</sub>-C<sub>6 </sub>alkyl, C<sub>1</sub>-C<sub>7 </sub>alkyl substituted with one or two OH groups, C<sub>3</sub>-C<sub>7 </sub>cycloalkyl, C<sub>3</sub>-C<sub>7 </sub>cycloalkyl substituted with one or two OH groups, C<sub>5</sub>-C<sub>7 </sub>cycloalkenyl, C<sub>5</sub>-C<sub>7 </sub>cycloalkenyl substituted with one, two or three C<sub>1</sub>-C<sub>3 </sub>alkyl groups, and phenyl;</claim-text><claim-text>R<sup>1 </sup>is selected from hydrogen,</claim-text><claim-text>C<sub>1</sub>-C<sub>6 </sub>alkyl,</claim-text><claim-text>C<sub>1</sub>-C<sub>7 </sub>alkyl substituted with one or two OH groups,</claim-text><claim-text>C<sub>3</sub>-C<sub>7 </sub>alkenyl,</claim-text><claim-text>phenyl optionally substituted with up to five (e.g. one, two or three) substituents selected from the group consisting of halogen (including Br, Cl, and F), C&#x2261;N, NO<sub>2</sub>, C<sub>1</sub>-C<sub>6 </sub>alkyl, C<sub>1</sub>-C<sub>6 </sub>alkyl comprising up to 5 halogen atoms (including Br, Cl, and F), C<sub>1</sub>-C<sub>6 </sub>alkyloxy, C<sub>1</sub>-C<sub>6 </sub>alkyloxy comprising up to 5 halogen atoms (including Br, Cl, and F), C<sub>3</sub>-C<sub>7 </sub>cycloalkyl, &#x2014;C(O)O&#x2014;R<sup>10 </sup>wherein R<sup>10 </sup>is selected from hydrogen and C<sub>1</sub>-C<sub>3 </sub>alkyl, and &#x2014;SR<sup>11 </sup>wherein R<sup>11 </sup>is selected from hydrogen and C<sub>1</sub>-C<sub>3 </sub>alkyl (including ethyl and isopropyl),</claim-text><claim-text>naphthyl optionally substituted with up to five (e.g. one, two or three) substituents selected from the group consisting of halogen (including Br, Cl, and F), C&#x2261;N, NO<sub>2</sub>, C<sub>1</sub>-C<sub>6 </sub>alkyl, C<sub>1</sub>-C<sub>6 </sub>alkyl comprising up to 5 halogen atoms (including Br, Cl, and F), C<sub>1</sub>-C<sub>6 </sub>alkyloxy, C<sub>1</sub>-C<sub>6 </sub>alkyloxy comprising up to 5 halogen atoms (including Br, Cl, and F), C<sub>3</sub>-C<sub>7 </sub>cycloalkyl, &#x2014;C(O)O&#x2014;R<sup>10 </sup>wherein R<sup>10 </sup>is selected from hydrogen and C<sub>1</sub>-C<sub>3 </sub>alkyl, and &#x2014;SR<sup>11 </sup>wherein R<sup>11 </sup>is selected from hydrogen and C<sub>1</sub>-C<sub>3 </sub>alkyl (including ethyl and isopropyl), and</claim-text><claim-text>C<sub>5</sub>-C<sub>10 </sub>mono- or bicyclic aryl wherein 1 or 2 C-atoms are replaced by a hetero atom independently selected from sulfur, nitrogen, and oxygen, optionally substituted with up to three (e.g. 1 or 2) substituents selected from the group consisting of halogen (including Br, Cl, and F), C&#x2261;N, NO<sub>2</sub>, C<sub>1</sub>-C<sub>6 </sub>alkyl, C<sub>1</sub>-C<sub>6 </sub>alkyl comprising up to 5 halogen atoms (including Br, Cl, and F), C<sub>1</sub>-C<sub>6 </sub>alkyloxy, C<sub>1</sub>-C<sub>6 </sub>alkyloxy comprising up to 5 halogen atoms (including Br, Cl, and F), C<sub>3</sub>-C<sub>7 </sub>cycloalkyl, &#x2014;C(O)O&#x2014;R<sup>10 </sup>wherein R<sup>10 </sup>is selected from hydrogen and C<sub>1</sub>-C<sub>3 </sub>alkyl, and &#x2014;SR<sup>11 </sup>wherein R<sup>11 </sup>is selected from hydrogen and C<sub>1</sub>-C<sub>3 </sub>alkyl (including ethyl and isopropyl);</claim-text><claim-text>R<sup>2 </sup>is H or methyl;</claim-text><claim-text>R<sup>4</sup>, R<sup>5</sup>, and R<sup>7 </sup>are independently selected from hydrogen and C<sub>1</sub>-C<sub>6 </sub>alkyl;</claim-text><claim-text>R<sup>6 </sup>is selected from hydrogen, C<sub>1</sub>-C<sub>6 </sub>alkyl (e.g. ethyl, isopropyl), and C<sub>3</sub>-C<sub>7 </sub>cycloalkyl;</claim-text><claim-text>R<sup>8 </sup>and R<sup>9 </sup>are independently selected from hydrogen, and C<sub>1</sub>-C<sub>6 </sub>alkyl, or</claim-text><claim-text>R<sup>8 </sup>and R<sup>9 </sup>form together with the C-atom to which they are attached a 3, 4, 5, 6, or 7-membered cycloalkyl ring.</claim-text></claim-text></claim><claim id="CLM-00022" num="00022"><claim-text><b>22</b>. The method according to <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the compound comprises a formula (Ib), a salt, or solvate thereof</claim-text><claim-text><chemistry id="CHEM-US-00012" num="00012"><img id="EMI-C00012" he="27.01mm" wi="53.93mm" file="US20230002334A1-20230105-C00012.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry><claim-text>wherein</claim-text><claim-text>R<sup>1 </sup>is selected from hydrogen,</claim-text><claim-text>C<sub>1</sub>-C<sub>6 </sub>alkyl,</claim-text><claim-text>C<sub>1</sub>-C<sub>7 </sub>alkyl substituted with one or two OH groups,</claim-text><claim-text>C<sub>3</sub>-C<sub>7 </sub>alkenyl,</claim-text><claim-text>phenyl optionally substituted with up to five (e.g. one, two or three) substituents selected from the group consisting of halogen (including Br, Cl, and F), C&#x2261;N, NO<sub>2</sub>, C<sub>1</sub>-C<sub>6 </sub>alkyl, C<sub>1</sub>-C<sub>6 </sub>alkyl comprising up to 5 halogen atoms (including Br, Cl, and F), C<sub>1</sub>-C<sub>6 </sub>alkyloxy, C<sub>1</sub>-C<sub>6 </sub>alkyloxy comprising up to 5 halogen atoms (including Br, Cl, and F), C<sub>3</sub>-C<sub>7 </sub>cycloalkyl, &#x2014;C(O)O&#x2014;R<sup>10 </sup>wherein R<sup>10 </sup>is selected from hydrogen and C<sub>1</sub>-C<sub>3 </sub>alkyl, and &#x2014;SR<sup>11 </sup>wherein R<sup>11 </sup>is selected from hydrogen and C<sub>1</sub>-C<sub>3 </sub>alkyl (including ethyl and isopropyl),</claim-text><claim-text>naphthyl optionally substituted with up to five (e.g. one, two or three) substituents selected from the group consisting of halogen (including Br, Cl, and F), C&#x2261;N, NO<sub>2</sub>, C<sub>1</sub>-C<sub>6 </sub>alkyl, C<sub>1</sub>-C<sub>6 </sub>alkyl comprising up to 5 halogen atoms (including Br, Cl, and F), C<sub>1</sub>-C<sub>6 </sub>alkyloxy, C<sub>1</sub>-C<sub>6 </sub>alkyloxy comprising up to 5 halogen atoms (including Br, Cl, and F), C<sub>3</sub>-C<sub>7 </sub>cycloalkyl, &#x2014;C(O)O&#x2014;R<sup>10 </sup>wherein R<sup>10 </sup>is selected from hydrogen and C<sub>1</sub>-C<sub>3 </sub>alkyl, and &#x2014;SR<sup>11 </sup>wherein R<sup>11 </sup>is selected from hydrogen and C<sub>1</sub>-C<sub>3 </sub>alkyl (including ethyl and isopropyl), and</claim-text><claim-text>C<sub>5</sub>-C<sub>10 </sub>mono- or bicyclic aryl wherein 1 or 2 C-atoms are replaced by a hetero atom independently selected from sulfur, nitrogen, and oxygen, optionally substituted with up to three (e.g. 1 or 2) substituents selected from the group consisting of halogen (including Br, Cl, and F), C&#x2261;N, NO<sub>2</sub>, C<sub>1</sub>-C<sub>6 </sub>alkyl, C<sub>1</sub>-C<sub>6 </sub>alkyl comprising up to 5 halogen atoms (including Br, Cl, and F), C<sub>1</sub>-C<sub>6 </sub>alkyloxy, C<sub>1</sub>-C<sub>6 </sub>alkyloxy comprising up to 5 halogen atoms (including Br, Cl, and F), C<sub>3</sub>-C<sub>7 </sub>cycloalkyl, &#x2014;C(O)O&#x2014;R<sup>10 </sup>wherein R<sup>10 </sup>is selected from hydrogen and C<sub>1</sub>-C<sub>3 </sub>alkyl, and &#x2014;SR<sup>11 </sup>wherein R<sup>11 </sup>is selected from hydrogen and C<sub>1</sub>-C<sub>3 </sub>alkyl (including ethyl and isopropyl);</claim-text><claim-text>R<sup>3 </sup>is selected from hydrogen, C<sub>1</sub>-C<sub>6 </sub>alkyl, C<sub>1</sub>-C<sub>7 </sub>alkyl substituted with one or two OH groups, C<sub>3</sub>-C<sub>7 </sub>cycloalkyl, C<sub>3</sub>-C<sub>7 </sub>cycloalkyl substituted with one or two OH groups, C<sub>5</sub>-C<sub>7 </sub>cycloalkenyl, C<sub>5</sub>-C<sub>7 </sub>cycloalkenyl substituted with one, two or three C<sub>1</sub>-C<sub>3 </sub>alkyl groups, and phenyl;</claim-text><claim-text>R<sup>2</sup>, R<sup>4</sup>, R<sup>5</sup>, and R<sup>7 </sup>are independently selected from hydrogen and C<sub>1</sub>-C<sub>6 </sub>alkyl;</claim-text><claim-text>R<sup>6 </sup>is selected from hydrogen, C<sub>1</sub>-C<sub>6 </sub>alkyl (e.g. ethyl, isopropyl), and C<sub>3</sub>-C<sub>7 </sub>cycloalkyl;</claim-text><claim-text>R<sup>8 </sup>and R<sup>9 </sup>are independently selected from hydrogen, and C<sub>1</sub>-C<sub>6 </sub>alkyl, or</claim-text><claim-text>R<sup>8 </sup>and R<sup>9 </sup>form together with the C-atom to which they are attached a 3, 4, 5, 6, or 7-membered cycloalkyl ring.</claim-text></claim-text></claim><claim id="CLM-00023" num="00023"><claim-text><b>23</b>. The compound of <claim-ref idref="CLM-00014">claim 14</claim-ref>, wherein the compound comprises a formula (Ib) a salt, or solvate thereof</claim-text><claim-text><chemistry id="CHEM-US-00013" num="00013"><img id="EMI-C00013" he="27.01mm" wi="53.93mm" file="US20230002334A1-20230105-C00013.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry><claim-text>wherein</claim-text><claim-text>R<sup>1 </sup>is selected from hydrogen,</claim-text><claim-text>C<sub>1</sub>-C<sub>6 </sub>alkyl,</claim-text><claim-text>C<sub>1</sub>-C<sub>7 </sub>alkyl substituted with one or two OH groups,</claim-text><claim-text>C<sub>3</sub>-C<sub>7 </sub>alkenyl,</claim-text><claim-text>phenyl optionally substituted with up to five (e.g. one, two or three) substituents selected from the group consisting of halogen (including Br, Cl, and F), C&#x2261;N, NO<sub>2</sub>, C<sub>1</sub>-C<sub>6 </sub>alkyl, C<sub>1</sub>-C<sub>6 </sub>alkyl comprising up to 5 halogen atoms (including Br, Cl, and F), C<sub>1</sub>-C<sub>6 </sub>alkyloxy, C<sub>1</sub>-C<sub>6 </sub>alkyloxy comprising up to 5 halogen atoms (including Br, Cl, and F), C<sub>3</sub>-C<sub>7 </sub>cycloalkyl, &#x2014;C(O)O&#x2014;R<sup>10 </sup>wherein R<sup>10 </sup>is selected from hydrogen and C<sub>1</sub>-C<sub>3 </sub>alkyl, and &#x2014;SR<sup>11 </sup>wherein R<sup>11 </sup>is selected from hydrogen and C<sub>1</sub>-C<sub>3 </sub>alkyl (including ethyl and isopropyl),</claim-text><claim-text>naphthyl optionally substituted with up to five (e.g. one, two or three) substituents selected from the group consisting of halogen (including Br, Cl, and F), C&#x2261;N, NO<sub>2</sub>, C<sub>1</sub>-C<sub>6 </sub>alkyl, C<sub>1</sub>-C<sub>6 </sub>alkyl comprising up to 5 halogen atoms (including Br, Cl, and F), C<sub>1</sub>-C<sub>6 </sub>alkyloxy, C<sub>1</sub>-C<sub>6 </sub>alkyloxy comprising up to 5 halogen atoms (including Br, Cl, and F), C<sub>3</sub>-C<sub>7 </sub>cycloalkyl, &#x2014;C(O)O&#x2014;R<sup>10 </sup>wherein R<sup>10 </sup>is selected from hydrogen and C<sub>1</sub>-C<sub>3 </sub>alkyl, and &#x2014;SR<sup>11 </sup>wherein R<sup>11 </sup>is selected from hydrogen and C<sub>1</sub>-C<sub>3 </sub>alkyl (including ethyl and isopropyl), and</claim-text><claim-text>C<sub>5</sub>-C<sub>10 </sub>mono- or bicyclic aryl wherein 1 or 2 C-atoms are replaced by a hetero atom independently selected from sulfur, nitrogen, and oxygen, optionally substituted with up to three (e.g. 1 or 2) substituents selected from the group consisting of halogen (including Br, Cl, and F), C&#x2261;N, NO<sub>2</sub>, C<sub>1</sub>-C<sub>6 </sub>alkyl, C<sub>1</sub>-C<sub>6 </sub>alkyl comprising up to 5 halogen atoms (including Br, Cl, and F), C<sub>1</sub>-C<sub>6 </sub>alkyloxy, C<sub>1</sub>-C<sub>6 </sub>alkyloxy comprising up to 5 halogen atoms (including Br, Cl, and F), C<sub>3</sub>-C<sub>7 </sub>cycloalkyl, &#x2014;C(O)O&#x2014;R<sup>10 </sup>wherein R<sup>10 </sup>is selected from hydrogen and C<sub>1</sub>-C<sub>3 </sub>alkyl, and &#x2014;SR<sup>11 </sup>wherein R<sup>11 </sup>is selected from hydrogen and C<sub>1</sub>-C<sub>3 </sub>alkyl (including ethyl and isopropyl);</claim-text><claim-text>R<sup>3 </sup>is selected from hydrogen, C<sub>1</sub>-C<sub>6 </sub>alkyl, C<sub>1</sub>-C<sub>7 </sub>alkyl substituted with one or two OH groups, C<sub>3</sub>-C<sub>7 </sub>cycloalkyl, C<sub>3</sub>-C<sub>7 </sub>cycloalkyl substituted with one or two OH groups, C<sub>5</sub>-C<sub>7 </sub>cycloalkenyl, C<sub>5</sub>-C<sub>7 </sub>cycloalkenyl substituted with one, two or three C<sub>1</sub>-C<sub>3 </sub>alkyl groups, and phenyl;</claim-text><claim-text>R<sup>2</sup>, R<sup>4</sup>, R<sup>5</sup>, and R<sup>7 </sup>are independently selected from hydrogen and C<sub>1</sub>-C<sub>6 </sub>alkyl;</claim-text><claim-text>R<sup>6 </sup>is selected from hydrogen, C<sub>1</sub>-C<sub>6 </sub>alkyl (e.g. ethyl, isopropyl), and C<sub>3</sub>-C<sub>7 </sub>cycloalkyl;</claim-text><claim-text>R<sup>8 </sup>and R<sup>9 </sup>are independently selected from hydrogen, and C<sub>1</sub>-C<sub>6 </sub>alkyl, or</claim-text><claim-text>R<sup>8 </sup>and R<sup>9 </sup>form together with the C-atom to which they are attached a 3, 4, 5, 6, or 7-membered cycloalkyl ring.</claim-text></claim-text></claim><claim id="CLM-00024" num="00024"><claim-text><b>24</b>. A consumer product comprising one or more compounds of formula (Ia) as defined in <claim-ref idref="CLM-00014">claim 14</claim-ref>.</claim-text></claim><claim id="CLM-00025" num="00025"><claim-text><b>25</b>. A consumer product comprising one or more compounds of formula (Ib) as defined in <claim-ref idref="CLM-00023">claim 23</claim-ref>.</claim-text></claim></claims></us-patent-application>